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Abstract 
Rotator cuff (RC) tendinopathy is defined as pain and dysfunction of one or more of the RC tendons (supraspinatus, 
infraspinatus, subscapularis and teres minor). Inflammation has been associated with this condition. Graduated exercise is 
the main treatment for RC tendinopathy, and comparable outcomes to surgery, have been reported for the range of 
conditions associated with RC tendinopathy. However both non-surgical and surgical outcomes are frequently sub-optimal 
and new treatment methods to support current practice and improve outcomes are required.  
 
A questionnaire investigation recruited 261 participants with shoulder pain from eight healthcare locations. Information 
was collected regarding beliefs and use of nutritional supplements. Supplement use was reported by 38% (100/261) 
respondents. Of those who were taking supplements, 82% (82/100) were taking them for shoulder pain. Fish oil 
supplements containing long-chain omega-3 polyunsaturated fatty acids (PUFAs) were the most popular dietary 
supplements. 
 
Long-chain mega-3 PUFAs have been recommended for people with tendinopathy due to their potential to reduce 
inflammation. This investigation compared exercise and PUFAs to exercise and placebo supplements in the treatment of 
people with RC tendinopathy.  
 
A double-blind placebo controlled randomized controlled trial was conducted in participants with RC tendinopathy 
recruited from hospital clinics. The active treatment group received nine opaque capsules of MaxEPA providing 1.53g 
eicosapentaenoic acid (EPA), 1.04g docosahexaenoic acid (DHA) and the placebo group received nine matching placebo 
capsules where the long-chain omega-3 fatty acids were replaced with oleic acid; all participants attended an eight week 
exercise programme. Participants were assessed, at pre-randomisation, eight weeks (primary outcome point), three 
months, six months and 12 months (secondary outcome point). Primary outcome was the Oxford Shoulder Score (OSS). 
Secondary outcomes included; the Shoulder Pain and Disability Index (SPADI), Patient Specific Functional Score, Euro Qol 
5D-3L, Short Form 36, global rating of change and impairment measures. Analysis was by intention-to-treat. A total of 73 
participants were randomized to treatment and data were available for the analysis of 36 in the PUFA supplement group 
versus 33 in the placebo. Both groups improved over the time course of the study. Plasma concentrations of EPA and DHA 
increased in the long-chain omega-3 PUFA supplemented group but not in the placebo, providing evidence that the 
participants took the supplements. There was no evidence of added benefit from long-chain omega-3 PUFA 
supplementation for the primary outcome change in OSS -0.23 (95% CI 3.89, 3.43) or in SPADI -1.68 (-12.64, 9.28) at two 
months. There was some evidence to suggest that SPADI was lower in the treatment group at three months. There was no 
difference in outcomes between groups at 12 months. Twelve participants undertook semi-structured face to face 
interviews to explore experiences, barriers, motivators and enablers to supplement use and exercise. The predominant 
enablers to exercise were found to be the perceived benefit from the exercises and extended follow up, with barriers being 
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lack of suitable equipment and pain. The enablers to supplement taking were found to be the perceived benefit of the 
supplements and a systematic pill taking routine. Barriers were the size, taste and quantity of supplements, remembering 
to take them, and, lack of perceived benefit. 
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Abbreviations 
Abbreviation Meaning 
ALA Alpha-linolenic acid 
ARA Arachidonic acid 
bFGF Basic fibroblast growth factor 
BMI Body mass index 
BMR Basal metabolic rate 
BP British Pharmacopeia 
CI Chief investigator 
Cm Centimetres 
COX Cyclooxygenase 
DHA Docosahexaenoic acid 
DHLA Dihomo-gamma linolenic acid 
EFSA European Food Safety Authority 
EPA Eicosapentaenoic acid 
EQ 5D 3L Euro Qol 5D 3L 
FAME Fatty acid methyl esters 
FID Flame ionization detector 
GC Gas chromatograph 
GLA Gamma-linolenic acid 
GROC Global rating of change 
H₂o₂ Hydrogen peroxide 
HHD Hand held dynamometer 
ICC Intra class correlation 
IL-1α Interleukin-1 alpha 
IL-1β Interleukin-1 beta 
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IL-6/8/10 Interleukin-6/8/10 
iNOS Inducible nitric oxide synthase 
IQR Interquartile range 
Kg Kilograms  
LA Linolenic acid 
LBP Low back pain 
LOX Lipoxygenase 
LPS Lipopolysaccharide 
LT Leukotriene 
LTB₄ Leukotriene B4 
LTC₄ Leukotriene C4 
LTD₄ Leukotriene D4 
LTE₄ Leukotriene E4 
MCIC Minimal clinically important change 
MCID Minimal clinically important difference 
MID Minimally important difference 
MUFA Monounsaturated fat 
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NHS National Health Service 
NRS Numerical rating scale 
NSAIDS Nonsteroidal anti-inflammatory drugs 
OA Osteoarthritis 
OSS  Oxford shoulder score 
PG Prostaglandin 
PGD₂ Prostaglandin D2 
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PGE₂ Prostaglandin E2 
PSFS Patient specific functional score 
PUFAs Polyunsaturated fatty acids 
RA Rheumatoid arthritis 
RC Rotator cuff 
RCT Randomised controlled trial 
RNI Reference nutrient intake 
ROM Range of motion 
SD Standard deviation 
SDC Smallest detectable change 
SEM Standard error of measurement or mean 
SF 36  Short Form 36 
SF 36 MCS Short form 36 mental component summary 
SF 36 PCS Short form 36 physical component summary 
SF 36 BP Short form 36 bodily pain 
SF 36 GH Short form 36 general health 
SF 36 MH Short form 36 emotional well being 
SF 36 PF Short form 36 physical functioning 
SF 36 RE Short form 36 role limitations due to emotional health  
SF 36 RP Short form 36 role limitations due to physical health 
SF 36 SF Short form 36 social functioning 
SF 36 VT Short form 36 vitality 
SPADI Shoulder pain and disability index 
TNFα Tumour necrosis factor alpha 
UK United Kingdom 
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UKUFF UK National rotator cuff trial 
VAS Visual analogue scale 
VEGF Vascular endothelial growth factor 
WOMAC Score Western Ontario and McMaster Universities Osteoarthritis Index 
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This thesis reviews the evidence for the efficacy of long-chain omega-3 polyunsaturated fatty acids (PUFA) in the treatment 
of rotator cuff (RC) tendinopathy. It explores the relationship between exercise, nutritional supplements and RC 
tendinopathy. A cohort of patients presenting with shoulder pain were surveyed about their attitudes to taking nutritional 
supplements. The potential role of long-chain omega-3 PUFAs in addition to exercise was investigated in the management 
of RC tendinopathy. The final stage of the study used qualitative methods to investigate the participants’ experiences, 
barriers, motivators and enablers to nutritional supplement use and exercise in RC tendinopathy.  
 
The primary function of the shoulder is to place the hand to perform a multitude of upper limb functional tasks requiring 
strength, power, endurance, stability and precision. The shoulder complex is the most mobile musculoskeletal region in the 
body. The RC muscles and tendons contribute both to stability and movement at the glenohumeral joint of the shoulder 
complex. The presence of pain and alterations in normal movement patterns often results in a substantial reduction in 
shoulder and subsequently upper limb function.  
 
It is estimated that up to 67% of the population will experience shoulder pain at some point in their lives (Chard, Hazleman 
et al. 1991, Luime, Koes et al. 2004). In a survey of general practices in Cambridge, United Kingdom (UK) the incidence of 
shoulder pain was found to be 9.5/1000 (Östör, Richards et al. 2005). The high incidence of musculoskeletal conditions 
involving the shoulder has considerable socio-economic implications due to time lost from work and associated healthcare 
costs (Ekberg, Bjorkqvist et al. 1994, Virta, Joranger et al. 2012). In a recent study conducted in Sweden, the mean total 
annual cost of a shoulder injury was found to be €4139 per patient, with sick leave contributing 84% of those costs (Virta, 
Joranger et al. 2012). Disorders of the shoulder contribute to 30% of all occupational musculoskeletal pathologies, which is 
equal to the proportion due to cervical spine pathology (Nygren, Berglund et al. 1995). The incidence of shoulder pain 
substantially increases with age, rising to approximately 20% in individuals aged over 70 years (Chard, Hazleman et al. 
1991). In contrast to prevalence, which describes the proportion of the population that has the condition at any one time 
(Jager, Zoccali et al. 2007), incidence describes the number of new cases or people acquiring the condition in the 
population. 
 
The majority of shoulder pain is believed to arise from the peri-articular soft tissues, especially the RC, (Uhthoff and Sarkar 
1990, Östör, Richards et al. 2005). This view is supported by research examining people working in industry, those being 
treated in primary care and workers’ compensation cases, which have demonstrated that RC tendinitis is the most frequent 
shoulder diagnosis, accounting for 85% of diagnoses made by general practitioners (van der Windt, Koes et al. 1996, 
Silverstein, Welp et al. 1998, Östör, Richards et al. 2005, Bishay and Gallo 2013).  
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The terminology used to describe disorders of the RC is inconsistent. This confuses understanding and can hinder 
comparison across research investigations. Chapter 2 reviews the terminology and explains why the term RC tendinopathy 
is used in this thesis.  
 
RC tendinopathy is associated with long-term morbidity and loss of function. RC tendinopathy is considered the most 
common of all tendinopathies with the annual incidence being over 1% (Chaudhury, Gwilym et al. 2010, Tashjian 2012).  
 
Exercise has been proven to be an effective treatment for RC tendinopathy with equivalent outcomes to surgery (Haahr 
and Andersen 2006, Ketola, Lehtinen et al. 2013). Although beneficial in reducing pain and improving function, many 
people completing a course of exercise therapy continue to experience pain and functional disability for up to one year 
(Ainsworth, Lewis et al. 2009, Holmgren, Bjornsson Hallgren et al. 2012, Lewis 2012, Litchfield 2013). The pain and 
functional disability is frequently long term, with over 50% of individuals experiencing on-going pain after three years 
(Macfarlane, Hunt et al. 1998).  
 
Exercise therapy does not always lead to a complete resolution of symptoms for those diagnosed with RC tendinopathy 
and as a consequence of this, other treatments are also recommended by healthcare professions. Corticosteroid and 
platelet rich plasma injections are increasingly being used in the non-surgical management of RC tendinopathy. These 
injections have been shown to be beneficial in the short term but at a year’s follow-up were shown to be no more effective 
than exercise (Hart 2011, Kesikburun, Tan et al. 2013). Similarly, in a recent review, surgery was found to be no more 
beneficial than non-surgical interventions (Tashjian 2013). 
 
In light of the limited benefit afforded by treatment currently regarded as best practice, there is a need to identify new and 
novel methods for treating for this common and disabling condition. The potential benefit of an long-chain omega-3 PUFA 
and an anti-oxidant supplement in the treatment of athletes with a range of tendinopathies including; supraspinatus, 
biceps, medial and lateral epicondylar, patellar and infraspinatus tendinopathies was highlighted by Mavrogenis et al 
(2004). A significant reduction in pain was observed in the long-chain omega-3 PUFA and anti-oxidant treatment group and 
this was hypothesised to be as a result of the formation of signalling molecules (eicosanoids) with a less potent 
inflammatory action. 
 
The dietary supplement market is a rapidly growing industry, with an annual UK turnover of in excess of £700 million, and 
sales are expected to reach £786 million by 2018 (http://www.euromonitor.com/vitamins-and-dietary-supplements-in-the-
united-kingdom/report). It is estimated that 40% of UK adults regularly use dietary supplements (Mason 2007). Despite this 
widespread use their role and benefit in tendon-related disorders has come under little rigorous scientific scrutiny. 
Recently, their role, use and general efficacy have also been challenged in the popular press and media (Sanders 2012). 
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This thesis presents four interrelated studies, which aim to add to the knowledge base regarding the use of nutritional 
supplements in shoulder pain; 
1. Reliability study investigating the intra- and inter-rater reliability of shoulder range of motion and strength 
(Chapter 6). 
2. Survey of shoulder pain and the use of nutritional supplements: a questionnaire based investigation (chapter 7). 
3. A double blind randomised controlled trial investigating the efficacy of long-chain omega-3 PUFAs and exercise in 
the treatment of RC tendinopathy (chapter 8).  
4. Exploring experiences, barriers, motivators and enablers to nutritional supplement use and exercise in RC 
tendinopathy (chapter 9). 
In order to be able to consider the potential beneficial effects of long-chain omega-3 PUFAs on RC tendinopathy it is first 
necessary to have a thorough understanding of RC tendinopathy and its pathophysiology. The following chapter will 
explore this topic in detail.  
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Introduction 
Establishing an understanding of the pathophysiological mechanisms of rotator cuff (RC) tendinopathy is crucial to 
comprehend why certain treatments might work and for guiding the development of new and novel treatments for the 
future. As such this chapter aims to:  
 Provide an overview of anatomy and function of the shoulder and of the RC.  
 Review the terminology associated with tendon related disorders of the RC.  
 Discuss the aetiology of RC tendinopathy. 
 
Anatomy and function of the shoulder 
The shoulder (Figure 2.1) is capable of the most extensive range of motion of any joint in the body (Quillen, Wuchner et al. 
2004, Longo, Berton et al. 2011). Its primary role is to position the hand in order to facilitate upper limb function (Peat 
1986, Myers and Lephart 2000). This function ranges from highly explosive overhead throwing actions (Anderson and 
Alford 2010) to positioning the hand in the field of vision for intricate prehensile activities for sustained periods of time 
(Peat 1986, Culham and Peat 1993). The upper limb is frequently used for activities involving weight bearing, such as during 
a push up, rock climbing and gymnastics, necessitating stability and resistance to compression at the glenohumeral joint. 
Additionally, when carrying a weight in the hand the shoulder needs to withstand forces that distract the shoulder. When 
shoulder function is compromised, substantial morbidity and disability follow (van der Windt, Koes et al. 1996, Winters, 
Jorritsma et al. 1999). 
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Chapter 23, Figure 23.3, Page 390 (Travell and Simons 1983). Myofascial pain and dysfunction: The trigger point manual. Vol 1: The 
upper extremities, Baltimore, Williams and Wilkins 
 
The shoulder joint consists of three bones; the scapula, humerus and the clavicle and four articulations; the glenohumeral 
joint, the acromioclavicular joint, the sternoclavicular joint and the scapulaothrocacic mechanism (Culham and Peat 1993). 
 
The glenohumeral joint is a multi-axial ball and socket joint comprising of the round humeral head and the shallow glenoid 
fossa of the scapula (Poppen and Walker 1976). In order to increase its joint surface area and stability without 
compromising the flexibility there is a fibrocartilaginous rim, the glenoid labrum surrounding the glenoid fossa (Cooper, 
Arnoczky et al. 1992). 
The acromioclavicular joint is a flat, gliding, synovial joint involving the articulation of the lateral end of the clavicle and the 
acromion process of the scapula. It provides additional flexibility and range of motion to the shoulder joint, which would 
not be possible with the glenohumeral joint in isolation, by allowing further rotation and adjustment of the scapula on the 
thorax. The acromioclavicular joint is also responsible for allowing the transmission of forces from the upper limb into the 
thorax and for suspending the upper limb (Lemos 1998). 
 
Figure 2.1 The shoulder complex and the rotator cuff 
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The shoulder gains its static stability from its joint capsule and the surrounding glenohumeral, coracohumeral and 
coracoacromial ligaments (Ishihara, Mihata et al. 2013). The coracoacromial arch consists of the corocoacromial ligament, 
acromion and coracoid process of the scapula. The coracoacromial arch forms the roof of the subacromial space which is 
found above the glenohumeral joint. The superior aspect of the humeral head and the greater tuberoisty of the humerus 
form the floor of the subacromial space. It is within this space that the subacromial bursa and the RC tendons are located 
(Standring 2005). 
 
Bursae are synovial lined sacs which are situated over bony prominences or surfaces where tendon friction may occur 
(Hirji, Hunjun et al. 2011). Their function is primarily to reduce any friction during movement. Approximately ten bursae 
have been identified in the shoulder (Hirji, Hunjun et al. 2011). The largest and most substantial bursa in the region is the 
subacromial bursa (Figure 2.3). It is located in the subacromial space, between the RC tendons and the under surface of the 
acromion (Standring 2005). Normally there is no communication between the glenohumeral joint and the subacromial 
bursa (Hirji, Hunjun et al. 2011).  
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Figure 2.2 Sub-acromial bursa of the shoulder 
 
 
Primal pictures (https://www.primalpictures.com/) 
 
Anatomy and function of the rotator cuff 
The RC is the name given to a group of muscles and their tendons that contribute to movement and stability at the 
glenohumeral joint. The four muscles and tendons of the RC are the; supraspinatus, infraspinatus, subscapularis and teres 
minor (Clark and Harryman 1992). The tendons of the RC form a convergent insertion into the greater and lesser 
tuberosities of the humerus (Clark and Harryman 1992, Barr 2004, Curtis, Burbank et al. 2006). The long head of biceps 
tendon should be considered functionally as part of the RC, due to its location between the subscapularis and 
supraspinatus tendons and the inter-digitation of their fibres (Barr 2004).  
 
Given the proximity of the RC muscles to the glenohumeral joint, they provide dynamic stability to the joint (Hess 2000), in 
flexion by controlling anterior translation of the humeral head by activating the posterior cuff and in the opposite in 
extension stopping posterior translation of the humeral head by activating the anterior cuff (Boettcher, Cathers et al. 2010, 
Sangwan, Green et al. 2014). 
Sub acromial 
bursa 
Biceps tendon  
Acromion 
Acromial clavicular joint Coracoacromial ligament  
Coracoid process 
Clavicle 
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Terminology associated with tendon related disorders of the rotator cuff 
A lack of consistency exists within clinical practice and research regarding the terminology used to define shoulder 
conditions involving the RC. RC disease, tendinitis, tendinosis, tendinopathy, impingement and subacromial impingement 
and tears and are often used inter-changeably within the literature (Rees, Stride et al. 2013, Dean, Gettings et al. 2015). 
Without a clear, agreed definition, it is difficult to interpret and compare results of randomised controlled trials (RCTs) that 
investigate RC tendinopathy. 
 
All terms essentially describe a similar clinical picture of pain and loss of shoulder function. The following section sets out 
to define these diagnostic terms. 
 
2.1.1 Rotator cuff disease 
RC disease is an overarching term which does not implicate any specific tendon pathology. It is used to describe the clinical 
presentation of symptoms in the absence of histological and imaging findings.  
 
2.1.2 Rotator cuff tendinitis 
Describes inflammation of the RC tendons (Bass 2012). The role of classic inflammation in the pathological process of RC 
disorders remains equivocal (Longo, Berton et al. 2011). Therefore tendinitis should only be used when a histological 
examination clearly demonstrates inflammation is present. 
 
2.1.3 Rotator cuff tendinopathy 
RC tendinopathy is a clinical classification and relates to the symptoms of shoulder pain and loss of function without 
reference to pathology (Lewis 2009). Shoulder pain is provoked with load, either through lifting or through resisted muscle 
tests performed during an examination (Littlewood, Ashton et al. 2012). 
 
2.1.4 Rotator cuff tendinosis 
RC tendinosis describes the degeneration of the RC tendons (Bass 2012) without the presence of inflammation. The term 
requires both imaging and histological confirmation and as such would be an inappropriate clinical diagnosis. 
 
2.1.5 Sub-acromial impingement/ impingement syndrome 
This term is used to describe the mechanical compression and irritation of sub-acromial structures (including the tendon 
and muscle of the supraspinatus, long head of biceps tendon and the sub-acromial bursa) between the coraco-acromial 
arch and humerus during elevation of the arm above 90° (Neer 1972, Neer 1983). This mechanism of RC injury has been 
questioned (Lewis 2014) and there exists a body of evidence to refute its validity (Brox, Gjengedal et al. 1999, Haahr, 
Ostergaard et al. 2005, Haahr and Andersen 2006, Kukkonen, Joukainen et al. 2014, Lewis 2014). 
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2.1.6 Rotator cuff tears (partial or full thickness) 
A RC tear describes discontinuity of the tendon fibres of the RC tendon(s), most commonly involving the supraspinatus 
near to its insertion (Freygant, Dziurzynska-Bialek et al. 2014). RC tears are diagnosed with imaging modalities such as 
ultrasound and MRI, however, there is a poor association between pain and the presence of a tear or tear size (Tempelhof, 
Rupp et al. 1999, Dunn, Kuhn et al. 2014).  
 
2.1.7 Subacromial burstis 
Sub-acromial bursitis is a condition which is characterised by inflammation of the sub-acromial bursa. The only method of 
confirming this diagnosis is via biochemical analysis, and cannot be made by any clinical assessment procedure or imaging 
technique. 
 
Use of tendinopathy in this thesis 
The biochemical and clinical terminology used to describe RC disorders have one unifying link in that they are used to detail 
a clinical picture: shoulder pain, made worse on movement and loading, especially with overhead activities and/or at night, 
commonly accompanied with weakness and loss of function. The pathological processes occurring within the tendon are 
not fully understood, nor are the causes and mechanisms of the pain. Treatment is often directed at the symptoms rather 
than the structural pathology and as such, it was decided that the term; tendinopathy, would be used within this thesis to 
describe the clinical presentation without any reference to the pathology.   
 
Aetiology of rotator cuff tendinopathy 
Although extensive research on RC tendinopathy exists, the exact causative mechanisms remain elusive. There are a 
number of mechanisms which have been proposed as underpinning this condition. The local, pathological tendon based 
mechanisms (Cook and Purdam 2008), the central nervous system modulatory mechanisms (Littlewood, Malliaras et al. 
2013) and the inflammatory mechanisms (Rees, Stride et al. 2013) will be discussed below because these are the 
mechanisms with most relevance to this thesis. Further understanding of mechanisms may assist researchers in developing 
improved treatment approaches more specifically directed at influencing them. 
 
2.1.8 Possible local tissue pathological mechanisms underpinning rotator cuff tendinopathy 
Models that suggest the pain experienced in tendinopathy is due to tissue injury or structural pathology with subsequent 
noiceptive input and pain in proportion to the degree of injury have been proposed (Cook and Purdam 2008, Lewis 2009). 
However, there appears to be a disassociation between pathology and pain (Cook and Purdam 2008, Drew, Smith et al. 
2014). 
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When comparing MRI findings in an aged-matched, symptomatic impingement syndrome group versus an asymptomatic 
group, Frost et al (1999) were unable to distinguish between the two groups based on the structural pathology. A RC tear 
also does not always equate to pain with asymptomatic tears in up to 40% of the general population and elite overhead 
athletes (Tempelhof, Rupp et al. 1999, Connor, Banks et al. 2003, Worland, Lee et al. 2003, Yamamoto, Takagishi et al. 
2010). In addition, as clinical outcomes improve in response to exercise therapy, a corresponding change in the 
pathological structure of the tendon is not observed (Drew, Smith et al. 2014). 
 
The lack of association between pain and pathology is a confounding factor in the local tissue pathology-pain mechanism 
model (Cook and Purdam 2008) and so additional explanations for the symptoms experienced in RC tendinopathy are now 
being sought. These include the involvement of the central nervous system (CNS) and inflammation.  
 
2.1.9 Possible central nervous system mechanisms underpinning rotator cuff tendinopathy 
The influence of the CNS has been widely recognised in other musculoskeletal conditions (Winkelstein 2004, Wand, 
Parkitny et al. 2011, Arendt-Nielsen, Skou et al. 2015, Pelletier, Higgins et al. 2015) and the potential for altered pain 
processing and centrally modulated pain has been recently investigated and discussed in RC tendinopathy (Gwilym, Oag et 
al. 2011, Littlewood, Malliaras et al. 2013). 
 
Neuroplasticity is the term used to refer to changes in the neuronal properties, structure and organisation of the nervous 
system in response to new experiences (Latremoliere and Woolf 2009). Neuroplastic changes have been demonstrated in 
response to experiences and behaviours (Recanzone, Merzenich et al. 1992, Pascual-Leone, Nguyet et al. 1995), motor 
learning (Bayona, Bitensky et al. 2005, Adkins, Boychuk et al. 2006), pain (Flor 2002, Pelletier, Higgins et al. 2015), injury 
(Elbert and Rockstroh 2004) and cognitive processes (Lotze and Halsband 2006). Neuroplastic changes are known to 
change or amplify sensory transmission and this can have functional implications. Sensory testing has demonstrated 
altered sensory transmission and processing in patellar tendinopathy (van Wilgen, Konopka et al. 2013) and lateral 
epicondylar tendinopathy (Fernandez-Carnero, Fernandez-de-Las-Penas et al. 2009). These studies found changes in 
perception thresholds to noxious and innocuous stimuli, evidence of neuroplaticity and central sensitisation.  
 
Central sensation occurs as a result of neuroplasticity (Latremoliere and Woolf 2009) and is an altered pain processing 
state with increased excitability and synaptic efficiency of the dorsal horn cells in the spinal cord (Gifford 1998). Central 
sensitisation is thought to occur as a result of significant nociceptor inputs following injury; however it can also persist in 
the absence of afferent stimulus, which is known as pain memory (Woolf 2011). Central sensitisation manifests itself as 
pain hypersensitivity and allodynia (the triggering of pain by non-noxious stimuli) (Woolf 2011). 
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The effect of central sensitisation has been investigated in patients undergoing sub-acromial decompression. Those 
patients who presented pre operatively with higher levels of central sensitisation and hyperalgeisa, as measured by 
mechanical pain threshold (punctuate stimuli) reported a significantly worse outcome post operatively (Gwilym, Oag et al. 
2011).  
Whilst the cause of the pain involved in RC remains unknown the integral role that the CNS may play in the pain 
presentation requires further investigation. 
 
2.1.10 Possible inflammatory mechanisms underpinning rotator cuff tendinopathy 
In relation to this thesis it is the potential inflammatory mechanisms which are of particular relevance. The presence of an 
inflammatory response in RC tendinopathy forms the theoretical basis for the potential efficacy of the long-chain omega-3 
PUFAs in the treatment of this condition.  
 
The involvement of the inflammatory response in the development or continuation of tendinopathy is subject to extensive 
debate (Longo, Berton et al. 2011). The beginning of 21st Century saw a shift from the inflammatory based tendinitis model 
of the 1970s to a degenerative model without the presence of inflammation and more recently to a model of degeneration 
alongside a chronic inflammatory response (Abate, Silbernagel et al. 2009, Rees, Stride et al. 2013). 
 
The term ‘inflammatory response’ encompasses a series of complex biological events which occur in the body as the 
normal defence response to harmful stimuli (such as damaged cells) through injury and pathogens (Calder 2011, Janssen 
and Henson 2012). It protects and attempts to heal through the elimination of pathogens and tissue repair processes 
(Calder, Albers et al. 2009). Inflammation is commonly categorised as either acute or chronic. Acute inflammation is short 
in duration and is the primary response by the body following injury, concluding with healing (Weiss 2008, Buckley, Gilroy 
et al. 2013). It is predominated by the infiltration of plasma proteins and leukocytes from the blood into the local area. A 
cascade of biochemical events allows maturing of the inflammatory response which, if not resolved, leads to a shift in the 
nature of the cells to chronic inflammation (Janssen and Henson 2012, Buckley, Gilroy et al. 2013).  
 
Chronic inflammation in contrast has been described as;  
“A prolonged, dysregulated and maladaptive response that involves active inflammation, tissue destruction and attempts 
at tissue repair.” Weiss (2008) pg 247.  
 
It is characterised by the infiltration of monocytes which differentiate locally into cells such as macrophages and 
lymphocytes (Maskrey, Megson et al. 2011). It is the process of resolution which is believed to be crucial to the switching 
off of the inflammatory response (Alessandri, Sousa et al. 2013).  
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The inflammatory component to RC tendinopathy is evidenced by the presence of inflammatory cells and the molecular 
mediators of inflammation (Gotoh, Hamada et al. 1997, Matthews, Hand et al. 2006, Millar, Hueber et al. 2010, Gumina, 
Natalizi et al. 2013). 
 
2.1.10.1 Cellular evidence of inflammation  
A complete absence of inflammatory cells within RC tendinopathy has been reported by histological studies, often 
descriptive in nature (Jozsa, Balint et al. 1982, Chard, Cawston et al. 1994, Hashimoto, Nobuhara et al. 2003). The use of 
basic histological techniques in these studies without the use of cell markers has meant that the potential role of 
inflammation in tendinopathy was overlooked. With the advent of new immune-histochemical techniques (Ramos-Vara 
2011) and the increased understanding of the process of chronic inflammation, the role of inflammation in tendinopathy 
has been revisited (Rees, Stride et al. 2013, Dean, Gettings et al. 2015).  
 
Significantly higher levels of inflammatory cells have been observed in human RC tendinopathy specimens compared to 
healthy control tendons (Gotoh, Hamada et al. 1997, Matthews, Hand et al. 2006, Millar, Hueber et al. 2010). These three 
studies have all examined RC tendinopathic tendon in comparison to control groups comprising of cadaver specimens 
(Gotoh, Hamada et al. 1997) or subscapularis tendons harvested from those undergoing shoulder stabilisation surgery 
(Matthews, Hand et al. 2006, Millar, Hueber et al. 2010). Two studies described the cellular differences without using 
statistical tests (Gotoh, Hamada et al. 1998, Matthews, Hand et al. 2006) which may have confounded the findings of the 
investigations. The final study by Millar et al (2010) investigated RC tendinopathy compared to RC tears and normal control 
RC tendon using statistical tests to examine the differences between the groups and between the different structural 
stages of tendinopathy. All three studies observed an increase in the number of macrophages in the RC tendinopathic 
specimens compared to the healthy controls. This finding supports the potential presence of inflammation in RC 
tendinopathy. 
 
Macrophages form a critical step in the inflammatory process as they are involved in promoting tissue repair through 
phagocytosis, the clearing up of damaged cells and the process of resolution (Brechot, Gomez et al. 2008). They also signal 
the release of cytokines (Cavaillon 1994). In the mouse model, reduction in macrophage concentrations has been shown to 
increase the tensile strength of healing Achilles tendons (de la Durantaye, Piette et al. 2014).  
 
Two studies observed an increase in mast cells in the tendinopathic RC specimens compared to the healthy control 
tendons (Matthews, Hand et al. 2006, Millar, Hueber et al. 2010). The importance of increases in mast cell density lies in 
their key role in the inflammatory process as they release histamine, prostaglandins, leukotrines, growth factors and 
proteinases (Kragsnaes, Fredberg et al. 2014). Mast cells have been demonstrated to exert pro-inflammatory effects in 
human tenocytes in vitro (Behzad, Sharma et al. 2013). The pro-inflammatory effects included; enhanced tenocyte survival 
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or proliferation, enhanced expression of the enzyme cyclooxygenase (COX)-2 and associated increased production of the 
inflammatory mediator prostaglandin E₂, which reduced type I collagen production (Behzad, Sharma et al. 2013). These 
effects may modulate tendon degeneration and repair and as such, a treatment aimed at inhibiting mast cells may provide 
beneficial effects in tendinopathy. 
 
2.1.10.2 Molecular evidence of inflammation  
Inflammation comprises many molecular elements (Rees, Stride et al. 2013) but transcription factors and cytokines are the 
two molecular pathways for which there is evidence to indicate that omega 3s PUFAs might have an beneficial effect. The 
presence of these molecules within RC tendinopathy further underpins the theoretical basis of this thesis. 
 
2.1.10.2.1 Transcription factors  
Transcription factors are proteins which function in the cell nucleus and are able to control the activity of a gene by 
governing whether the gene’s deoxyribonucleic acid (DNA) is transcribed into ribonucleic acid (RNA) (Gilmore 2006, 
Whitfield, Wang et al. 2012). Nuclear factor-κB (NFκB) is the primary transcription factor involved in inflammatory 
signalling pathways (Kumar, Takada et al. 2004, Sigal 2006). It regulates numerous cytokines (including IL-1, IL-2, IL-6, IL-12, 
TNFα, VEGF), chemokines (including monocyte chemo attractant protein-1), adhesion molecules, E-selectin, inducible nitric 
oxide synthase (iNOS), growth factors and cyclooxygenase-2 (Ghosh and Karin 2002, Meffert, Chang et al. 2003, Gumina, 
Natalizi et al. 2013). It has been demonstrated to control anti apoptotic gene expression (Taylor 2008) and contribute to 
the formation of angiogenesis (Min, Kim et al. 2003). 
 
Gumina et al (2013) investigated the role that NFκB might have to play in the development and healing of RC tears. 
Samples of RC tendon were excised during surgery in 63 patients who had sustained a non-traumatic tear. Increased levels 
of activated p65 factor (one of the five transcription factors which make up NFκB) were observed on the margins of the 
tendon rupture which correlated positively with size of tear. The control tissue used within this study was samples of 
‘uninjured’ subscapularis tissue excised with the supraspinatus tissue; these samples of subscapularis in the majority of 
samples also showed increased levels of p65 factor and as such cannot be considered as a control. This study used 
immune-histochemical staining methods and the results would have been usefully further validated by polymerase chain 
reaction analysis. The association between activated NFκB and RC tendinopathy is an important one and in part based on 
its ability to regulate inflammatory cytokines. 
 
2.1.10.2.2 Cytokines 
Cytokines are small cell signalling protein molecules which regulate the body’s responses to infection, inflammation and 
trauma (Maffulli, Longo et al. 2011). It is through their role in cell proliferation, differentiation, chemotaxis, apoptosis and 
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matrix synthesis, that cytokines have the potential to significantly impact RC tendinopathy (Savitskaya, Izaguirre et al. 
2011). They are considered vital to the initiation and perpetuation of RC pathology in humans (Millar, Wei et al. 2009). 
 
Cytokines have also been shown to have a direct influence on pain within human musculoskeletal conditions by activating 
nociceptive sensory neurones (Zhang and An 2007). Pro-inflammatory cytokines (IL-1β and TNF α) (Zhang, Li et al. 2002, 
Ozaktay, Kallakuri et al. 2006, Schaible, von Banchet et al. 2010) are thought to directly modulate neuronal activity in the 
peripheral and CNS (Zhang and An 2007). 
 
Increased expression of inflammatory cytokines (IL-1α, IL-1β, IL-6, IL-8, IL -33 and tumour necrosis factor α), have 
consistently been observed in patients with RC tendinopathy (Gotoh, Hamada et al. 1997, Sakai, Fujita et al. 2001, Blaine, 
Kim et al. 2005, Voloshin, Gelinas et al. 2005, Molloy, Kemp et al. 2006, Ko, Wang et al. 2008, Millar, Wei et al. 2009, 
Blaine, Cote et al. 2011, Savitskaya, Izaguirre et al. 2011, Millar, Gilchrist et al. 2015). It has been suggested that 
macrophage derived, pro-inflammatory interleukins such as IL- 1β or IL-33 might be an initiator of tendinopathy 
(Mobasheri and Shakibaei 2013, Millar, Gilchrist et al. 2015) as is seen in osteoarthritis (Wojdasiewicz, Poniatowski et al. 
2014).  
 
Increased levels of pro-inflammatory interleukins (IL-1β, IL-1α and IL-6 ) have also been identified in RC tendon from 
patients with associated sub-acromial bursitis (Blaine, Cote et al. 2011) and within the subacromial bursa in patients with 
RC tears. (Voloshin, Gelinas et al. 2005). This involvement of the bursal tissue alongside a RC tear would support co-
treatment or systemic treatment to address the bursal reaction as well as the tendinopathy.   
 
Increased levels of systemic pro-inflammatory cytokines (IL-1β, IL6, IL8, IL10, VEGF, bFGF, agiogenin) have been observed in 
one study in the peripheral blood serum of individuals with RC tendinopathy compared to an age and gender matched 
control group (Savitskaya, Izaguirre et al. 2011). However the RC group had a higher BMI (1.4kgm2) which may have 
impacted on the levels of circulatory inflammatory cytokines as they have been shown to be raised with increasing 
adiposity (Harford, Reynolds et al. 2011).  
 
Modification of cytokine expression is an alluring prospect for possible treatment development but as yet has only been 
preliminarily investigated in the rodent model. The mechanical properties of healing tendon in IL-6 deficient mice were 
found to be inferior to normal mice (Lin, Cardenas et al. 2006). Also, TNFα blockade has been found to improve the 
strength of early (second and fourth but not eighth postoperative weeks) tendon to bone healing in rats (Gulotta, 
Kovacevic et al. 2011).  
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Summary 
In conclusion, whilst much is still being unravelled about the pathophysiology of RC tendinopathy there does appear to be 
evidence for an inflammatory component at the cellular and molecular level. The accumulation of inflammatory cells in 
human tendons (Gotoh, Hamada et al. 1997, Matthews, Hand et al. 2006, Millar, Hueber et al. 2010) and animal model 
(Andersson, Backman et al. 2011, Pingel, Wienecke et al. 2013) and increased levels of pro inflammatory cytokines in 
human tendinopathic RC tissue (Sakai, Fujita et al. 2001, Blaine, Kim et al. 2005, Voloshin, Gelinas et al. 2005) and in the 
animal models (Koshima, Kondo et al. 2007, Millar, Wei et al. 2009, Dohnert, Venancio et al. 2012, Legerlotz, Jones et al. 
2013) support this hypothesis. 
 
The pathophysiology of this common disorder is clearly multifactorial and treatment needs to be designed to address 
different aspects of the pathophysiology. Current treatment options do not achieve optimal outcomes, with one third of 
patients still presenting with pain and disability after intervention (Seitz, McClure et al. 2011). This thesis is designed to 
assist in the development of novel treatment options for RC tendinopathy.  
 
The next chapter will discuss the assessment of RC tendinopathy and the non-surgical treatment options which are of 
relevance to this thesis.  
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Chapter 3 : Rotator cuff tendinopathy. 
Assessment & non-surgical management: 
Review of the Literature 
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Clinical assessment and diagnosis of rotator cuff tendinopathy 
Rotator cuff (RC) tendinopathy is defined as pain and dysfunction of one or more of the deep tendons of the shoulder 
known as the rotator cuff (supraspinatus, infraspinatus, subscapularis and teres minor). It is characterised by pain, 
limitation of active range of motion of the shoulder joint and subsequent loss of function (Lewis 2009, Maffulli 2011). The 
term RC tendinopathy is a clinical classification and relates to the symptoms of pain and loss of function without reference 
to pathology (Lewis 2009).  
 
Clinical assessment involves a detailed and comprehensive subjective history (including the elimination of causation due to 
systemic health problems) followed by a combination of impairment measures such as range of movement, strength 
testing, postural assessment, palpation, special orthopaedic tests, and finally appropriate validated functional disability 
measurements or patient reported outcome measures (Litaker, Pioro et al. 2000). The clinical diagnosis of RC tendinopathy 
is based on common diagnostic criteria rather than one specific test. However, the presenting clinical features of RC 
tendinopathy are frequently inconsistent (Via, De Cupis et al. 2013). 
 
3.1.1 Subjective history  
The following are features of the subjective history suggestive of RC tendinopathy: 
 Symptom duration of more than three months (Littlewood, Ashton et al. 2012). 
 Antero-lateral shoulder pain (Gumina, Candela et al. 2014). 
 Intermittent shoulder ache (Shin 2011). 
 Night pain which can wake the patient from sleep (Litaker, Pioro et al. 2000). 
 Weakness and/or loss of shoulder function (especially activities involving hand behind back postures 
and overhead activities) (Shin 2011). 
 People older than 40 years (Burbank, Stevenson et al. 2008). 
 Functional limitations of the individual in activities relating to different positions of the upper limb 
(Longo, Berton et al. 2011). 
 
3.1.2 Objective assessment 
The following are features of the objective evaluation which support a diagnosis of RC tendinopathy: 
 Muscle weakness or atrophy of the RC muscles (Shin 2011). 
 Pain on palpation of the peri-articular soft tissue structures of the glenohumeral joint (Mattingly and 
Mackarey 1996). 
 Pain exacerbated through resisted movements, usually external rotation and abduction (Lasbleiz, Quintero 
et al. 2014). 
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3.1.2.1 Palpation 
Tendon palpation is used as part of the clinical examination of RC tendinopathy (Mattingly and Mackarey 1996, McShane, 
Graveley et al. 2004). The most effective positions to palpate the individual tendons of the RC was examined in 12 
cadavers, looking for the point at which the tendons were maximally exposed with the least amount of overlying soft tissue 
(Mattingly and Mackarey 1996). This study verified that the most effective position for palpating the supraspinatus tendon 
was that suggested by Cyriax (1993) (maximal shoulder adduction, medial rotation and elbow flexed to 90° in a hand 
behind back posture) (Cyriax and Cyriax 1993) but with added glenohumeral joint hyperextension. It was noted that in this 
position however it is difficult to differentiate between the long head of biceps and supraspinatus tendons. The palpation 
of supraspinatus as part of the assessment of a patient with shoulder pain was also supported by Toprak et al (2012), who 
examined 69 participants with unilateral shoulder pain of more than six months duration and with no deficit in range of 
motion and no history of surgery. The positions used to palpate the RC of tendons were not described, making translation 
of the findings problematic and not allowing comparison to be made with the findings of Mattingly and MacKarey (1996). 
Palpation of supraspinatus was found to have a higher level of sensitivity (92% [95% CI= 78-95]) than palpation of the other 
RC tendons and to be superior to both Neer’s and Hawkin’s Kennedy tests (Toprak, Ustuner et al. 2013). However the 
specificity of the supraspinatus palpation test was low (41% [95%CI= 18-64]). The reference standard used was 
ultrasonography. The appropriateness of ultrasonogrophy as a reference test is uncertain as RC tears have been identified 
in people without symptoms (Tempelhof, Rupp et al. 1999, Yamaguchi, Tetro et al. 2001). 
 
Similarly in a study investigating the clinical features of bursal side partial thickness RC tears 89.5% (34/38) of patients had 
tenderness of the greater tuberosity on palpation (Xiao, Cui et al. 2010). The position, pressure and method used to 
palpate the greater tuberosity in this study, however, were not detailed and the study was of poor methodological quality, 
with inadequate reporting.  
 
Uncertainty exists regarding of the sensitivity of palpation of the greater tuberosity in RC tendinopathy. However palpation 
is used clinically (Mattingly and Mackarey 1996, McShane, Graveley et al. 2004). Whilst palpation cannot confirm a 
diagnosis, pain on palpation of the great tuberosity assists in forming a clinical picture implicating the tendons of the RC, 
and as such palpation formed part of the inclusion criteria. 
 
3.1.2.2 Special orthopaedic tests 
Special orthopaedic tests aim to assist the diagnosis of RC tendinopathy by stressing potentially pathological structures in 
order to assess their integrity and function (Biederwolf 2013). They are often used clinically to differentiate between 
different structures (Biederwolf 2013). 
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There are 21 clinical tests for RC disorders described in the literature (Longo, Berton et al. 2011). These include; the full 
can, empty can or Jobe’s, Neer’s, Hawkins-Kennedy, drop arm, palpation of the supraspinatus, painful arc, resisted muscle 
tests, Gum-turn, drop-arm, lift-off, bear-hug, belly-press, belly off, Napoleon, drop sign, lag signs and  muscle atrophy. 
 
Several systematic reviews including one Cochrane review have been carried out examining the evidence to support 
diagnostic physical tests for the RC (Hughes, Taylor et al. 2008, Lewis 2009, Hegedus, Goode et al. 2012, Hanchard, Lenza et 
al. 2013, Hermans, Luime et al. 2013, Somerville, Willits et al. 2014). The overwhelming conclusion of these reviews in that 
there is no one specific test which is capable of differentially diagnosing RC tendinopathy due the tests lack of specificity in 
being able to test one tendon in isolation. Tests have also been described and named in inconsistent ways and with 
differing positive criteria thereby making it difficult to robustly compare tests (Longo, Berton et al. 2011). There is also 
great variation in how the tests are performed and interpreted, further complicating the analysis of the given tests 
(Hanchard, Lenza et al. 2013).  
A battery or collection of tests is recommended to improve the clinical accuracy of diagnosis of RC tendinopathy 
(Somerville, Willits et al. 2014) but their limited value in making a diagnosis of tendinopathy is acknowledged (Hegedus, 
Goode et al. 2012). When used in combination, if a negative result is obtained using the Neer, Hawkins-Kennedy and empty 
can tests it has been suggested that a diagnosis of RC tendinopathy can be excluded (van Zuydam, van Rensburg et al. 
2015). However, this is not a finding supported by the comprehensive meta-analysis conducted by Hegedus (2012). The 
low negative likelihood ratios of the Neer (0.47 [95 CI=0.39-0.56]) and Hawkins-Kennedy (0.46 [0.36-0.60]) make it unlikely 
that a diagnosis of RC tendinopathy could be ruled out if these were negative (Hegedus, Goode et al. 2012).  
 
Uncertainty exists regarding the usefulness of special orthopaedic tests in the diagnosis of RC tendinopathy to definitively 
confirm which RC tendon is associated with symptoms (Hegedus, Goode et al. 2012). However, these tests are used 
extensively both in clinical assessment (Hegedus, Goode et al. 2012, Biederwolf 2013) and research investigations (Haahr, 
Ostergaard et al. 2005, Ketola, Lehtinen et al. 2009, Ketola, Lehtinen et al. 2013) involving the RC. While these special 
orthopaedic tests (empty and full can, Neer’s impingement sign and Hawkins-Kennedy) cannot confirm a diagnosis with 
certainty, positive findings (pain and / or weakness) they help build a clinical picture that the symptoms are related to the 
RC tendons, and as such formed part of the inclusion criteria in the RCT.  
 
Problems in deriving a definitive diagnosis 
The main difficult in accurately diagnosing RC tendinopathy is that there is not a gold standard test which can be used as a 
comparative consistently within both clinical and research fields (Lewis 2009, Somerville, Bryant et al. 2013). Imaging is 
commonly used as a reference standard with which to compare clinical diagnostic tests (Longo, Berton et al. 2011). 
However, findings from both magnetic resonance (MRI) and ultrasound (US) images have proven to demonstrate a poor 
correlation with symptoms and function (Frost, Andersen et al. 1999, Worland, Lee et al. 2003). When comparing MRI 
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findings in an aged matched symptomatic sub acromial impingement syndrome group versus an asymptomatic group, 
Frost et al (1999) were unable to distinguish between the two groups based on the structural pathology. Furthermore, up 
to 40% of the general population and elite overhead athletes have asymptomatic RC tears (Tempelhof, Rupp et al. 1999, 
Connor, Banks et al. 2003, Worland, Lee et al. 2003, Yamamoto, Takagishi et al. 2010). This presence of full thickness tears 
in asymptomatic individuals further questions the applicability and usefulness of imaging (Frost, Andersen et al. 1999).  
 
Findings at surgery have been used as the ‘gold standard’ comparator test however there is a poor level of association 
between symptoms and structural compromise of the RC (Milgrom, Schaffler et al. 1995, Frost, Andersen et al. 1999, 
Tempelhof, Rupp et al. 1999) which questions the use of surgical structural findings as a valid reference (Lewis 2009, Lewis 
2011). 
 
Non-surgical Management of Rotator Cuff tendinopathy 
A wide range of non-surgical treatment options exist for RC tendinopathy. Exercise is increasingly regarded as the optimal 
treatment option for RC tendinopathy (Lewis, McCreesh et al. 2015) and will be discussed below. Other therapeutic 
approaches such as; electrotherapy, frictions massage and taping (Pegreffi, Paladini et al. 2011, Michaleff and Kamper 
2013, Shakeri, Keshavarz et al. 2013, Gebremariam, Hay et al. 2014, Osborne, Gowda et al. 2015), pharmacological 
approaches and invasive procedures, such as; injections, acupuncture and surgery, are outside the scope of this thesis, but 
have been discussed elsewhere (Settergren 2013, Toliopoulos, Desmeules et al. 2014, Balasubramaniam, Dissanayake et al. 
2015, Louwerens, Veltman et al. 2015).  
 
3.1.3 Exercise and rotator cuff tendinopathy 
Exercise therapy is the main treatment offered by physiotherapists in the management of RC tendinopathy. A number of 
studies have demonstrated a clear and beneficial effect of a graded and structured exercise programme for patients 
diagnosed with this condition (Bang and Deyle 2000, Haahr and Andersen 2006, Kuhn 2009, Kukkonen, Joukainen et al. 
2014, Littlewood, Malliaras et al. 2014, Littlewood, Bateman et al. 2016). Graded and structured exercise therapy has been 
demonstrated to have an equivalent effect to both injection therapy and surgery for this condition in the short and long 
term (one to eight years) (Haahr, Ostergaard et al. 2005, Haahr and Andersen 2006, Ketola, Lehtinen et al. 2009, Ketola, 
Lehtinen et al. 2013). The requirement for surgery has also been shown to be significantly reduced following a graduated 
and structured exercise programme (Holmgren, Bjornsson Hallgren et al. 2012, Kuhn, Dunn et al. 2013). The benefits of 
exercise are wide reaching with improved general health and, when compared to surgery, a reduction in the economic and 
financial burden of surgery (Lewis 2011, Tashjian 2013, Toliopoulos, Desmeules et al. 2014, Lewis, McCreesh et al. 2015). 
Surgery also carries risks of post-operative infection and complications (Moosmayer, Lund et al. 2010). A Cochrane review 
examining surgery for RC tendinopathy published in 2008 concluded that no recommendations could be made regarding 
the efficacy or the safety of surgery for RC disease (Coghlan, Buchbinder et al. 2008). 
43 
 
 
Exercise is an overarching term and includes a variety of interventions including strengthening exercises, eccentric, 
concentric, weight bearing, non-weight bearing, proprioception exercises, flexibility and stretching or range of motion 
exercises (Kuhn 2009). Various rehabilitation protocols have been advocated by various authors with little consensus 
within the literature regarding the optimal rehabilitation protocol. 
 
3.1.3.1 What is the most appropriate type of exercise intervention? 
The marked heterogeneity of approaches and types of exercise intervention within the literature makes comparison 
difficult and the recommendation of one programme or method challenging (Hanratty, McVeigh et al. 2012, Gebremariam, 
Hay et al. 2014). However the unifying objectives of exercise therapy are; reduction of pain, restoration of function and 
range of motion, guide the clinical prescription of exercise for RC tendinopathy.  
 
A recent systematic review examined the evidence for loaded exercise (exercise against gravity or resistance) in the 
treatment of RC tendinopathy (Littlewood, Ashton et al. 2012). Only four studies met the inclusion criteria, one of which 
investigated a non-clinical population (Ludewig and Borstad 2003). The exercise programmes were applied in different 
ways, from home exercise to supervised exercise with a physiotherapist, making a definitive comparison difficult. Two of 
the studies included in that review used a no intervention group as their control group (Ludewig and Borstad 2003, 
Lombardi, Magri et al. 2008). Without any intervention and no interaction with a therapist the confounding factor of the 
potentially beneficial patient-therapist relationship is then not controlled for (Littlewood, Ashton et al. 2012). However the 
results suggest that both supervised and home exercise programmes consisting of loaded exercises might be more 
effective than no intervention or placebo. 
 
Two studies have investigated the effects of isometric elbow flexion contractions in healthy individuals and concluded that 
post contractions the pressure pain ratings were decreased and pain threshold was increased (Hoeger Bement, Dicapo et 
al. 2008, Lemley, Drewek et al. 2014). Due to the lack of an alternative exercise group in either study it is hard to draw 
conclusions about the reduction in pain being as a result of isometric exercise specifically or exercise in general.   
Evidence exists that glenohumeral external and internal rotations have opposing effects on subacromial pressure (Werner, 
Blumenthal et al. 2006), with external rotation lowering pressure. Additionally, exercises to depress the humeral head may 
also be warranted (Lewis 2009). 
 
In their pilot and later well-designed RCT, Littlewood et al (2014 and 2015) demonstrated that one exercise had equivalent 
effects on function and pain to usual physiotherapy (a range of interventions including advice, stretching, exercise, manual 
therapy, massage, strapping, acupuncture, electrotherapy and corticosteroid injection) as measured by the Shoulder Pain 
and Disability Index (SPADI) at three, six and twelve months. These findings indicate that one appropriately targeted 
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exercise might provide as much benefit and less burden than several exercises targeting the same structure. This is 
particularly interesting in the clinical context where exercise adherence is frequently poor (Vermeire, Hearnshaw et al. 
2001, Hayden, van Tulder et al. 2005) and any strategy to simplify an exercise programme to make it more achievable is 
welcomed. 
 
3.1.3.2 Individual or group exercise? 
No evidence or guidance could be found pertaining to the relative efficacy of group exercise versus individualised exercise 
or one to one treatment in RC tendinopathy. Evidence does exist within the field of low back pain (LBP) suggesting that 
group exercise is as beneficial as individual treatment in LBP population (Lewis, Hewitt et al. 2005, Kaapa, Frantsi et al. 
2006). There are reduced health care costs associated with group exercise when compared to individual treatment (Lewis, 
Hewitt et al. 2005). 
 
3.1.3.3 Supervised or self-managed programme? 
The findings reported by Littlewood et al (2014 & 2015) also indicate that a self-management programme might be as 
effective as one to one individualised physiotherapy treatment (Littlewood, Malliaras et al. 2014, Littlewood, Bateman et 
al. 2016). However, there was no statistically significant reduction in the total number of treatment sessions in the self-
managed group when compared to the usual physiotherapy group (Littlewood et al 2015). Whilst not observed in the study 
by Littlewood, a self-management programme, hypothetically has the potential of being less burdensome in terms of time 
and healthcare costs.  
 
3.1.3.4 Is the additional of manual therapy to exercise beneficial in the treatment of rotator cuff tendinopathy?  
Manual therapy is defined by the American Academy of Orthopaedic Manual physical Therapists as; 
“Any ‘hands-on’ treatment provided by the physical therapist. Treatment may include moving joints in specific directions 
and at different speeds to regain movement (joint mobilisation and manipulation), muscle stretching, passive movements 
of the affected body part, or having the patient move the body part against the therapist’s resistance to improve muscle 
activation and timing. Selected specific soft tissue techniques may also be used to improve the mobility and function of 
tissue and muscles” (AAOMPT 2008) pg8. 
 
The addition of manual therapy to exercise for RC tendinopathy has been the subject of several systematic reviews 
(Desmeules, Cote et al. 2003, Camarinos and Marinko 2009, Ho, Sole et al. 2009, Braun, Bularczyk et al. 2013). The 
conclusion of these reviews are equivocal. Ho et al (2009) concluded that manual therapy did not confer any additional 
benefit over other interventions. The other three systematic reviews (Desmeules, Cote et al. 2003, Braun, Bularczyk et al. 
2013) concluded that there is a trend exists suggesting that manual therapy combined with exercise improves pain in 
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individuals with RC tendinopathy. The differences between the conclusions of the systematic reviews is likely to be due to 
the inclusion of a no benefit trial (Çitaker, Taşkiran et al. 2005) and the qualitative analysis using levels of evidence to 
define treatment effectiveness in the review by Ho et al (2009).  
 
The studies included in the reviews vary in their methodological quality. The lack of blinded assessors (Conroy and Hayes 
1998, Bang and Deyle 2000, Çitaker, Taşkiran et al. 2005) or subjects (Bang and Deyle 2000, Çitaker, Taşkiran et al. 2005) 
(although this is difficult in manual therapy trials) and the lack of concealed allocation (Conroy and Hayes 1998, Bang and 
Deyle 2000, Çitaker, Taşkiran et al. 2005) introduces a high risk of bias. This makes affirmative conclusions difficult to draw. 
All the reviews agree, with the current evidence from the studies investigating manual therapy in RC tendinopathy, the 
heterogeneity of the populations studied, of the interventions and of the outcomes measures used within the trials, again 
making the drawing of definite conclusions difficult.  
 
The most recent review was conducted as a meta-analysis and included 21 studies (Desjardins-Charbonneau, Roy et al. 
2015). A statistically significant decrease in pain (mean difference, 1.0; 95% confidence interval: 0.7, 1.4), as reported on a 
10-cm visual analog scale, was observed when manual therapy was given in addition to an exercise programme (n=226). 
Whether this 1 point difference represents a meaningful difference is debatable  as the minimal clinically important 
difference (MCID) of the 10 point VAS pain scale is 1.4cm (Tashjian, Deloach et al. 2009). The authors of the meta-analysis 
comment, due to the 1cm mean difference being within the 95% confidence interval, it is possible that manual therapy 
might have a clinically meaningful effect. 
 
In a trial involving 120 people diagnosed with RC tendinopathy of more than three months duration, 59 received manual 
therapy and a home exercise programme and 61 received sham ultrasound over a period of 10 weeks. (Bennell, Wee et al. 
2010). The combined exercise and manual therapy group achieved significantly improved scores on the SPADI, but only at 
22 weeks (the end assessment point) and not at the primary outcome point of 11 weeks. This suggests that any assessment 
of physiotherapy intervention should be assessed over the longer term. 
 
The type of manual therapy in the reported studies varies and included; mobilisations with movement (MWMs), end of 
range mobilisations, manual muscle techniques and manipulations. No consensus has been reached on the optimal 
methods. There is some evidence from a randomised controlled trial (RCT) (Delgado-Gil, Prado-Robles et al. 2015) just 
published that mobilisations with movement (MWMs) over a period of four sessions improves pain related to movement. 
This was a well-conducted trial, which builds on previous studies that have used MWMs for the treatment of RC 
tendinopathy (Ho, Sole et al. 2009, Djordjevic, Vukicevic et al. 2012).  
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3.1.3.5 What is the optimal duration of treatment? 
The optimal duration of exercise treatment is unknown. Since the durations of exercise within existing studies differ, any 
recommendation of an optimal time frame would be problematic (Hanratty, McVeigh et al. 2012, Gebremariam, Hay et al. 
2014). However taking those studies which have shown positive outcomes from exercise treatment for RC tendinopathy 
(Bang and Deyle 2000, Haahr and Andersen 2006, Ketola, Lehtinen et al. 2009, Kuhn 2009, Ketola, Lehtinen et al. 2013, 
Kukkonen, Joukainen et al. 2014, Littlewood, Malliaras et al. 2014, Littlewood, Bateman et al. 2016) the range of treatment 
sessions was between four and 19. The median number of sessions was 8.5 [inter quartile range= 6.25-16]. 
 
3.1.3.6 Summary  
Whilst exercise provides the basis for treatment for RC tendinopathy the optimal exercise intervention, duration and mode 
of administration remains unclear. Exercise commonly results in a reduction in pain and concomitant increase in function 
but the gains are modest, with the improvements post treatment often just over the threshold of MCID values for the 
outcomes used (Littlewood, Bateman et al. 2016). Methods to enhance the gains made with exercise would be a valuable 
way to assist those with RC tendinopathy further. 
  
Dietary intervention and rotator cuff tendinopathy 
Consideration of the causative factors of rotator cuff tendinopathy (Chapter 2) highlights the potential role that lifestyle 
has to play in the development of this common condition. The role of diet is a relatively new consideration in the 
treatment of tendinopathies, but its inclusion may be important in the holistic and comprehensive management of 
patients. 
 
Habitual diet appears to have an influence on chronic low grade systemic inflammation (Galland 2010). Current evidence 
suggests that following a Mediterranean diet (rich in fruit, vegetables, nuts, olive oil and whole grains)(Esposito, Marfella et 
al. 2004, Centritto, Iacoviello et al. 2009) and consuming long-chain omega-3 polyunstaurated fatty acids (PUFAs) (Lennie, 
Chung et al. 2005, Clarke, Shipley et al. 2009, Riediger, Othman et al. 2009) and monounsaturated fatty acids (MUFAs) 
(Basu, Devaraj et al. 2006, Devaraj, Kasim-Karakas et al. 2006, van Dijk, Feskens et al. 2009) is associated with reduced 
levels of inflammatory markers in serum. Conversely, a diet high in saturated fatty acids (Arya, Isharwal et al. 2006, 
Margioris 2009), trans fatty acids (Mozaffarian, Katan et al. 2006, Mozaffarian, Aro et al. 2009), and a high omega-
6:omega-3 PUFA ratio (Guebre-Egziabher, Rabasa-Lhoret et al. 2008, Olsen, Fenton et al. 2013) from food is associated 
with increased levels of inflammatory markers.  
 
Inflammatory processes are known to induce oxidative stress (excessive production of free radicals or reactive oxygen 
species) and reduce cellular antioxidant defence (Khansari, Shakiba et al. 2009). One way in which diet appears to influence 
tendinopathy is as a result of oxidative stress. Radak et al (2002) reported that mature rats fed a restricted diet (resulting in 
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a relative reduction of free radicals) demonstrated significantly less tendon degeneration in comparison to rats fed a 
normal diet (Radak, Takahashi et al. 2002).  
 
3.1.4 Review of previous PUFA dietary interventions in tendinopathies 
To date two studies have investigated the effects of a combined long-chain omega-3, omega-6 PUFA and antioxidant 
supplement compared to a placebo tablet with differing conclusions. 
 
Mavrogenis et al. (2004) investigated the use of long-chain omega-3 PUFAs and antioxidants in the treatment of tendon 
disorders in athletes. In this double-blinded study, 40 recreational athletes with a variety of tendon pathologies were 
randomized to placebo tablets and 16 treatments of ultrasound, or tablets containing essential fatty acids (long-chain 
omega-3 PUFAs and omega-6 GLA fatty acids) and antioxidants and 16 treatments of ultrasound. After 32 days there was a 
mean decrease in pain score in 99% of the treatment group and 31% of the control group. Although confidence intervals 
were not reported, the difference in pain levels was statistically significant (P<0.001) in favour of the experimental group. 
There was an approximate five-point reduction (on a ten-point scale) in pain (SD approximate 1.0) in the experimental 
group at one month, and an approximate two-point reduction (SD approximate 1.5) in the placebo group. This study 
provided a valuable insight into the potential of these compounds in the management of tendon pathology but was at high 
risk of bias. In this study, 20 subjects were randomized to each group (40 in total), nine subjects were lost to follow-up 
(three in treatment group and six in placebo group), and final follow-up (subjective pain scores and estimated levels of 
sports activity) occurred at 32 days. The study group comprised tendon pathologies from different regions of the body 
including the shoulder, elbow, and knee. There were 12 subjects with a tendon pathology of the shoulder. Ten were 
diagnosed as having supraspinatus tendinopathy (five per group) and two as having infraspinatus tendinopathy (both in the 
experimental group). In general, the regional tendon pathologies were not equally distributed between the two groups. No 
adverse effects were reported by any of the participants in this study. Data analysis was not conducted by an intention-to-
treat analysis and non-compliers were excluded from data analysis. Nine subjects were excluded from the analysis due to 
non-adherence (defined as failure to document test medication taken or training activity carried out in their diary) or 
‘protocol violation’. 
 
The authors recommend that additional studies are needed to verify their findings further. Additionally, it is not known 
whether the benefit in the experimental group was due to the individually active substances alone, or to being combined 
with ultrasound therapy. It is also not known from this study whether the long-chain omega-3 PUFA, or the antioxidants or 
the combination of both active substances were responsible for the beneficial effect. 
 
Roe et al (2005) investigated the efficacy of the same supplement from the same manufacturer at the same dose (although 
not for the same duration) as used by Mavrogenis group but in lateral epicondylitis. This was a double-blinded study with 
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concealed allocation of 60 participants (55 completed) with lateral epicondyilitis. The participants were randomised to 
placebo (unspecified contents other than not containing vitamins or essential fatty acids) or tablets containing the essential 
fatty acids (omega 3 PUFAs and omega 6 GLA) and antioxidant tablet for eight weeks. Both groups also received eight 
sessions of trigger point therapy (one per week) and a structured and graded home exercise programme of eccentric 
exercises, lasting for the whole study period (24 weeks). There were no statistically significant between group differences 
observed in pain reduction levels at any of the time points (p=0.16 at eight weeks and p=0.76 at 24 weeks). There was a 
clinically meaningful mean reduction in pain in both groups on a 10cm VAS scale within both groups of 3cm (95%CI=2.5-4) 
at eight weeks which continued to reduce up to 24 weeks. Maximum grip and pain free grip were statistically significantly 
higher in the treatment group at baseline but no between group differences we observed at follow up (at eight, 12 or 24 
weeks). A within group change from the baseline in grip strength was only observed at 12 and 24 weeks, not at eight. In 
this study, 30 subjects were randomised to each group (60 in total), five subjects were lost to follow up and it is not 
reported to which treatment groups they were allocated. Analysis was on a complete case basis and not on an intention to 
treat principal, and the final follow up was at six months. There was a large variation in the duration of symptoms with 
those in the treatment group (18 months; SD=22 months) having a mean duration of symptoms twice as long as those in 
the placebo group (8 months; SD=4 months). The longer duration of symptoms in the treatment group is likely to be 
accompanied with a poorer prognosis (Feng, Guo et al. 2003). With such inequality in duration of symptoms at the start of 
treatment between groups it is not possible to draw definitive conclusions from this study.  
 
Conclusions  
The diagnosis of RC tendinopathy is commonly made on the basis of a clinical assessment. It is difficult to make a definitive 
diagnosis due to the poor level of association between symptoms and structural compromise of the RC on imaging 
(Milgrom, Schaffler et al. 1995, Frost, Andersen et al. 1999).  
 
Exercise is the mainstay of treatment but affords limited gains (Littlewood, Bateman et al. 2016). Supplementation with 
long-chain omega-3 PUFAs and antioxidants has been suggested as a possible adjunct to treatment for tendinopathies but 
existing evidence has reached equivocal findings (Roe, Brox et al. 2000, Mavrogenis, Johannessen et al. 2004). 
 
It is feasible that a novel approach to RC tendinopathy management, a long-chainomega-3 PUFA supplement, promoting 
resolution to inflammatory processes, may positively influence biochemical mechanisms proposed to underpin RC 
tendinopathy. The following section will discuss long-chain omega-3 PUFAs and how they may positively influence RC 
tendinopathy. 
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Chapter 4 : The role of polyunsaturated fatty 
acids & their potential to influence rotator cuff 
tendinopathy: Review of the literature 
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Introduction 
In order to consider the mechanisms underpinning a potential association between long-chain omega-3 polyunsaturated 
fatty acids (PUFA) and rotator cuff (RC) tendinopathy it is necessary to understand the potential mechanisms that PUFAs 
might impact upon the pathophysiology of RC tendinopathy discussed in the preceding chapters. The section that follows 
provides background information regarding the history of PUFAs, their chemical family and sources. Their anti-
inflammatory mechanism will be discussed as well as the potential role for their use in the treatment of RC tendinopathy. 
 
Dietary fat consists mainly of triacylglycerols which have three fatty acids esterified onto the glycerol backbone(Sanders 
2016). There are three main classes of fatty acids: saturated, monounsaturated and polyunsaturated fatty acids (Figure 
4.1). Saturated fatty acids are generally straight chain aliphatic hydrocarbon molecules (typically 2-22 carbon atoms long) 
with a carboxyl group at one end and a methyl group at the other end with each carbon linked by single bonds (Shahidi 
2006). As chain length of the saturated fatty acid increases so does the melting point, such that the major dietary saturated 
fatty acids, palmitic (16:0) and stearic (18:0) acids, are solid at room temperature (Shahidi 2006). Monounsaturated fatty 
acids are fatty acids containing a single double bond usually 9- carbon atoms from the terminal methyl group (Insel, Turner 
et al. 2006). The double bonds are normally in the cis-configuration (where the hydrogen atoms adjacent to the double 
bond are on the same side) this puts a kink in the molecule which has the effect of reducing the melting point such that 
oleic acid (18:1n-9) has a melting point around 14C° compared with stearic acid which has a melting point of 69 C° 
(Edelstein 2013). Polyunsaturated fatty acids have two or more double bonds in the molecule and even lower melting 
points (Sanders 2016).  
Figure 4.1 Types of fatty acid 
 
Taken from Sanders TAB (1994) Dietary fats: a briefing paper prepared for the Health Education Authority (with permission) (Sanders 
and Health Education 1994). 
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The major dietary polyunsaturated fatty acids are linoleic and linolenic acid and are of plant origin (Sanders 2016). These 
polyunsaturated fatty acids unlike saturated and monounsaturated fatty acids cannot be synthesis de novo in the body and 
some are regarded as essential nutrients (Das 2006). This is because mammals lack the necessary enzyme to insert a double 
bond beyond the seven carbon from the terminal methyl group (Nakamura and Nara 2004). Linoleic acid (18:2n-6) was first 
discovered to be an essential nutrient and its major metabolite arachidonic acid was shown to be more potent than linoleic 
at preventing the essential fatty acids deficiency syndrome (Le, Meisel et al. 2009). In the 1960’s and 1970’s metabolites of 
arachidonic acid, such as prostaglandins and leukotrienes, were shown to be important signalling molecules involved in the 
regulation of many physiological functions including inflammation (Funk 2001). PUFAs derived from linoleic acid and its 
metabolites regulate a broad range of bodily functions including blood clotting, blood pressure, development and 
functioning of the brain and nervous system. The term eicosanoid is now used to describe oxygenated metabolites derived 
from 20 carbon polyunsaturated fatty acids (Agarwal, Reddy et al. 2009). For many years alpha linolenic acid (18:3n-3) was 
regarded as partially essential owing to its ability to correct some but not all of the signs of essential fatty acid deficiency in 
animals. However, its metabolite docosahexaenoic acid (22:6n-3; DHA), is a major component of the lipid in membranes of 
the retina and brain and its replacement by the corresponding metabolite, docosapentaenoic acid (22:5n-6), results in 
impairment in visual function and learning ability (WHO/FAO 2010). Although DHA can be synthesised from linolenic acid, 
its rate of synthesis may be insufficient in the preterm infant and so needs to be supplied in the diet (Lapillonne and Jensen 
2009). 
 
Fish oil is unusual in that it contains high amounts of eicosapentaenoic (20:5n-3; EPA) and docosahexaenoic (22:6n-3; DHA) 
acids. The fatty acids originate from algae and plankton in the marine food chain and accumulate in marine life up the food 
chain. The consumption of fish oil containing EPA and DHA, which are often referred to as long-chain long-chain omega-3 
fatty acids, exerts a number of pharmacological properties including potentially an anti-inflammatory effect. Some of these 
effects are thought to result from competition with metabolites from linoleic acid (the omega-6 fatty acids). Linolenic acid 
found in vegetable oils such as rapeseed and soybean oil can be converted to EPA and DHA (Figure 4.2) albeit slowly 
(Brenna 2002, Burdge and Calder 2005). However, the consumption of linolenic acid does not appear to have the same 
anti-inflammatory effects as the preformed EPA and DHA (Calder 2006).  
 
Long-chain omega 3 and Omega 6 PUFAs constitute important structural parts of phospholipid cell membranes which have 
vital and varied physiological functions (Simopoulos 1999, Burdge and Calder 2005). The makeup of phospholipid cell 
membranes influences permeability to other molecules or membrane fluidity to assure the correct environment for 
membrane protein function and lipid raft formation (Yaqoob 2009). Lipid rafts are regions of the phospholipid cell 
membranes which serve to co-locate proteins involved in intra-cellular signalling (Calder and Yaqoob 2007). Subsequently 
PUFAs affect the behaviour of membrane bound enzymes, receptors and signal transduction(Wall, Ross et al. 2010). 
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Importantly in the treatment of RC tendinopathy, PUFAs are also believed to play a role in regulating the inflammatory 
response (Calder 2006, Das 2006). 
 
Omega-3 PUFAs (also known as n-3 PUFA or ω-3 PUFA) have the first double bond at carbon number 3 counting from the 
methyl end. The major omega-3 PUFAs in the diet are: 
1. Alpha-linolenic acid (18:3n-3; ALA )  
2. Docosahexaenoic acid (22:6n-3; DHA) 
3. Eicosapentaenoic acid (20:5n-3; EPA) 
 
Omega-6 PUFAs (also known as n-6 or ω-6 PUFA) have the first double bond at carbon number 6 counting from the methyl 
end. The major n-6 PUFAs in the diet are: 
1. Linolenic acid (18:2n-6; LA) 
2. Gamma-linolenic acid (18:3n-6; GLA) 
3. Dihomo-gamma linolenic acid (20:3n-6; DHLA)  
4. Arachidonic acid (20:4n-6; ARA) 
 
There is competition between the omega-6 and omega-3 series of fatty acids both for conversion to longer chain 
metabolites but also in the synthesis of eicosanoids. Generally, the eicosanoids formed from arachidonic acid are 
biologically active and those from EPA are inactive. However, more recently, novel metabolites called neuroprotectins and 
resolvins have been identified which may have anti-inflammatory effects (Serhan, Chiang et al. 2008). 
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Figure 4.2 The essential fatty acids and their metabolites. 
 
 
Legend: Δ6D, Δ6 desaturase; Δ5D, Δ5 desaturase; COX, cylco-oxygenase; 5-LOX, 5-lipoyxygenase; PG, prostaglandins. 
Taken from Sanders TAB (2015) Functional Dietary Lipids, Woodhead Publishing, Kidlington (with permission).  
 
The intake of longchain omega-3 fatty acids is derived mainly from the consumption of oily fish and fish oil supplements. 
Intakes are negligible in some groups such as vegetarians (Sanders 2014). The United Kingdom (UK) government 
recommends an intake of two portions of fish a week, one of which should be oily, which would supply approximately 
0.45g of longchain omega-3 fatty acids. The intakes of long-chain omega-3 fatty acids from food are typically less than 0.1 
g/d. The National Diet and Nutrition Survey (NDNS) results from years 1-4 (combined) of the rolling programme 
(2008/2009-2011/2012) found that in all age groups the mean intake of oily fish was well below the weekly recommended 
levels (one portion, 140g/week). In adults aged between 19 and 64 years the mean consumption was found to be 54g per 
week (men consuming 52g and women 54g) and in the over 65 age groups the mean weekly consumption of oily fish was 
found to be 90g (103g for men and 81g for women) (Public Health Engand 2014). However, a significant proportion of the 
middle-aged and older population reported taking fish oil supplements. Typically commercially purchased fish oils contain 
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approximately 30-35% long-chain omega 3s, thereby a 1g fish oil capsule would contain 300mg of omega 3 PUFA (Jacobson 
2008).  
 
Anti-inflammatory properties of n-3 PUFA and mechanisms of action 
PUFAs are believed to influence inflammation via a number of different mechanisms, including; 
 PUFA derived eicosanoids (prostaglandins, leukotrienes, resolvins, protectins). 
 Down regulated expression of inflammatory cytokine genes- NFκB pathway (Calder 2015).  
 
4.1.1 PUFA derived eicosanoids 
Eicosanoids are pivotal mediators and regulators of the inflammatory response and are derived from 20-carbon PUFAs, 
largely ARA and EPA (Funk 2001, Tilley, Coffman et al. 2001, Miles and Calder 2012). They include prostaglandins, 
thromboxanes, leukotrines and hydroxyeicosatet-raenoic acids (Funk 2001). These signalling molecules modulate the 
intensity and duration of the inflammatory response (Lewis, Austen et al. 1990, Tilley, Coffman et al. 2001). The overall 
physiological outcome is dependent on the timing of the eicosanoid production, the type of cells present, the nature of 
inflammatory stimulus and the levels of eicosanoids synthesised (Calder 2008). The phospholipids of neutrophils, 
lymphoctyes and monocytes in those consuming a typical western diet contain 10-20% of ARA, 0.5-1& EPA and 2-4% DHA 
(Caughey, Mantzioris et al. 1996, Healy, Wallace et al. 2000, Yaqoob, Pala et al. 2000, Kew, Mesa et al. 2004, Rees, Miles et 
al. 2006). This represents a proportionally high level of ARA in the phospholipid membrane and subsequently ARA becomes 
the major substrate for eicosanoid synthesis (Calder 2001, Simopoulos 2002). Metabolism of ARA by COX results in the 
inflammatory 2-series prostaglandins (PG) and the 2 series thromboxanes (Tilley, Coffman et al. 2001, Bagga, Wang et al. 
2003). Monocytes and macrophages produce prostaglandin E2 (PGE₂) and mast cells produce prostaglandin D2 (PGD₂) 
(Kang and Weylandt 2008). Metabolism of ARA by the 5-lipoxygenase (5-LOX) enzyme results in hydroxyl and hydroperoxy 
derivatives and the 4-series leukotrienes (LT) (Haeggstrom and Funk 2011). With neutrophils, monocytes and macrophages 
producing leukotriene B4 (LTB₄) (Sperling 1998) and mast cells, basophils and eosinophils producing leukotriene C4 (LTC₄), 
leukotriene D4 (LTD₄) and leukotriene E4 (LTE₄). In general the eicosanoids synthesised from ARA, via cyclooxygenase (COX) 
and lipoxygenase (LOX) enzymes, are largely ascribed to being pro inflammatory (Bagga, Wang et al. 2003). For example 
LTB₄ leads to the production of inflammatory cytokines such as tumour necrosis factor alpha (TNFα), interleukin-1beta (IL-
1β) and interleukin-6 (IL-6) by macrophages (Tilley, Coffman et al. 2001). The generalisation of all ARA derived eicosanoids 
being pro inflammatory is recognised as being an over simplification (as Lipoxin A₄ is anti-inflammatory and PGE₂ is known 
to have both pro and anti-inflammatory effects). However, in excessive concentrations they can contribute to the 
development of inflammatory disorders (Calder 2009); for example, a common characteristic of rheumatoid arthritis is the 
excessive production of ARA synthesised eicosanoids (Miles and Calder 2012).  
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Significant decreases have been observed in the production of PGE₂ and 4 series LT production by human inflammatory 
cells following supplementation with fish oils over a period of weeks (Caughey, Mantzioris et al. 1996, von Schacky 2004, 
Rees, Miles et al. 2006). 
 
EPA also acts as a substrate for COX and LOX enzymes but results in the 3-series PGs and TXs (rather than the 2 series), the 
5 series LTs, and the hydroxyl-EPAs eicosanoids (Kang and Weylandt 2008). The eicosanoids derived from EPA are 
considered to be less inflammatory or even anti-inflammatory and less biologically active, when compared to eicosanoids 
synthesised from ARA (Bagga, Wang et al. 2003). A clear demonstration of the difference in potency of inflammatory 
properties of ecosanoids produced from ARA versus EPA can be seen in the action of LTB₄ versus LTB₅. EPA derived LTB₅ is 
10-100 times less powerful as a neutrophil chemotactic agent than ARA derived LTB₄ and therefore much less inflammatory 
(Goldman, Pickett et al. 1983, Lee, Mencia-Huerta et al. 1984). 
 
There are two predominant COX isoforms; COX 1 (which is synthesised at a constant rate regardless of the physiological 
demand or the concentration of substrate) and COX 2 (whose synthesis is increased in response to an inflammatory 
stimulus (Miles and Calder 2012). In the rabbit model of RC tendinopathy COX-2 expression was found to be stimulated by 
IL-1β within the torn tendon but also within the articular chondrocytes (Koshima, Kondo et al. 2007). Within humans, 
Volshin et al (2005) reported that at the time of surgery in  10 individuals with RC tears there was a significant increase in 
COX 1 and COX 2 in those with RC tears, although this was also observed to a lesser extent in the control group all be it to a 
lesser extent. However the control group was undergoing shoulder surgery for other shoulder conditions, including; 
shoulder instability (n = 7) and fracture of the proximal humerus (n = 1) and so raises the question as to whether this was a 
true control group. Eicosanoids produced by both the COX and LOX pathways (including PGE2, leukocytes such as 
neutrophils and monocytes have been found within the tendon and bursal tissue of individuals with RC tendinopathy 
(Matthews, Hand et al. 2006). 
 
Non-steroidal anti-inflammatory (NSAIDs) medications are widely used in the management of RC tendinopathy due to their 
dual effect of anti-inflammatory and analgesic properties.(Pegreffi, Paladini et al. 2011). Their use of NSAIDs in RC 
tendinopathy has been subject to a recent systematic review and meta-analysis (Boudreault, Desmeules et al. 2014). 
Nineteen trials were reviewed and the authors concluded that in the short term (four weeks) NSAIDs are effective at 
reducing pain in individuals with RC tendinopathy (Boudreault, Desmeules et al. 2014). NSAIDs were found also to be as 
effective as corticosteroid injections in the management of pain and reduced function in the short term (Boudreault, 
Desmeules et al. 2014). NSAIDs are COX inhibitors and their efficacy in RC tendinopathy lends weight to the argument that 
the COX pathway has an important role to play in the pathogenesis of the condition.  
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Summary 
With longchain omega-3 PUFA supplementation the availability of ARA for metabolism is reduced as EPA and DHA displace 
it from membrane phospholipids. This results in fewer inflammatory eicosanoids being produced due in part to the reduced 
bioavailability of ARA as a substrate. The potential role for the use of long-chain omega-3 PUFA in the treatment of RC 
tendinopathy is an alluring one and the reduction in inflammatory eicosanoids being produced may in part explain its 
biological plausibility. 
 
4.1.2 Resolvins and protectins 
Resolvins (resolution phase interaction products) are potent anti-inflammatory lipid mediators derived directly from EPA 
and DHA via COX and LOX pathways (Serhan, Hong et al. 2002, Hong, Gronert et al. 2003). EPA is the substrate for E series 
resolvins and DHA is the substrate for D series resolvins. DHA gives rise to protectins which are similar molecules to 
resolvins. Resolvins and protectins have been shown to have strong anti-inflammatory and immunoregulatory potential, 
through the removal of leukocytes and cellular debris (Serhan, Hong et al. 2002, Schwab, Chiang et al. 2007, Serhan, Lu et 
al. 2007). They have been shown to reduce neutrophil infiltration at sites of inflammation (Serhan, Hong et al. 2002) and 
regulate and inhibit leukocytes and cytokines thereby decreasing the magnitude of the inflammatory response and possibly 
aiding its resolution (Serhan, Clish et al. 2000, Janakiram and Rao 2009). For example, resolvin D1 has been shown to inhibit 
IL-1β and protectin D1 inhibits TNF-α and IL-1β (Serhan, Chiang et al. 2008). 
 
The understanding of the physiology of the resolution to inflammation is still evolving and there is little human research on 
resolvins or protectins (Miles and Calder 2012, Dakin, Dudhia et al. 2013). The ability to augment or support the resolving 
processes through the supplementation with EPA and DHA would be very appealing and therapeutically valuable if proven 
to be effective.  
 
4.1.3 Down regulated expression of inflammatory cytokine genes: NFκβ pathway  
Long-chain omega-3 PUFAs also have the potential to affect inflammation though altered inflammatory gene expression, 
largely via the nuclear factor kappa-light-chain-enhancer of activated B-cells (NFκβ) pathway (Calder 2006). NFκβ is the 
primary transcription factor involved in inflammatory signalling pathways (Kumar, Takada et al. 2004, Sigal 2006). It 
regulates numerous cytokines (including IL-1, IL-2, IL-6, IL-12, TNFα), chemokines (including IL-8 and monocyte chemo 
attractant protein-1), adhesion molecules, E-selectin, inducible nitric oxide synthase (iNOS) and COX-2 (Ghosh and Karin 
2002). Several substances and molecules induce NFκβ activity including ROS, TNFα, IL-1β and bacterial lipopolysaccharides 
(LPS), cocaine and ionising radiation (Renard, Zachary et al. 1997, Chandel, Trzyna et al. 2000, Hargrave, Tiangco et al. 2003, 
Qin, Wilson et al. 2005, Fitzgerald, Meade et al. 2007). 
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EPA has been demonstrated to block NFκβ activity through the reduced degradation of the inhibitory sub unit of NFκβ, Iκβ 
in cultured pancreatic cells and human monocytes (Lo, Chiu et al. 1999, Novak, Babcock et al. 2003, Zhao, Joshi-Barve et al. 
2004).  
 
This is in concordance with the finding that transgenic mice (who endogenously biosynthesise omega-3 PUFA from omega-
6 PUFA) were protected from experimental colitis by DHA derived resolvin E1 (Hudert, Weylandt et al. 2006). The authors 
concluded that the protection from the inflammatory response might be via reduction in NFκβ activity and subsequent 
expression of TNFα, iNOS and IL-1β (Hudert, Weylandt et al. 2006).  
 
LPS or endotoxins, induce an inflammatory response by activating NFκβ. EPA and DHA have been demonstrated to inhibit 
LPS-induced production of inflammatory proteins such as COX-2, iNOS, TNFα, IL-1, IL-6, IL-8 and IL-12 in numerous cell 
types including endothelial cells (Khalfoun, Thibault et al. 1997), macrophages (Lee, Sohn et al. 2001), monocytes (Babcock, 
Helton et al. 2004) and dendritic cells (Weatherill, Lee et al. 2005, Kong, Yen et al. 2010). Conversely, saturated fatty acids 
were found to enhance NFκβ activity in macrophages and dendritic cells (Weatherill, Lee et al. 2005).  
 
The generation of IL-1β , IL-6 and TNFα by LPS stimulated macrophages was reduced with a fish oil diet in mice (Yaqoob and 
Calder 1995). This effect is mirrored in healthy human studies where supplementation with fish oil decreased synthesis of 
IL-1β, Il-6 and TNFα by LPS stimulated monocytes and lymphocytes (Abbate, Gori et al. 1996, Caughey, Mantzioris et al. 
1996, Baumann, Hessel et al. 1999, Trebble, Arden et al. 2003, Ferrucci, Cherubini et al. 2006). However some 
investigations have failed to show an effect of long-chain omega-3 PUFAs on cytokine concentration (Yaqoob, Pala et al. 
2000, Thies, Miles et al. 2001, Kew, Mesa et al. 2004). It is unclear as to the reason for this discordance of results but the 
reasons may lie in dosage or duration of supplementation with EPA and EHA, technical or methodological factors.  
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4.1.4 Review of dosage and duration of intake of long-chain omega-3 PUFA used in musculoskeletal conditions  
Dosage of long-chain omega-3 PUFA 
Whether long-chain omega-3 PUFA are capable of producing and the exact doses required to elicit a beneficial or 
therapeutic effect in musculoskeletal conditions is unknown. The anti-inflammatory effects of long-chain omega-3 PUFA do 
appear to be dose dependent (Rees, Miles et al. 2006). It has been suggested from human studies in healthy participants 
that a daily intake of EPA and DHA of 2g or more is required to influence the inflammatory response (Calder 2011). Anti-
inflammatory effects of long-chain omega- PUFA have been observed in RA with doses between 2.6g and 7.1g/day (James 
and Cleland 1997) but not at a dose of 1.0g/day (Geusens, Wouters et al. 1994). However, there is very little literature 
regarding the dose required to elicit an anti-inflammatory or beneficial response in other musculoskeletal conditions. Table 
4.1 details the dose, duration and outcome of studies which have investigated the efficacy of long-chain omega-3 PUFA on 
musculoskeletal conditions (other than RA). A range from 600mg to 5.1g/day EPA and DHA combined has been used for 
between one week and 10.5 weeks with little consensus on what dose or time duration is optimal.  
 
There is robust evidence that long-chain omega-3 PUFA have a modest beneficial effect on the symptoms of rheumatoid 
arthritis (RA) (Fortin, Lew et al. 1995). A recent systematic review on the effects on clinical outcomes of long-chain omega-3 
PUFA on RA including 23 studies concluded that there is evidence to support the benefits to joint swelling and pain, 
duration of morning stiffness, global assessments of pain and disease activity and reduction of NSAIDs use (Miles and 
Calder 2012). A range of 1.5 to 7g (with a mean of 3.5g/day) EPA and DHA per day has been used in studies on patients 
with RA (Calder 2008). The authors of a meta-analysis published in 2012 suggested that in RA in order to achieve maximum 
benefit, supplementation with ≥2.7g EPA+DHA and for duration of over three months is optimal (Lee, Bae et al. 2012). In 
one study investigating the effect of dosage of long-chain omega-3 PUFA on patients with RA, one group (n=20) were 
provided with a lower dose (27mg/kg EPA + 18mg/kg per day DHA) and one a high dose (n=17) (54mg/kg EPA + 36mg/kg 
DHA per day) compared to a control group (n=12) taking olive oil, all supplements were taken for 24 weeks. Both doses of 
EPA and DHA were found to have a similar therapeutic benefit but the higher dose had a shorter period to response. A 
significant improvement from baseline was observed in the high dose group in the number of tender joints at 18 weeks 
(p=0.04) and at 24 weeks (p=0.05) (Kremer, Lawrence et al. 1990). Thus indicating that higher doses might elicit a response 
quicker but with little added benefit otherwise.  
 
The proportion of EPA and DHA in red blood cell membrane lipids increases in a dose dependent manner (Sanders, Hall et 
al. 2011). The same phenomenon occurs in white blood cells, one study of healthy male volunteers of over 40 years of age, 
eight participants were randomly assigned to one of six groups (Healy, Wallace et al. 2000). Each group took a different 
dietary supplement, four of which contained differing concentrations of fish oil (most concentrated was 0.6g EPA plus 1.7g 
DHA) for 12 weeks. The levels of EPA and DHA were observed to increase in the neutrophil phospholipids in a dose 
dependent fashion in the groups taking the three most concentrated doses of EPA and DHA.  
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There does appear to be a ‘critical’ dose of EPA and DHA certainly in RA. Individuals with RA were given 2.6g/day long-chain 
omega-3 PUFA or 1.3g/day compared to two placebo groups who were given differing concentrations of olive oil for 12 
months (Geusens, Wouters et al. 1994). Only the group taking 2.6g/day long-chain omega-3 PUFA demonstrated significant 
improvements in a range of outcomes including reduction of pain and anti-rheumatic medication. These findings are 
supported by those from a dose-response study in healthy volunteers where an EPA intake of 1·4g/day for three months 
was found to be insufficient to impact ex vivo PGE2 production as compared to an EPA intake of 2·7g/ day which was found 
to significantly decrease PGE2 production (Rees, Miles et al. 2006). These findings would suggest an intake of EPA between 
1.4 and 2.7g/day is required to elicit an anti-inflammatory effect. 
 
A dose of 2.6g EPA and DHA (3g long-chain omega-3 fatty acids) was selected for the main randomised controlled trial 
component investigating the efficacy of long-chain omega-3 PUFAs in the treatment of RC tendinopathy based on the lower 
predicted efficacy level . 
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Table 4.1 Doses of long-chain omega-3 PUFAs used in musculoskeletal conditions 
Condition  Sample size Supplement per day Duration of 
supplementation 
Outcome  Reference 
Tendinopathies Control: 20 (14 
completed) 
PUFA; 20 (17 
completed) 
3.0g EPA, 2.1g DHA, 2.7g GLA plus100 
mg selenium, 15 mg zinc, 1 mg vitamin 
A, 2.2 mg vitamin B6, 90 mg vitamin C 
and 15 mg vitamin E 
32 days Decreased pain score in PUFA group of 
99% compared to control= 31% 
(P<0.001), 5 pain reduction on pain VAS 
in PUFA group vs. 2 point in control  
(Mavrogenis, 
Johannessen et al. 
2004) 
Lateral epicondylitis Control: 30 
PUFA; 30  
3.0g EPA, 2.1g DHA, 2.7mg GLA plus100 
mg selenium, 15 mg zinc, 1 mg vitamin 
A, 2.2 mg vitamin B6, 90 mg vitamin C 
and 15 mg vitamin E 
8 weeks No between group differences. Both 
groups improved over 24 month follow 
up. Significant difference in duration of 
symptoms at baseline 
(Roe, Odegaard et 
al. 2005) 
Muscle soreness post 
exercise 
 Control:10 
PUFA=10  
 
1.3g EPA +0.3g DHA 6 weeks No differences between group in muscle 
soreness but significant reduction in 
lipid perioxidation and DNA damage in 
long-chain omega-3 PUFA group. 
(Gray, Chappell et 
al. 2014) 
Non-surgical neck or back 
discogenic pain  
250 questionnaires 
sent , 125 returned 
2.4g (EPA + DHA combined) for 2 weeks 
for 1.2g (EPA +DHA combined) for 4 
weeks 
75days 59% reported discontinuing NSAIDs, 
60% stated improved joint pain, 88% 
reported continue to take long-chain 
omega-3 PUFAs 
(Maroon and Bost 
2006) 
Delayed onset muscle 
soreness following 
eccentric exercise 
Treatment group 
=69 
 
2.7g (EPA + DHA combined) 30 days Reduced delayed onset muscle soreness, 
lower lactate and CRP levels were 
observed in PUFA group,  
(Lembke, Capodice 
et al. 2014) 
Exercise induced 
inflammation in biceps 
11 3.0g (EPA +DHA combined) 7 days Muscle soreness was 15% less in PUFA 
group (p=0.004) 
Jouris 2011 
Moderate-severe Hip and 
knee osteoarthritis 
177 600mg long-chain omega-3PUFA  (no 
ratio of EPA/DHA given) and 1.3g fish oil 
(no further details given) 1.5g 
glucosamine sulphate, +vitaminsA,D & E 
26 weeks Pain reduction ≥80% as measured by 
WOMAC score was statistically 
significantly better in treatment group.  
(Gruenwald, 
Petzold et al. 2009) 
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Legend: PUFA= poly unsaturated fatty acid, DHA= docosahexaenoic acid, EPA: eicosapentaenoic acid, GLA= gamma-linolenic acid, VAS= visual analogue scale, DNA= 
deoxyribonucleic acid, NSAIDs= non-steroidal anti-inflammatory drugs, WOMAC score= Western Ontario and McMaster Universities Osteoarthritis index. 
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Duration of supplementation 
The incorporation of long-chain omega-3 PUFA into the membrane phospholipids of the cells involved in inflammation 
appears to be time dependent (Browning, Walker et al. 2012). This has implications for the duration of supplementation 
but also the follow up period where any improvement in a condition might be observed. Yaqoob et al (2000) investigated 
the effects of taking 3.2g (EPA + DHA) for 12 weeks and plasma phospholipid and peripheral blood mononuclear cell fatty 
acid composition was examined every four weeks. A maximal effect was observed four weeks after starting 
supplementation, where there was a 10 fold increase in the proportion of EPA in the plasma phospholipids and a four-fold 
increase in the peripheral blood mononuclear cell fatty acid composition in the long-chain omega-3 PUFA group. There was 
also a 20% decrease in the proportion of ARA in the plasma phospholipids and peripheral blood mononuclear cells in the 
long-chain omega-3 PUFA group during the supplementation period (Yaqoob, Pala et al. 2000). 
 
Similarly, Healy et al (2000) found that the increases in EPA and DHA in the neutrophil phospholipids peaked at four weeks 
after supplementation with no further increases observed thereafter (Healy, Wallace et al. 2000). This might suggest that 
an intake of four weeks is sufficient to effect an anti-inflammatory change. 
 
The optimal duration of intake is unknown for the use of PUFA supplements in RC tendinopathy. Previous studies have 
used a range of intake duration from seven days to 24 weeks in musculoskeletal conditions (see Table 4.1 above).  
 
4.1.5 Review of previous associations/interventions with diet in rotator cuff tendinopathy 
The rationale underpinning marine fish oil supplementation in RC tendinopathy lies in the anti-inflammatory effects of 
long-chain omega-3 PUFAs. Whilst long-chain omega-3 PUFAs have been found to have some beneficial effects on a range 
of inflammatory conditions (including, RA, Crohn’s disease, Colitis, obesity, chronic obstructive pulmonary disease, asthma, 
atherosclerosis, neurodegenerative disorders and Type One diabetes) (Calder 2011), it is not possible to directly translate 
the research carried out in other inflammatory pathologies and other joints (Sanders 2014). However, the up regulation of 
pro-inflammatory cytokines and eicosanoids is one unifying characteristic of these conditions (Calder, Albers et al. 2009). 
Whilst their mechanism of action remains under scrutiny there are multiple possible mechanisms by which n-3 PUFAs exert 
their anti-inflammatory influence including the decreased production of inflammatory cytokines and eicosanoids and 
increase the production of resolvins and protectins (Calder 2011).  
 
There is consistent evidence indicating the potential benefits of dietary supplementation as an adjunct in the treatment of 
conditions thought to be associated with, or mediated by inflammatory cytokines and/or oxidative stress (Calder 2001). 
Two trials of poor methodological quality have reported conflicting findings as to the efficacy of long-chain omega-3 PUFAs 
for the treatment of tendinopathies (Mavrogenis, Johannessen et al. 2004, Roe, Odegaard et al. 2005). Whilst the potential 
for dietary supplementation of long-chain omega-3 PUFAs and antioxidants to reduce the disability and morbidity 
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associated with RC tendinopathy and subacromial bursal pathology is appealing it has not yet been formally investigated 
(Lewis and Sandford 2009).  
 
Conclusions  
Long-chain mega-3 PUFAs have an anti-inflammatory effect, when consumed at adequate doses (Calder 2011). The 
mechanism by which they have an anti-inflammatory effect is not entirely known but they have the potential to target the 
inflammatory mediators of RC tendinopathy through a variety of mechanisms including EPA and DHA derived eicosanoids, 
the increased production of protectins and resolvins and through the down regulation of the inflammatory gene pathways 
(Calder 2015).  
 
Rationale for thesis  
The above review of the literature identifies that there are limitations in the current knowledge base regarding the effect 
of PUFAs on RC tendinopathy. This is a very new area of research and only a few dietary supplementation trials have been 
conducted on tendinopathies. Many have not been placebo-controlled or double blinded, or have been under powered 
(too small a sample size) to detect a change in the selected outcomes. Furthermore they have been at risk of bias with data 
not analysed on an intention to treat basis. 
 
Due to the uncertainty in the evidence, this thesis sets out to address a number of these issues. 
 
Aims and objectives of thesis  
1. To investigate the extent of the current use of dietary supplements in a cohort of individuals with shoulder pain. 
2. To explore the reasons for or for not taking supplements and any associations.  
3. To conduct a double blinded RCT to evaluate the efficacy of exercise and PUFA in the treatment of RC 
tendinopathy. 
4. To conduct a qualitative study to investigate issues around adherence to carrying out an exercise programme for 
RC tendinopathy and taking the dietary supplements provided within the RCT. 
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Chapter 5 : Methods  
65 
 
Introduction 
As outlined in Chapter one, the aim of this thesis was to establish the effectiveness of long-chain omega-3 PUFA in the 
treatment of rotator cuff (RC) tendinopathy. To achieve this, this research investigation involved four interrelated studies; 
 
1. Reliability study investigating the intra and inter-rater reliability of shoulder range of motion and strength (Chapter 
6). 
2. Survey of shoulder pain and the use of nutritional supplements: a questionnaire based investigation (Chapter 7). 
3. A double blind randomised controlled trial investigating the efficacy of long-chain omega-3 polyunsaturated fatty 
acids and exercise in the treatment of RC tendinopathy (Chapter 8). 
4. Exploring experiences, barriers, motivators and enablers to nutritional supplement use and exercise in rotator RC 
tendinopathy (Chapter 9). 
This chapter will describe the methods used in these investigations, including; outcome measures, data collection, power 
calculations and statistical analyses. 
 
Outcome measures 
Health related outcome measures are tools used to evaluate the extent to which healthcare objectives have been 
achieved, as well as measuring health status and health related quality of life, and impact of a disease or condition 
(Garratt, Schmidt et al. 2002, Haywood 2006).  
 
Health related outcome measures are important throughout the spectrum of health care provision; from the individual 
patient and clinician evaluating the effectiveness and efficacy of treatment and progress, to political (e.g. United kingdom 
Department of Health) and other health funding bodies (e.g. NHS Clinical Commissioning Groups) assessing the benefit of 
care in relation to cost. In research, health related outcome measures allow the comparison of different treatments for a 
specific population of patients. The selection of any health related outcome measurement tool is dependent on the 
question that is being asked and its context (Cano and Hobart 2011).  
 
Outcome measures need to be valid and reliable with a known minimum error, easily accessible to patients and healthcare 
professionals with minimal responder or clinician burden and applicable or relevant to the patient group being examined 
(Collins and Roos 2012). The validity of an instrument is its ability to measure what it purports to measure (Velentgas, 
Dreyer et al. 2013). The reliability refers to the instruments ability to record the same outcome in the same conditions over 
time (Velentgas, Dreyer et al. 2013).  
 
The minimally clinically important difference (MCID, also known as the minimally clinically important change MCIC) is the 
smallest change in an outcome measure that would equate to an important change to the patient (McGlothlin and Lewis 
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2014). The minimal detectable change (MDC) is the smallest change that can be detected beyond error (Kovacs, Abraira et 
al. 2008). It is recognised that no single outcome measure can appropriately measure all aspects and the impact of a 
condition on a patient’s life (Porter 2010). The World Health Organisation (2002) international classification stated that a 
patient’s health condition was dependent on; body function and structure, activity and participation and thus a battery or 
combination of outcome measures should be used to cover these factors.  
 
It has been argued there is need for agreement on core outcome sets appropriate for specific areas (such as 
musculoskeletal research conducted on the shoulder) so that the findings of investigations may be accurately compared 
(Gargon, Gurung et al. 2014, Page, McKenzie et al. 2015). Currently there is no core outcome set for the shoulder. There 
are several widely used condition specific outcome questionnaires but with little agreement as to which are the most 
responsive for RC tendinopathy. 
 
Disability and impairment are interlinked but are measured in different ways in the context of their definition. Impairment 
is defined by the American Medical Association (AMA) as “significant deviation, loss, or loss of use of any body structure or 
body function in an individual with a health condition or disease” and disability as “activity imitations and/or participation 
restrictions in an individual with a health condition, disorder or disease” (Rondinelli 2008). Impairment measures include 
methods such as goniometry to measure loss of range of motion. Disability and functional measures include disease 
specific measures such as the Oxford Shoulder Score (Dawson, Fitzpatrick et al. 1998, Dawson, Rogers et al. 2009) used 
within this thesis for the measurement of the extent of disability or functional limitation. 
 
Table 5.1 Outcome measures used within each chapter of the thesis. 
 
Chapter Outcome measures used 
Chapter 6: Reliability study: the intra- and 
inter-rater reliability of shoulder range of 
motion and strength. 
 Impairment measure: range of motion of the 
shoulder using an inclinometer 
 Impairment measure : strength measurement of 
the shoulder using the JTECH power II commander 
 
Chapter 7: Shoulder pain and the use of 
nutritional supplements; A questionnaire 
based investigation. 
 Oxford Shoulder Score (OSS) 
 Shoulder Pain And Disability Index (SPADI ) 
 Short Form 36 (SF 36) 
 Euro Qol 5D 3L (EQ5D 3L 
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Chapter 8: A randomised controlled trial of 
long-chain polyunsaturated fatty acids in the 
treatment of RC tendinopathy. 
 OSS 
 SPADI 
 SF36  
 EQ5D 3L 
 Numerical rating score of pain 
 Patient specific functional score (PSFS) 
 Global impression of change 
 Shoulder range of motion  
 Strength assessment of shoulder 
 Adherence indices; fatty acid composition in blood 
plasma, capsule count, recorded capsule count.  
 Four-day food diaries. 
 
Chapter 9: Exploring experiences, barriers, 
motivators and enablers to nutritional 
supplement use and exercise in RC 
tendinopathy: A qualitative study. 
Qualitative interviews 
 
5.1.1.1 Measurement of range of motion  
Measurement of physiological shoulder movement is an important part of the clinical examination of a patient with RC 
tendinopathy. The physiological movements that are most commonly measured include shoulder flexion, abduction, 
external rotation and the movement of placing the hand behind back (Ginn, Herbert et al. 1997, Alvarez, Litchfield et al. 
2005, Lewis, Green et al. 2005, Lewis, Wright et al. 2005). Being able to place your hand behind your back is essential for 
normal and routine function in activities of daily living such as; tucking in a shirt, reaching for something in a back pocket, 
attending to personal hygiene, and for women, closing and opening a bra. These functional activities are commonly 
described by people with RC tendinopathy as activities that are associated with significant pain and restriction in 
movement and function. Subsequently measurement of range of motion is recommended by both the Society of American 
Shoulder and Elbow Surgeons and the American Academy of Orthopaedic Surgeons (Kumar and Satku 1994). Within the 
literature a variety of methods have been used to clinically measure shoulder range of movement (ROM) including, tape 
measurements, goniometry, inclinometers, visual estimation, digital devices and photography (Kessel 1982, Riddle, 
Rothstein et al. 1987, Williams and Callaghan 1990, Croft, Pope et al. 1994, Kumar and Satku 1994, Youdas, Carey et al. 
1994, Trombly 1995, Green, Buchbinder et al. 1998, Hayes, Walton et al. 2001, Reese and Bandy 2002, Ellenbecker 2004). 
The positions for the measurement of ROM have not been standardised and several positions have been documented 
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including sitting in a chair with support (Trombly 1995), in a chair without support, lying supine, side lying, lying prone and 
in standing (Clarkson 2000, Reese and Bandy 2002, Ellenbecker 2004). The point at which measurements are made has also 
lacked consistency with measurements being made of shoulder active range, passive range and range to the first point of 
pain (Green, Forbes et al. 1998, de Winter, Heemskerk et al. 2004, van de Pol, van Trijffel et al. 2010).  
 
Clinically, either visual estimation or goniometry, are commonly used to measure shoulder range of motion. However, the 
reliability of these methods is uncertain (Croft, Pope et al. 1994, Terwee, de Winter et al. 2005). Valentine and Lewis (2006) 
examined the intra-observer reliability, in participants with shoulder pain and asymptomatic individuals, of measuring the 
physiologic movements of shoulder; flexion, abduction in the plane of the scapula, external rotation with the arm by the 
side, and internal rotation. The authors found that following their measurement protocol the majority of the main 
physiologic movements of the shoulder were measured with good to excellent intra-tester reliability (Valentine and Lewis 
2006). At the time of current thesis trial design, the methodology reported by these authors had the best proven reliability 
of all methods (Hayes, Walton et al. 2001, Edwards, Bostick et al. 2002) of range of motion measurement of the shoulder in 
the target population and therefore was used within the study for investigation of reliability and use in the main clinical 
investigation. 
 
5.1.1.2 Measurement of strength 
The evaluation of shoulder flexion, abduction, internal and external rotation strength, the full and empty can tests (also 
known as Jobe’s test) (Jobe and Moynes 1982, Itoi, Kido et al. 1999) as well as the strength of elbow flexion (as a result of 
the multi-joint function of the biceps brachii), are routinely performed as part of an examination of shoulder function. 
Clinically, if available, the strength of the symptomatic shoulder is usually compared to the asymptomatic side. Muscle 
strength testing using hand held dynamometers (HHDs) has been shown to exhibit good-to-excellent reliability (Hayes, 
Walton et al. 2002, Bohannon 2005, Kolber and Cleland 2005, Tyler, Nahow et al. 2005) and may be more sensitive for 
detecting deficits in shoulder external rotation strength than isokinetic devices (Tyler, Nahow et al. 2005). Findings from 
the reliability study (Chapter 6) indicated  that the hand-held JTech PowerTrack™ II Commander HHD (JTECH Medical, Salt 
Lake City, UT, USA) demonstrated good to excellent intra- and inter-tester reliability for the measurement of asymptomatic 
shoulder strength (Dollings, Sandford et al. 2011). The mean of three tests was found to produce more reliable 
measurements than just one measurement (Dollings, Sandford et al. 2011). These findings support those of other reliability 
trials’ investigations for testing shoulder strength using hand-held dynamometers (Agre, Magness et al. 1987, Leggin, 
Neuman et al. 1996, Balogun, Powett et al. 1998, Hayes, Walton et al. 2002, Vermeulen, Bock et al. 2005). However as a 
result of different devices being tested using different research protocols, extrapolating the findings between studies is 
difficult. 
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Summary 
The assessment method used for measuring strength and shoulder range of motion demonstrated good to excellent 
reliability for intra-rater reliability re-assessment by both examiners and inter-rater reliability between examiners (Chapter 
6) and subsequently these methods were employed in the randomised control trial (Chapter 8). 
 
5.1.2 Patient reported outcome measures-used in Chapters 6, 7 and 8 
Significant emotional impact from the functional and social limitations and pain experienced with RC tendinopathy has 
been reported (Minns Lowe, Moser et al. 2014). It is therefore important that these areas are assessed in any outcome 
measurement tool. 
 
5.1.2.1 Disease specific self-reported disability 
 
5.1.2.1.1 Oxford Shoulder Score (OSS) 
The Oxford Shoulder Score (OSS) (Appendix 11.1) (Dawson, Fitzpatrick et al. 1998, Dawson, Rogers et al. 2009) consists of 
twelve questions, four pertaining to pain (33% of total score) and eight (67% of total score) to assess activities involved in 
daily function. The OSS was originally scored out of 60 (each item was marked 1-5 with 1 equating to no pain or no 
functional limitation) and the best score was 12 (Dawson, Fitzpatrick et al. 1998). A revised scoring system was suggested 
in 2009 in response to criticism that the original scoring system was counterintuitive and causing confusion (Dawson, 
Rogers et al. 2009). In the revised version each item is rated on a five part Likert scale where 0 is the worst and 4 the best 
so that a score of 0 equates to maximal disability and 48 to no disability (Dawson, Rogers et al. 2009). The questionnaire 
asks the respondent to recall symptoms over the past four weeks. The tool takes two to four minutes to complete by the 
respondent. The OSS has been demonstrated to be responsive in RC tendinopathy and surgery (Dawson, Hill et al. 2002, 
Ekeberg, Bautz-Holter et al. 2008, Allom, Colegate-Stone et al. 2009).  
 
The OSS has been shown to display both good internal consistency (the correlation between different items that propose 
to measure similar constructs (Barker, Pistrang et al. 2002)) Cronbach’s α=0.94, and test-retest reliability (the examination 
of consistency over time (Barker, Pistrang et al. 2002)) Pearson coefficient= 0.98 (Huber, Hofstaetter et al. 2004). The test 
re-test reliability of the OSS has been examined in participants with subacromial impingement (Cloke, Lynn et al. 2005) and 
RC tendinopathy (Ekeberg, Bautz-Holter et al. 2008).  
 
Recently, the smallest detectable change and MCIC of the OSS has been found to be 5 and 6 respectively (Ekeberg, Bautz-
Holter et al. 2010, van Kampen, Willems et al. 2013).  
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The OSS was developed as a post-operative tool and there is little existing evidence of its psychometric properties with 
patients undergoing non-surgical management (Bot, Terwee et al. 2004, Roy, MacDermid et al. 2009, Angst, Schwyzer et al. 
2011). 
 
5.1.2.1.2 Shoulder Pain and Disability Index (SPADI) 
The Shoulder Pain and Disability Index (SPADI) (Appendix 11.2) is a 130 point, 13 item self-administered questionnaire 
covering two domains, pain (five items) and function (eight items)(Roach, Budiman-Mak et al. 1991). Each question is 
scored on a numerical ration scale with 0 representing ‘no pain or no difficulty’ and 10 ‘worst pain imaginable or so difficult 
it required help. Each question is weighted equally within the domain and each domain carries equal weighting in the 
overall score which is expressed as a percentage, where 100% represents maximum pain and disability. The questions 
pertaining to the domain of pain require the respondent to recall pain relating to specific defined activities that captures 
information not sought on other shoulder specific questionnaires. The SPADI requires the respondent to recall their 
symptoms over the past week unlike the OSS which asks for recall over the preceding 4 weeks. It takes approximately two 
minutes to complete and so the burden on the respondent is low, it is also easy and quick to score (Angst, Schwyzer et al. 
2011). 
 
The MCIC for the SPADI has been reported to be 8 (Schmitt and Di Fabio 2004), 10 (Paul, Lewis et al. 2004), 13.8 (Williams, 
Holleman et al. 1995) and 20 points (Ekeberg, Bautz-Holter et al. 2010). The SPADI has been demonstrated to be 
responsive to change and be able to discriminate between those who are improving and those who are not (Williams, 
Holleman et al. 1995). 
 
The OSS was originally designed to be a primary outcome measure in randomised controlled trials (Dawson, Rogers et al. 
2009) and has been used in a UK nationwide RC trial (UKUFF trial) (Carr, Rees et al. 2014). Despite some of the limitations 
of the OSS it is widely used as a research and clinical outcome tool throughout the UK and in a survey of 217 NHS shoulder 
surgeons 69% reported using the OSS as their preferred outcome (Varghese, Lamb et al. 2014). It was due to this clinical 
utility, its use in the large UKUFF trial and the information available at the time of the design of the study that the OSS was 
selected at the primary outcome measure.  
 
The primary outcome point within the main study was following the two months of intervention. The next outcome point 
was one month later (three months from baseline). The SPADI was selected as an outcome in the main study to capture 
any change between two and three months in particular as it asks the participant to recall the symptoms in the last week 
rather than the preceding month.  
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5.1.2.2 Measurement of self-reported pain 
Pain associated with RC tendinopathy is often chronic in nature and as such, has a substantial impact on the individual, 
including their physical, emotional and cognitive function, as well as their productivity, ability to work and earn an income 
as well as detrimentally impacting on social function (Minns Lowe, Moser et al. 2014). Recall of pain is difficult with the 
memory of pain often influenced by contextual factors and this makes the accurate measurement of pain problematic 
(Wiech and Tracey 2009).  
 
Pain is commonly recognised as a key feature in the spectrum of pathology of RC tendinopathy and was listed by people 
diagnosed with pain associated with suprapsinatus tendinitis as their predominant symptom (Nyman, Palenius et al. 2012). 
Therefore the valid and reliable measurement of pain is essential when considering and comparing the effectiveness of 
intervention across two groups and carrying out any shoulder assessment. However, as the nature of pain is subjective, 
personal and private, objective assessment of this domain is difficult (Breivik, Borchgrevink et al. 2008). 
 
The very nature of pain makes its objective measurement impossible (Breivik, Borchgrevink et al. 2008). Clinically the most 
commonly used tools to assess the intensity of pain are the Visual Analogue Scale (VAS) and the Numerical Rating Scale 
(NRS). These are one dimensional tools which have been shown to assess pain reliably both at rest and during function 
(Ferreira-Valente, Pais-Ribeiro et al. 2011). The VAS and NRS have been reported to correlate well in the assessment of the 
intensity of pain (Ferreira-Valente, Pais-Ribeiro et al. 2011). They are best used to rate the intensity of pain immediately, 
although they can be used for worst, least or average pain score recall over a period of a week (Singer, Kowalska et al. 
2001, Breivik, Borchgrevink et al. 2008). However, the NRS is preferable over the VAS as it is more practical to administer as 
there is no requirement for pen or paper and appears to be easier to comprehend for most people (Breivik, Borchgrevink 
et al. 2008).  
 
The NRS is an 11 point scale anchored on the left with 0 representing no pain and 10 as the worst pain imaginable on the 
right. It has been shown to be reliable and valid within the shoulder (Mintken, Glynn et al. 2009). It is the most responsive 
commonly used pain measure and is able to detect gender difference in pain intensity (Ferreira-Valente, Pais-Ribeiro et al. 
2011). The minimally clinically important difference has been established for the NRS in a cohort of patients with shoulder 
pain (Mintken, Glynn et al. 2009). Participants referred with shoulder pain to an out-patient physiotherapy clinic completed 
a quick DASH and NRS at their baseline visit. They then repeated them along with rating their global impression of change 
two to four weeks later following physiotherapy treatment. The MCID for shoulder pain on movement measured on the 
numerical rating scale NRS scale was found to be 1.1 points (Mintken, Glynn et al. 2009). The percentage changes in pain 
intensity has been classified with a 10-20% decrease equating to a minimally important change, 30% to a moderately 
important change and 50% signifying a substantial improvement (Dworkin, Turk et al. 2008).    
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The initiatives on methods, measurement and pain assessment in clinical trials (IMMPACT), recommends the use of the 
NRS and the number of analgesics being taken to measure pain intensity in clinical trials (Dworkin, Turk et al. 2005). On this 
basis and the practicality of its use the NRS (Appendix 11.18) was selected along with the SF 36 pain sub-scale (discussed 
below, Appendix 11.3) to measure self-reported pain within the RCT.  
 
5.1.2.3 Health related quality of life 
Generic patient rated outcome measures such as the Short Form (SF) 36 (Ware and Sherbourne 1992) evaluate the broader 
aspects of a participants’ health. Normative data is available allowing comparison with responses from a population of 
people without shoulder symptoms (Fitzpatrick, Davey et al. 1998). Due to the multidimensional nature of health related 
quality of life measures they can reveal unanticipated side effects of treatment that region specific outcome measure may 
miss (Guyatt, King et al. 1999, Wiebe, Guyatt et al. 2003).  
 
These broader quality of life measures were included due to their ability to provide more generalised health information. 
Chronic pain is recognised to have an impact on physical, emotional and social functions and as such important to 
measure. Another reason for selecting the SF 36 was its ability to capture this information (Bergman, Jacobsson et al. 
2004). It was also determined to be important to include both region specific and more global quality of life measures in 
order to evaluate comprehensively any change during the trial, as a study comparing the validity of five shoulder 
questionnaires commented that whilst these shoulder specific questionnaires gave a measure of severity it did not give an 
indication of overall health (Beaton and Richards 1996). 
 
5.1.2.3.1 Medical Outcomes Study 36- item short form (SF-36) 
The SF 36 is a 36 item questionnaire which is grouped into eight domains, scaled from 0-100, with a higher score 
representing better health. The domains either physically or emotionally focused and include; physical functioning (PF), 
role limitations due to physical health (RP), role limitations due to emotional health (RE), energy and fatigue (vitality) (VT), 
emotional well-being (MH), social functioning (SF), bodily pain (BP) and general health (GH). There are also two summary 
measures, physical component summary (PF, RP, BP, GH) and the metal health component summary score (VT, SF, RE, 
MH).  
 
The SF 36 is the most commonly used measure of generic health status in health care research (Ware and Sherbourne 
1992, Garratt, Schmidt et al. 2002). It is frequently used as an outcome measure in the field of RC research allowing 
comparison between studies (Ware and Sherbourne 1992, Bennell, Wee et al. 2010). It can be self-administered or with 
assistance, on paper or online. It takes approximately five to thirty minutes to complete and is quick to score using on line 
tools (http://www.sf-36.org/demos/SF-36.html).  
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The EQ 5D 3L (or EuroQol, Appendix 11.4), like the SF 36, is a generic preference-based tool for the measurement of self-
reported health-related quality of life (Brooks 1996), and is comprised of two components. The first of which evaluates five 
dimensions: mobility, self-care, activity, pain and depression and anxiety (evaluated together). Each dimension can be 
scored as one of three levels, no impairment, mild to moderate impairment and severe impairment. The scores are scaled 
from -0.04 (worse than death) to 1.00 (perfect health). The second component of the EQ 5D 3L is the EQ VAS (visual 
analogue scale) where participants are asked to rate their health status a scale from 0 to 100 where 0 represents ‘worst 
imaginable health’ and 100 ‘best imaginable health’.  
 
During the period the main RCT was running, the EQ 5D 3L was replaced by the EQ 5D 5L due to problems with the 3L 
version delineating small but important clinical changes in health status and the presence of a ceiling effect (when a 
measure has a distinct upper limit for potential responses and a large number of respondents score at or near the upper 
limit (Pickard, De Leon et al. 2007, Janssen, Pickard et al. 2013, Lim, Harris et al. 2015). The 5L version differs from the 3L in 
that there are five levels (no problem, slight problem, moderate problem, severe problem and extreme problem) within 
each dimension rather than three (Obradovic, Lal et al. 2013). The EQ 5D 5L was not available at the time of the start of the 
current investigation as because of this the EQ 5D 3L was used.  
 
The EQ 5D 3L has demonstrated good test re test reliability (van Agt, Essink-Bot et al. 1994). It is quick to complete and 
score. It is commonly included in other trials investigating RC tendinopathy (Odenbring, Wagner et al. 2008, Hultenheim 
Klintberg, Karlsson et al. 2011, Krischak, Gebhard et al. 2013) and allows an effective measure of general health status 
(Coretti, Ruggeri et al. 2014).  
 
5.1.2.4 Restoration of functional activity 
The measures of restoration of functional activity were only used in Chapter 8. 
 
5.1.2.4.1 Patient specific functional score  
The Patient Specific Functional Score (PSFS) is a questionnaire that is used to quantify and measure an individual’s key 
activity limitations (Sterling and Brentnall 2007, Horn, Jennings et al. 2012, Nicholas, Hefford et al. 2012) (Appendix 11.5). 
The participant selects three activities, movements or posture that is causing concern or difficulty in relation to their 
shoulder problem. It is possible that these activities might not be included on one of the standardised questionnaires (OSS, 
SPADI). Due to the self-generating nature of the items selected will commonly differ from individual to individual and are 
therefore not necessarily comparable across individuals (Jolles, Buchbinder et al. 2005). However, it is this individualised 
nature that allows the PSFS to capture an individual’s change in function that might not be identified on the self-reported 
function measure the OSS, the primary outcome measure in the RCT. The questions should be tailored so that they are 
pertinent and meaningful to the individual but this does require more involvement from the participant as they have to 
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self-generate the activity in question and prioritisation of which functions are more problematic for them and thus warrant 
inclusion. It has been recommended that participants are assisted in the process of using the PSFS and completion of this 
tool may be a collaborative effort (Stratford, Gill et al. 1995)  
 
The PSFS has been validated for other musculoskeletal conditions including low back pain and the upper extremity 
(Maughan and Lewis 2010, Hefford, Abbott et al. 2012) but not yet specifically the shoulder. The PSFS has demonstrated 
moderate to excellent reliability, validity and sensitivity to change and it has recently been shown to be able to be capable 
of assessment of group level change and between group discrimination in group level data (Abbott and Schmitt 2014). 
 
The MID for the PSFS (on a scale from 0 to 10) ranged from 1.3 (small change) to 2.3 (medium change) to 2.7 (large change) 
(Abbott and Schmitt 2014). A large study of 1708 patients with a range of musculoskeletal disorders were recruited from 
physiotherapy clinics and their physical function was assessed at baseline and on discharge, using the PSFS, region specific 
outcomes and the global rating of change (Abbott and Schmitt 2014). The PSFS was found to perform better than the 
comparison measures in most categories. The concurrent, convergent and discriminate validities, the scale consistency, 
distribution and responsiveness of the PSFS were supported by the results and found for both between group 
discrimination and within-groups assessment of change over time (Abbott and Schmitt 2014). 
. 
5.1.2.5 Global rating of change  
The global rating of change (GROC) was again only used in Chapter 8. The examiner asked participants at two, three, six 
and 12 months “How much do you feel you have improved or worsened from your first day in the study?” Participants 
were asked to rate their improvement or deterioration on a Likert scale as a percentage, with 100% equating to full 
improvement. The global rating of change is often used to evaluate if a patient or participant perceives a change in their 
symptoms during treatment from baseline. As such, it can be used to divide participants into responders and non-
responders (Copay, Subach et al. 2007). The GROC score is quick to complete and poses little respondent burden. However, 
as it is a one item summary score it is unlikely to be able to detect subtle changes and is subject to influence from current 
general health, state of mind and expectations from treatment (Fitzpatrick, Davey et al. 1998, Kamper, Maher et al. 2009). 
 
5.1.3 Anthropometric measurements 
Anthropological measurements were taken only in Chapter 8 and refer to the measurement of humans. Within the RCT the 
anthropometric data collected included the participant’s height, weight and waist circumference. 
The height and weight measurements were taken in the clinical ward and the waist circumference in the assessment room 
both of which were located in the clinical research facility at St. Thomas’s Hospital, London, UK. 
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5.1.3.1 Height 
Height was measured using a wall mounted manual stadiometer (SECA, Brimingham, UK). The participant was asked to 
remove their shoes and the investigator ensured that they were standing upright with their heels and shoulders against the 
measuring rod, their knees and back straight and looking straight ahead. The measuring slide was then pushed down onto 
the head, compressing the hair, but not bending the measuring slide. The reading was recorded to the nearest 0.1cm. 
5.1.3.2 Weight 
Weight was measured on calibrated digital scales (SECA, Birmingham, UK) which were accurate to 0.1kg. Participants were 
asked to remove their shoes and any outdoor clothing but to remain in light clothing as it was an open ward environment. 
They then stepped onto the scales and stood upright and still whilst the measurement was being taken. The reading was 
recorded to the nearest 0.1kg. 
  
5.1.3.3 Waist circumference 
Waist circumference was measured in standing as the mid-point between the lowest rib and the iliac crest (Mason and 
Katzmarzyk 2009). The measurement was taken just prior to the physical examination whilst the participant was undressed 
and at the end of expiration using a non-stretch measuring tape placed onto the skin. Care was taken to ensure the tape 
was placed horizontally and flat. The reading was recorded to the nearest 0.1cm. 
 
5.1.4 Fatty acid analysis within plasma samples blood samples 
The fatty acid composition of the total plasma lipid was measured within this study as opposed to the specific phospholipid 
class. The measurement of the total plasma lipid determines nonesterified and esterified fatty acid species as a sum 
(Lepage and Roy 1986). The reason chosen to determine the fatty acid composition of the total plasma lipid was due to 
fatty acid intake becoming distributed throughout all plasma lipid classes (phospholipid, triacylglycerols, diacylglycerols, 
monoacylglycerols, non-esterified fatty acids) in a complex way highlighting the problematic approach of selecting a 
particular class as the most reflective of dietary intake. Use of total lipid fatty acid determination is simpler from a 
biochemical standpoint and yet allows demonstration of incorporation of the consumed fatty acid and hence adherence of 
supplement intake without having to consider interactions between various lipid classes (Lepage and Roy 1986). Moreover, 
the measurement of total plasma lipid fatty acids is more robust, analytically, because it circumvents the need for a pre 
separation into individual lipids (which inevitably incurs loss of analyte) prior to the preparation of the more volatile fatty 
acid methy esters which is a prerequisite for analysis by gas chromatography (Lepage and Roy 1986). Plasma lipids have 
been shown to be good indicies of intake of EPA and DHA (Sanders, Lewis et al. 2006), are much easier to measure directly 
than phospholipids (Lepage and Roy 1986) and are widely used (Kuratko and Salem 2009). 
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5.1.5 Dietary analysis 
In order to ascertain the proportions of different fats and especially fatty acids, and to evaluate any change in relative 
proportions in the participants diet at baseline and then at one year, a dietary analysis method was required. A four day 
diary (Appendix 11.16) was used in this investigation and involved detailed food intake on two weekdays and two weekend 
days. This was because an individual’s food and drinking habits may vary during the working week and over the weekend. 
This information would not be captured on a 24 hour recall dietary analysis. The four day food diary allowed detailed 
estimation of the energy and macronutrient intake as well as micronutrients for each participant and also allowed the 
participants’ to describe portion size allowing an estimation of the quantity of food consumed to be made. With detailed 
descriptions of the foods consumed coding could be undertaken to give an accurate estimation of the energy, micro and 
macronutrient components of the diet. This accuracy guided selection of the four day food diary over a food frequency 
questionnaire which relies on accurate recall and does not detail portion sizes (Kipnis, Subar et al. 2003). 
 
Data Collection methods  
 
5.1.6 Methods for Chapter 6: Reliability study 
5.1.6.1 Measurements 
The range of motion measurements assessed in this study were: shoulder joint flexion, abduction, external rotation and 
hand behind back. Shoulder joint flexion and abduction were assessed using an inclinometer (Acuangle™, anglelevel) 
(Figure 5.1). The shoulder strength measurements assessed were; flexion, abduction, abduction in an internally and 
externally position of the shoulder, colloquially termed the empty and full can position respectively, shoulder internal and 
external rotation and elbow flexion and extension. The strength measurements were assessed using a JTech PowerTrack™ 
II Commander hand held dynamometer, using the concave pressure pad for comfort (JTech Medical, Salt Lake city, UT, 
USA) (Figure 5.2). The strength tests were all assessed with the participant sitting on a treatment plinth (with no back 
support) with their hips and knees at 90° and their feet flat on a footstool. The range of motion tests were assessed in 
standing. 
 
5.1.6.2 Raters  
The chief investigator and co-investigator were both musculoskeletal physiotherapists with more than 10 years of clinical 
experience. To ensure proficiency of use with the inclinometer and the hand held dynamometer both testers participated 
in a minimum of three hours training with both measurement tools.  
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5.1.6.3 Assessment of participants  
Participant’s attended one assessment session of 150 minutes duration. All testing was carried out in a private room at 
Guy’s Campus, King’s College London. During testing the room temperature and lighting were kept constant and any 
external noise kept to a minimum to prevent distraction. At the assessment the participants were given a full verbal 
explanation of the testing procedure by the co-researcher (Hannah Dollings) and provided with an information sheet which 
clearly set out the purpose of the study (Appendix 11.7). Those willing to participate in the study were asked to sign and 
date the consent form (Appendix 11.8). Participants were required to expose their shoulders with male participants 
removing their shirts and female participants wearing vest tops. They were all asked to remove their shoes and socks.  
 
Demographic data and subjective history information including height, weight, age, hand dominance, occupation and 
current sporting activities were recorded. Each participant was screened for any shoulder pathology using Neers test, 
Hawkin’s and Kennedy, resisted shoulder external rotation and palpation of the greater tuberoisity (Litaker, Pioro et al. 
2000, Hegedus, Goode et al. 2008).  
 
Each participant’s shoulder range of motion was measured followed by their shoulder strength in each data collection 
phase. A computer generated randomisation sequence determined which shoulder was tested first for the participant and 
which examiner tested first. There was a fifteen minute break between each test each testing sequence taking 
approximately twenty five minutes in duration. 
 
The break between testing sequences served to minimize examiner bias and the recollection of any previous 
measurements taken. The data collection sequencing was organised as follows: participant one measured by examiner A 
(first data collection phase for examiner A), simultaneously participant two measured by examiner B (first data collection 
phase for examiner B); fifteen minute break; participant one measured by examiner B (first data collection phase for 
examiner B), simultaneously participant two measured by examiner A (first data collection phase for examiner A); fifteen 
minute break: participant one measured by examiner A (second data collection phase for examiner A), simultaneously 
participant two measured by examiner B (second data collection phase for examiner B); fifteen minute break, participant 
one measured by examiner B (second data collection phase for examiner B), simultaneously participant two measured by 
examiner A (second data collection phase for examiner A). This process continued for all the participants. 
 
5.1.6.4 Shoulder range of motion assessment  
Four physiological shoulder movements were measured in a consistent order, flexion, abduction, external rotation the 
functional movement of ‘hand behind back’, and were measured in two separate occasions on both shoulders of each 
participant by each of the two examiners. All the movements were measured in standing and followed a similar 
methodology (for flexion, abduction and external rotation) as described by Valentine and Lewis (2006). The participants 
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were asked to assume ‘a comfortable and natural standing position’. They were asked to gently flex and extend their head 
and to stop in a position which felt natural and comfortable and to flex and extend their shoulders and again stop in a 
position which felt natural and comfortable. Finally they were invited to take a breath and breathe out and adopt a 
standing posture which felt natural and comfortable.  
 
The upper limb joint positions, placement of the instruments and tester position are detailed in Table 5.4. The tests were 
all conducted bilaterally. Each participant performed the movement three times and the examiner verbally relayed the 
measurements to an independent observer who recorded each set of measurements. The mean of the three values was 
used for data analysis, having been found more reliable than a single measure (Dollings, Sandford et al. 2011). The 
abduction and flexion measurements were recorded in degrees and the external rotation and hand behind back in 
centimetres and also anatomical landmarks for the hand behind back measurement.  
 
Table 5.2 Upper limb joint positions, placement of measuring instruments and movements 
 
Movement Inclinometer placement/ Tape 
measure placement 
Movement Position of investigator 
Shoulder flexion Proximal end of inclinometer 
placed at deltoid insertion on 
anterior aspect of upper arm 
along shaft of humerus.   
With elbow extended, 
participants were asked to raise 
their arm up in front of them 
leading with their thumb. In 
sagittal plan 
Lateral to participant 
Shoulder abduction Proximal end of inclinometer 
placed at deltoid insertion on 
lateral aspect of upper arm 
along shaft of humerus.   
Elbow extended, participants 
were asked to raise their arm 
out to the side and up, leading 
with their thumb. In 45° off 
sagittal and frontal planes 
Lateral to participant. 
External rotation  Measurement taken from radial 
styloid to umbilicus. 
Elbow by the side of the body, 
flexed to 90° with the forearm 
in neutral. Participants were 
asked to ER until end of range. 
In frontal plane 
In front of participant 
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Hand behind back Measurement taken from C7 to 
radial border of the nail fold of 
the thumb.   
Anatomical landmark also 
noted.  
Shoulder internal rotation and 
elbow flexion, taking the hand 
as high as possible behind the 
participants back, leading with 
the thumb. 
Behind participant 
Legend: C7= 7th cervical vertebrae, ER= external rotation 
5.1.6.5 Shoulder strength assessment 
Participants were asked to assume a relaxed sitting posture and relax their upper limbs. The assessment protocol included testing 
seven different strength measurements; shoulder abduction, flexion, full can test and empty can test, external and internal 
rotation and elbow flexion. To ensure that the joint positions listed in the protocol were adhered to, the shoulder and elbow 
positions were measured using the inclinometer (Green, Buchbinder et al. 1998, Valentine and Lewis 2006). The upper limb joint 
positions, placement of the instruments and tester position are detailed in Table 5.3. The tests were all conducted bilaterally.  
 
The concave testing pad for the JTech PowerTrack™ II Commander hand-held dynamometer (HHD) was selected for use in 
the investigation as it conformed to the contours of the forearm and was considered to be more comfortable for the 
participants. When pressure is placed on the testing pad the force is calculated and displayed in either pounds or Newton. 
The two PowerTrack™ II Commander HHDs used in the investigation were factory calibrated and automatically calibrated 
when they are switched on. The two HHDs were calibrated and checked for accuracy by the medical devices department at 
St Thomas’ Hospital, London, UK for accuracy. Each participant was tested with the same HHD.  
 
The tests were performed as ‘make’ tests (i.e. a maximal contraction exerted against a stationary dynamometer) and this was 
repeated three times with a five second rest between each contraction. A stopwatch was used to time the five second rest and 
also to ensure each isometric contraction lasted for five seconds. The testing was then repeated by the same investigator on the 
contra lateral shoulder. Following both shoulders being tested the participant had a break of 15 minutes. The testing procedure 
was then completed on both shoulders by the second investigator. All measurements were recorded in pounds. The order of 
investigators and shoulder testing were randomised by a computer generated randomisation chart.  
 
Standardised instructions were read out to each participant during each isometric contraction: “Hold it there, don’t let me 
move you (two seconds), now push as hard as you can, keep pushing, keep pushing and relax (three seconds)” (Sisto and 
Dyson-Hudson 2007). The investigators provided resistance with their dominant right hand. The muscle force generated 
during each test and displayed in pounds on the console was documented by an independent observer. The investigators 
and subjects were blinded to the measurements throughout. The observer also monitored the time taken between the 
tests. 
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Table 5.3 Detailing the position and resistance applied for each strength test 
Muscle test Inclinometer placement Testing position of limb Body part 
stabilised 
HDD 
placement 
Investigator 
position 
Direction of force  
Shoulder 
abduction 
Proximal end of inclinometer 
placed at deltoid insertion on 
lateral aspect of upper arm 
along shaft of humerus.   
Elbow extension, shoulder 
10° abduction 
Medial 
epicondyle 
Lateral aspect 
of humerus, 
just proximal 
to the elbow 
Lateral to 
subject, stride 
standing. 
Medially directed 
force, 
perpendicular to 
limb. 
Shoulder 
flexion 
Proximal end of inclinometer 
placed at deltoid insertion on 
anterior aspect of upper arm 
along shaft of humerus.   
Elbow extension, shoulder 
10° flexion 
Posterior elbow Anterior 
aspect of 
humerus, just 
proximal to 
the elbow 
Anterior to 
subject, stride 
standing. 
Anterior to 
posterior force, 
perpendicular to 
limb. 
Full can test Proximal end of inclinometer 
placed at deltoid insertion on 
anterior aspect of upper arm 
along shaft of humerus.   
Elbow extension, upper 
limb 90° elevation in 
scapular plane, forearm 
pronated with upper limb 
internally rotated. 
Anterior elbow Volar aspect of 
the forearm 
just proximal 
to volar wrist 
crease 
Lateral and 
posterior to 
limb 
Downward force, 
perpendicular to 
limb.   
Empty can 
test 
Proximal part of inclinometer 
placed at deltoid insertion on 
anterior aspect of upper arm 
along shaft of humerus.   
Elbow extension, upper 
limb 90° elevation in 
scapular plane, forearm 
supinated with upper limb 
externally rotated. 
Posterior elbow Dorsal aspect 
of the forearm 
just proximal 
to dorsal wrist 
crease  
Lateral and 
posterior to 
limb 
Downward force, 
perpendicular to 
limb.   
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Muscle test Inclinometer placement Testing position of limb Body part 
stabilised 
HDD 
placement 
Investigator 
position 
Direction of force  
Shoulder 
external 
rotation 
Distal part of inclinometer 
placed at lateral wrist crease 
along radius 
Upper arm in a neutral 
position at trunk, elbow 
flexed to 90°, forearm in a 
neutral position so palm 
facing inwards 
Medial wrist Dorsal aspect 
of forearm 
with distal 
part of pad at 
dorsal wrist 
crease 
Lateral to 
subject stride 
standing 
Medially directed 
force, 
perpendicular to 
limb. 
Shoulder 
internal 
rotation 
Distal part of inclinometer 
placed at lateral wrist crease 
along radius 
Upper arm in a neutral 
position at trunk, elbow 
flexed to 90°, forearm in a 
neutral position so palm 
facing inwards 
Medial wrist Volar aspect of 
forearm with 
distal part of 
pad at volar 
wrist crease 
Medial to 
limb, lateral to 
subject, stride 
standing 
Laterally directed 
force, 
perpendicular to 
limb. 
Elbow 
flexion 
Distal part of inclinometer 
placed at lateral wrist crease 
along radius 
Upper arm in a neutral 
position at trunk, elbow 
flexed to 90°, forearm 
supinated 
Posterior wrist Volar aspect of 
forearm with 
distal part of 
pad at volar 
wrist crease 
Lateral to 
subject 
Downward force, 
perpendicular to 
limb. 
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Figure 5.1 Inclinometer 
 
Figure 5.2 The JTech Power Track  II Commander HHD 
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5.1.7  Methods for Chapter 7; Shoulder pain and the use of nutritional supplements: A 
questionnaire based investigation 
A descriptive cross sectional survey methodology was employed using paper based questionnaire 
booklets (Appendix 11.12). Questionnaires are the most commonly used tool in survey research 
(Shaughnessy, Zechmeister et al. 2011) and it was felt that this was the best method available to 
collect the required data. A paper based questionnaire was selected to ensure ease of completion 
at the eight different research sites where on-line surveys might have been more difficult and 
introduced a bias in that only those proficient with computer use might have taken part. It also 
importantly allowed participants to feel under no obligation to participate as it was their decision 
to return the questionnaire or not. This process also allowed the participants to complete the 
questionnaire at a location of their choice and taking as much time as they required. 
 
Figure 5.3 Positioning of participant on plinth in a relaxed seated posture for the strength assessment. 
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5.1.7.1 Data collection  
The data collection period spanned six months from September 2011 until February 2012. 
Potential participants with a diagnosis of shoulder pain were invited to participate in the study by 
their treating physiotherapist. Those who expressed an interest in taking part were given a 
participant information sheet to read and were encouraged to discuss with their physiotherapist 
as well as family or friends (Appendix 11.10) to help inform the decision whether to participate or 
not. Participants were aware that their decision to participate or not would not influence the 
treatment that they would receive. On the next visit to the clinic (on average one week later) 
those who were still interested in taking part completed a witnessed informed consent document 
(Appendix 11.11). They were then given the set of questionnaires in a booklet form (Appendix 
11.12). The questionnaire booklet took approximately 30 minutes to complete and the 
participants were informed they could complete the forms before or after their clinic visit or if 
they preferred, at home. Once the questionnaire was completed it was placed in an envelope that 
was provided with the booklet and securely sealed. There was no identifiable personal 
information contained in the questionnaires or the envelopes. Subjects were required to 
complete these forms on one occasion only. The participant then returned the enveloped to their 
treating physiotherapist and this marked the end of their involvement in the study.  
 
Each questionnaire was coded for the site where the participant was recruited. Once the set of 
questionnaires had been completed at each site or the end of data collection period (end 
February 2011), whichever was sooner, the completed anonymised questionnaires were returned 
by secure special delivery (Royal Mail) to JL (co-supervisor) at an NHS site. The booklets were then 
securely stored in a locked cabinet in a locked office. 
 
5.1.8 Methods for chapter 8; the efficacy of long-chain omega-3 PUFAs and exercise in the 
treatment of rotator cuff tendinopathy:  a randomised controlled trial. 
5.1.8.1 Study design  
A two arm parallel randomised placebo-controlled trial was chosen as the design for this study as 
the longevity of the study and the prolonged washout period required would make a cross over 
design impractical. Participants were randomly allocated to treatment.  
 
The treatment allocation (Group A or Group B) was effected by Professor Tom Sanders, Kings 
College London (primary supervisor) who was not involved in the data collection component of 
the study. The allocation of treatment (A or B) was held by Professor Sanders and was concealed 
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until the study was completed and data for the primary and secondary outcomes had been 
entered into the statistical database.  
 
5.1.8.2 Controlling bias 
Bias in research investigations is defined as an inclination towards prejudiced consideration of a 
research question and undermines the finding and conclusions of a research investigation 
(Pannucci and Wilkins 2010). Bias is not a dichotomous entity, it is present to some extent in 
every investigation (Pannucci and Wilkins 2010) and can occur at any point in the research 
process.  
 
There are two types of bias;  
 Random bias where results are due to sampling variability or measurement error. This is 
most commonly detected and corrected with statistical analysis (Sica 2006) 
 Systemic bias where reproducible errors and inaccuracies produce false values and distort 
the investigation. This is very difficult to determine as it is down largely to human nature 
(Adebiyi 2010). 
 
Sources of bias include, flawed study design, selection bias, measurement bias, intervention bias 
and reporting bias (Sica 2006). In order to mitigate against these potential sources of bias, the 
following was methods were utilized. 
 
 Randomisation: refers to the process of assigning participants to trial treatment groups. 
This helps ensure that the treatment groups will be comparable for both known and 
unknown variables (Beam 2002). Within this study a computer generated unpredictable 
randomisation code was created prior to the study starting and was not broken until all 
data analysis was complete. It was kept sealed and locked in a cabinet within Professor 
Sander’s office at Kings College London.  
 
 Allocation concealment: refers to the technique used to ensure that the randomisation 
sequence is applied without the person assigning the participants to the treatment groups 
knowing what the next treatment would be (Dettori 2010). In this study the person 
assigning the participant study code and therefore treatment group had no knowledge of 
which supplements (the placebo or long-chain omega-3 PUFA) were in the sealed opaque 
containers which bore the participant number on them and numbers were given 
sequentially to participants. It would have been impossible for the person assigning to the 
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treatment groups to know which supplement corresponded with which participant 
number. 
 
 Placebo control: refers to the use of a sham treatment that is designed to have no real 
effect as a comparator to the active treatment (Wang 2003). In this study a placebo 
supplement which simulated the long-chain omega-3 PUFA in every way other than the 
ingredient long-chain omega-3 PUFAs was used.  
 
 Blinding: refers to the process of concealing the assigned treatment from those 
participants in the study (participant blinding), from those involved in their treatment 
(treater or care giver blinding) and from those collecting, managing and analysing the 
data (assessor blinding) so that the knowledge of treatment group does not influence 
their practice or behaviour (Day and Altman 2000). Adequate blinding of all three 
categories (participant, treater and assessor blinding) results in a double-blind trial. 
Blinding as carried out in the following ways within this trial: 
 
 Participant blinding; participants were blinded to the treatment group they were 
allocated. The placebo and long-chain omega-3 PUFA supplements looked the same in 
appearance and both were flavoured with peppermint to try and prevent any fish odour 
from the long-chain omega-3 PUFA supplements.  
 
 Treater or care-giver blinding; the physiotherapists in the shoulder exercise class were 
aware that the participant was on the trial but were not aware of their study number nor 
which supplement they were taking.  
 
 Assessor blinding; the assessors were unaware which participant numbers corresponded 
to which supplement until data analysis had been completed.  
 Intention to treat analysis includes all the participants of a trial in the treatment group to 
which they were assigned at the start of the trial. It is regardless of their adherence to the 
treatment, whether they received the assigned treatment or not and regardless of 
whether they withdrew from the study. (Gupta 2011). The concept is summed up by 
“once randomised, always analysed” (Wertz 1995). The data within this study was 
analysed on an intention to treat basis. 
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5.1.8.3 Outcome points 
Outcomes were measured at baseline, after the intervention (two months), at three months, six 
months and one year. The study took place between 18/12/2008 and 18/1/2013. The primary 
outcome point was at two months, which corresponded with the end of treatment intervention 
and aimed to detect the combined change in outcome measures corresponding with the 
completion of the shoulder exercise class and the supplements. The three and six month 
assessment points were included to assess any changes following cessation of the intervention. 
The one year assessment marked the end of each participant’s involvement in the study and 
represented the longevity outcome. Follow up at one year was deemed necessary to provide 
adequate follow up time for assess outcomes in patients with RC tendinopathy. This time point 
has been used in other investigations (Haahr, Ostergaard et al. 2005, Kukkonen, Joukainen et al. 
2014, Littlewood, Bateman et al. 2016). 
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Table 5.4 data collected at each time point 
Data Collected Baseline  2 months  3 months  6 months 12 months 
Demographic information •#     
Symptomatic shoulder  •#     
Dominance •#     
Weight (kg) •#    • 
Height (cm) •#    • 
Duration of symptoms •#     
Onset: Trauma / non-traumatic •#     
Nature of symptoms: Constant pain / Pain only with movement •#     
Night pain: Yes / No •#     
Possible to sleep on painful side: Yes / No •#     
Analgesic use •#     
Smoking: No / Yes (if yes, how many?) •#     
Neer’s impingement sign •#     
Hawkins impingement test •#     
Palpation of greater tuberoisity •#     
Bilateral shoulder ROM with NRS: Flexion, Abduction, ER, Hand behind back • • • *• *• 
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Bilateral shoulder strength: Abduction, ER & IR, Elbow flexion, ‘Full can’ test, 
‘Empty can’ test 
• • • • • 
Disability scores (OSS and SPADI) • • • • • 
NRS  • • • • • 
Patient specific functional score •     
Quality of life measures (SF 36 and EQ5D3L) • • • •  
Global Impression of Change  • • • • 
Blood tests • •    
4 day food diary  •    • 
Legend: NRS (Numerical Rating Scale), ROM (range of motion), ER (external rotation),  IR (internal rotation), OSS (Oxford shoulder score), SPADI (shoulder pain and 
disability index), SF 36 (short form 36), EQ5D3L (EuroQol 5D3L) • (information collected at specified timepoint) #=pre randomisation
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5.1.8.4 Interventions  
5.1.8.4.1 Supplements  
The active treatment used in this trial MaxEPA (Seven Seas Ltd, Hull, UK, MHRA product 
licence 19488/0353). These capsules were provided as opaque gelatine coated capsules, oval 
in shape and brown tan in colour to disguise the content, containing 170mg EPA, 115mg DHA, 
2 units/g tocopherols acetate (vitamin E). The placebo supplement looked identical and 
contained a mixed inert oil (olive oil BP containing the same amount of vitamin E and 
antioxidants as the active treatment) and did not contain any EPA or DHA with the EPA and 
DHA being replaced by oleic acid. Participants in both groups were asked to take nine soft 
shell capsules per day for a total of two months. The capsules were supplied in identical plain 
white plastics tubs which had a tamper proof seal. Each participant was supplied with three 
tubs of capsules containing 201 capsules per tub, 603 in total. The participants were 
requested to return any unused capsules at the end of the study.  
 
The participants were provided with verbal and written instructions on how to take the 
capsules. It was suggested that they took the capsules three times a day with breakfast, lunch 
and dinner to aid adherence to the supplement regime. Patients were advised however, that 
they could take them in any number, up to nine at one time, and at any time of the day but 
advised to always take them with a drink, during or just after a meal, in order to aid their 
digestion and minimise any possible side effects.  
 
A label on the outside of the container reminded the participants that nine capsules should be 
taken per day. The label also provided contact details for the chief investigator should any 
participant have any concerns or questions. They were instructed not to store the capsules in 
direct sunlight or above 25°C to prevent any oxidation of the oils.  
 
The decision to use MaxEPA supplements was based on the availability of a matched placebo 
supplement. MaxEPA is also available to prescribe and is featured in the British National 
Formulary 55th edition, 2008 (Joint, Formulary et al. 2008).  
 
The dose level of 2.6g/d was based on similar studies showing beneficial effects on 
inflammatory musculoskeletal disorders at similar doses (discussed in Chapter 4). 
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5.1.8.5 Duration  
Eight weeks was selected as the supplement intervention duration period in this study. This 
time frame was chosen as it has been reported that it takes eight to twelve weeks until the 
benefits of taking the supplements are noticed in clinical outcomes (Fortin, Lew et al. 1995, 
James and Cleland 1997).  
 
Studies also suggest that an intake of four weeks might be sufficient to effect an anti-
inflammatory change (Healy, Wallace et al. 2000, Yaqoob, Pala et al. 2000). Maximal increases 
in EPA into the phospholipids were observed in both studies four weeks after starting 
supplementation. Further evidence to support this decision is presented in Chapter 4. 
 
The participants in this study attended a structured shoulder class for eight weeks. In order to 
aid adherence and avoid unnecessary follow ups it was decided that this too should be the 
duration of supplementation, given that the optimal duration of supplementation is currently 
unknown. 
 
5.1.8.6 Quality assurance 
A sample of the remaining capsules was returned to Seven Seas after the study had finished 
for analysis to confirm that they were MaxEPA and placebo capsules and to ensure that no 
oxidation of the oils had taken place. The laboratory results confirmed that the capsules were 
as stated and that the levels of EPA and DHA in the MaxEPA capsules were as expected. The 
results also confirmed that no oxidation of the oils had taken place (Appendix 11.17). 
 
5.1.8.7 Dietary Intake  
A four day food diary was used to assess dietary intake at baseline and 12 months (Appendix 
11.16). These were then coded and analysed using NetWISP version 3.0 (Tinuviel Software, 
UK) by the CI. 
 
5.1.8.8 Rotator Cuff tendinopathy exercise group 
Participants were asked to attend the RC exercise group once a week for a period of eight 
weeks (eight classes in total). The RC exercise group involved education and advice and a ten 
station circuit. Each class was approximately one hour in duration. 
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5.1.8.8.1 Quality assurance and standardisation of exercise group between sites 
In order to standardise this intervention the same exercise group was run in each of the four 
participating sites. Standardised exercise pictures and booklets to follow were produced 
(Appendix 11.19) and it was ensured that the exercise classes were run with a choice of 
timings to enable ease of attendance and maximise recruitment.  
 
5.1.8.8.2 Format of rotator cuff exercise group 
The study exercise programme consisted of a ten minute warm up, ten exercises of thirty 
seconds duration, each designed with three levels of progression to accommodate each 
participant’s ability, a ten minute warm down and a ten minute education/advice session. The 
exercises aimed to improve strength of the RC muscles, improve proprioception, and 
encourage the transference of strength from the lower limb to the upper limb. They also 
aimed to improve exercise tolerance. The topics covered during the eight education sessions 
included; shoulder anatomy, pain, pacing and coping with flare ups, benefits of exercise and 
mobilisations, role of diagnosis and imaging, relaxation techniques and questions and answer 
sessions . Classes were run with a maximum of 15 participants and were run with two 
physiotherapists attending and one physiotherapy assistant. One of the exercise stations 
included manual therapy where a physiotherapist would perform manual therapy techniques 
on the study participants. Their techniques typically involved Mulligan Mobilisation with 
Movements (Kachingwe, Phillips et al. 2008, Teys, Bisset et al. 2008, Teys, Bisset et al. 2013) 
and were included to facilitate improvements in shoulder range of motion and function, as 
well as to help reduce pain. 
 
This format of incorporating exercise with education and advice conducted under the 
guidance of a physiotherapist is the recommended best practice treatment approach for RC 
tendinopathy (BMJ 2013). 
 
Participants were also requested to continue their exercise program at home. To facilitate 
this, an exercise booklet was provided (Appendix 11.19). Participants documented in their 
study diaries (Appendix 11.20) how many exercise sessions they managed to complete each 
week and any comments relating to their symptoms, the exercises or the supplements. 
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5.1.8.9 Recruitment of participants 
The study aimed to recruit men and women aged 18 to 80 years, who were referred for 
physiotherapy at one of four physiotherapy departments within the UK NHS.  
 
The four participating physiotherapy departments were: 
 St Thomas’ Nation NHS Trust Hospital, Waterloo, London SE1 
 Guy’s Hospital, London Bridge, London SE1 
 St George’s NHS Trust, Tooting, London SW18 
 Health at the Stowe, Westminster Primary Care Trust / Central London Community 
Healthcare NHS Trust, W2 
All patients referred from general practitioners, extended scope practitioners and medical and 
surgical consultants with a diagnosis of RC tendinopathy at the four participating 
physiotherapy sites were considered for appropriateness to participate. Patients were 
deemed suitable for inclusion in the study if they met all of the inclusion criteria and did not 
fulfil any of the exclusion criteria (Table 5.5) Patients fulfilling the inclusion criteria and 
interested in taking part in the research study were asked by their physiotherapist to read the 
patient information leaflet (Appendix 11.14) and informed that the chief investigator or 
secondary investigator would be in telephone contact in the following week to discuss the 
study in greater depth and answer any questions. During the subsequent telephone 
conversation the screening questions were reassessed, and the study protocol described to 
the potential participant. If the potential participant provided verbal consent to take part in 
the research an appointment was arranged within the Guy’s and St Thomas’ Trust Clinical 
Research facility located at St Thomas’ Hospital, London SE1, to perform screening tests, 
obtain written consent and to conduct the baseline assessment.  
 
Table 5.5 Inclusion and exclusion criteria 
 
Inclusion criteria Exclusion criteria 
1. Unilateral shoulder pain of more than 3 
months duration (anterior &/or antero-
lateral location) 
2. Pain produced or increased during flexion 
&/or abduction &/or external rotation of 
1. Known allergy to fish or fish products. 
2. Unwilling to take fish oils 
3. Currently taking high dose fish oils 
(over 1g daily). 
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the symptomatic shoulder. 
 
4. At least four of the following: 
-positive Neer’s impingement sign 
-positive Hawkins & Kennedy test 
-pain & weakness reproduced on full &/or 
empty can test. 
-pain & weakness on resisted shoulder 
external rotation 
-pain on palpation over greater tuberosity 
of humerus. 
5. Absence of exclusion criteria 
 
4. Diabetes 
5. Pregnancy or breast feeding 
6. Reproduction of shoulder symptoms 
during active cervical spine 
movements 
7. Post traumatic onset of symptoms 
8. Radiographic or clinical evidence of 
shoulder instability (sulcus, 
anterior/posterior draw, relocation 
test, apprehension test). 
 
 
 
5.1.8.9.1 Justification for inclusion criteria  
The accurate diagnosis of RC tendinopathy is recognised to be problematic (Lewis, McCreesh 
et al. 2015) with special orthopaedic tests having questionable validity and role (Hegedus, 
Goode et al. 2012, Lewis, McCreesh et al. 2015) (see Chapter 3.3.2). However, clinically 
combinations of special orthopaedic tests are used to aid diagnosis, (Somerville, Willits et al. 
2014, van Zuydam, van Rensburg et al. 2015). These include; Neer’s impingement sign, 
Hawkins Impingement test, and palpation of the greater tuberosity. Other similar 
investigations have used these the same diagnostic criteria for RC tendinopathy as those used 
within this study (Ludewig and Borstad 2003, Littlewood and May 2007, Lombardi, Magri et al. 
2008). 
 
5.1.8.9.2 Justification for exclusion criteria 
Known allergy to fish or fish products/unwilling to take fish oils; this is due to the fact that the 
active supplements were derived from fish with no vegetarian option available.  
 
Currently taking high dose fish oils (over 1g daily); this would have meant that the subject may 
have already been taking a ‘therapeutic dose’, thereby possibly negating any potential benefit 
from taking a high dose. 
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Pregnancy or breast feeding; due to possible complications of the high dose long-chain 
omega-3 PUFA crossing the placenta or transferring into the breast milk and ethical 
restrictions.  
 
Reproduction of shoulder symptoms during active cervical spine movements: as this would 
have been indicative of symptoms originating from the cervical spine rather than the RC. Pain 
from the 5th or 6th cervical vertebrae often refers to the shoulder (Carette and Fehlings 2005).  
 
Post traumatic onset of symptoms: this may represent a different patho-aetiology than non-
traumatic tendinopathy (Sørensen, Bak et al. 2007). 
 
Radiographic or clinical evidence of shoulder instability (sulcus, anterior/posterior draw, 
relocation test, apprehension test): this would suggest that the symptoms are originating from 
the shoulder instability rather than RC tendinopathy (Magee 1997). 
 
Conditions such as diabetes and rheumatoid arthritis were excluded because of the known 
adverse effects of the conditions on healing and tendon status and their potential to introduce 
confounding influence on the study findings (Chen, Shapiro et al. 2003, Miranda, Viikari-
Juntura et al. 2005, Pegreffi, Paladini et al. 2011, Titchener, White et al. 2014, Zakaria, Davis et 
al. 2014, Lin, Lin et al. 2015). 
 
Although RC tendinopathy most commonly affects people over the age of 40 years it can 
affect people of all ages (Carr and Harvie 2005) and so men and women from 18 to 80 years 
were recruited into the study.  
 
5.1.9 Participant flow through the investigation 
5.1.9.1 Consent and randomisation 
On attending the first appointment at the clinical research facility the participant’s 
involvement in the study was further discussed and any questions answered before written 
consent (Appendix 11.15) was obtained. Participants were consented into the study by the CI 
or the co researcher (Hannah Dollings). Both researchers had completed good clinical practice 
training and had been qualified as physiotherapists for over 10 years. Once consent had been 
given the participants were assigned a sequential study number. This study number 
corresponded to a container of supplements which had either been filled with supplement A 
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or supplement B. The randomisation of the supplements was computer generated by 
Professor Tom Sanders who kept the code sealed until after all data had been collected and 
entered into data spreadsheets for analysis. This occurred in August 2014.  
 
5.1.10 Outcome measures 
The primary outcome measure was the Oxford Shoulder Score (assessing self-reported 
disability). This has been previously described at the beginning of this chapter. 
The secondary outcome measures are presented in table 5.6. 
 
Table 5.6 Secondary outcome measures 
 
Outcome measures 
 Numerical rating score for pain 
 Shoulder pain and disability index (SPADI) 
 Patient specific functional score (PSFS): a questionnaire used to quantify activity 
limitation and measure functional outcome in areas chosen by the patient 
specifically 
 EuroQol D5-3L (EQ-D5-3L) health questionnaire: a measure of health related 
quality of life 
 Short Form-36 
 Global rating of change 
 Range of glenohumeral range of motion (flexion/abduction/internal and external 
rotation, hand behind back) 
 Shoulder strength (shoulder flexion/abduction/full can and empty can/internal and 
external rotation and biceps strength) 
 
5.1.10.1 Secondary outcome measures selected 
The self-reported disability measure (SPADI), pain measure (NRS), restoration of function 
measure (PSFS), health related quality of life measures (EQ5D-3L and SF36) and global rating 
of change (GROC) have all been described previously in this chapter.  
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In studies investigating RC tendinopathy a reduction in range of motion and strength has been 
consistently reported (Lewis, McCreesh et al. 2015). The assessment method for measuring 
ROM and strength by both the CI and co-researcher demonstrated excellent clinical reliability 
as shown in the reliability study presented in Chapter 6.  
 
Impairment measures are commonly used in clinical practice and therefore they were 
included in the battery of assessments for this study. However it is noted that they generally 
have a low responsiveness (Croft, Pope et al. 1994, Terwee, de Winter et al. 2005) which limits 
their ability to detect clinically important change in a patient’s health over time.  
 
5.1.10.2 Calibration of measuring devices 
The accuracy of the tape measure was checked monthly, comparing 1cm on the tape to 1cm 
on a metal ruler. To ensure accuracy of the inclinometer the CI calibrated the inclinometer 
scale (displayed in 2° increments) against an electrical inclinometer (Saunders Digital 
Inclinometer; the Saunders Group, Chaska, Minnesota, USA). The JTech Power Track II 
Commander was calibrated according to the manufacturer’s instructions by the biomedical 
physics department at St Thomas’ NHS Trust on an annual basis.  
 
5.1.10.3 Format and standardisation of assessments 
The baseline evaluation included history taking, impairment measures, and completion of 
outcome questionnaires, weight, height and measurement of waist circumference. Blood 
samples were taken by one of the two clinical research facility nurses (registered nurses).  
 
A 5ml sample was taken and collected in an EDTA and plasma tube, processed and frozen at -
80°C for analysis at the end of the study. In order to ensure standardisation of this assessment 
between participants and over time, a specific assessment order was adhered to: 
1. Study, including involvement required by the participant was verbally reviewed and 
any questions answered. 
2. Screening tests for RC tendinopathy performed; (Neer impingement sign (Neer 1983), 
Hawkins-Kennedy impingement test (Hawkins and Kennedy 1980), palpation of 
greater tuberosity (Xiao, Cui et al. 2010) and pain on resisted shoulder abduction and 
/or external rotation) (O'Kane and Toresdahl 2014). Absence of exclusion criteria 
checked. 
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3. Written consent obtained 
4. Study participant number issued 
5. Venous blood sample taken from the median cubital or cephalic veins at the elbow by 
the clinical research facility nurse.  
6. Weight, height and waist circumference measured as detailed above in section 5.2.3. 
7. Subjective history taken (Appendix 11.18) 
8. Impairment measures in the following order; ROM for shoulder flexion, abduction, 
external rotation, hand behind back, strength testing (make tests) for shoulder flexion, 
abduction, empty can and full can test positions, internal and external rotation and 
elbow flexion. The positions and method used are those described in the reliability 
range of motion study undertaken by the CI and co researcher and presented in Table 
5.2. 
9. Participant completed outcome measures in the following order; OSS, SPADI, PSFS, 
EQD5, SF36. 
10. Questionnaires checked by investigator for completeness. 
11. Instruction on completion of the diary sheet and the four day food diary. 
 
12. Three containers of capsules and instructions on how to take them, issued. 
13. Follow up appointments arranged and a CI contact details card given. 
 
The participants were advised as to the possible side effects of the supplements, that 
included; stomach upset and dark stools, and were advised to contact the CI or co-researcher 
if the experienced any adverse effects or concerns. Participants were asked to document in 
their exercise diary how many capsules they had taken each day, if there were any side 
effects, how much exercise they had carried out or if they had attended the exercise group 
and to note any other comments they wishes to share. 
 
Two month assessment- Immediately post treatment  
The CI (or co-researcher in the absence of CI) reassessed the participants following the 
completion of the supplements and exercise class. This assessment took place approximately 
eight weeks from baseline. The assessment involved the same questionnaires and physical 
tests as baseline and blood tests. In addition, the participants were asked to rate any 
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improvement or regression as a percentage improvement or worsening from baseline. The 
participants were asked to hand in their completed exercise and supplement diary sheets, 
their completed four day food dairy if they had not already returned it by post and any unused 
capsules. Participants were asked to continue their exercises as instructed following the 
exercise class. 
 
Three and six month assessments 
Participants were assessed at three and six months by the CI (or co-researcher) using the same 
questionnaires and physical tests as in assessment at two months. All outcome measures 
assessed at baseline were completed. No blood tests were taken at these assessments. In 
addition, participants were also asked if they were still doing their exercises and also the 
frequency, nature and duration of exercises. 
 
Twelve month assessment 
One year assessment occurred at approximately one year from baseline. This assessment 
replicated the three and six month assessments. In addition, the participants were sent a 4 
day food dairy a week prior to their appointment for assessment which they were asked to 
return at the time of their final assessment. At the end of the one year follow up assessment 
the participant’s involvement in the study was finished.  
 
5.1.10.4 Observation of the assessment of the participants  
Matt Morrisey PhD (supervisor prior to leaving Kings College London, London, UK) and Jeremy 
Lewis PhD (co-supervisor) observed the CI and the co-researcher during an initial participant 
assessment. This was to ensure quality and consistency of the assessment procedures and 
that the methods used to obtain consent were considerate and appropriate.  
 
5.1.10.5 Ascertaining adherence to the intervention 
Plasma fatty acid analysis, capsules returned and self-report numbers of capsules taken were 
all used as measures of adherence with the supplement intervention. Attendance at the 
exercise class and documentation of exercises undertaken gave an indication regarding the 
adherence with the exercise intervention. Excellent attendance was rated as eight classes 
attended out of eight, good attendance as six or seven classes, satisfactory attendance as four 
or five classes and poor attendance as three or fewer classes attended. 
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5.1.10.5.1 Markers of compliance to the supplement intervention 
Blood plasma levels of EPA and DHA were measured using gas chromotagography. The 
relative proportions of fatty acids within the plasma total lipids were evaluated using a one-
step direct transesterification procedure (described below). Following supplementation with 
DHA and EPA a corresponding rise in levels of the DHA and EPA in the plasma total lipids were 
expected (Sanders, Lewis et al. 2006). This has been in used as a measure of compliance to 
long-chain omega-3 PUFA intervention in other studies (Sanders, Hall et al. 2011, Hall, Hay et 
al. 2013). 
 
Any unused capsules were returned and counted to give a returned pill count. This was then 
subtracted from the number of capsules given (603) and the number of capsules consumed by 
the participant calculated. Pill count is another commonly used measure of compliance and 
has been recommended as the standard for assessing medication adherence in clinical trials 
and practice (Lee, Grace et al. 2007). The tally of the number of capsules taken recorded daily 
in the study diary (Appendix 11.20) was also noted.  
 
5.1.10.5.1.1 Venepuncture 
Blood samples at baseline and two months at the end of intervention were obtained following 
fasting (nothing but water) from 10pm the previous evening. All blood samples were 
undertaken by a trained phlebotomist working within the clinical research facility. As per 
facility protocol, thorough hand washing procedures were performed prior to each blood 
sample being taken. A tourniquet was applied around the upper arm and tightened. An 
antiseptic swab was then used to clean the ante brachial fossa where the blood was to be 
taken from. The vacutainer method (Becton-Dickinson, Oxford, UK OX4 4DQ) was used. The 
needle was screwed into the disposable vacutainer holder, unsheathing it, and inserting it into 
the median cubital or cephalic vein with minimal pressure. The vacutainer was the attached 
and the tourniquet released. The samples were collected in EDTA anticoagulated tubes.  
 
5.1.10.5.1.2 Sample processing  
After collection the vacutainers containing the blood were inverted ten times. They were kept 
at room temperature and allowed to stand for a minimum of 30 minutes, but not more than 
one hour, to allow for clotting before centrifugation. They underwent centrifugation for 15 
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minutes at 1300 revolutions per minute (RPM) at 4°C. The plasma and serum were then 
pippeted into two x 1ml aliquots for storage.  
 
5.1.10.5.1.3 Coding and storage of samples 
The vacutainers were all labelled prior to each visit with the subject ID, initials and date of 
birth using a permanent marker. Eppendorf tubes (2.0ml everyday SC Microtube Skirt NS) 
were labelled prior to each visit using permanent marker. The format of the labelling is 
depicted in Figure 5.4. 
 
Figure 5.4 Labelling used on Ependorf tubes 
 
CI Study name ID number and initials visit 
FS Sh 01/ XX 1 
Test:       Serum/plasma 
Date:    10.10.2010                                                                                                                                  
 
Legend: CI (chief investigator), ID (Identification), FS (Fiona Sandford), SH (shoulder) visit 1 states visit 
they were attending –pre or post intervention blood sample.  
 
Cryovial boxes were used to store the samples in the -80°C freezers at Kings College London 
Franklin Wilkins building, waterloo campus or the clinical research facility. Several 
participants’ samples were stored in one box. Each box was clearly labelled with the CI’s 
name, Kings College London, the study name, the ethics reference, the type of samples, the 
date of the initial and end sample collection and the contact number of the CI. The samples 
were placed in the -80°C freezers no more than 10 hours following collection and kept in a 4° 
refrigerator until point of freezing. Ten hours at 4° is considered an acceptable time frame as 
whole blood stored at room temperature for seven days showed only very minimal changes in 
a wide range of analytes, including lipids (Clark, Youngman et al. 2003). Similarly analyte 
stability has been found to be preserved for up to five years when stored at -80°C (Clark, 
Youngman et al. 2003). The storage of samples at -70°C was found to be preferable than at -
20°C with regards to analyte stability (Cray, Rodriguez et al. 2009). 
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5.1.10.5.1.4 Analytical methods 
A one-step direct transesterification procedure was used to determine the fatty acid 
composition of the plasma samples collected. This method was adapted from the one 
described by Lepage and Roy (1986) and is the method used commonly for this type of 
analysis within the Nutritional Sciences Laboratory at Kings College London, London UK 
(Lepage and Roy 1986). The principal behind the method is that total lipids are transesterified 
with hydrogen chloride as a catalyst in a methanol:toluene solution. Gas chromatography, in 
the presence of a 15:0 internal standard, is then used to perform the fatty acid methyl ester 
analysis. The reagent is produced by adding acetyl chloride to methanol. An internal standard 
is 50mg pentadecanoic acid/ml, methanol:toluene (4:1 by volume). 
 
Table 5.7 Materials used, and their suppliers, for fatty acid extraction. 
 
Item  Supplier  
Toluene AR  BDH Merck Ltd, Poole, Dorset UK 
Hexane Puriss  BDH Merck Ltd, Poole, Dorset UK 
Methanol AR  BDH Merck Ltd, Poole, Dorset UK 
Acetyl chloride AR  BDH Merck Ltd, Poole, Dorset UK 
6% potassium carbonate in distilled water  BDH Merck Ltd, Poole, Dorset UK 
Internal standard: pentadecanoic acid  Sigma, BDH Merck Ltd, Poole, Dorset UK 
External standards: Sigma 189-1, 189-
2,189.3  
Sigma, BDH Merck Ltd, Poole, Dorset UK 
MaxEPA  Seven Seas Ltd, Hull, UK  
BPX70 column (25 m X 220 μm X 0.25 μm)  SGE Analytic Science, 
 Milton Keynes  
Gas chromatography  Agilent 7890A GC;  
Agilent Technologies  
Legend: AR= authentic reference, μm=micrometre, GC=gas chromatography. MaxEPA (PUFA 
supplement, seven seas). Internal standard = 50mg pentadecanoic acid/ml, methanol:toluene 
(4:1 by volume). 
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The internal standard was prepared by adding 5ml of 1mg/ml internal standard in methanol to 
75ml methanol. Toluene was then added to this solution to make up to a total of 100ml. The 
solution was chilled on ice in a conical flask and acetyl chloride (10ml) was added drop-wise 
whilst swirling the flask in a fume cupboard. The reagent was cooled before using. It remained 
stable for two weeks at room temperature.  
 
Fatty acid methyl ester standards of Sigma 189-1, 189-2 and 189-3 dissolved in hexane 
1mg/ml and fatty acid methyl ester of MaxEPA as a reference standard for DHA and EPA 
dissolved in hexane 1mg/1ml. 
 
Sample preparation: 
Samples were prepared by pipetting 0.1ml plasma into a tube fitted with a Teflon lined screw 
cap (16x25mm) using a positive displacement pipette. Then 2.2ml of internal standard 
solution was added to the tube. The tube was then sealed and heated in a water bath for two 
hours at 60°C. Once cooled, 5ml of 6% potassium carbonate was added and the sample was 
centrifuged at 2500rpm for 10 minutes. The upper phase was then transferred into an amber 
vial for gas chromatography analysis. 
 
Fatty acid methyl esters (FAMEs) were separated on an Agilent 7890 Gas Chromatograph (GC) 
(Agilent Technologies, Santa Clara, CA, USA) fitted with a flame ionization detector with a 25m 
BPX70 column (SGE Analytical Science, Milton Keynes, UK). In order to establish the identities 
of the GC separated FAMEs and hence the parent fatty acids, the chromatographic peak 
retention times of the sample chromatograms were compared with those obtained from the 
analysis of authentic reference standards (FAME mixtures: 189-1, 189-2, 189-3 spanning the 
long-chain class: 14:0-22:6n-3) run under identical GC conditions. Giving the elution order of 
the FAMEs as supplied by the manufacturer, the chromatographic peaks were labelled 
through peak retention time matching. For quantitative analysis, the time integrated flame 
ionization detector (FID) responses (peak areas) for the sample chromatograms were 
tabulated for each FAME species. The proportion in percentage terms by weight of each fatty 
acid was calculated by expressing the peak area of each species as a percentage of the total 
area by summation (excluding the 15:0 internal standard reference peak). 
 
5.1.10.5.1.5 Calculations: 
The fatty acid composition was calculated as per the equation below:  
104 
 
Fatty acid composition = area of fatty acid interest  
                                        (total area- area of internal standard) 
 
Table 5.8 Operating conditions of gas chromatography (Algilent 7890A) 
 
Injector  
Type  Front injector  
Injection volume  5ml  
Inlet detector  
Injection mode  Split 50:1  
Inlet temperature  240°C  
Gas  
Carrier gas  Hydrogen at 1 ml/minute  
Make up gas  Nitrogen  
Column  
Column  BPX 70 SGE (25 m x 220 m x 0.25m).  
Oven  
Temperature/programme  Initial temperature 160°C, held for 4 min, then 
ramped 10°C/min for 10 min to 200°C, then 
40°C/min for 10 min to 240°C.  
Run time  29 min  
Detector  
Type  Front Ionisation Detector (FID)  
Detector temperature  250°C  
Data acquisition rate:  20Hz  
 
An example of the GC trace can be seen below showing the peaks of the different fatty acids 
identified by retention time with standards of known composition obtained from Sigma 
Aldrich (BDH, Poole, Dorset).  
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Figure 5.5 Gas chromatogram trace of fatty acid methyl esters from a plasma sample including 
the internal standard 15:00 methyl ester. 
 
 
 
5.1.10.6 Adverse events 
Adverse events were defined as side effects due to taking the supplements or the exercise 
therapy which required medical intervention.  
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5.1.11 Methods for Chapter 9: Exploring barriers, motivators and enablers to nutritional 
supplement use and exercise in rotator cuff tendinopathy: a qualitative study. 
 
5.1.11.1 Study design 
Qualitative methods were employed to explore factors affecting adherence to a prescribed 
exercise programme and with taking the provided supplements. They were considered the 
most appropriate method to use to yield the breadth of information required (Patton 2002). 
Qualitative research is exploratory by nature, used to further understand and discover 
people’s beliefs, attitudes and behaviour (Barker, Pistrang et al. 2002). It is used to understand 
the reasons behind decisions and behaviours. It uses unstructured information gathered 
through a variety of methods such as focus groups, interviews and survey or correspondence 
(Patton 2002). Smaller sample sizes are generally required in qualitative research than 
quantitative research due to the breadth of information acquired from each participant 
(Marshall and Rossman 2006).  
 
5.1.11.2 Data collection  
Interviews were conducted by the physiotherapist researcher (CI) in a quiet assessment room 
within the Clinical Research Facility at St Thomas’ Hospital, London, UK. This provided a 
confidential environment and one which the participant was familiar with as all their previous 
assessments had been carried out in this room. Interviews were conducted by the CI and were 
audio recorded on two digital Dictaphones to ensure accuracy and preservation of the 
information if there was a fault with one of the Dictaphones. The interviews were transcribed 
verbatim by the CI and checked for accuracy against the original recording. Participants were 
offered a copy of the transcript of the interview. A naturalism mode of transcription was used 
where the transcript matches as closely as possible the actual interview with every utterance 
recorded (Oliver, Serovich et al. 2005). 
 
Statistical analysis 
Statistical analysis of the data was conducted using SPSS for windows version 22.0 (IBM 
Software, Hampshire, UK). A p-value of less than 0.05 was considered statistically significant. 
Standard distributional checks were made. For each of the outcome measures analysed, 
univariate descriptive statistics were summarised by randomised group to provide an 
overview of the data. Summary measures for the baseline characteristics of each group were 
presented as mean and standard deviation for continuous ‘approximate’ normally distributed 
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variables, medians and interquartile ranges for non-normally distributed variables, and 
frequencies and percentages for categorical variables. Univariate analyses were performed to 
compare study group using appropriate statistical tests according to the type and the 
distribution of the data: independent t-test or Mann-Whitney for continuous variables and chi 
squared or fisher’s exact test for categorical variables. For clarity of the presentation, specific 
statistical analyses and power calculations for each investigation are presented within the 
related chapter.  
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Chapter 6 : Reliability study- The 
intra- and inter-rater reliability of 
shoulder range of motion and 
strength 
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Introduction 
This study was carried out in order to investigate the intra-rater and inter-rater reliability of 
the chief investigator (Fiona Sandford) and co-investigator (Hannah Dollings) in the 
assessment of: shoulder range of motion (Flexion, abduction, external rotation and hand 
behind back) and shoulder strength (flexion, abduction, empty can position and full can 
position, internal and external rotation and elbow flexion). These impairment measurements 
form part of the secondary outcome measures in the main clinical study (Chapter 8). The 
investigation for the reliability of strength testing has been published (Dollings, Sandford et al. 
2011) (Appendix 11.30). 
 
Methods 
6.1.1 Design 
This study followed a non-experimental, two-examiner, within-subject, repeated measures 
design. Participants were assessed on one occasion only. 
 
6.1.2 Participants  
This study was approved by the Biomedical & Health Sciences, Dentistry Sciences & 
Engineering Research Ethics Subcommittee at Kings College London (BDM/09/09-86) 
(Appendix 11.6). Participants were recruited by verbal invitation from Guy’s Campus and 
friends and family. Inclusion criteria involved; anyone over the age of 18 years of age and with 
no history of shoulder pain. Exclusion criteria were: individuals under 18 years old, a history of 
shoulder pain, anyone with a history of shoulder pain, pregnancy and an inability to give 
informed consent. Any potential participant was excluded if they had shoulder pain on testing 
during the Neer sign and Hawkin’s test, resisted external rotation, as well as palpation for pain 
around the region of the greater tuberosity (Lewis, Green et al. 2005, Lewis, Wright et al. 
2005, Michener, Walsworth et al. 2009).  
 
6.1.3 Measurements 
Full details of the measurements taken, positions and instruments can be found in Chapter 
5.3.1. The range of motion measurements assessed in this study were: shoulder joint flexion, 
abduction, external rotation and hand behind back. Shoulder joint flexion and abduction were 
assessed using an inclinometer (Acuangle®, anglelevel) (Figure 5.1). The shoulder complex 
strength measurements assessed were; flexion, abduction, abduction in an empty and full can 
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position, internal and external rotation and elbow flexion and extension. The strength 
measurements were measured using a JTech PowerTrack™ II Commander hand-held 
dynamometer (Figure 5.2). 
 
6.1.4 Sample size calculation 
For a true reliability of 0.8 against an alternative reliability 0.9, based on a 5% level of 
significance and a power of 80% (β=20), for two testers, it was calculated that 46 participants 
would be required (Walter, Eliasziw et al. 1998). Measurements were taken bilaterally on 23 
participants who consented into the study, thereby making measurements on 46 shoulders. 
 
6.1.5 Data Analysis 
Intra and inter-rater reliability were calculated using intra-class correlation coefficients (ICC), 
95% confidence intervals (95% CI), standard error of measurement (SEM) and the smallest 
detectable difference (SDD) (Portney and Watkins 2000). The mean value of the three 
measurements was used for each movement or strength test in order to calculate the intra 
and inter-rater reliability.  
 
ICC values greater than 0.75, were considered to indicate good reliability and those greater 
than 0.91, indicative of excellent reliability (Portney and Watkins 2000). The 95% CI were 
calculated using ICC model 2,1. ICC model 2 was selected for use in the data analysis as it is 
considered to be the most appropriate to generalise the findings of the study using these 
methods of measurement to other clinicians with similar characteristics (Portney and Watkins 
2000). The data was analysed using SPSS Version 22 (SPSS Inc, Chicago, Il, USA). The options of 
two way random and absolute agreement were selected when analysing using the SPSS 
programme. 
 
Results  
Twenty-three asymptomatic participants we recruited into the study. Sixteen females (70%) 
and seven males (30%) with a mean age of 37 years (SD 35.4 years range 22 to 73 years). The 
mean height was 173.4cm (SD 17.7, range 163cm to 188cm). Mean weight was 69.9kg 
(SD30.4kg, range 52kg to 95kg). Mean body mass index was 23.2 kg/m ² (SD 7.1kg/m², range 
18.4kg/m² to 28.4 kg/m²). The majority of participants were employed (87%) and undertook 
some physical activity per week (82.6%). Twenty (87%) individuals were right-hand dominant. 
The participant demographics are presented in Table 6.1 below.  
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Table 6.1 Participant demographics 
 
 Participants  (n=23) 
Age in years 33 (29-37) 
Height (cm) 173.40 (17.7) 
Weight (kg) 69.90 (30.4) 
Body mass index (BMI) (kg/m²) 23.18 (7.1) 
Occupation Retired =3 (13%) 
Medical profession= 9 (39%) 
Desk based= 11 (48%) 
Activity level No regular activity= 4 (17%) 
Walk more than 45mins per day=6 (26%) 
CV activities 1-3 x/week= 7 (30%) 
CV activities 4x/week= 6 (26%) 
Hand dominance 
 
Right hand dominant= 20 (87%) 
Left hand dominant= 3 (13%) 
Legend: Summary measures represent means (standard deviation), median (interquartile range) or 
numbers (percentages). CV=cardiovascular 
 
6.1.6 Strength measurements 
The intra-rater (ICC 2,3) results for both testers were excellent for all tests, with the exception 
of left shoulder flexion (tester A, ICC 2,3=0.89), right shoulder flexion (tester B, ICC 2,3=0.90) 
and right shoulder full can test (tester A ICC2,3=0.90. The two SEM results ranged from 1.3kg 
(right empty can test) to 3.2kg (left shoulder flexion) for tester A and from 0.9kg (left empty 
can test) to 2.5kg (left elbow flexion and right shoulder flexion). 
 
The inter-rater (ICC2,3) results for all measurements were excellent, with the exception of 
abduction (ICC 2,3 = 0.77/0.87 , right/left). The two SEM measurements ranged from 0.9kg 
(right empty can test) to 4.1kg (right elbow flexion). 
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Table 6.2 Mean strength measurements for each test, intra and inter rater reliability and SEM in kg, continued on next page. 
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 error of measurement, CI=95% confidence interval, SD=standard deviation. Inter-rater reliability calculated using ICC 2,3 and intra-rater reliability calculated using 
ICC 2,1. 
 
STRENGTH MEASUREMENTS Flexion (kg) Abduction (kg) Full can (kg) Empty can (kg) 
rater Right  Left  Right Left  Right Left Right Left 
Mean (SD) [range]  12.7 (4.3) 
[6.3-25.2] 
12.2 (4.4) 
[6.6-24.6] 
12.5 (3.4) 
[7.2-22.2] 
12.1 (3.7) 
[5.6-25.5] 
6.4 (3.2) 
[2.5-15.6] 
6.1 (3.6) 
[2.6-15.5] 
5.6 (2.4) 
[2.3-11.5] 
5.7 (2.6) 
[2.0-9.8] 
Inter-rater reliability 
ICC2,3 A vs B (95%CI) 
SEM (2SEM) (kg) 
AvsB 0.91  
(0.79, 0.96) 
1.3 (2.6) 
0.92  
(0.87, 0.97) 
1.2 (2.3) 
0.77 
(0.45, 0.91) 
1.5 (3.1) 
0.87  
(0.63, 0.95) 
1.3 (2.6) 
0.97  
(0.92, 0.99) 
0.6 (1.3) 
0.96 
(0.92, 0.99) 
0.8 (1.5) 
0.97  
(0.93, 0.99) 
0.5 (0.9) 
0.96  
(0.92, 0.99) 
0.6 (1.2) 
Intra-rater reliability 
Rater A (95%CI) 
SEM (2SEM)(kg) 
A 0.97  
(0.89, 0.98) 
0.9 (1.7) 
0.89  
(0.62, 0.92) 
1.6 (3.1) 
0.94  
(0.86, 0.98) 
0.9 (1.7) 
0.94  
(0.86, 0.98) 
0.9 (1.9) 
0.9 
(0.78, 0.96) 
0.1 (2.0) 
0.96  
(0.85, 0.99) 
0.7 (1.4) 
0.94  
(0.85, 0.98) 
0.6 (1.2) 
0.93  
(0.83, 0.97) 
0.7 (1.4) 
Intra rater reliability 
Rater B ICC2,1(95%CI) 
SEM (2SEM)(kg) 
B 0.89  
(0.75, 0.95) 
1.2 (2.5) 
0.92  
(0.82, 0.97) 
1.2 (2.3) 
0.93 
(0.85, 0.97) 
0.8 (1.5) 
0.92  
(0.81, 0.97) 
1.0 (2.0) 
0.95  
(0.88, 0.98) 
0.7 (1.4) 
0.98  
(0.96, 0.99) 
0.5 (1.0) 
0.95 
(0.88, 0.98) 
0.7 (1.4) 
0.97  
(0.92, 0.99) 
0.5 (0.9) 
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Legend: SEM=standard error of measurement, CI=95% confidence interval, SD=standard deviation. Inter-rater reliability calculated using ICC 2,3 and intra-rater 
reliability calculated using ICC 2,1. 
STRENGTH MEASUREMENTS cont External rotation (kg) Internal rotation (kg) Elbow flexion ( kg) 
rater Right  Left  Right Left  Right Left 
Mean (SD) [range] 
 
9.4 (3.5) 
[6.5-17.8] 
9.7 (3.7) 
[5.0-19.8] 
12.3 (5.0) 
[5.45-23.5] 
12.1 (5.6) 
[5.3-25.6] 
18.1 (6.9) 
[7.9-31.2] 
16.9 (7.1) 
[8.7-43.8] 
Inter-rater reliability ICC2,3  
A vs B (95%CI) 
SEM (2SEM) (kg) 
AvsB 
0.92 
(0.81 to 0.97) 
1.0 (2.0) 
0.94  
(0.82 to 0.98) 
1.0 (2.0) 
0.93  
(0.57 to 0.98) 
1.3 (2.6) 
0.94  
(0.86 to 0.97) 
1.5 (2.9) 
0.91  
(0.68 to 0.97) 
2.1 (4.1) 
0.93  
(0.83 to 0.97) 
2.0 (3.9) 
Intra-rater reliability rater A 
ICC 2,3(95%CI) 
SEM (2SEM) (kg) 
A 
0.97 
(0.93 to 0.99) 
0.6 (1.2) 
0.98  
(0.96 to 0.99) 
0.7 (1.3) 
0.97 
90.92 to 0.99) 
0.9 (1.7) 
0.98  
(0.96 to 0.99) 
0.9 (1.9) 
0.98  
(0.96 to 0.99) 
1.2 (2.3) 
0.98  
(0.97 to 0.99) 
1.1 (2.2) 
Intra-rater reliability rater B 
ICC2,3(95%CI) 
SEM (2S2SEM) (Kg) 
B 
0.96 
(0.90 to 0.98) 
0.7 (1.4) 
0.95  
(0.87 to 0.98) 
0.8 (1.5) 
0.98  
(0.97 to 0.99) 
0.7 (1.4) 
0.97  
(0.94 to 0.99) 
0.9 (1.7) 
0.98  
(0.94 to 0.99) 
0.8 (1.6) 
0.96 
(0.91 to 0.98) 
1.3 (1.5) 
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ROM measurement  
The intra-rater ICC (2,1) reliability measurements were found to be good to excellent for all 
ranges of motion measurements. With the exception of left hand behind back, which had 
excellent reliability (ICC 2,1=0.93), good reliability was found for the measurements of 
external rotation and hand behind back for both testers. Excellent reliability was 
demonstrated for all measurements of flexion and abduction by both testers, with the 
exception of right shoulder flexion (ICC 2,1 = 0.90). The two SEM measurements ranged 
from 8.2° (right shoulder flexion) to 9.2° (left shoulder abduction) for tester A and 4.0° 
(right shoulder flexion) to 13.6° (right shoulder abduction) for tester B. For hand behind 
back and external rotation two SEM results ranged from 2.8cm (right shoulder external 
rotation) to 4.3cm (left hand behind back). For tester A and 2.5cm (left hand behind back) 
to 4.6cm (right hand behind back) for tester B. 
 
The inter-rater ICC 2,3 reliability results demonstrated good reliability other than those for 
flexion which demonstrated excellent reliability (ICC2,3= 0.91/0.92 right/left). The two SEM 
measurements ranged from 7.9° (left shoulder flexion) to 10.2° (right shoulder abduction) 
and 3.0cm (right shoulder external rotation) to 3.9cm (right hand behind back). 
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Table 6.3 Mean range of motion for each test, intra and inter rater reliability and SEM in degrees or cm. 
Legend: SEM=standard error of measurement, CI=95% confidence interval, SD=standard deviation. Inter-rater reliability calculated using ICC 2,3 and intra-rater reliability 
calculated using ICC 2,1 
RANGE OF MOTION MEASUREMENTS Flexion (degrees) Abduction (degrees) External rotation (cm) Hand behind back (cm) 
rater Right  Left  Right Left  Right Left Right Left 
Mean (SD) [range] 
 
169.0 (13.7) 
[141.8, 202.0] 
166.9 (14.0) 
[145.0, 201.8] 
166.1 (12.8) 
[142.5, 196.5] 
164.9 (12.2) 
[145.5, 196.3] 
41.3 (4.3) 
[34.1, 51.0] 
40.5 (5.2) 
[31.8, 51.5] 
15.7 (4.9) 
[5.8, 22.8] 
12.7 (4.5) 
[4.5, 21.5] 
Inter-rater reliability ICC2,3 A vs 
B (95%CI) 
SEM (2SEM) 
AvsB 
0.91 
(0.84, 0.96) 
4.2 (8.3) 
0.92  
(1.87, 0.96) 
4.0 (7.9) 
0.84 
(0.73, 0.92) 
5.1 (10.2) 
0.88  
(0.79, 0.94) 
4.2 (8.4) 
0.88 
(0.79, 0.94) 
1.5 (3.0) 
0.86  
(0.75, 0.93) 
2.0 (3.9) 
0.84  
(0.73, 0.92) 
2.0 (3.9) 
0.84  
(0.73, 0.92) 
1.8 (3.6) 
Intra-rater reliability rater A 
(95%CI) 
SEM (2SEM) 
A 
0.90 
(0.70, 0.95) 
4.6 (9.2) 
0.91 
(0.80, 0.96) 
4.3 (8.5) 
0.91  
(0.81, 0.96) 
4.3 (8.6) 
0.91  
(0.80, 0.96) 
4.1 (8.2) 
0.87 
(0.72, 0.94) 
1.4 (2.8) 
0.85 
(0.68, 0.93) 
2.0 (3.9) 
0.83 
(0.65, 0.93) 
2.0 (3.9) 
0.77 
(0.55 0.90) 
2.1 (4.3) 
Intra-rater reliability rater B 
ICC2,1(95%CI) 
SEM (2SEM) 
B 
0.98 
(0.96, 0.99) 
2.0 (4.0) 
0.92  
(0.81, 0.96) 
3.9 (7.8) 
0.91 
(0.79 0.96) 
6.8 (13.6) 
0.94 
(0.86, 0.97) 
2.6 (5.3) 
0.90 
(0.78, 0.96) 
1.5 (3.0) 
0.90 
(0.79, 0.96) 
1.7 (3.4) 
0.80 
(0.59, 0.91) 
2.3 (4.6) 
0.93 
(0.85, 0.97) 
1.2 (2.4) 
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Discussion  
This reliability study examined the intra and inter-rater reliability of clinical methods for 
measuring both shoulder strength and range of motion. The methodologies used and 
described within this reliability study are simple to use and time efficient. 
 
6.1.7 Strength measurement 
The Jtech Power Track II Commander hand-held dynamometer was used together with a 
specific testing protocol to measure isometric muscle strength of particular shoulder muscle 
groups in asymptomatic participants performing ‘make’ tests. The measurement methodology 
of strength assessment utilised by the CI and the co-investigator demonstrated good inter-
rater reliability (ICC2,3 ≥0.77) and intra-rater reliability (ICC2,1 ≥0.89) in pain and symptom 
free individuals. 
 
The findings of the present study support those of other investigations examining the 
reliability of measuring shoulder strength using hand held dynamometers, with similar findings 
of greater reliability of intra-rater reliability than inter-rater reliability (Agre, Magness et al. 
1987, Leggin, Neuman et al. 1996, Balogun, Powett et al. 1998, Hayes, Walton et al. 2002, 
Vermeulen, Bock et al. 2005). However differing methodologies, devices and research 
protocols make it difficult to make comparisons across studies.  
 
6.1.8 Range of motion  
The methods described utilised an inclinometer to measure shoulder flexion and abduction in 
degrees and a tape measure to assess shoulder external rotation range of motion and hand 
behind back in cm.  
 
The measurement methodology of shoulder ROM measurement utilised by the CI and the co-
investigator demonstrated good inter-rater (ICC2,1≥ 0.89) and intra-rater (ICC 2,1≥0.77) 
reliability in pain and symptom free individuals. External rotation and hand behind back 
measurements were associated with poorer reliability than flexion and abduction. This is 
possibly due to the use of a tape measure and anatomical landmarks for the external rotation 
and hand behind back measurements which may have more potential for inaccuracy than with 
inclinometer placement. The measurement of hand behind back is cited in the literature as 
having poor reliability (Hayes, Walton et al. 2001, Edwards, Bostick et al. 2002, Hayes, Walton 
et al. 2002). However the intra and inter-rater reliability results of the measurement of hand 
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behind back were found to be similar to other studies (Green, Forbes et al. 1998) and much 
better than those found previously by Hayes et al (2001) ICC2,1=0.39 and Edwards et al (2002) 
ICC ≤ 0.25for both intra and inter-rater reliability). Similar methodology was employed in all 
three studies (Green, Forbes et al. 1998, Hayes, Walton et al. 2001, Edwards, Bostick et al. 
2002) and also in the present reliability study. However, Hayes et al (2001) and Green et al 
(1998) carried out their measurements in symptomatic patient populations. This is a potential 
reason for the differences in the reported outcomes. Despite the previously reported poor 
reliability hand behind back was selected as an outcome measure in this study and the main 
RCT due to its clinical utility and common restriction of range as a presenting feature in RC 
tendinopathy (Valentine and Lewis 2006). The American Academy of Orthopaedic Surgeons 
and Society of American Shoulder and Elbow Surgeons (Kumar and Satku 1994) also 
recommend the assessment of hand behind back due to its functional importance in so many 
activities of daily living. It is recognised that the measurement of hand behind back is not a 
valid measure of internal rotation of the shoulder (Mallon, Herring et al. 1996) and is subject 
to interference from pain and conditions located elsewhere in the upper limb (thumb, wrist 
and elbow) which might adversely affect the reliability of the measurement.  
Both the intra and inter-rater reliability of shoulder abduction, flexion and external rotation 
measurements were found to be similar to previous studies measuring both symptomatic and 
asymptomatic participants when using similar methodologies (Valentine and Lewis 2006) and 
methodologies with differences such as lying down and plane of movement (Green, 
Buchbinder et al. 1998)  
 
6.1.9 Study limitations  
One limitation of this study is that the study participants were asymptomatic individuals with 
an average age of 33 (SD 35.4) years. Therefore generalisation of the results of this study to 
individuals of any other age range or a population of individuals with specific or generic 
shoulder symptoms is questionable.  
 
Another limitation lies in the fact that the test, retest periods were short in duration. The 
consistency in the mean strength between measurements would indicate that fatigue was not 
an issue within the study but there may have been a learning effect present. This is relevant as 
the tests within each sequence were carried out in a standardised order (Portney and Watkins 
2000). Testing over a period of days might have been preferable but was not possible within 
the time constrains of this reliability study. It could also be argued that any differences found 
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between values tested over days may have been due to participant related reasons rather 
than testing procedure.  
 
Conclusion  
The findings of this study suggest, that; 
 Using the methods employed in the population investigated in this study, and used as 
outcome measures in the main investigation demonstrate good to excellent intra and 
inter-rater reliability for the measurement of shoulder strength and range of motion.  
 The SEM findings provide guidance for values that maybe considered as a real change 
in strength and range of motion.  
 Further research is required to determine the intra- and inter- tester reliability in 
symptomatic in individuals. 
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Chapter 7 : Shoulder pain and the use 
of nutritional supplements: A 
questionnaire based investigation 
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Introduction 
The printed press (Griffiths 2014, O'Connor 2015) and social media (e.g. 
http://www.webicina.com/nutrition) increasingly focus on food, nutrition and health, and the 
conclusions reached in these communications may impact on the perceptions of wider the 
community including healthcare workers, patients and those wishing to prevent illness 
(Swinburn and Egger 2002). References to food and nutritional supplements are published 
regularly and an example is depicted in Figure 7.1.  
 
Figure 7.1 An example of an article pertaining to nutritional supplements in the printed press 
  
http://metro.co.uk/2013/07/31/are-vitamin-supplements-really-the-answer-to-our-health-prayers-
3904559/ 
 
It is estimated that 35-40% of adults in the United Kingdom (UK) regularly use dietary 
supplements, making the annual UK market alone in 2012 an estimated £738 million 
(http://www.euromonitor.com/vitamins-and-dietary-supplements-in-the-united-
kingdom/report). 
 
There has been a steady increase in the use of dietary supplements for musculoskeletal 
conditions, such as glucosamine (Ostojic, Arsic et al. 2007), and polyunsaturated fatty acids 
(Maroon and Bost 2006). This is potentially supported by published research investigation that 
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have concluded significant benefit in taking nutritional supplements for a cohort of athletes 
with multiple tendinopathies (Mavrogenis, Johannessen et al. 2004). This investigation 
however was at a high risk of bias due to data analysis being conducted as an on-treatment 
(and not an intention-to-treat) basis, and non-compliers being excluded from data analysis. 
Supplement use in individuals with tendinopathy remains controversial and unregulated and 
lacks guidance from the findings of appropriately designed and controlled research 
investigations. These issues need to be addressed to understand better the relative benefit of 
nutritional supplements in those with tendinopathy. One step in this process is to determine 
how many people are taking supplements for shoulder pain, together with the reasons for 
taking as well as not taking supplements.  
 
This study aimed to establish: the extent of use; beliefs surrounding use; and any perceived 
side effects of usage of supplements in people experiencing shoulder pain and supports the 
main randomised controlled trial (The efficacy of polyunsaturated fatty acids and exercise in 
the treatment of RC tendinopathy ISRCTN 17856844). 
 
Aim of research: 
The objective was: 
To evaluate the current use of self-prescribed dietary or nutritional supplements in a cohort of 
patients with shoulder pain. 
 
The primary research questions for this chapter were: 
(i) How many people are taking supplements to aid their recovery from shoulder pain? 
(ii) What are the reasons for people with shoulder pain choosing to use or not to use 
nutritional supplements?  
 
Design, setting and methods 
A descriptive survey methodology was employed using paper based questionnaire booklets 
(Appendix 11.12). Questionnaires are the most commonly used tool in survey research 
(Shaughnessy, Zechmeister et al. 2011) and it was felt that this was the best method available 
to collect the required data. A paper based questionnaire was selected to ensure ease of 
completion at the eight different research sites where on-line surveys might have been more 
difficult and introduced a bias in that only those proficient with computer use might have 
taken part. It also importantly allowed participants to feel under no obligation to participate 
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as it was their decision to return the questionnaire or not. This process also allowed the 
participants to complete the questionnaire in a place of their choice and taking as much time 
as they required. 
 
7.1.1 Sample size 
A sample of convenience was used from eight locations within the United Kingdom (UK). They 
were selected to represent a diversity of locations and healthcare settings (both public and 
private). In addition, the locations were selected due to the willingness of at least one 
member of the physiotherapy team at each site to act as the principal investigator at that site 
and take on local responsibility for the study. 
 
A total of 325 questionnaire booklets were sent in batches of 50 booklets to each of the five 
participating National Health Service (NHS) site and in batches of 25 to the three participating 
private physiotherapy clinics. The difference in the number of questionnaires sent out was 
due to the estimated number of eligible patients who would be seen within that setting in the 
time frame given. This information was provided by the local investigators. The NHS sites had 
a higher volume of patients with shoulder pain being seen by the service and so had a larger 
potential recruitment pool from which to recruit. 
 
7.1.2 Ethical approval  
Ethical approval was granted from West London Research Ethics Committee three, National 
Research Ethics Service, Room 4W/12, 4th Floor West, Charring Cross Hospital, Fulham Palace 
Road, London W6 8RF on 12th July 2010 (REC re: 10/H0706/41) (Appendix 11.13). A principal 
investigator was identified at each site. Local Research and Development approval was sought 
and granted at each separate site prior to the study commencing at that site. Participants gave 
written informed consent (Appendix 11.11). 
 
7.1.3 Positionality of researcher 
The chief investigator (FS) was responsible for developing the research protocol, recruiting the 
clinical sites and ensuring local research and development ethical approval was granted, 
analysing the data and coding and generating the themes from the subjective data. Cross 
verification or researcher triangulation was achieved with a supervisor (JL) independently 
coding and analysing the subjective responses generated from the open questions and 
consensus being reached as to the themes and sub-themes. 
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7.1.4 Study design 
The survey comprised of four sections: (i) the background of the participants, (ii) for those not 
taking supplements, their reasons and beliefs regarding supplements, (iii) for those taking 
supplements, their beliefs and reasons for doing so and (iv) the last section of the survey 
comprised of four patient reported outcome measures. These were; 
 
1. Oxford Shoulder Score (OSS) (Dawson, Rogers et al. 2009) 
2. Shoulder Pain and Disability Index (SPADI) (Breckenridge and McAuley 2011) 
3. SF-36 (Ware and Sherbourne 1992) 
4. Euro Qol EQ-D5 3L(Brooks 1996) 
 
7.1.5 Questionnaire design 
Individual questions were devised by the CI using the available literature on supplement use 
to shape topic areas. The questions were discussed and reviewed by JL (co-supervisor).  
 
Once the initial survey was formulated, it was then peer reviewed by a focus group of nine 
physiotherapists at St Thomas’ Hospital, London, UK who were working within upper limb 
rehabilitation. These physiotherapists independently reviewed the questionnaire. It was also 
piloted by ten patients who were attending the shoulder exercise class at the same hospital. 
The patients were approached and asked to read a questionnaire that would be used in a 
study. The ten patients who volunteered were a sample of convenience and were advised that 
completing or not completing the review of the questionnaire would not affect their 
treatment. All aspects of the survey were reviewed including; intelligibility, terminology, 
relevance and comprehensiveness. The feedback gained from the physiotherapists and 
patients informed the final content of the survey and questions were re-worded and altered 
as indicated. Terminology such as “nutritional” was highlighted as possibly being confusing 
and so terms such as these were altered and some questions re-worded to ensure clarity. 
 
7.1.6 Questionnaire content 
The initial questions of the questionnaire sought demographic information. These questions 
included the participant’s age, gender, height, weight, ethnicity (participants were asked to 
select one of 19 choices), duration of shoulder pain in months (participants selected zero-six 
weeks, six weeks to three months or more than three months given), education level (none, 
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secondary, higher), type of employment (manual, non-manual or not sure) and ability to work 
with shoulder problem (yes or no). 
Participants were then asked if they were currently taking supplements. 
 
Those who said they were not taking supplements were asked to consider why they were not 
taking supplements and asked to tick the sentences in the box below that corresponded to 
their views. 
 
I don’t believe in taking food/nutritional supplements 
There is no evidence/ scientific basis for taking them 
I am scared of any side effects 
I have tried them but they didn’t help (what did you try?) 
I would like to take them but they are too expensive 
I would like to take them but I don’t know what to take  
I don’t know what food/ nutritional supplements are 
Anything else you think is relevant 
 
Those participants who said they were taking supplements were directed to another set of 
questions which asked them to list the supplements they were taking. They were also asked to 
comment on and tick the statements in the box below, which best represented their views  
 
Of these which ones if any are you taking for your shoulder pain 
Any benefit for your shoulder pain? 
Where did you first learn about these supplements? 
Estimated monthly cost of the supplements you are taking for your shoulder 
Would you recommend these supplements to others? 
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Any side effects? 
Anything else? 
 
7.1.7 Participants and recruitment 
Patients seeking treatment for their shoulder pain were recruited from eight physiotherapy 
departments. Five National Health Service (NHS) sites and three private clinics, providing a 
sample that included; rural, costal and inner city locations (both London and Nottingham). 
Theywere selected to give greater transferability of the findings to the population of the UK. 
 
7.1.8 Inclusion criteria:  
Patients suffering with shoulder pain of more than one month duration and over 16 years of 
age. 
 
7.1.9 Exclusion criteria:  
16 years of age or under 
 
7.1.10 Data collection  
The data collection methods are described in Chapter 5.  
 
Potential participants with a diagnosis of shoulder pain were invited to participate in the study 
by their treating physiotherapist. Following the completion of a consent form they were then 
given the set of questionnaires in a booklet form (Appendix 11.12). Once the questionnaire 
was completed it was placed in a sealed envelope and returned to the physiotherapist. The 
completed anonymised questionnaires were returned by secure special delivery (Royal Mail) 
to JL (co-supervisor) at an NHS site. The booklets were then securely stored in a locked cabinet 
in a locked office. 
 
7.1.11 Data analysis 
Data was entered onto an excel spreadsheet and then transferred to SPSS for Windows 
version 22.0 (IBM Software, Hampshire, UK) by the C I (FS). For the open questions a thematic 
style of analysis was used to explore across the data set to identify repeating patterns of 
meaning. The data was read and re-read to aid familiarisation and then codes were generated 
using Nvivo V10 software (QSR International (UK) Ltd, London UK) by the CI (FS). The codes 
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were grouped and discussed between JL (co-supervisor) and the CI (FS), to produce agreed 
themes. Extracts from the questionnaires were chosen by the CI (FS) to demonstrate the 
themes.  
 
Triangulation was achieved through the discussions between the researchers regarding codes, 
themes and analysis. 
 
7.1.12 Statistical analysis 
Both univariate and multivariate analyses were 
 used to assess for associations between participant demographics and supplement use.  
 
Findings and results  
261 out of a possible 325 questionnaires were returned representing an 80% return rate. No 
questionnaires had to be discarded due to being incomplete.  
 
The demographic characteristics are detailed in Table 7.2. The level of disability reported by 
the respondents as measured by the OSS and SPADI lies in the ‘moderate’ category and is 
similar to other studies on shoulder pain (Ekeberg, Bautz-Holter et al. 2010, Younis, Sultan et 
al. 2011). There were more female respondents than male at a ratio of approximately 1.6:1 
(female: male). The majority of the sample was white (94%). The average body mass index 
was above the desirable ‘healthy’ range (18.5-24.9kg/m²) (WHO 1998). Approximately 45% of 
respondents reported to be unable to work due to their shoulder pain and the majority (79%) 
had experienced shoulder pain for more than three months.  
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Table 7.1 Demographic characteristics of respondents 
 
Variable  Value 
Gender Female 162 (62%) 
Age in years (SD)  50 (16.5) 
Body mass index (kgm⁻²)  27 (5.9) 
Ethnicity Not stated 
Asian  
Black  
Mixed  
White  
3 (1.1%) 
7 (2.7%) 
3 (1.1%) 
3 (1.1%) 
246 (94.3%) 
Type of practice NHS 
Private  
200 (76.6%) 
61 (24.4%) 
Education Higher  
Secondary 
None 
No response 
113 (43.3%) 
68 (26.1%) 
3 (1.1%) 
77 (29.5%) 
Employment Full time 123 (47.1%) 
 Part time 42 (16.1%) 
 Homemaker 7 (2.7%) 
 Retired 63 (24.1%) 
 Unemployed 9 (3.4%) 
 No response 17 (6.5%) 
Type of work Manual 84 (32.2%) 
 Non-manual 95 (36.4%) 
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 Not sure 3 (1.1%) 
 No response 79 (30.3%) 
Number unable to work due to shoulder 
pain 
No response  30 (11.5%) 
117 (44.8%) 
Duration of shoulder pain 0-6 weeks 
6 weeks- 3 months 
More than 3 months 
No response 
10 (3.8%) 
29 (11.1%) 
207 (79.3%) 
15 (5.7%) 
Oxford shoulder score 
0-48 48=highest 
 31 (10.4) 
SPADI 
0-100; 100=highest 
 45 (25.3)† 
EQ-5D 
-0.5-1.0; 1=highest 
 0.69 (0.59-0.80) † 
EQ-5D health quality VAS 
0-100; 100=highest 
 69 (24.1) 
SF36 mental component summary  
0-100; 100=highest 
 46 (16.2) 
SF36 physical component summary 0-
100; 100=highest 
 37 (14.0) 
Legend: SF36 =short form 36 item quality of life questionnaire, Summary values are given as mean and 
(standard deviation) other than when represented by† and the median and (interquartile range) is 
given. 
 
The numbers of respondents taking supplements for any condition or reason was 100 (38%). 
Of these 100 respondents, 82 reported taking supplements to help them with their shoulder 
pain.  
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Table 7.2 Supplement use within this cohort 
 Information for those taking 
supplements  
Information from the 
whole cohort  
N 100 (38%) 261 (100%) 
Taking supplements for 
shoulder pain 
82/100 (82%) 82/261 (31%) 
 
Taking omega 3 or cod liver oil 
for shoulder pain 
52/100 (52%) 52/261 (20%) 
Legend n=number, numbers and percentages presented 
 
The reasons given by the 161 respondents not taking supplements were varied citing different 
themes, and are detailed in table 7.3.  
 
Fifty per cent of respondents stated their reasons for not taking supplements were either ‘I 
don’t believe in them or there is no scientific basis’. The other most regularly cited reason was 
that participants would like to take them but did not know what to take.  
 
Table 7.3 The reasons given by respondents for not taking supplements 
Reason  n=161 
There is no evidence/scientific basis for taking them  33 (20.5%) 
I don’t believe in taking food/ nutritional supplements 50 (31.1%) 
I am scared of any side effects 11 (6.8%) 
I have tried them but they didn’t help 27 (16.8%) 
I would like to take them but they are too expensive 31 (19.3%) 
I would like to take them but I don’t know what to take 51 (31.7%) 
I don’t know what food/nutritional supplements are 12 (7.5%) 
Legend n=number. Numbers and (percentages) presented. 
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Of the 82 respondents who reported they were taking the supplements to aid with their 
shoulder pain, 80% felt that they were having no or minimal benefit. This is further supported 
by 50% reporting they would not recommend or would be unsure about recommending them 
to others. The estimated monthly cost of the supplements being taken for shoulder pain 
ranged from £0.30 to £48.00 with the median value being £5.50. The figures are detailed in 
Table 7.4 on the next page.  
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Table 7.4 Perceptions regarding supplement use from those who reported taking them 
Are the supplements you are 
taking for your shoulder having 
any benefit on your pain 
None 41/82 (50%)  
Minimal 25/82 (30.5%) 
Good 8/82 (9.9%) 
Very good 4/82 (4.9%) 
Excellent 4/82 (4.9%) 
Don’t know  6/82 (7.4%) 
Estimated monthly cost   £5.50†               Range (0.30-48.00) 
Would you recommend these 
supplements to others  
No 8/82 (9.8%) 
Unsure 33/82 (40.2%) 
Yes 39/82 (47.6%) 
No response 2/82 (2.4%) 
Legend: Actual numbers and percentages given other than †which denotes median value and range 
 
Respondents reported first learning of their supplements through a variety of means (Figure 
7.2) with the largest percentage being from friends and family (34%), followed equally by 
health care professionals (22%) and media (21%).  
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Figure 7.2 Bar chart showing where participants first learnt about the supplements they are 
taking. 
 
A wide variety of supplements were listed as being taken to aid with shoulder pain and these 
can be seen in Table 7.5 along with the median daily dose consumed. 
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Table 7.5 Supplements listed as being taken for shoulder pain 
 
Supplement Number of 
times listed  
Median daily dose in mg 
(interquartile range) 
Daily dose range 
in mg 
Rosehip 
 
2 4500 (4000-4500 50th 
percentile)  
4000-4500 
Glucosamine  31 500 (500-1000) 100 – 1500 
Chondroitin 11 400 (400-500) 100- 1000 
Cod liver oil 35 525 (500-1000)  120-1000 
Omega 3 24 1000 (510-1000)  75-2500 
Flax seed oil  2 7000  7000 
Multi vitamins 5 450 (70-500)  50-800 
Apple cider vinegar 1 15 ml  15 ml 
Devils claw extract 2 Mean=482.50 (SD=60.10) 440-525 
Vitamin D 3 62.50 (13.75 – 325)  10-400 
Vitamin C  3 1000 (300-1000)  60-1000 
Calcium 3 500 (140-1500)  30-1500 
Methylsulfonymethane 1 1000 1000 
Hyaluronic acid  1 750 750 
Legend: Median values and interquartile ranges given other than when mean is stated and mean 
values are given with SD= standard deviation  
 
Of the 59 respondents who reported taking fish oil (omega 3 PUFAs and cod-liver oil) for their 
shoulder pain, the dose of fish oils taken is detailed in Table 7.6. 
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Table 7.6 Reported intakes of oil and intakes of eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) in 59 respondents who reported consuming fish oil supplements 
 
Supplement Oil g/wk Range g/wk EPA g/wk DHA g/wk 
Cod Liver Oil 
(n=35) 
3.68 (3.5,7.0) 0.84-45.5 0.40 (0.38,0.76) 0.31 (0.29, 0.58) 
Omega 3 (n=24) 7.0 (3.58- 7.0) 0.53 – 17.5 1.26 (0.64, 1.26) 0.84 (0.43, 0.84) 
Flax oil (n=1) 49000 N/A   
Legend: Data are median values with interquartile ranges /wk= per week, n= number 
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Table 7.7 Unadjusted associations between taking supplements and demographic factors 
Legend: Summary measures are represented as means (standard deviation) and numbers 
(percentages). NHS= National Health service, BMI= body mass index, OSS= Oxford Shoulder Score, 
SPADI= Shoulder pain and disability index SF36 PCS= short form 36 physical component score, SF36 
MCS= short form 36 mental component score, EQ 5D= Euro Qol 5D 
Associations were examined using univariate analysis, other than ED 5D where median and IQR are 
presented and a Mann Whitney test was used. *represents a statistically meaningful association. 
Variable Taking supplements  P value 
N=82 Yes No  
Age in years (SD) 54 (17.0) 47 (15.7) 0.0015* 
Female gender 69 (69%) 93 (58%) 0.069 
Male gender 31 (31%) 68 (42%) 0.069 
White ethnicity 96 (96%) 151 (94%) 0.576 
Higher education 42 (64%) 71 (60%) 0.739 
Employed  54 (58%) 111 (73%) 0.019* 
Non-manual work 37 (63%) 58 (47%) 0.049* 
Duration >3 months 80 (86%) 127 (83%) 0.530 
Private 23 (23%) 38 (24%) 0.911 
NHS 77 (77%) 123 (76%) 0.911 
BMI 27 (5.1) 27 (6.3) 0.9232 
OSS  30 (9.9) 31 (10.8) 0.4846 
SPADI 24 (43-68) 22 (42-65) 0.4313 
SF36 PCS 37.6 (14.02) 38.46 (14.62) 0.108 
SF36 MCS 47.24 (15.46) 45.61 (16.71) 0.432 
EQ5D 0.69 [0.52-0.76] 0.73 [0.59-0.80] 0.168 
EQ 5D Health status 68.39 (21.62) 69(25.58) 0.844 
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The data were examined to see if there were any associations between demographic variables 
and taking supplements. Positive associations were found between supplement taking and 
age (the older the participant the more likely they were to take supplements), employment 
and non-manual work (Table 7.7). 
 
Following multivariate analysis of the data, only the female gender and age remained 
significantly associated with supplement use. Being female was strongly associated with over 
2-fold higher taking supplements as compared to males (Adjusted odds ratio: 2.2, 95% CI = 
[1.05-4.61]; p=0.04). A 2% increase in uptake was observed for every additional year in age 
(adjusted odds ratio: 1.0, 95%CI = [0.99-1.05]; p=0.05). 
 
7.1.13 Subjective information from questionnaire 
Several themes were highlighted within the open questions and free text sections of the 
questionnaires. These related to reasons for taking or not taking supplements.  
 
7.1.13.1 Balanced diet: 
The importance participants place on a balanced diet was high, with some expressing the fact 
their diet is well balanced and healthy would mean that nutritional supplements were not 
required. 
 
“I believe good nutrition is important and I’m unsure about food supplements.” Participant 22. 
“It’s all a load of old tosh if you ask me. Nutritional supplements can’t be worth it if you have a 
balanced diet.” Participant 56. 
“I have a healthy diet so don’t feel I need to take supplements.” Participant 98. 
“I have previously taken supplements for body building but not for eight years. Since then I 
have found a balanced diet is more sustainable and easier on digestion.” Participant 225. 
 
“I think people should be able to get most of the nutrients needed from a balanced diet.” 
Participant 109. This participant, who held the belief that most nutrients should be available 
from a balanced diet, was also taking evening primrose, cod-liver oil and vitamin B12. This 
demonstrates that this belief was held by both those who were taking supplements and those 
who were not. This is a view which is also held by some health professionals working in the 
speciality of Nutrition (Sanders 2014). Frequently repeated messages from the government 
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and NHS recommending and highlighting the benefits of a balanced diet are likely to have had 
an influence on the participant’s beliefs (NHS) 
(http://www.nhs.uk/livewell/5aday/pages/5adayhome.aspx). 
 
Others felt that because their diet was lacking in a particular area e.g. poor fish intake or if 
they’d had a particular day where their diet was poorer then they might take supplements to 
‘compensate’ for this perceived deficiency. 
 
“Most things you can get from a balanced diet. The only reason I take supplements is because I 
do not eat much fish.” This statement was made by Participant 78 who reported taking cod 
liver oil for their shoulder pain.  
 
Other drivers cited for taking supplements were the perceived benefits that participants felt 
they experienced from taking the supplements. 
 
“My shoulder can be more painful on days I don’t take a tablet [Cod liver oil].” Participant 42. 
“As each additional supplement was taken the benefit seemed to increase.” This statement 
was made by Participant 132 who was taking glucosamine, methyl sulfonylmethanemethone, 
marine chondroitin sulphate, devils claw extract, and hyaluronic acid for shoulder pain. 
 
“It’s difficult to tell any direct effect, but I tend to feel that things might well be worse i.e. more 
general stiffness if I didn’t take them.” This statement was made by Participant 131 who 
reported taking glucosamine for shoulder pain. This echoes the sentiment that participants 
reported that often supplements were used to prevent colds or joint problems rather than to 
treat symptoms which were already present. 
 
“They [glucosamine and chondroitin] are used for prevention more than pain relief.” 
Participant 79. 
 
There was a belief that supplements would aid in the recovery from shoulder pain, 
“I believe the fish oil will assist in muscle recovery.” Participant 246. 
 
Others reported that whilst they believed that supplements worked for other conditions they 
doubted that they would work for their shoulder pain;  
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“Don’t see any harm in the things but I question for this [shoulder pain] use.” Participant 115. 
“I do believe that food/nutritional supplements can be effective for some conditions but not 
specifically for my shoulder pain.” Participant 231. 
 
Respondents also described the lack of perceived benefit when they had previously taken 
supplements which led to them stopping.  
 
“Used to take glucosamine/chondriotin but too expensive so I stopped and felt no difference at 
all.” Participant 170. 
“Because these supplements take months to start working and I forget to take them I have 
never felt any benefit from their use.” Participant 166. 
“I have tried things like cod-liver oil when I had inflammatory arthritis in my teens but unsure if 
this helped or not so do not take any longer.” Participant 212. 
“I have tried some intermittently but often motivation wanes as I’m unsure whether they 
work.” Participant 232. 
 
This reduction in motivation when a supplement does not have obvious immediate benefits is 
a key point and links into the importance of perceived benefit of a treatment and adherence. 
Evidence suggests that people are more likely to adhere to a treatment if they believe that it is 
beneficial (van den Bemt, Zwikker et al. 2012, Sjolander, Eriksson et al. 2013, Venkatachalam, 
Abrahm et al. 2015). This was a predominant theme found in the qualitative study (Chapter 9).  
 
Several participants reported forgetfulness and memory as a reason for not taking 
supplements. This was also highlighted in the interview responses of the participants in the 
main RCT and presented in Chapter 9. 
“I forget to take them.” Participant 247. 
 
Some respondents reported side effects or the potential for side effects as reasons for not 
taking supplements. A few cited bowel habits or upset stomach whilst previously taking a 
variety of supplement.  
 
“Glucosamine upsets my stomach.” Participant 186. 
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The physical factors of taste and size of capsules or tablets were also highlighted as barriers to 
taking supplements and this is echoed again in the exploring attitudes study (Chapter 9).  
“Started to take Glucosamine but too large to swallow.” Participant 165. 
 
“I did not like the taste of cod liver oil. I am worried if I take supplements I will put on weight.” 
Participant 100. This participant highlights concerns regarding the possible unwanted side 
effects of taking a supplement. The perceived potential benefit for this participant did not 
outweigh the potential disadvantage or risk she perceived. 
 
Surprisingly only one participant mentioned any potential negative health side effects which 
have been reported in the press and media from taking nutritional supplements. 
“Even supplements of vitamins and minerals found in the diet can be unhealthy in large 
amounts (e.g. fat soluble vitamins).” Participant 47. 
 
7.1.13.2 Marketing and evidence 
The theme of over exaggerated claims and lack of regulation as well as the perception of the 
lack of scientific evidence supporting their use was regularly highlighted in the subjective 
comments repeatedly by respondents. 
“I think about taking them but they seem to make extravagant claims which I don’t believe.” 
Participant 37. 
“I’m largely unconvinced by the arm of half science shouted out in adverts for them.” 
Participant 115. 
 
This issue of aggressive marketing was raised several times,  
“On the whole I think they are a waste of money. They are heavily marketed and poorly 
regulated.” Participant 47.    
 
There is publicity in the media regarding nutritional supplements (Greiner, Clegg Smith et al. 
2010). With news articles highlighting their benefit for a wide range of conditions and it’s 
likely that that this widespread almost daily exposure to these reports might influence the 
wider population and their interest in the use of nutritional supplements (Rahmawaty, 
Charlton et al. 2013). This can also be seen in the number of participants (29%) reporting that 
it was through the media or press and internet that they first learnt about the particular 
supplements they were taking. 
142 
 
 
Several respondents reported that they had “never considered it.” Participant 144 or 
“Honestly never given them a thought, never had it suggested, never tried them.” Participant 
257. This was coupled with some reporting whilst they had heard of supplements they, “don’t 
know which ones to take.” Participant 39. 
 
Finally, the financial burden of supplement taking was mentioned by some as a barrier. 
“Don’t fancy spending money.” Participant 257. 
“On the whole I think they are a waste of money.” Participant 47. 
 
Respondents also discussed the physical burden of taking more pills that the participant 
perceived as “unnecessary” as a reason for them not taking supplements, 
“I am taking eight tablets per day. I don’t need any more (unnecessary) plus pain killers.” 
Participant 258. 
 
Discussion of results  
This study aimed to evaluate the current use of self-prescribed dietary or nutritional 
supplements in a cohort of patients with shoulder pain and the results provide valuable 
information regarding supplement use in this cohort of patients. Thirty eight percent of the 
sample reported taking supplements. This is in concordance with the 35-40% range found in 
other larger scale surveys within the UK (Mason 2007)(http://www.euromonitor.com/). Of 
those who reported taking supplements, 82% reported taking them in part to aid their 
recovery of their shoulder pain. Just over half of those taking supplements were taking fish oils 
for their shoulder pain. The questionnaire design did not capture information as to whether 
those taking supplements started taking supplements after developing shoulder pain or 
whether they were taking them previously. This limitation needs to be addressed in future 
research. Some participants highlighted in the comments or open questions that they had 
been taking supplements previously, but that they felt that the supplements were helping 
with their shoulder pain. Interestingly, when asked if they would recommend these 
supplements to others, 50% were unsure or said no and only 20% reported that they felt the 
supplements they were taking had a good/very good or excellent effect on their shoulder 
pain. This in part may be due to the supplements being taken having limited efficacy in 
shoulder pain and the doses at which they were being taken largely being sub-therapeutic 
doses. This will be further explored in the next section.  
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7.1.14 Dietary supplements used 
Table 7.19 details the supplements that were listed as being taken and the scientific 
justification or rationale for their use in shoulder pain.  
 
The weekly intake of the long-chain omega-3 polyunsaturated fatty acids in grams was 
calculated from the data to ascertain if an anti-inflammatory effect might have elicited at the 
doses stated. A weekly intake of 7.00g of omega 3 fish oil would equate to a weekly dose of 
1.26g EPA and 0.84g DHA. This is calculated using the reference values that 1.00g of long-
chain omega-3 fish oils contains on average 0.18g EPA and 0.12g DHA (Schuchardt and Hahn 
2013). This is a sub therapeutic dose and as such would not be expected to provide any anti-
inflammatory action. A daily intake in excess of 2.00g of EPA and DHA combined is widely 
considered to be required to elicit any anti-inflammatory effects (Calder 2011). Similarly an 
intake of 3.68g of cod liver oil per week would also be considered as a sub-therapeutic dose. 
An intake of 3.68g of cod liver oil would equate to 0.40g/wk of EPA and 0.30g/wk of DHA. This 
is calculated using the reference values that a one a day capsule contains on average 0.50g of 
cod liver oil. The EPA content is 10.3g/100g and the DHA content is 8.3g/100g, therefore a one 
a day capsule would provide 0.05g EPA and 0.04g DHA (MAFF 1998). This is well below the 
14.00g recommend weekly intake of EPA and DHA to elicit an anti-inflammatory response 
(Calder 2011). However, a typical cod-liver oil capsule provides 5 μg vitamin D3 which is a 
significant intake (100% RDA for food labelling purposes).  
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Table 7.8 Supplements taken for shoulder pain listed by respondents and evidence to support their use. 
Supplement Evidence to support  References 
Rosehip  
 
Metal analysis of three RCTs (287 patients and a median trial-duration of 3 
months)-looking at osteoarthritis (OA) all supported by the manufacturer 
showed a reduction in pain scores in rosehip powder group (145 patients) 
compared to placebo (142 patients) in patients with osteoarthritis: effect size 
of 0.37 [95% confidence interval (CI): 0.13-0.60], P=0.002. 
(Cohen 2012) 
(Christensen, Bartels et al. 2008) 
Glucosamine sulphate & 
Chondriotin sulphate 
Cochrane review concludes that there is evidence to support the use of 
glucosamine sulphate and chondriotin sulphate in combination to reduce 
pain. 
3 animal studies  
(Towheed, Anastassiades et al. 2001, 
Towheed, Maxwell et al. 2005) 
Cod liver oil & omega-3 PUFAs  The evidence for their efficacy has been reviewed previously in chapter 4.  
Flax seed oil  Flax seed oil is Flaxseed oil contains 53% 18:3 Omega-3 fatty acids (mostly 
ALA) and 13% 18:2 Omega-6 fatty acids and so would provide some of the 
anti-inflammatory effects (although to a lesser degree due to the conversion 
from ALA as EPA and DHA) 
(Kaithwas, Mukherjee et al. 2011) 
Multi vitamins No evidence found to support its use in tendinopathy  
Apple cider vinegar No evidence found to support its use in tendinopathy  
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Devils claw extract Inconclusive evidence regarding whether it works or whether it is safe for use 
in OA  
Some evidence to suggest devil’s claw extract has a synergistic action with 
morphine in neuropathic rats.   
(Brien, Lewith et al. 2006) 
(Parenti, Arico et al. 2015) 
Vitamin D Low serum vitamin D levels were not found to be related to tear size or the 
degree of fatty infiltration in RC muscles. Vitamin D levels also had no 
correlation with functional outcomes post arthroscopic repair. Results are 
suggestive that vitamin D levels are not a risk factor for severity of a RC tear or 
for healing post repair. 
(Angeline, Ma et al. 2014, Ryu, Kim et al. 
2015) 
 
Vitamin C  Only evidence found from an animal study: injected high dose vitamin c into a 
surgically cut Achilles rat tendon showed improved healing response in the 
earlier signs of angiogenesis and collagen synthesis..  
(Omeroglu, Peker et al. 2009) 
Calcium No evidence found to support its use in tendinopathy  
Methylsulfonylmethane Inconclusive evidence when used post operatively with a combination of 
other supplements. Inconclusive evidence to support its use in OA. 
(Brien, Prescott et al. 2011, Gumina, Passaretti 
et al. 2012, Notarnicola, Pesce et al. 2012) 
Hylauronic acid  Evidence available for the use of inject able Hyaluronic acid but not oral 
supplementation  
 
Legend: RCT= Randomised controlled trial; ALA=Alpha linolenic acid; PUFAs= Polyunsaturated fatty acids; EPA= Eicosapentanaeoic acid; DHA= 
Docosahexaenoic acid; OA= Osteoarthritis; RC= Rotator cuff. 
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Of the supplements listed as being taken (Table 7.10) to aid with shoulder pain the four most 
commonly reported were; (i) cod liver oil (67.3%, 35/52), (ii) glucosamine sulphate (59.6%, 
31/52) and (iii) chondroitin (21.2%, 11/52) (often taken in combination) and (iv) Omega 3 
PUFA (46.2%, 24/52). This is a similar finding to another much larger study of 25,639 men and 
women as part of The European Prospective Investigation into Cancer (EPIC) where the most 
commonly used supplement was also found to be cod liver oil (Lentjes, Welch et al. 2014). It is 
probable that the extensive use of cod liver oil originates from is historical use. Cod liver oil 
has been used for centuries to treat a variety of ailments from rheumatism to rickets 
(Rajakumar 2003). By the second world war the therapeutic benefits of cod liver oil were well 
recognised and it was routinely give to children to prevent rickets due to its relatively high 
vitamin D content (Rajakumar 2003). The mean age in this study was 50 years and these 
would be the children of the children of the pre and post war years and so it is probable that 
they were introduced to the benefits of cod liver oil through their family and this has been 
handed down from generation to generation. This is mirrored in the fact that it was 
recommendations from friends and family which ranked the highest amongst all sources of 
learning about supplements. A retail study (Mintel Report 2012) found that personal 
recommendation also carried the greatest weight influencing supplement use (Richmond 
2012).  
 
Glucosamine ranked the second most commonly used supplement in the questionnaire and 
was often taken with chondritin. There are two types of glucosamine commonly taken for 
osteoarthritis; glucosamine sulphate (also known as the Rotta preparation of glucosamine) 
and glusosamine hydrochloride. Within the study results only two respondents reported they 
were taking specifically glucosamine sulphate.  
 
Two Cochrane reviews have demonstrated that glucosamine (in the form of glucosamine 
sulphate) and Chondroitin effectively reduce pain and promote restoration of healthy joint 
tissue in individuals with osteoarthritis (Towheed, Anastassiades et al. 2001, Towheed, 
Maxwell et al. 2005). The Cochrane review in 2001 concluded that whilst there was evidence 
to support the use of glucosamine sulphate in osteoarthritis these findings could not be used 
to support the efficacy of different preparations of glucosamine by different manufacturers 
(Towheed, Anastassiades et al. 2001). Importantly, the Cochrane review in 2005 found that 
the pooled results for pain and function outcomes in those RCTs in which glucosamine 
hydrochloride was compared to placebo did not reach statistical significance (Towheed, 
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Maxwell et al. 2005). A meta-analysis, which has been frequently cited, included ten published 
trials investigating the efficacy of glucosamine and chondroitin for osteoarthritis of the hip 
and knee concluded that when compared to a placebo, glucosamine, chondroitin and a 
combination of the two do not reduce pain or improve joint space narrowing (Wandel, Juni et 
al. 2010). However, half the trials that were included in this analysis used glucosamine 
hydrochloride, and these trials showed no benefit. The other five trials investigated 
glucosamine sulphate and did show a benefit. When the results of the 10 trials were 
combined the significance showed in the glucosamine sulphate trials was diluted and thus the 
conclusion that glucosamine and chondroitin gave no added benefit over a placebo in 
osteoarthritis was potentially made erroneously. The type of glucosamine (hydrochloride or 
sulphate) is therefore critical when considering the research and for patient use. 
 
This target population of the current survey study was general shoulder pain and so it is 
possible that the diagnoses of some of the participants might have been shoulder 
osteoarthritis. For this there is evidence of adequate quality to support the use of glucosamine 
sulphate. Three animal studies have investigated the efficacy of glucosamine on the healing of 
surgical tendon repairs (Oryan, Moshiri et al. 2011, Ozer, Taskesen et al. 2011, Taskesen, 
Ataoglu et al. 2015) results are only preliminary but suggest enhanced maturation of the 
tenoblasts and stimulation of collagen synthesis. This may warrant further investigation. The 
animal studies mimicked a surgical repair procedure rather than tendinopathy. No evidence 
could be found to support the use of glucosamine (sulphate or hydrochloride) in the 
treatment of tendinopathies. 
 
7.1.15 Sources influencing supplement use 
As previously discussed, friends and family ranked first in the responses to “Where did you 
first learn about these supplements?” 
 
The influence of the media and internet when considering supplement intake is widespread as 
indicated by the results of this questionnaire study with 29% of respondents taking 
supplements reporting that it was through the media or internet that they first learnt of the 
supplements. These findings are in agreement with those of another questionnaire study 
where participants described the powerful positive influence the media (books and 
magazines) on an individual’s decision to use dietary supplements (Conner, Kirk et al. 2001). 
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The influence of health care practitioners (including doctors, physiotherapist, pharmacists and 
dieticians) ranked third.  
 
7.1.16 Industry regulation and quality of evidence 
Dietary supplements are covered by food law not by that pertaining to medicines. Explicit 
claims about the treatment or prevention of diseases or disorders are prohibited. However, 
health claims are permitted under the provisions of the European Union Health Claims 
Regulation (EC No 1924/2006) which came into force in 2007 and applies to all member 
states. The list of authorised health claims is under article 13 of the regulation which came 
into force at the end of 2014. In addition, some supplements/foods are covered by the 
European Framework Directive on Foods for Particular Nutritional uses (also called ‘PARNUTs 
foods’) which was first introduced in 1989, amended in 1999 and updated in 2009. It covers a 
range of products such as meal replacements, gluten free products and infant formulas. The 
basic tenets of food law is that it is illegal to sell food that is injurious to health or is not of the 
nature, substance and quality demanded and this provides the consumer with protection and 
peace of mind. 
 
However, unlike drugs, foods have no required specification of formulation. The components 
must all be of food quality and any additives must be on the permitted list and the ingredients 
lists must be given in decreasing order. Without central standardisation of the individual 
ingredients within supplements it is left to the individual manufacturers to regulate (FDA 
2014). This lack of central standardisation of the supplements was highlighted in some of the 
respondents’ comments. There is a move towards greater regulation of the industry which it is 
hoped will lead to better protection and education for the consumer and hopefully 
necessitate well designed research trials investigating the efficacy of nutritional supplements. 
Two areas of legislation that have been introduced in the last decade have had a significant 
impact on nutritional and health messaging on foods and nutritional supplements within the 
European Union (EU). The first piece of legislation was the Directive 2002/46/EC whose aim is 
to protect consumers against potential health risks from foods and nutritional supplements 
and to ensure that consumers are not provided with misleading information. The introduction 
of the Health Claims regulation (EC1924/2006) by the European parliament ensured that any 
manufacturer making nutritional or health claims must comply with this legislation. Food 
labelling is covered by separate legislation. At the time of undertaking this study, those 
wishing to provide nutritional information on a label had to do so in accordance with the 
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provision of the food information to consumers Regulation (EU) 1169/2001. However new 
mandatory nutrition labelling has been introduced Regulation (EU) 1169/201 and will become 
enforced by December 2016. This regulation combines two earlier directives (90/496/EEC – 
Nutrition labelling for foodstuffs and 2000/13/EC – labelling, presentation and advertising of 
foodstuffs). 
 
Despite this lack of standardisation of dietary supplements, in one survey of 118 patients from 
general practices in Calgary, Canada, 68% of respondents stated that they felt that 
supplements were safer than prescription medication (Durante, Whitmore et al. 2001).  
 
Associated with this lack of industry regulation with regard to implied health claims is the 
perception that the scientific evidence for the claims that are being made by the 
manufacturers is inadequate to support their use. With respect to the current survey, 20% of 
respondents who were not taking supplements felt that there was insufficient evidence to 
support their use. The questionable quality of evidence available was alluded to by one 
participant calling the evidence “half arm science”. The table detailing the evidence to support 
the use of the supplements listed (Table 7.8) illustrates the paucity of evidence currently 
available for the use of these supplements for shoulder pain.  
 
7.1.17 Sociodemographic drivers 
In terms of associations or drivers to supplement use, the only demographic variables which 
were found to be strongly associated to taking supplements were female gender and age. The 
positive association between female gender and supplement use is one commonly found 
within the literature (Conner, Kirk et al. 2001, Durante, Whitmore et al. 2001, Beitz, Mensink 
et al. 2004, Cox, Koster et al. 2004, Timbo, Ross et al. 2006, Pillitteri, Shiffman et al. 2008, van 
der Horst and Siegrist 2011). Increasing age is also considered as a common driver to 
supplement use (Conner, Kirk et al. 2001). Other factors which have been found on previous 
studies such as educational level, and employment status (MacLennan, Wilson et al. 2002) 
were not found to be associated with increased supplement use within this study.  
 
The level of disability as measured by the OSS, mean= 31 (SD=10.4) and the SPADI , mean=45 
(25.3) indicated a mild to moderate level of disability from their shoulder pain (Dawson, 
Fitzpatrick et al. 1996). It is interesting that level of disability was not found to be associated 
with supplement intake. Whilst there was no association found in this study it is commonly 
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reported finding those with better health or less disease severity have a greater supplement 
intake (Dickinson and MacKay 2014). There was also no association found between general 
quality of life and health status scores and supplement use.  
 
7.1.18 Reasons for taking  
Some respondents reported taking supplements to rectify a perceived deficiency in their diet 
or to ameliorate/ as a remedy against their unhealthy diet. This finding was mirrored in 
another study who found that it was either the health conscious who were taking the 
supplements or those who were countering a perceived deficiency in their diet (van der Horst 
and Siegrist 2011). 
 
7.1.19 Financial burden 
This study also set out to establish the estimated monthly cost of the supplements being taken 
for shoulder pain. The monthly cost ranged from an estimated 30 pence to £48.00, with a 
median value of £5.50. This financial burden associated with purchasing supplements was 
reported by some participants, who were not taking supplements, as one of the reasons for 
not taking them. Taking cod liver oil for shoulder pain was associated with much lower costs 
than the other supplements and this reflects the retail price of cod liver oil which is 7 pence 
per one a day in capsule form as compared to 14 pence per one a day in capsule form for high 
strength omega-3 PUFA (http://www.seven-seas.com/). 
 
7.1.20 Limitations 
This study only gives an overview of the likely reasons for consuming dietary supplements for 
shoulder pain. There was little information collected on the social and psychological factors 
that might influence supplement use.  
 
The paper based nature of the survey might have been a little cumbersome and better return 
rates might have been found with an on-line survey. However this paper based method was 
selected due to the lack of on-line availability at the different sites.  
 
The very nature of the study using a self-reported questionnaire challenges the validity of the 
information gathered. Self-reported behaviour does not always mirror actual behaviour and 
the information being collected was personal and possibly controversial, the taking of dietary 
supplements to promote health or as a self-prescribed treatment (Chandon, Morwitz et al. 
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2005, Owens, Toone et al. 2014). This effect was minimised by the anonymous nature of the 
survey. 
 
There was no sample size calculation conducted for this study rather a sample of convenience 
which carries the inherent bias that the sample is unlikely to be representative of the wider 
population thereby limiting the ability to make generalisations from the sample here to the 
wider should pain population. A sample of convenience was chosen in this study due to the 
restrictions of time and cost on the study. A retrospective sample size calculation with 
95%confidence interval and 6% margin of error would suggest that 267 responses were 
required based on a UK shoulder pain population of 2% of the national population .(Linsell, 
Dawson et al. 2006). 
 
The design of the questions failed to elicit from the participants if the supplement had been 
started pre or post the onset of the shoulder pathology. This was not detected in the pilot of 
the questionnaire but it is highlighted as something which would be important to investigate 
in any future work.  
 
No association was found between supplement use in the private sector as compared to the 
NHS. However just under 25% of the returned questionnaires were from the private sector. 
Therefore, whilst no association was found in the current survey, a more balanced study may 
identify different findings. The reasons for the fewer responses from the private clinics were a 
reported lower shoulder caseload than in the larger NHS hospitals. In addition, there were 
only three private clinics included in the survey, compared to five NHS sites. Future research 
would benefit from a more balanced recruitment from these two healthcare sectors.  
 
Conclusions  
The reasons for taking or not taking dietary supplements for shoulder pain are likely to be 
numerous and complex and include; social, psychological, economic and educational factors. 
This study offers an insight into some of the reasons that individuals with shoulder pain take 
dietary supplements. It has informed the knowledge base of the extent of supplement use in 
those with shoulder pain and some of the socio demographic drivers for their use.  
 
The mean weekly dose found in this study of EPA and DHA via omega 3 PUFA supplements 
(1.26g EPA and 0.84g DHA) or cod liver oil (0.40g of EPA and 0.3g DHA) would be considered a 
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sub-therapeutic dose. With this in mind and the fact that supplement takers generally had 
adequate intakes of vitamins and minerals from their diet (Public Health Engand 2014) raises 
the question; Are supplements being taken for shoulder pain which are unnecessary and a 
financial burden to the user? However what is unknown is the potential role of dietary 
supplements in prevention and treatment of shoulder pain or tendinopathy.  
 
The following chapter aims to provide more information on the potential role of dietary 
supplements in the treatment of RC tendinopathy; a double blind placebo controlled 
randomised controlled trial investigating the efficacy of long-chain omega-3 PUFAs and 
exercise in the treatment of RC tendinopathy.  
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Introduction 
Evidence suggests that people living in the United Kingdom (UK) consume a diet which is rich 
in omega 6 polyunsaturated fatty acids (PUFAs) and comparatively low in long-chain omega 3 
PUFAs (Public Health Engand 2014). This is in part due to the fact that the average intake of 
oily fish, the primary source of dietary long-chain omega-3 PUFA, is well below that of the UK 
governments recommendation of one oily fish portion per week (NHS). PUFA supplements 
have been suggested as a means of bridging this deficit. Supplementation with long-chain 
omega-3 PUFAs as a self-administered intervention has been recommended for a number of 
health conditions including, heart disease (Kris-Etherton, Harris et al. 2002), asthma 
(Mickleborough, Lindley et al. 2006), and rheumatoid arthritis (James, Proudman et al. 2010) 
due to their anti-inflammatory effects.  
 
Rotator cuff (RC) tendinopathy has been associated with inflammation (Longo, Berton et al. 
2011), increases in matrix metalloprotinases (Voloshin, Gelinas et al. 2005) and inflammatory 
cytokines (Gotoh, Hamada et al. 1997, Sakai, Fujita et al. 2001, Blaine, Kim et al. 2005, 
Voloshin, Gelinas et al. 2005, Molloy, Kemp et al. 2006, Ko, Wang et al. 2008, Millar, Wei et al. 
2009, Blaine, Cote et al. 2011, Savitskaya, Izaguirre et al. 2011, Millar, Gilchrist et al. 2015) 
resulting in the clinical presentation of pain and loss of shoulder function. Although exercise is 
the main intervention for RC tendinopathy, complete relief of symptoms and restoration of 
full function is not achieved in all those with this condition (Littlewood, Malliaras et al. 2015). 
As the outcomes of current surgical and non-surgical treatments are frequently sub-optimal 
there is the need to explore additional treatment options that may contribute to enhanced 
outcomes. Supplements of long-chain omega-3 PUFAs have anti-inflammatory effects (James, 
Proudman et al. 2010) and may be a potential treatment for individuals suffering pain 
associated with RC tendinopathy (Mavrogenis, Johannessen et al. 2004). The study conducted 
by Marvrogenis et al (2004) provided a valuable insight in the potential of long-chain omega-3 
PUFA and antioxidants in the management of tendinopathy. However, the study was at high 
risk of bias due to data analysis not being on an intention to treat basis, and the final outcome 
time point was 32 days, which did not allow for the long term benefit of supplementation to 
be assessed. It was decided; therefore, to conduct a placebo controlled randomized controlled 
trial of a long-chain omega-3 PUFA supplement in conjunction with exercise in the treatment 
of RC tendinopathy. 
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Methods 
8.1.1 Hypotheses 
Primary hypothesis: 
Long-chain omega 3 PUFA supplementation will result in significant improvement in disability 
(as measured by the Oxford Shoulder Score (OSS)) when compared to placebo when assessed 
at two months, three months, six months and one year.  
 
Secondary hypothesis:  
Long-chain omega 3 PUFA supplementation will result in significant improvement in the 
experience of pain (as measured by numerical rating score and SF 36) when compared to 
placebo when assessed at two months, three months, six months and one year. 
 
8.1.2 Objectives 
To measure disability and function in participants enrolled into a randomised controlled trial 
of an intake equivalent to 2.6g/day of Eicosapentaenoic acid (EPA) and Docoshexaenoic acid 
(DHA) for two months in men and women with RC tendinopathy. 
 
8.1.3 Outcome measures 
Primary outcome: 
Disability as measured by OSS. 
 
Secondary Outcomes: 
1. Disability as measured by the Shoulder Pain and Disability Index (SPADI). 
2. Pain measured by Numerical Rating Scale (NRS) and Short Form (SF) 36 bodily pain 
(BP) domain. 
3. Quality of life measured by SF 36 and Euro Qol 5D 3L 
4. Function measured by Patient Specific Functional Score (PSFS). 
5. Global perception of change score. 
6. Impairment measures; range of motion and strength. 
Full details and justification of the methods used are discussed in chapter 5. 
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8.1.4 Markers of adherence to the intervention 
Plasma fatty acids, capsules returned and self-report numbers of capsules taken were used as 
measures of adherence with the supplement intervention. Attendance at the exercise class 
and documentation of home exercises undertaken gave an indication regarding adherence 
with exercise intervention.  
 
8.1.5 Study design  
A two arm parallel design randomised placebo-controlled trial with participants randomly 
allocated to treatment groups. Group allocation was concealed until the study was completed 
and data for the primary and secondary outcomes had been entered into the statistical 
database and analysed.  
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Figure 8.1 Study design 
PROM= patient rated outcome measures (OSS, SPADI, NRS, SF36, PSFS, EQD5 and global perception of change).  
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8.1.6 Sample Size  
Sample size calculations were based on a change in OSS as the primary outcome. At the time of the 
study design and ethics application, the minimal clinically important difference was not published for 
the OSS, but from previous work (Ainsworth, 2006) was estimated, conservatively, to be 5 which is 
equivalent to a 21% change from the midpoint of the scale which runs from 0 to 48. A change of 6 
has recently been shown to be the minimal important difference (MID) and smallest detectable 
change (SDC) for the OSS (van Kampen, Willems et al. 2013). The standard deviation of the OSS is 
based on previous research conducted by Ainsworth (2006) and is 5.87. The sample size was 
calculated to be 29 subjects in each of the two groups (58 in total), to detect a 5 point change at 
P<0.05 with a 90% power. Allowing for a dropout rate of 10% (Ainsworth, Lewis et al. 2009), the 
study aimed to randomise 32 participants into each arm of the investigation.  
 
8.1.7 Test materials  
The active treatment used in this trial MaxEPA (Seven Seas Ltd, Hull, UK, MHRA product licence 
19488/0353). These capsules were provided as opaque gelatine coated capsules, oval in shape and 
brown tan in colour to disguise the content, containing 170mg EPA, 115mg DHA, 2 units/g 
tocopherols acetate (vitamin E). The placebo supplement looked identical and contained a mixed 
inert oil (olive oil BP containing the same amount of vitamin E and antioxidants as the active 
treatment) and did not contain any EPA or DHA with the EPA and DHA being replaced by oleic acid. 
Participants in both groups were asked to take nine soft shell capsules per day for a total of two 
months. The capsules were supplied in identical plain white plastics tubs which had a tamper proof 
seal. Each participant was supplied with three tubs of capsules containing 201 capsules per tub, 603 
in total. The participants were requested to return any unused capsules at the end of the study. 
 
The instructions of how and when to take the capsules were stuck on the tubs of supplements and 
reiterated to the participants verbally.  
 
8.1.7.1 Recruitment of participants 
The study aimed to recruit men and women aged 18 to 80 years, who were referred to 
physiotherapy for treatment at one of four participating NHS physiotherapy departments within 
London, UK.  
Inclusion criteria were:  
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(i) Unilateral shoulder pain of more than 3 months duration. 
(ii) Pain produced or increased during shoulder flexion and/or abduction and/or external rotation of 
the symptomatic shoulder. 
 (iii) At least four of the following: positive Neer’s impingement sign, positive Hawkins & Kennedy 
test, pain and weakness reproduced on full and/or empty can test, pain and weakness on resisted 
shoulder external rotation, pain on palpation over greater tuberosity of the humerus.  
 
Exclusion criteria were:  
(i) Allergy to or unwilling to take fish oils, current use (over 1g/d) fish oils.  
(ii) Diabetes. 
(iii) Pregnancy or breast feeding. 
(iv) Reproduction of shoulder symptoms during active cervical spine movements. 
(v) Post traumatic onset of symptoms.  
(vi) Radiographic or clinical evidence of shoulder instability (sulcus, anterior/posterior draw, 
relocation test, apprehension test).  
 
Participants were recruited once they had been referred to physiotherapy from their treating 
physiotherapist at the initial assessment session, who provided the individual with the patient 
information leaflet (Appendix 11.14) and if the potential participant expressed interested in taking 
part in the study, consent was sought for the chief investigator (CI) to telephone or email the 
individual. During the subsequent telephone conversation the screening questions were reassessed, 
and the study protocol described to the potential participant. If the potential participant provided 
verbal consent to take part in the research an appointment was arranged within the Guy’s and ST 
Thomas’ Trust Clinical Research facility located at St Thomas’ Hospital, London SE1, to perform 
screening tests, obtain written consent and to conduct the baseline assessment.  
 
8.1.8 Ethical approval, clinical governance and R&D approval 
Ethical approval was obtained from Bromley Research Ethics Committee, Bromley Primary Care 
Trust, Bassetts House, Broadwater Gardens, Farnborough, Kent BR6 7UA (REC ref: 08/H0805/21) on 
28th May 2008 (Appendix 11.13). Participants gave written informed consent (Appendix 11.15) and 
received remuneration for public transport travel costs involved in taking part in the study. 
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This trial was registered at Current Controlled Trials (http://www.controlled-trials.com as 
ISRCTN17856844). 
 
8.1.9 Data analysis 
Statistical analysis of the data was conducted using SPSS for windows version 22.0 (IBM Software, 
Hampshire, UK). Standard distributional checks were made, and where appropriate, analyses were 
attempted following log transformation.  
 
The data was analysed on an intention-to-treat basis, including all randomised participants whom 
provided follow up data and each participant was analysed in their original randomized groups. 
Treatment effects are shown as the comparisons between the treatment groups at each outcome 
point during of the study, adjusted for baseline values.  
 
Analysis of covariance (ANCOVA) tests were carried out for a within subject factor (assessment time 
point) and a between group factor (supplement type; placebo or treatment) with OSS as the 
dependent variable, the treatment allocation as the predictor factor, age, gender and body mass 
index (BMI) as co-variates and the baseline OSS as an offset variable. A mixed model ANCOVA 
analysis was also used to look for change over the whole study period in each outcome measure 
adjusting for the baseline measurements. Similar analyses were conducted for secondary outcomes 
efficacy analysis; ANCOVA and mixed model ANCOVA. 
 
Results 
8.1.10 Participant recruitment 
During the recruitment period of December 2008 to January 2013, 134 patients were identified, by 
physiotherapists at the four participating sites for inclusion into the study. Following either a 
telephone conversation or a face to face meeting with the chief investigator (CI) or principal 
investigator (PI), 61 of these potential participants were deemed ineligible or they declined to be 
recruited into the trial.  
 
The reasons for the exclusion of potential participants deemed ineligible or who declined to be 
consented into the trial are detailed in Figure 8.3. In total 73 participants were consented into the 
study. 
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Figure 8.2 CONSORT diagram 
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Fourteen potential participants declined to take part due to either having to start taking 
or change their current fish oil use. The red bars in Figure 8.3 detail their reasons. 
 
Figure 8.3 Reasons for exclusion of potential participants 
 
 
8.1.11 Participant retention and attrition 
At two months 71 (96%) participants were reassessed; at three months 62 (85%) participants were 
reassessed; at six months 63 (86%) participants were reassessed; and at twelve months 65 (89%) 
participants were reassessed. There was no statistically significant difference in the attrition rate 
between groups. Participant attrition and retention during the study are presented in a CONSORT 
diagram (Figure 8.2). 
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8.1.12 Participant demographic characteristics 
The baseline participant demographics in each treatment group and the baseline outcome measures 
are presented in Table 8.1 and Table Appendix 11.21) respectively. More participants in the placebo 
group reported use of analgesic medication (P=0.02; Chi-squared test) but otherwise there were no 
other significant differences between groups.  
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Table 8.1 Participant demographic data 
Variable  Placebo n=35 Treatment n=38 
Gender: male  20 (57.1%) 17 (44.7%) 
Age (years) 52.03 (16.19) 52.24 (12.0) 
Body mass index (kg/m⁻²) 28.85 (8.44) 27.45 (5.17) 
Waist circumference (cm) 98.84 (16.41) 94.81 (12.97) 
Current smoker 5 (14.3%) 5 (14.3%) 
Plasma EPA & DHA (wt%) 3.85 (1.48) 4.07 (1.82) 
Analgesia medication  10 (28.6%)* 3 (7.9%) 
Statin medication  7 (20%) 6 (15.79%) 
Symptom duration (months) 10 (4-18) 9 (6-19.5) 
Mechanism of injury: 
Insidious 
Accident/fall 
Lifting/repetitive movement 
Exercise 
 
17 (48.6%) 
5 (14.3%) 
6 (17.1%) 
7 (20.0%) 
 
21 (55%) 
8 (21.1%) 
6 (15.8%) 
3 (7.9%) 
Able to sleep on symptomatic shoulder 17 (48.6%) 17 (44.7%) 
Aggravating movement: 
Flexion 
Abduction 
Hand behind back 
External rotation 
None 
 
23 (65.7%) 
4 (11.4%) 
4 (11.4%) 
1 (2.9%) 
3 (8.6%) 
 
20 (52.6%) 
5 (13.2%) 
10 (26.3%) 
0 (0%) 
3 (7.9%) 
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Legend: n=number, EPA= eicosapentaenoic acid, DHA=docosahexaenoic acid, wt%= percentage weight. Summary 
measures represent means/N (SD/ %/range). Differences between groups test with Mann-Whitney test or Chi-squared 
test. * denotes P=0.03 
 
 
8.1.13 Baseline characteristics of participants completing and those not completing the trial 
Although not necessary due to the very low rate of missing data, a post hoc analysis has been 
performed to explore the data to establish whether there were any significant differences between 
those who completed the trial to the primary outcome point (two months) and the one year point 
and those who did not. 
 
There were no statistical differences between the baseline characteristics population who 
completed the intervention and attended for assessment at the primary end point (two months) and 
those who did not. Further details can be found in Appendix 11.22. 
 
8.1.14 Adherence to the interventions 
There was no significant difference between groups in the number of capsules taken throughout the 
intervention from either the returned capsules count (mean difference= 38.17 during the two 
months, 95%CI of the difference= 102.69; 26.04, p=0.24 analysed using independent t test) or the 
documented capsules consumption (mean difference= 16.87 capsules during the two months, 95%CI 
of the difference= -92.82 to 59.07; p=066 analysed using independent t test). This information is 
detailed in Table 8.2. 
 
Table 8.2 Showing the number of capsules taken according to the pill count and documented in the 
diaries 
 Placebo  Treatment  P 
Value 
Number of capsules  taken from count 
% of capsules taken 
n=27   425 (122) 
84% (24%) 
n=34   463 (126) 
92% (25%) 
0.24 
Documented capsules taken in diary 
%of capsules taken 
n= 21  406 (133) 
81% (26%) 
n= 26   423 (125) 
84% (25%) 
0.66 
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Legend; n= number. Summary measures are means and (SD) analysed using independent 
samples t test. 
 
There was a statistically significant difference in the blood plasma levels of long-chain omega-3 
PUFAs (EPA and DHA) at the end of the intervention between the two groups (mean 
difference=2.35, 95%CI= 1.58,3.12, p˂0.001). This information is detailed in Figure 8.4. 
 
Figure 8.4 Graph showing the rise in EPA and DHA plasma levels within the treatment group, within 
group caparisons made using a paired samples t test.  
 
 
 
Legend: EPA= eicosapentaenoic acid, DHA= docosahexaenoic aicd, wt%= percentage weight, Δ= mean 
difference and 95% confidence interval between baseline and follow-up. 
 
W
T 
%
 
EPA (20:5n-3) DHA (22:6n-3) 
Δ 2.6 (95% CI 1.9-3.3) 
Δ 1.5 (95% CI 1.1-1.9) 
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Table 8.3 Details the plasma fatty acid analysis pre and post intervention in the treatment and placebo groups. 
 
Fatty Acid Baseline (n=73) Placebo (n=33) Treatment (n=36) Treatment effect  P value 
SFA 28.19 (4.04) 28.77 (2.59) 27.77 (3.40) -1.06 (-4.26, 2.14) 0.51 
14:0 1.22 (0.38) 1.14 (0.45) 1.14 (0.33) 0.05 (-0.13, 0.22) 0.58 
16:0 20.28 (2.01) 20.52 (1.49) 19.57 (2.19) -0.71 (-1.42, -0.01) 0.05 
18:0 7.08 (1.12) 7.11 (0.65) 7.06 (0.88) 0.07 (-0.16, 0.29) 0.09 
MUFA 22.28 (5.35) 22.98 (3.95) 20.55 (4.92) -1.50 (-4.29, 1.30) 0.29 
16:1n-7 1.70 (0.62) 1.58 (0.53) 1.60 (0.56) 0.07 (-0.14, 0.28) 0.49 
18:1n-9 19.43 (4.38) 19.98 (3.24) 17.47 (4.14)  -1.76 (-3.09, -0.43) 0.01 
18:1n-7 1.45 (0.20) 1.42 (0.18) 1.48 (0.22) 0.10 (0.03, 0.17) 0.01 
PUFA 38.39 (6.15) 39.92 (9.76) 41.58 (10.05) 1.09 (-3.70, 5.88) 0.65 
18:2n-6 25.23 (3.97) 26.28 (5.21) 24.54 (3.70) -1.69 (-3.03, -0.34) 0.02 
20:3n-6 1.61 (0.85) 1.45 (0.28) 1.17 (0.32) -0.29 (-0.44, -0.14) <0.01 
20:4n-6 6.42 (1.83) 6.36 (1.56) 6.02 (1.45) -0.44 (-0.91, 0.03) 0.07 
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Fatty Acid Baseline (n=73) Placebo (n=33) Treatment (n=36) Treatment - placebo 
(95%CI) 
P value 
22:4n-6 0.34 (0.13) 0.36 (0.11) 0.32 (0.12) -0.01 (-0.05, 0.03) 0.62 
22:5n-6 0.49 (0.21) 0.57 (0.16) 0.55 (0.16) 0.02 (-0.03, 0.08) 0.43 
18:3n-3 0.87 (0.31) 0.81 (0.26) 0.89 (0.32) 0.07 (-0.04, 0.18) 0.19 
20:5n-3 1.21 (0.90) 1.27 (0.99) 3.67 (2.27) 2.35 (1.58, 3.13) <0.001 
22:5n-3 0.60 (0.17) 0.63 (0.25) 0.90 (0.38) 0.28 (0.16, 0.40) <0.001 
22:6n-3 2.14 (0.78) 2.19 (0.94) 3.52 (1.33) 1.28 (0.83, 1.74) <0.001 
 
Mean values (SD) and treatment effect is active treatment – placebo (95% CI). Probability is derived from ANCOVA with the treatment value as the 
dependent variable and the treatment group as the between subject factor with baseline value, age, gender and BMI as covariates. SFA= saturated fatty acid, 
MUFA= monounsaturated fatty acid, PUFA= polyunsaturated fatty acid. 
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The number of shoulder classes attended did not differ between groups (treatment-placebo 
mean difference=-1.14 classes, 95%CI of the difference= -0.05, 2.79; p= 0.10). The mean 
attendance in the placebo group as ranked by the criteria set out in the method (Chapter 5) 
was classed as good (attended six to seven classes out of the eight available, mean= 6.58 
classes, SD= 2.06) and the mean attendance in the treatment group was satisfactory (attended 
four to five classes out of the eight available, mean= 5.20 classes, SD=2.89). 
 
There were no differences in reported home exercise duration: those in the placebo group 
documented a mean of 11.74 (SD=9.80) minutes per day and the treatment group 10.74 (SD= 
7.27) minutes per day. 
 
8.1.15 FUNCTION 
8.1.15.1 Primary outcome: Oxford Shoulder Score (OSS) 
8.1.15.1.1 Primary efficacy analysis- intention to treat analysis 
Both groups demonstrated a significant reduction in disability, as measured by the OSS, at 
each follow-up when compared to the baseline. There was on average a 25% reduction in 
disability (95% CI =15.34, 34.62) in the placebo group and 25% reduction (95% CI=13.48, 
36.23) in the intervention group at two months from baseline (Table 8.5). The mean 
improvement in the OSS score at two months was 8.22 in the placebo group and 6.65 in the 
treatment group. Both of these represent a clinically meaningful change in disability (van 
Kampen, Willems et al. 2013).  
 
There was no statistically significant difference in the change in the primary outcome, OSS 
score, between the two groups at two months (adjusted mean difference= -0.07, 95%CI (-2.61, 
2.46) P=0.95) and up to 12 months (adjusted mean difference= -0.34, 95%CI (-3.29, 2.60) 
P=0.82). These results are displayed in Table 8.4 and Figure 8.5. 
 
The differences for the improvement in the OSS scores between groups using a mixed model 
analysis up to 12 months indicated no significant treatment effect (P=0.89,(95%CI=-1.29,1.84).  
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Table 8.4 Oxford Shoulder Score (OSS) at each assessment point 
Time point Placebo Treatment Treatment 
Effect 
(95% CI) 
P t-test 
 
P Ancova  
Baseline n=35, 31.71(8.40) n=38, 32.03(7.85)    
2 months n=33, 39.93 (7.2) 
Δ=25% (15-34) 
n=37, 38.68 (8.02) 
Δ=25%(14-36) 
-0.23 
(-3.89,3.43) 
0.95 0.82 
3 months n=31,39.45 (6.62) 
Δ=27% (16-37) 
n=31, 40.48 (7.4) 
Δ=30%(17-42) 
-0.57 
(-2.54, 4.60) 
0.56 0.3 
6 months N=30, 42.10(4.81) 
Δ=33% (21-46) 
N=33, 41.61(7.18) 
Δ=35% (20-51) 
-0.49 
(-3.60, 2.62) 
0.73 0.91 
12 months N=32, 43.06(5.50) 
Δ=41% (27-55) 
N=33, 43.03(6.93) 
Δ=38% (22-55) 
-0.03 
(-3.14, 3.07) 
0.82 0.89 
 
Legend; n= number, CI= 95% confidence interval of the difference. Summary measures are means and 
(SD) analysed using independent samples t test and between group comaprison by and ANCOVA 
adjusted for baseline value, age, gender and BMI. Δ= percentage change from baseline (95% CI of 
change). Treatment effect is the difference between active treatment and placebo. 
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Figure 8.5 Oxford Shoulder Score (OSS) at each assessment point. Error bars= 95% confidence 
interval  
 
 
 
8.1.15.1.2 Participants achieving clinically important change in disability 
The primary outcome time point was eight weeks, and at this time-point 16/37 (43.2%) of the 
participants in the PUFA supplement group and 15/33 (45.4%) of the participants in the 
placebo group demonstrated a clinically important improvement in perceived level of 
disability (a six point or higher improvement on the OSS). No participants in the placebo group 
and 1/37 (2.7%) in the treatment group showed a clinically important deterioration (a six 
point or higher reduction in OSS) at this time point. There was no statistically significant 
difference between the supplement groups for the clinically important improvement (p=0.85) 
and clinically important deterioration (p=0.34). 
 
At three months, 22/31 (71%) of the PUFA supplement group and 20/31 (64.5%) of the 
placebo group reported a clinically important improvement in perceived level of disability 
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(p=0.58). No participants in either group reported a clinically important deterioration in 
perceived level of disability.   
 
At six months 21/33 (63.6%) of the participants in the PUFA supplement group and 20/30 
(66.7%) of the participants in the placebo group demonstrated a clinically important 
improvement in perceived level of disability (a six point or higher improvement on the OSS). 
No participants in the placebo group and 2/33 (6.1%) in the treatment group showed a 
showed a clinically important deterioration (a six point or higher reduction in OSS) at this time 
point. There was no statistically significant difference between the supplement groups for the 
clinically important improvement (p=0.80) and clinically important deterioration (p=0.17). 
 
At the final assessment point, one year, 26/33 (78.8%) of the participants in the PUFA 
supplement group and 23/32 (71.9%) of the participants in the placebo group demonstrated a 
clinically important improvement in perceived level of disability (a six point or higher 
improvement on the OSS). No participants in the placebo group and 1/33 (3%) in the 
treatment group showed a showed a clinically important deterioration (a six point or higher 
reduction in OSS) at this time point. This participant reported re-injuring their shoulder whilst 
lifting a heavy object between three and six months and self-referred to her general 
practitioner.  
 
There was no statistically significant difference between the two groups for the clinically 
important improvement (p=0.52) and clinically important deterioration (p=0.32). 
 
8.1.15.2 Secondary outcomes: Shoulder Pain and Disability Index (SPADI) 
A statistically significant reduction in level of perceived disability as measured by SPADI was 
observed in both groups over the duration of the study (two months; placebo mean 
difference= 16.93, 95% CI=10.93, 22.93, p=0.00, long-chain omega-3 PUFA mean difference= 
15.85, 95%CI= 9.52, 22.17, p=0.00; 12 months; placebo mean difference= 15.73 95%CI= 8.15, 
23.30, p=0.00, long-chain omega-3 PUFA mean difference= 7.82, 95%CI=0.93, 14.71, p=0.03). 
 
The PUFA supplement group showed a statistically significant change when compared to the 
placebo group (adjusted mean difference= -8.25, 95%CI=-15.56, -0.94; p=0.03, analysed by 
ANCOVA adjusted for baseline) at three months (Table 8.5 and Figure 8.6). It would be 
questionable whether a difference of 8.25 is clinically meaningful when the MICD of the SPADI 
174 
 
has been reported to range from 8-20 (Williams, Holleman et al. 1995, Paul, Lewis et al. 2004, 
Schmitt and Di Fabio 2004, Ekeberg, Bautz-Holter et al. 2010). The line graph shows clearly 
that the mean SPADI score then remained almost static at that level in the long-chain omega-3 
PUFA supplement group from three months to the end of the trial at 12 months. This suggests 
that the treatment group reached almost maximal improvement at three months which was 
nine months earlier than the placebo group who had a higher mean SPADI (greater disability) 
score at three months and continued to improve more slowly to the six month outcome point 
and end of the trial at 12 months. 
 
There were no significant differences reported for the reduction in the SPADI scores between 
groups using a mixed model analysis up to 12 months (p=0.38). 
 
Table 8.5 Shoulder pain and disability index (SPADI) scores across all assessment points 
 
Legend: n=number CI=95%confidence interval of the difference. Summary measures are mean values 
with SD in parenthesis. Probability is from an independent samples t test and between group treatment 
effects are derived from univariate ANCOVA adjusted for baseline value, age, gender and BMI. 
Treatment effect is the difference between active treatment and placebo. 
 
Time point  Placebo Treatment Treatment effect 
(95% CI) 
P value 
Baseline n=35, 43.12 (21.49) n=38, 38.74 (22.27)   
2 months n=33, 25.10 (22.78)  n=36, 23.43 (23.07) 0.27 (-8.26, 8.80) 0.95 
3 months n=31, 25.34 (21.09) n=31, 13.89 (18.14) -8.49 (-16.24 -0.73) 0.03 
6 months n=30, 16.85 (18.33) n=33, 13.26(19.01)  -3.00 (-12.10, 6.11) 0.51 
12 months n= 32, 9.85 (2.39) n= 33, 11.20(19.2) 2.03 (-6.38, 10.49) 0.63 
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Figure 8.6  Shoulder pain and disability index (SPADI) score across all assessment points. Error 
bars= 95% confidence interval. 
 
 
8.1.15.3 Patient Specific Functional Score (PSFS) 
A statistically significant improvement in function, as measured by the Patient Specific 
Functional Score (PSFS), was demonstrated by participants in both groups throughout the 
duration of the study (two months; placebo mean difference= -21.16,95% CI=-34.42,-10.90, 
p=0.00, long-chain omega-3 PUFA mean difference= -28.24, 95%CI= -38.04, -18.45, p=0.00; 12 
months; placebo mean difference= -19.69 95%CI= -29.97, -9.41, p=0.00, long-chain omega-3 
PUFA mean difference= -13.26, 95%CI= -22.74, -3.79  p=0.00). 
 
There were no between group differences in functional improvement as measured by the 
PSFS at any time point up to 12 months (adjusted mean difference= 1.55, 95%CI=-9.81, 12.90, 
p=0.79 using ANCOVA adjusted for baseline). 
 
There were no significant differences found in the PSFS scores between groups using a mixed 
model analysis up to 12 months (p=0.39). 
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Table 8.6 details the Patient specific functional score across all time points for both groups 
Time point  Placebo Treatment Treatment effect 
(95% CI) 
P value 
Baseline n=35, 38.38 (19.73) n=38, 36.75 (20.44)   
2 months n=33, 58.43 (24.07) n=37, 64.55 (24.07) 6.08 (-5.96, 18.11) 0.32 
3 months n=31, 68.87 (22.42) n=31, 72.04 (21.90) 5.19 (-6.12, 16.49) 0.36 
6 months n=30, 72.89 (21.20) n=33, 76.57 (21.25) 5.18 (-5.67, 16.02) 0.34 
12 months n=32, 78.80 (23.77) n=33, 80.44 (21.81) 4.17 (-6.68, 16.10) 0.41 
Legend: n=numbers, CI=95% confidence interval of the difference. Summary measures are means and 
(SD) analysed using independent samples t test and treatment effects (difference between active and 
placebo treatments) are derived from univariate ANCOVA adjusted for baseline value, age, gender and 
BMI. 
 
8.1.16 PAIN 
Pain within the study was measured using the Numerical Rating Scale (NRS) and Short form 36 
(SF36) bodily pain (BP) component score. 
 
8.1.16.1 Numerical Rating Scale (NRS) 
A statistically significant reduction in level of reported pain as measured by NRS was observed 
in both groups over the duration of the study (at two months; placebo mean difference= 2.18 
(95% CI=1.24, 3.12, p<0.01), long-chain omega-3 PUFA mean difference= 2.13 (95%CI= 1.10, 
3.14, p<0.01); at 12 months; placebo mean difference= 1.95 (95%CI= 0.87, 3.04, p=0.01), long-
chain omega-3 PUFA mean difference= 1.18 (95%CI=0.04, 2.31, p=0.04). 
 
There were no statistically significant between group differences in reduction of pain levels at 
the primary outcome point at two months (adjusted mean difference=0.26 (95%CI= -0.04, 
0.56, p=0.08 using ANCOVA adjusted for baseline) and also at 12 months (adjusted mean 
difference= 0.27 95%CI= -0.03, 0.57 p=0.07 using ANCOVA adjusted for baseline).  
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There were also no significant differences found in the improvement in the NRS scores 
between groups using a mixed model analysis up to 12 months (p=0.50). 
 
Table 8.7 details the Numerical rating scale scores across all time points for both groups 
Time point  Placebo Treatment Treatment effect 
(95%CI)⁺ 
P value  
Baseline n=35, 6.26 (1.83) n=38, 6.0 (2.14)   
2 months n=33, 4.0 (2.47) n=36,3.75 (2.51) -0.07 (-1.28, 1.15) 0.91 
3 months n=31, 3.53 (2.49) n=31,2.56 (2.05) -0.92 (-2.09, 0.26) 0.12 
6 months n=30, 3.30 (2.68) n=32,2.86 (2.44) -0.24 (-1.73, 1.25) 0.75 
12 months n= 32, 2.11 (2.39) n= 33, 2.1 (2.53) 0.04 (-1.18, 1.26) 0.95 
Legend: n=numbers, CI=95% confidence interval of the difference. Mean values (SD). Treatment effect 
is the difference in change from baseline between groups with 95% CI adjusted for age, gender and 
BMI. Probability is from analysis of variance at each time point. 
 
8.1.16.2 SF 36 Bodily Pain  
Both treatment groups showed a statistically significant decrease in pain as measured by the 
SF36 (BP) at the primary outcome point of two months (placebo, mean difference= -14.25, 
95%CI= -19.29, -9.21, p= 0.00 and long-chain omega-3 PUFA mean difference= -15.11, 95%CI=-
22.89, -7.33, p=0.00 using ANCOVA adjusted for baseline). At the longevity outcome point of 
12 months only the long-chain omega-3 PUFA supplement group showed a statistically 
significant change (placebo mean difference= -5.13, 95%CI= -14.95, 4.69, p=0.30 and long-
chain omega-3 PUFA mean difference= -9.30, 95%CI= -16.82, -1.78, p=0.02 using ANCOVA 
adjusted for baseline) demonstrated a reduction in pain as measured by the SF36 (BP) score 
over the 12 month period.  
 
There was no statistically significant difference between groups at the primary outcome point 
of two months (mean difference= 1.79, 95%CI= -6.17, 9.75 p=0.66 using ANCOVA adjusted for 
baseline) or at 12 months (mean difference= 9.37, 95%CI= -1.08, 19.83, p= 0.08 using ANCOVA 
adjusted for baseline). 
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Table 8.8 details the SF 36 Bodily Pain scores across all time points for both groups. 
Time 
point  
Placebo Treatment Treatment effect 
(95% CI) 
P value 
Baseline n=35, 47.89(19.07) n=38, 51.61(21.70)   
2 months n=32, 64.66(19.72) n=36, 67.31(18.09) 1.73 (-6.29, 9.74) 0.67 
3 months n=31, 62.23(20.29) n=31, 71.06(19.09) 6.69 (-1.79, 15.16) 0.12 
6 months n=30, 73.37(18.25) n=32, 74.47(21.46) 2.87 (-6.13, 11.86) 0.53 
12 months n= 32, 69.63(22.20) n= 32, 80.22(19.39) 11.57 (0.85, 22.30) 0.04 
Legend: n=numbers, CI=95% confidence interval of the difference. Summary measures are means and 
(SD) analysed using independent samples t test and treatment effects (difference between active and 
placebo treatments) are derived from univariate ANCOVA adjusted for baseline value, age, gender and 
BMI. 
 
8.1.17 HEALTH RELATED QUALITY OF LIFE MEASURES 
8.1.17.1 EQ 5D-3L  
There was no statistically significant improvement found in health related quality of life 
function, as measured by the EQ 5D 3L, demonstrated by participants in either group 
throughout the duration of the study, other than for the placebo group at 12 months (two 
months; placebo mean difference= -0.04, 95% CI=-0.11, 0.04, p=0.33, long-chain omega-3 
PUFA mean difference= -0.10, 95%CI= -0.18, -0.03, p=0.10; 12 months; placebo mean 
difference= -0.08, 95%CI= -0.14, -0.01, p=0.02, long-chain omega-3 PUFA mean difference= -
0.02, 95%CI= -0.10, 0.05, p=0.54 using ANCOVA adjusted for baseline). 
 
There were no statistically significant between group differences for change in health related 
quality of life over the study period (two months; mean difference= 0.58, 95%CI=-0.03, 0.14 
p=0.18; 12 months mean difference=0.82, 95%CI= -0.05, 0.10, p=0.45). 
 
There were no significant differences found  in the EQ5D 3L score changes between groups 
using a mixed model analysis up to 12 months (p=0.26). 
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Table 8.9 details the EQ 5D 3L scores across all time points in both groups. 
Time point  Placebo Treatment Treatment effect  
(95% CI) 
P value 
Baseline n=34, 0.68 (0.23) n=38, 0.70 (0.26)   
2 months n=33, 0.74 (0.17) n=37, 0.79 (0.23) 0.06 (-0.03, 0.15) 0.17 
3 months n=30, 0.78 (0.13)  n=31, 0.82 (0.16) 0.27 (-0.04, 0.10) 0.44 
6 months n=30    0.80 (0.19)  n=33, 0.83 (0.13) 0.03 (-0.04, 0.10) 0.46 
12 months n= 32, 0.82 (0.15) n= 33,0.86(0.17) 0.05 (-0.02, 0.12) 0.17 
Legend: n=numbers, CI=95% confidence interval of the difference. Summary measures are means and 
(SD) analysed using independent samples t test and treatment effects (difference between active and 
placebo treatments) are derived from univariate ANCOVA adjusted for baseline value, age, gender and 
BMI. 
 
8.1.17.2 EQ D5-3L – health status 
The EQ D5 measuring health status showed that only the treatment group showed a 
statistically significant improvement in health status at the primary outcome point (placebo 
mean difference= -2.94 95%CI=-8.21, 2.33, p=0.26, long-chain omega-3 PUFA group, mean 
difference=-10.36, 95%CI= -16.52, -4.20, p=0.00). Neither group showed an improvement in 
health status in the period two to 12 months (placebo mean difference= -0.13, 95%CI= -8.37, 
8.12, p=0.98, omega3 PUFA mean difference= 2.65, 95%CI= -4.99, 10.28, p=0.49). 
 
There were no statistically significant between group differences for change in health status at 
two months (mean difference= 3.78, 95%CI= -2.07, 9.62, p=0.20 using ANCOVA adjusted for 
baseline), or 12 months (mean difference= 1.16, 95%CI=-8.25, 10.56, p=0.81). 
 
There were no significant differences found for change in health status between groups using 
a mixed model analysis up to 12 months (p=0.19). Table 8.11 details the EQ 5D Health Status 
scores across all time points for both groups. 
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Table 8.10 EQ 5D Health status scores across all assessment points 
Time point  Placebo Treatment Treatment effect 
(95% CI) 
P value 
Baseline n=34, 72.91 (13.59) n=38, 70.24(19.39)   
2 months n=33, 78.27 (13.94) n=36, 80.19(12.00) 4.44 (-1.44, 
10.32) 
0.14 
3 months n=31, 79.31 (11.77)  n=31, 82.39(14.24) 4.88 (-0.26, 
10.02) 
0.06 
6 months n=30, 82.77 (9.04)  n=33, 82.15(12.27)  1.19 (-3.96, 6.34) 0.66 
12 months n= 32, 78.66 (21.19) n= 33, 79.12(16.90) 2.65 (-7.10,12.39) 0.59 
Legend: n=numbers, CI=95% confidence interval of the difference. Summary measures are means and 
(SD) analysed using independent samples t test and treatment effects (difference between active and 
placebo treatments) are derived from univariate ANCOVA adjusted for baseline value, age, gender and 
BMI. 
 
8.1.17.3 Short Form 36 
Short form 36 (SF36) was analysed in each of its eight domains and the results are presented 
in Appendix 11.23 for each domain, other than the two which showed a statistically significant 
result, the SF 36 BP detailed in the pain section above (8.3.7.2) and SF 36 Physical Functioning 
below. Further analysis investigated the physical component scores and the mental 
component scores as a summary measure together.  
 
8.1.17.4 SF36 – Physical Functioning 
Both treatment groups showed an improvement in physical functioning as measured by the 
SF36 physical function sore over the 12 month period. There was a statistically significant 
difference between the two groups in favour of the treatment group at six months (p=0.029 
95%CI=-0.01 to 0.38). Table 8.11 details the SF 36 Physical Functioning scores across all time 
points for both groups.  
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Table 8.11 SF 36 Physical Functioning across all assessment points 
Time point  Placebo Treatment Treatment effect 
(95% CI) 
P value 
Baseline n=35, 65.86 (20.77) n=38, 68.16(23.20)   
2 months n=32, 76.72 (19.90) n=36, 78.47(19.00) 1.64 (-5.57, 8.85) 0.65 
3 months n=31, 74.19 (20.86) n=31  83.23(15.84) 5.13 (-1.72, 11.99) 0.14 
6 months n=30, 77.50 (18.65)  n=32, 84.84(12.15) 7.95 (0.86, 15.04) 0.029 
12 months n= 32,79.38 (19.71) n= 32,79.69(23.35) -1.49 (-11.78, 8.81) 0.77 
Legend: n=numbers, CI=95% confidence interval of the difference. Summary measures are means and 
SD analysed using independent samples t test and treatment effects (difference between active and 
placebo treatments) are derived from univariate ANCOVA adjusted for baseline value, age, gender and 
BMI. Scores are an aggregate percentage where 0= worst possible functioning and 100=best.  
 
8.1.17.5 SF 36 – Summary measures 
8.1.17.5.1 Physical component summary (PCS) 
Both treatment groups demonstrated a statistically significant change form baseline to two 
months (placebo mean difference= -6.82, 95%CI=-8.97, -4.66, p=0.00, long-chain omega-3 
PUFA mean difference= -5.38, 95%CI=-7.68, -3.07, p=0.00). This was not continued at 12 
months with neither group showing a statistically significant change between two and 12 
months (placebo, -2.61, 95%CI=-6.94, 0.91, p=0.14, long-chain omega-3 PUFA mean 
difference=-0.19, 95%CI=-3.77, 3.39, p=0.91). 
 
There were no between group differences observed across all time points (two months, mean 
difference= -0.73, 95%CI= -4.94, 3.76, p=0.79; 12 months mean difference= -0.59, 95% CI= -
4.94, 3.76, p=0.79). 
 
There were no significant differences found for the change in SF 36 physical component 
summary score between groups using a mixed model analysis up to 12 months (p=0.77). 
Table 8.12 details the SF 36 Physical Component scores across all time points for both groups. 
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Table 8.12 SF 36 Physical component summary (PCS) across all assessment points 
Time point  Placebo Treatment Treatment effect 
(95% CI) 
P value 
Baseline n=35, 37.95 (8.18) n=38, 41.54 (8.26)   
2 months n=32, 45.55 (8.16) n=36, 46.77 (8.77) -0.40 (-3.36, 2.56) 0.79 
3 months n=31, 43.20 (8.42) n=31, 48.02 (8.76) 1.07 (-2.27, 4.41) 0.52 
6 months n=30,47.06 (6.61) n=32, 47.60 (11.39) -0.45 (-5.36, 4.46) 0.86 
12 months n= 32, 47.62 (8.92) n= 32, 49.14  (8.85) -0.44 (-5.00, 4.13) 0.85 
Legend: n=numbers, CI=95% confidence interval of the difference. Summary measures are means and 
SD analysed using independent samples t test and treatment effects (difference between active and 
placebo treatments) are derived from univariate ANCOVA adjusted for baseline value, age, gender and 
BMI. Scores are an aggregate percentage where 0= worst possible functioning and 100=best.  
 
8.1.17.5.2 Mental component summary (MCS) 
Neither group showed a statistically significant change at two months (placebo mean 
difference= 2.38, 95%CI= -0.19, 4.95, p=0.07, long-chain omega-3 PUFA mean difference= -
1.53, 95%CI= -4.90, 1.84, p=0.49) or 12 months (placebo mean difference= 0.31, 95% CI=-2.70, 
3.33, p=0.83; long-chain omega-3 PUFA= 0.92, 95%CI=-2.96, 4.80, p=0.63). 
 
At baseline there was a statistical difference between groups with the placebo group starting 
with a higher score, better functioning metal component (mean difference=5.03, 95% CI 
=0.74, 9.32, p=0.02). Following this there were no between group differences in the remainder 
of the study period (two months; mean difference= 2.86, 95%CI= -2.24, 5.96, p=0.37; 12 
months mean difference= 0.59, 95%CI=-3.33, 4.52, p=0.76)  
 
There were no significant differences found for the change in SF 36 mental component 
summary score between groups using a mixed model analysis up to 12 months (p=0.83). 
Table 8.13 details the Mental Component Summary scores across all time points for both 
groups. 
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Table 8.13 SF 36 Mental component summary (MCS) scores across all assessment points 
Time point  Placebo Treatment  Treatment effect 
(95% CI) 
P value  
Baseline n=35, 54.67 (8.03) n=38, 49.64 (10.13)    
2 months n=32, 52.44 (8.82) n=36, 50.93 (10.70) 1.90 (-2.25, 6.01) 0.36 
3 months n=31, 55.94 (6.15) n=31, 52.96 (8.69) -0.40 (-3.76, 2.97) 0.82 
6 months n=30, 54.20 (7.13) n=32, 51.13 (9.46) -0.31 (-4.05 3.43) 0.87 
12 months n=32, 52.65 (8.42) n=32, 50.80 (9.94) 1.52 (-2.36, 5.40) 0.45 
Legend: n=numbers, CI=95% confidence interval of the difference. Summary measures are means and 
SD analysed using independent samples t test and treatment effects (difference between active and 
placebo treatments) are derived from univariate ANCOVA adjusted for baseline value, age, gender and 
BMI. Scores are an aggregate percentage where 0= worst possible functioning and 100=best. Treatment 
effect is the difference between active treatment and placebo. 
 
8.1.18 GLOBAL PERCEPTION OF CHANGE  
Both groups reported a greater than 50% improvement over the intervention. There was no 
statistical difference between the groups of the level of perceived change across all time 
points (three months, mean difference=5.72, 95%CI= -4.32, 15.75, p=0.26, 12 months, mean 
difference=-2.56, 95%CI=-15.73, 10.61 , p=0.70).  
 
Twenty six percent of participants at 12 months rated their improvement as being 100% and 
58% rated their improvement as 90% or better. Table 8.15 details the Global Perception of 
Change scores across all time points for both groups. 
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Table 8.14 Global perception of change scores across all assessment points 
Time point  Placebo Treatment Treatment effect 
(95% CI) 
P value 
2 months n=33, 54.09 (30.12) n=37, 55.27 (30.73) -0.05(-14.91, 14.82) 0.10 
3 months n=31, 66.13(22.29) n=31, 70.81 (25.27) 7.00(-5.60, 19.60) 0.27 
6 months n=30, 75.57  (20.57) n=33, 74.18(32.29) -2.01(-16.60, 12.59) 0.78 
12 months n= 32, 80.00 (22.51) n= 33,77.97 (32.58) -1.33(-16.01, 13.35) 0.86 
Legend: n=number, 95% CI=95% confidence interval of the difference. Summary measures are means 
and SD (95% confidence intervals) analysed using independent samples t test and treatment effects 
(difference between active and placebo treatments) are derived from univariate ANCOVA adjusted for 
baseline value, age, gender and BMI. 
 
8.1.19 IMPAIRMENT MEASURES 
8.1.19.1 Range of motion 
A statistically significant improvement was observed across both groups within the 12 months 
(p≤0.02) for all range of motion measurements other than shoulder joint abduction in the 
placebo group (p=0.06). 
 
The results showed statistically greater improvement in symptomatic shoulder flexion and 
abduction range at three months in the treatment group when compared to the placebo 
group (for flexion mean difference = 7.71, 95%CI= 2.37, 12.86, p=0.01, for shoulder abduction, 
mean difference=10.41, 95%CI= 3.12, 17.70, p=0.01). There were no statistically significant 
differences in the other movements of shoulder external rotation or hand behind back (Table 
11.24 in Appendices). 
 
8.1.19.2 Strength 
A statistically significant improvement was observed across both groups within the 12 months 
(p≤0.03) for all strength measurements other than elbow flexion in the placebo group 
(p=0.11).  
 
No statistically significant differences were observed between the groups in all strength 
measurements over all time points, other than shoulder external rotation at 12 months (mean 
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difference= -0.94, 95%CI=-4.16, 2.27, p=0.01). Whilst this is a statistically significant difference 
in favour of the treatment group, it is not believed to be clinically significant. These results 
indicate that shoulder strength measures were unaffected by the type of supplement taken 
(Table 11.25 in Appendicies). 
 
8.1.20 Dietary intake of study participants  
The dietary intake of the participants analysed from the data provided in their four day food 
diaries is detailed in Table 8.15. The estimated nutrient intake from the four day food diaries 
completed at baseline and trial end point (12 months) and were analysed for consistency of 
nutrient intake over the trial period. There were no statistically significant differences in pre 
and post-trial fatty acid intakes for the participants. However there were significant 
differences in intake in zinc, folate and vitamin A between the two groups. 
 
This data is also compared to the data published in the national average taken from the 
National Diet and Nutrition Survey (Public Health Engand 2014) (table 8.16). 
 
Table 8.15 Dietary intake of study participants 
 Placebo  
(n=30) 
Treatment 
(n=31) 
Mean Difference  
(95%CI adjusted 
for baseline) 
P value of the 
difference 
Energy (MJ/day) 
Baseline 7.48 (2.08) 7.31 (2.12)   
1 year 6.90 (2.17) 7.09 (2.03) 0.78 (-0.82, 1.46) 0.57  
Protein (% energy) 
Baseline 17.02 (2.81) 17.66 (4.13)   
1 year 17.34 (3.38)) 18.50 (3.91) 0.16 (-0.68, 3.08) 0.21 
CHO (% energy) 
Baseline 42.00 (9.28) 44.57 (8.48)   
1 year 40.57 (8.15) 42.56 (8.81) -0.10 (-6.26, 3.04) 0.49 
Fat (% energy) 
Baseline 36.58 (7.38) 36.00 (7.64)   
1 year 37.58 (6.35) 36.04 (7.47) -0.06 (-4.77, 3.15) 0.68 
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SFA (% energy) 
Baseline 13.97 (5.66) 13.26 (4.30)   
1 year 15.16 (6.23) 14.22 (6.02) -0.03 (-3.54, 2.87) 0.84 
MUFA (% energy) 
Baseline 11.66 (3.02) 11.73 (3.70)   
1 year 11.16 (2.59) 10.58 (2.90) -0.06  (-1.88, 1.19) 0.65 
PUFA (% energy) 
Baseline 6.01 (2.01) 5.90 (2.07)   
1 year 6.86 (3.17) 6.42 (3.64) 0.03 (-1.92, 2.26) 0.87 
Omega-3 PUFA (g/day) 
Baseline 0.06 (0.18) 0.06 (0.18)   
1 year 0.07 (0.16) 0.24 (0.57) 0.19 (-0.11,0.45) 0.23 
EPA (g/day) 
Baseline 0.02 (0.05) 0.02 (0.08)   
1 year 0.02 (0.03) 0.05 (0.13) 0.14 (-0.04, 0.09) 0.36 
DHA (g/day) 
Baseline 0.01 (0.06) 0.03 (0.10)   
1 year 0.03 (0.08) 0.08 (0.31) 0.12 (-0.09, 0.21) 0.46 
Dietary fibre (g/d) 
Baseline 16.72 (7.09) 18.80 (7.51)   
1 year 13.87 (4.46) 16.59 (5.75) 0.15 (-1.23, 4.43) 0.26 
Potassium (mg) 
Baseline 2696.17 (782.38) 2770.4800 
(907.05) 
  
1 year 2403.37 (675.96) 2695.20 
(880.15) 
0.21  
(-101.48, 769.32) 
0.13 
Calcium(mg)  
Baseline 707.43 (213.41) 653.80 
(234.56) 
  
1 year 716.05 (289.21) 683.17 
(320.80) 
0.22 (-158.81, 
185.95) 
0.87 
Iron(mg/d) 
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Baseline 10.38(3.69) 10.31 (4.18)   
1 year 9.07 (3.71) 10.48 (3.00) 0.24 (-0.33, 3.57) 0.10 
Zinc(mg/d) 
Baseline 8.21 (2.80) 8.00 (3.07)   
1 year 7.20 (2.30) 8.57 (2.69) 0.31 (0.13, 3.11) 0.03* 
Thiamin (mg/d) 
Baseline 1.37 (0.42) 1.38 (0.58)   
1 year 1.27 (0.46) 1.38 (0.46) 0.15 (-0.13, 0.41) 0.31 
Riboflavin (mg/d)    
Baseline 1.50 (0.83) 1.42 (0.74)   
1 year 1.39 (0.53) 1.43 (0.67) 0.10 (-0.23, 0.48) 0.49 
Niacin (mg niacin equivalents/d) 
Baseline 33.11 (3.21) 33.50 (13.03)   
1 year 32.43 (12.43)  33.08 (12.97) 0.09 (-4.26, 8.66) 0.50 
Folate (μ g/d)    
Baseline 204.50 (73.41) 211.77 (94.63)   
1 year 188.37 (57.79) 217.88 (88.54) 0.27 (4.07, 78.80) 0.03* 
B12     
Baseline 5.83 (9.13) 4.17 (2.69)   
1 year 4.16 (2.38) 6.68 (2.71) 0.11 (-1.00, 2.18) 0.51 
Vitamin A (retinol equivalents/d)  (μ g/d) 
Baseline 2796.09 
(1351.99) 
2585.29 
(1595.22) 
  
1 year 2222.89 (955.50) 3590.83 
(2839.86) 
0.31 (148.17, 
2679.90) 
0.03* 
Vitamin D (μ g/d) 
Baseline 1.80 (1.38) 2.13 (2.52)   
1 year 2.72 (2.73) 2.63 (2.17) -0.27 (-1.63, 1.38) 0.86 
Legend: CI=95% CI, CHO=carbohydrate, EPA= eicosapentaenoic acid, DHA= docosahexaenoic acid, 
SFA=saturated fatty acid, MUFA=monounsaturated fatty acid, PUFA= polyunsaturated fatty acid. 
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From the values below (Table 8.16) the dietary intake of the study participants’ was largely in 
line with the national average. 
 
Table 8.16 Mean dietary intake of study participants as compared to national average values 
 Trial participants (N=61) National Diet & Nutrition 
survey 
P-value 
 Men (n=30) Women(n=30) Men Women  
Mean energy (MJ)      
19-64 years 7.758 (2.00) 7.403 (1.83) 8.88 6.78 0.99/0.99 
65 & over 8.197 (2.52) 8.845 (0.71) 8.14 6.35 0.99/0.75 
Protein (% energy) 17.667% 
(3.92) 
16.309% 
(2.59) 
17.50% 0.82 
CHO (% energy) 39.432% 
(8.39) 
46.943% 
(8.00) 
47.20% 0.47 
Fat (% energy) 37.156% 
(7.22) 
35.588% 
(7.40) 
35.50% 0.72 
SFA (% energy) 13.937% 
(4.26) 
12.254% 
(3.81) 
13.20% 0.98 
MUFA(% energy) 12.808% 
(2.87) 
11.566% 
(3.31) 
12.50% 0.81 
PUFA (% energy) 6.037% 
(1.69) 
6.316%    
(2.16) 
5.50% 0.87 
Legend; CHO=carbohydrate, SFA=saturated fatty acid, MUFA=monounsaturated fatty acid, PUFA= 
polyunsaturated fatty acid.  
 
8.1.21 Consistency of exercise class at each site 
Observation of the shoulder classes periodically at all sites confirmed that all groups 
continued to run as described in Chapter 5 (5.3.3.8.2). 
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8.1.22 Quality control of PUFA supplements  
A sample of the long-chain omega-3 PUFA supplements were returned to Seven seas for 
analysis after the last participant had finished the intervention period. The supplements were 
analysed for any oxidation and levels of EPA and DHA. The results showed no oxidation had 
occurred outside expected limits and the content of the supplements remained unchanged 
(Appendix 11.17). 
 
8.1.23 Adverse events 
No serious adverse events were reported. Two participants (39 and 61) stopped taking the 
capsules due to issues with indigestion or upset stomach. The participant information sheet 
stated “reported side effects have included an upset stomach or stomach pain, black tarry 
stools, bruising and heartburn”. Three participants reported that they were unable to take the 
full number of capsules each day due to feeling uncomfortable or having difficult taking the 
capsules (Participants 25, 72 and 75). Others reported feelings of heartburn or nausea but 
reported continuing to take the full number of capsules each day. 
 
8.1.24 Sensitivity analysis  
The study was powered taking into account a 10% drop out but only a 4% drop out was 
observed at the primary outcome point. Given this low rate no multiple imputation methods 
were needed and no sensitivity analysis was indicated.  
 
The data was explored as a post hoc analysis to see if there were any statistically significant 
differences between those who ‘adhered ‘to the long-chain omega-3PUFA supplements and 
those who did not. When a level of 4.2 percentage weight total long-chain omega-3 PUFAs is 
applied as the cut off point for adherence in the post supplementation plasma fatty acid 
analysis, a similar picture is seen as in the intention to treat analysis in the primary and 
secondary outcome measures. Similarly missing number imputation does not produce any 
statistically significant results in the primary outcome measure for either group across all time 
points.  
 
8.1.24.1 Does level of EPA and DHA in plasma correlate to an improvement in OSS, SPADI, 
NRS or SF36 bodily pain outcomes? 
A post hoc analysis of the effect of increased EPA and DHA within the plasma and the 
improvement in disability and pain at the primary outcome point of two months using 
regression and (partial correlations), adjusted for treatment group was conducted. There was 
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no evidence within this sample that there is a relationship between EPA and DHA plasma 
levels and reduction in disability as measured by the OSS and SPADI. However a relationship 
between increasing EPA and DHA plasma levels and decreasing reported pain as measured by 
the NRS was found (correlation= -31% for EPA and 32% for DHA, p=0.01 for both EPA and 
DHA). For each unit increase of EPA and DHA there was on average a 9% and 14% change 
observed in the NRS score respectively.  
 
8.1.25 Summary 
From the results presented in the study sample, we observed that there was no statistical 
difference detected between the two groups over each time point up to 12 months, 
suggesting that no added benefit was afforded by taking the PUFA supplement in terms of 
disability as measured by the primary outcome. There was a statistically significant difference 
between the two groups in disability as measured by the SPADI in favour of the treatment 
group at three months but this benefit had disappeared by 12 months. This might suggest that 
the addition of a PUFA supplement might improve speed of recovery of function between two 
and six months.  
 
There was a statistically significant difference found at 12 months in the treatment group with 
regards to pain measured by the SF 36 BP component and at three months as measured by 
the SPADI pain sub scale. This finding was not supported by the other two pain measurement 
outcomes. 
 
Discussion 
This study set out to compare the efficacy of long-chain omega-3 PUFA supplements to a 
placebo supplement in the treatment of RC tendinopathy. This study demonstrated that 
individuals with RC tendinopathy who participated in an eight week exercise class and took 
either long-chain omega-3 PUFA supplements or placebo supplements reported statistically 
significant improvements in disability (as measured by the OSS) at two months, three months, 
six months and one year. Improvement in disability was similar in both supplement groups. 
These results provide insufficient evidence to reject the null hypothesis that there is no 
difference between the two treatment groups at two, three, six or twelve months.  
 
There was a clinically and statistically significant reduction in pain and disability score in both 
groups. The mean increase in the OSS score in the long-chain omega-3 PUFA group was 6.65 
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points and the corresponding result in the placebo group was 8.22 points at two months, both 
groups achieving the MICD (van Kampen, Willems et al. 2013). When reviewing results from 
the one of the secondary outcome measures, the SPADI, the long-chain omega-3 PUFA group 
achieved a more rapid improvement in disability than the placebo group. The long-chain 
omega-3 PUFA group demonstrated a 64% improvement from baseline at three months, 
compared to a 42% in the placebo group, which had then equalled out by the six month 
assessment. 
 
8.1.26 Baseline demographic data 
Participants who consented and took part in this study were typically in their 50th decade 
(mean age 52.14 years, SD = 14.06) and were evenly distributed between men and women. 
This demographic presentation is typical of other RC populations in clinical trials in the UK and 
Scandinavia (Ketola, Lehtinen et al. 2013, Kukkonen, Joukainen et al. 2014, Littlewood, 
Malliaras et al. 2014). Baseline OSS scores of 32 in the current trial were slightly higher 
(indicating less severe disability) than other published RC tendinopathy trials (Ainsworth, 
Lewis et al. 2009) but similar to others (Ekeberg, Bautz-Holter et al. 2010, Younis, Sultan et al. 
2011). The baseline SPADI scores of 41 were similar to other RC tendinopathy trials 
(Engebretsen, Grotle et al. 2009, Yiasemides, Halaki et al. 2011, Kromer, de Bie et al. 2013). 
The similarity in the baseline level of disability as measured by OSS and SPADI compared to 
other trials, indicates the level of disability and demographics are suitably representative of 
the RC tendinopathy population within the UK and Scandinavia that have participated in 
research investigations. The average body mass index of the participants in this study was 
28.15 which is categorised as overweight, and 70% of participants were  classed as overweight 
(BMI of 25-30) or obese (BMI of ≥30). However this is reflective of  in the general population 
with 50-60% being classed as overweight or obese within this age range (Public Health Engand 
2014).  
 
The mirroring of the characteristics of the general RC tendinopathy population within the UK 
allows the generalisation of the findings of this study with more certainty to the wider RC 
tendinopathy population. 
 
Participants were recruited from four NHS physiotherapy sites located across London. These 
locations included both suburban and inner city sites. This range in recruitment locations 
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encouraged a diverse study population which would be representative of the country as a 
whole, allowing wider generalisation of any results across the UK. 
 
8.1.27 Participation and attrition 
Retention was excellent throughout the study with 96% retention (70/73) at primary outcome 
point of two months and 89% retention (65/73) at one year. This compares favourably with 
other trials conducted on similar RC tendinopathy populations (Lewis 2012, Littlewood, 
Bateman et al. 2016).  
 
The sample size calculation identified that 29 participants were required in both groups. The 
required numbers of participants were reassessed at both the primary and end outcome 
points, thereby reducing the risk of a type two error or false negative due to underpowered 
sample groups.  
 
Although not significant a slightly larger proportion of participants not completing the study at 
one year had been allocated to the placebo group. There was a higher level of disability in the 
non-completers at baseline and subsequent attrition may have affected outcome. However 
percentage of non-completers was so low it is probable that any effect would be negligible.  
 
8.1.28 Reasons for clinical outcomes and explanation of results 
Regression to the mean is a statistical phenomenon which describes the tendency for extreme 
symptoms at baseline to return to a more central distribution on follow up and final 
assessments (Morton and Torgerson 2005).  
 
Individuals with chronic musculoskeletal conditions such as RC tendinopathy tend to seek 
help, treatment and enrol in research at the peak of their symptoms. Natural improvement 
most usually follows and post intervention or final assessment scores will often have 
improved, even if therapy is ineffective (Krogsboll, Hrobjartsson et al. 2009). The effect of 
regression to the mean was minimised within this study through random allocation, the use of 
multiple baseline measurements and the analysis of the data with ANCOVA, which adjusts for 
baseline value of each variable (Barnett, van der Pols et al. 2005). 
 
In this study, the greatest change in reduction in disability occurred at two months from 
baseline. During this time participants completed the intervention, the exercise class, home 
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exercise programme and supplements for two months. Both groups also showed an 
improvement in reported disability at three, six and twelve months when compared to the 
baseline. This improvement might reflect natural recovery of RC tendinopathy. Due to the lack 
of a non-treatment group it is not possible to determine how much of the change reported at 
the outcome points was due to regression to the mean, natural recovery, the immediate or 
longer term effects of attending an exercise class and home exercises, or the immediate or 
longer term influence of the supplements. However natural recovery is unlikely to account for 
the whole effect observed in the cohort given the long duration of symptoms and the 
moderate disability at baseline, both of which have been associated with a poorer prognosis 
(Kuijpers, van der Windt et al. 2004, Thomas, van der Windt et al. 2005). In addition, minimal 
improvements in pain and function have been observed in other studies with participants with 
RC tendinopathy over similar duration and with control groups receiving no intervention 
(Ludewig and Borstad 2003, Lombardi, Magri et al. 2008, Clement, Nie et al. 2012). 
 
Another contributing factor to a patient’s outcome is the placebo effect (Barker, Pistrang et al. 
2002). The placebo effect is a commonly recognised phenomenon and is defined as the 
psychological or physiological effect of an inert intervention which is designed to have no 
specific effect other than satisfying the patient (Price, Finniss et al. 2008). The placebo effect is 
thought to contribute approximately 30% and spontaneous recovery 10% of total outcome of 
an intervention for a chronic pain condition (Krogsboll, Hrobjartsson et al. 2009). The placebo 
effect has been reported to have the greatest influence over pain patient reported outcomes 
(Hrobjartsson and Gotzsche 2001, Hrobjartsson and Gotzsche 2004). 
 
In this study there was a blinded placebo supplement control group which was used as a 
comparison with the long-chain omega-3 PUFA supplement intervention group The allocation 
of a supplement to the control group (as compared to a control group not taking any 
supplement) aimed to reduce the possibility that any positive study findings were related to 
the influence of the placebo effect of being provided with supplements rather than any 
potential benefits of the long-chain omega-3 PUFA components of the supplements. However, 
the equivalent improvement in both the treatment groups may in part have been attributable 
to a placebo effect. 
 
Changes in psychological or social factors might also explain the similar clinical outcomes 
between the treatment groups in this study. The shoulder exercise group educated 
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participants in the importance of exercise and relaxation, pain management and their 
condition. In addition, participants in the study had more regular follow up and reassessment 
for a longer duration than ‘normal’ treatment. During these follow up visits the participants 
were encouraged to continue with their exercise programme and any questions answered. 
They would also be given an indication of any improvement. Improved coping strategies 
(Minns Lowe, Moser et al. 2014) have been reported to improve clinical outcome for RC 
tendinopathy and higher levels of therapist supervision has been shown to have a positive 
influence on reduction in pain in low back pain exercise treatment (Reilly, Lovejoy et al. 1989). 
 
8.1.28.1 Aspects of the interventions  
8.1.28.1.1 Content of long-chain omega-3 PUFA supplement 
It is possible that the long-chain omega-3 PUFA supplement provided at the 9g/d dose was 
inadequate to appropriately influence the proposed inflammatory mechanisms and the 
symptoms of RC tendinopathy. The dosage of long-chain omega-3 PUFA and GLA was higher in 
the studies conducted both by Mavrogenis et al (2004) and Roe et al (2005). Whilst positive 
effects were noted at that dose given in the Mavrogenis et al (2004) experimental group, 
similar outcomes were not observed in study conducted by Roe et al (2005). The relationship 
observed in this study with EPA and DHA and pain (as measured by NRS) would lend weight to 
the argument of investigating the efficacy of higher doses of long-chain omega-3 PUFA. 
However caution must be taken when looking at the results of the association of EPA and DHA 
with pain. It may be a case of multiplicity where if hypotheses are tested on different subsets 
of the data, the likelihood that some will appear falsely positive may increase (Lord, Gebski et 
al. 2004). 
 
The literature regarding what dosage is required in unclear (4.2.4) and the dose selected in 
this study chosen on the basis it was at the lower limit of that which might elicit an anti-
inflammatory effect but not high enough to cause gastro-intestinal problems.  
 
Compliance to the intervention was generally good with good corroboration between reports 
of the number of capsules taken and the number of capsules returned. Independent 
verification that the participants were taking the supplements was provided by the significant 
increases in the proportions of EPA and DHA in plasma lipids. Furthermore, there was no 
evidence that dietary intake of the participants changed over the period of the study. There 
were, however, considerable variations in the size of the increases in EPA and DHA within the 
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participants allocated to the long-chain omega-3 treatment and this may reflect differences in 
body size as well as the intake of other fatty acids particularly omega-6 fatty acids in the 
background diet. High intakes of linoleic acid have the effect of reducing the incorporation of 
EPA and DHA into phospholipids and cholesterol esters which are major lipid classes in plasma 
total lipids. The increases in EPA and DHA are comparable with other studies that have used 
intakes of long-chain omega-3 PUFA in the range of 2-3g/d. MaxEPA which was used in the 
present study contains in total approximately 35% long-chain omega-3 fatty acids (including 
18:4n-3, 20:4n-3, 22:5n-3), with EPA and DHA typically providing 18% and 12% of the fatty 
acids. Allowing for the non-fatty acid components, the calculated intake of total long-chain 
omega-3 fatty acids would be close to 3g/d. This is the level where triglyceride lowering 
effects are noted as well as effects on blood pressure. Even if an allowance is made for 
incomplete consumption (eight versus nine capsules/d), this still would provide an intake of 
2.7g/d of long-chain omega-3 fatty acids. While higher intakes of long-chain omega-3 PUFAs 
might have anti-inflammatory effects, the safety of higher intakes taken for long-periods of 
time is less well established. The findings of this study, therefore, are relevant to clinical 
practice. 
 
Both the placebo and long-chain omega-3 PUFA supplements contained the same amount of 
antioxidants per capsule and the intake of nine capsules per day would have equated to; 12mg 
tocopheryl acetate (vitamin E), 270 μg retinol equivalents Vitamin A and 2.25 μg vitamin D. 
These values are well below the reference nutrient intake (RNI) for adults of vitamin A (600μg 
retinol equivalents for women and 700μg for men) and the food labelling recommended daily 
allowances (RDA).  Most adults depend on exposure to sunlight for vitamin D but the 
Department of Health has recently proposed that all adults should have 10μg vitamin D/d in 
winter months which is an intake unlikely to be achieved without supplementation. The UK 
has no RNI for vitamin E  but the for the European Nutritional Labelling Directive species as 
reference intake of 12mg/d. What is unknown is the contribution of the vitamin E, D and A to 
the overall treatment effect in this study as there was no arm without supplementation.  
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8.1.28.1.2 Content of the placebo supplement 
The placebo capsules contained inert oil (refined olive oil British Pharmacopeia (BP) 
specification) and the same anti-oxidants as in the active capsules. The major fatty acid in the 
placebo was oleic acid. The intake of this fatty acids would be no more than 5g greater than in 
the active capsules. Oleic acid typically accounts for 12% of the dietary energy intake which on 
2000 kcal/d is 27g/d. Consequently, the increase in oleic acid intake attributable to the 
supplements would be estimated to be small (2% energy). Most studies using MaxEPA have 
used olive oil- BP as a placebo and while health claims have been made for virgin olive oil 
(Buckland and Gonzalez 2015), these are attributed to non-fatty acid components which are 
present in much lower quantities in the British Pharmacopeia specification than in refined 
olive oil. 
 
Whilst it is unlikely, it is not known whether or not the contents of the placebo capsules 
contributed to the overall treatment effect, due to the lack of a no supplement arm.  
 
8.1.28.1.3 Duration of treatment 
It is possible that the duration of the treatment was also not sufficient to achieve clinically 
significant results. Two months supplementation was selected on the duration in previous 
trials and evidence suggesting that there is a maximal incorporation into the plasma 
phospholipids at four weeks (Healy, Wallace et al. 2000, Yaqoob, Pala et al. 2000). The positive 
results reported by Mavrogenis et al (2004) were seen at 32 days, which was half the duration 
of the intervention and first outcome point of the current study. It is however common in 
trials of long-chain omega-3 PUFAs for the treatment of the symptoms of rheumatoid arthritis 
and osteoarthritis, for supplementation to lasts up to six months in duration. It is not possible 
to say whether ongoing supplementation would have afforded any additional benefit in this 
study.  
 
8.1.28.1.4 Adherence to treatment  
The adherence rate within this study was evaluated using return capsule count, total plasma 
lipid analysis, diary recollections and attendance to shoulder class group. The capsule counts 
indicated that 61% of participants consumed >90% of the capsules provided. This is lower than 
other trials investigating efficacy of long-chain omega-3 PUFAs (Sanders, Hall et al. 2011). 
However the mean (92%) and median capsule counts (97%) compare favourably to other 
reported efficacy trials (Kremer, Lawrence et al. 1990). No adherence rates with the 
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supplementation were given by ether of the previous studies investigating the efficacy of long-
chain omega-3 PUFAs and tendinopathy (Mavrogenis, Johannessen et al. 2004, Roe, Odegaard 
et al. 2005). 
 
The adherence rate to the exercise class was not significantly different between groups (p= 
0.10) and so any influence of non-adherence is likely to have been present equally in both 
groups. The mean adherence rate to the shoulder exercise class across the groups was 
placebo group (mean= 6.58 classes, SD= 2.06, 82% attendance) and the long-chain omega-3 
PUFA group (mean= 5.73 classes, SD= 2.73, 67% attendance). This is similar to reported 
adherence with a self-management programme for RC tendinopathy (adherence rate=78%, 
although adherence data was only available on 29% of participants) (Littlewood, Bateman et 
al. 2016). When the percentage of participants completing all eight shoulder classes offered 
(overall=37%; placebo group = 46%, treatment group= 11%) the adherence rate to the classes 
is comparatively low to other adherence rates for shoulder exercise classes (92% (Bennell, 
Wee et al. 2010). The low level of attendance to all eight classes offered when compared to 
the placebo group may have introduced a masking effect on any benefit the long-chain 
omega-3 supplements may have had.  
 
8.1.28.1.5 Inclusion of exercise 
The primary outcome point and first follow up occurred at eight weeks. During this time 
participants attended up to eight shoulder exercise groups. Improvement in disability has 
been documented following such an exercise programme for a median of eight and a half 
weeks (Bang and Deyle 2000, Haahr and Andersen 2006, Ketola, Lehtinen et al. 2009, Kuhn 
2009, Ketola, Lehtinen et al. 2013, Kukkonen, Joukainen et al. 2014, Littlewood, Malliaras et al. 
2014, Littlewood, Bateman et al. 2016).  
 
Improvement in disability associated with attendance to the exercise group may have 
overshadowed any change in disability directly associated with long-chain omega-3 PUFA 
supplement use. However, a well-structured exercise programme is the current best practice 
intervention for those with RC tendinopathy (Lewis, McCreesh et al. 2015) and subsequently 
potentially unethical to withdraw this intervention. 
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8.1.28.2 Appropriateness of outcome points 
The timing of the follow up assessments may have been a contributing factor in the results of 
this study. The primary outcome point was immediately after the intervention ceased (both 
the supplementation and the exercise class). It may also have been that any effect of the 
intervention (exercise and supplements) may take longer than two months to become 
beneficial. However, the data detail that there was rapid improvement in all outcomes scores 
in the first two months. Nevertheless, the effect of long-chain omega-3 PUFA 
supplementation would be expected to persist for at least a further month because the 
turnover of lipids in white blood cells, which are involved in inflammation, is slow. Kremer et 
al (1990) reported benefits in clinical measures for six weeks following discontinuation of long-
chain omega-3 PUFA supplements and attributed this improvement to decreasing levels of IL 1 
(Kremer, Lawrence et al. 1990).  
 
8.1.28.3 Appropriateness of primary outcome measure 
It is possible that the OSS which was the primary outcome in this study was not sensitive 
enough to detect any change attributable to the long-chain omega-3 PUFA supplements. A 
statistically significant difference in reduction in disability (as measured by SPADI) was seen at 
three months. However this was not mirrored in the OSS. This is in despite of reported good 
correlation between the OSS and SPADI (correlation coefficient= 0.85) and good agreement 
between the scores (weighted kappa=0.79) (Cloke, Lynn et al. 2005). One reason for the 
difference in the scores of the SPADI and OSS at three months is the recall period stated by 
each of the different questionnaires. The SPADI asks the respondent to recall symptoms 
during the past week, whereas for the OSS the respondent recalls symptoms over the past 
four weeks. Between the primary outcome point at two months and the subsequent follow up 
at three months there was only a four week break. It is possible that any additional benefit 
that was experienced during the period between two and three months was not recorded by 
the OSS due to the recall period.  
 
At the time the study was being designed, the OSS was commonly used clinically practice in 
the UK and in research and its use has been supported (Cloke, Lynn et al. 2005). However 
Cloke et al (2005) reported that whilst their data support the use of the OSS, it also indicated 
that the SPADI might be preferable in terms of test-retest reliability. For each item within the 
questionnaires the weighted kappa coefficients were moderate to very good for the SPADI 
(0.51 to 0.80) but only fair to good for the OSS (0.13 to 0.78) (Cloke, Lynn et al. 2005). 
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Subsequent research by Ekeberg et al (2008) has found the SPADI to be significantly (p˂0.05) 
more responsive than the OSS at two and six weeks using the standard response mean and 
reliable change proportion (Ekeberg, Bautz-Holter et al. 2008).  
 
8.1.29 Comparisons of findings to other studies 
The findings of the current study are in agreement with other similar studies, where one 
treatment approach has not be found to confer additional benefit to another in the treatment 
of RC tendinopathy (Ludewig and Borstad 2003, Faber, Kuiper et al. 2006, Bennell, Wee et al. 
2010, Littlewood, Bateman et al. 2016).  
 
Two previous randomised controlled trials investigating the efficacy of long-chain omega-3 
PUFA supplements and tendinopathies have been identified (Mavrogenis, Johannessen et al. 
2004, Roe, Odegaard et al. 2005). Mavrogenis et al. (2004) reported a significant improvement 
in pain after 32 days of supplementation with long-chain omega-3 PUFA and an antioxidant 
pill in a group of recreational athletes with a range of tendinopathies. This was a double 
blinded study and had a matched placebo control group; however the study is at risk of bias 
due to methodological flaws. Data analysis was not on an intention to treat basis and non-
compliers were excluded from data analysis. In this study, 20 subjects were randomized to 
each group (40 in total), nine subjects were lost to follow-up (three in treatment group and six 
in placebo group), and final follow-up (subjective pain scores and estimated levels of sports 
activity) occurred at 32 days. The study group was comprised of tendon pathologies from 
different regions of the body including the shoulder, elbow, and knee. In the shoulder region, 
there were 12 subjects in total, ten were diagnosed as having supraspinatus tendinopathy (ten 
in total, with five in each group), and two as having infraspinatus tendinopathy (two in total, 
with both in the experimental group). In general, the regional tendon pathologies were not 
equally distributed between the two groups. No adverse effects were reported by any of the 
participants in their study. Nine subjects were excluded from the analysis due to non-
adherence (defined as failure to document test medication taken or training activity carried 
out in their diary) or ‘protocol violation’. This study provided a valuable insight in the potential 
of these compounds in the management of tendon pathology but it is not known if the benefit 
in the experimental group was due to the individually active substances or the combination 
with ultrasound therapy. It is also not known from this study if the beneficial effect was due to 
the PUFA or the antioxidants of the combination of both active substances. 
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Roe et al (2005) also investigated the efficacy of the same supplement from the same 
manufacturer at the same dose, but not for the same duration, as Mavrogenis et al (2004) 
they confined their investigation to people diagnosed with lateral epicondylitis. Their study 
design was a double blinded RCT with concealed allocation of 60 participants (55 completed). 
The participants were randomised to placebo or capsules containing the essential fatty acids 
(omega 3 PUFAs and omega 6 GLA) and antioxidant tablet for eight weeks. Both groups also 
received eight sessions of trigger point therapy (one per week) and a structured and graded 
home exercise programme of eccentric exercises, lasting for the whole study period (24 
weeks). There were no statistically significant differences observed in pain reduction levels 
between groups at all time points (p=0.16 at eight weeks and p=0.76 at 24 weeks). There was 
a clinically meaningful mean reduction in pain in both groups on a 10cm VAS scale within both 
groups of 3cm (95%CI=2.5-4) at eight weeks which continued to reduce up to 24 week. 
Analysis was on a complete case basis and not on an intention to treat principal. The final 
follow up was at six months. There was a large variation in the duration of symptoms with 
those in the treatment group (18 months; SD=22 months) having a mean duration of 
symptoms twice as long as those in the placebo group (8 months; SD=4 months). The longer 
duration of symptoms in the treatment group is likely to be accompanied with a poorer 
prognosis (Bartolozzi, Andreychik et al. 1994). With such inequality in duration of symptoms at 
the start of treatment between groups it is not possible to draw definitive conclusions from 
this study. 
 
Mavrogenesis et al (2004) reported a significant reduction in pain within the treatment group 
at four weeks but Roe et al (2005) found no added benefit of the essential fatty acid and 
antioxidant supplement at eight weeks. The dosage of EPA and DHA was twice as high in these 
two studies than in the current study (5.1g/day EPA and DHA versus 2.6g/day in the current 
study) and additionally contained 2.7g/d GLA. The participants in the Mavrogenis et al (2004) 
and Roe et al (2005) studies were also given an antioxidant tablet containing 100μg selenium, 
15mg zinc, 1mg vitamin A, 2.2g vitamin B₆. 90mg vitamin C and 15mg vitamin E. It is possible 
that the greater dose, theadditional antioxidants and GLA might have been the reason for the 
decrease in pain scores observed in the Mavrogeneis et al (2004) study. However the same 
dosage was used in the Roe et al (2005) study for a longer duration and no additional benefit 
was observed in the treatment group within this study. Interestingly, there was a greater 
decrease in mean pain scores in the Roe et al (2005) study and Mavrogenis et al (2004) studies 
than that observed in the current study (5 VAS points, 3.2 VAS points and 2.2 NRS points 
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respectively). This may be reflective of the different tendinopathies (a wide range of chronic 
tendon disorders by Marvrogenis group and lateral epicondylitis by Roe group) being 
investigated in the studies, the different adjunct treatments (ultrasound by Marvrogenis et al 
(2004), and trigger point therapy and exercise used by Roe et al (2005) and the different pain 
measurement tools (VAS as compared to NRS, Mavrogenis et al (2004) and Roe et al (2005) 
respectively). 
 
In addition, another reason for differing outcomes between the Mavrogenis et al (2004) and 
the current study and that conducted by Roe et al (2005) might be due to the longer duration 
of symptoms in the treatment groups of the current study (mean duration being nine months) 
and that of Roe et al (2005) (mean duration being 18 months) when compared to Mavrogenis 
et al (2004) (mean duration of symptoms being six months) with poor prognosis being 
associated with longer duration of symptoms (Bartolozzi, Andreychik et al. 1994). Disability 
scores were not assessed by either Mavrogenis et al (2004) or Roe et al (2005), subsequently 
further comparison between these studies cannot be made.  
 
A thirty percent change in baseline OSS score was observed in the long-chain omega-3 PUFA 
group at three months within the current study. This is identical to the percentage change of 
OSS score from baseline observed in another study investigating the efficacy of an exercise 
programme for massive RC tears (Ainsworth, Lewis et al. 2009). The mean changes in SPADI 
scores at three months observed in this study are in agreement when compared to other 
studies investigating exercise for RC tendinopathy (Engebretsen, Grotle et al. 2009, 
Yiasemides, Halaki et al. 2011, Kromer, de Bie et al. 2013). The average reduction in SPADI 
scores in other investigation of RC tendinopathy and exercise in excess of 20 points at three 
months. In the current study the mean reduction in the treatment group at three months 
from baseline was 24.95 points.  
 
This agreement in change in disability scores with previous studies investigating the efficacy of 
exercise for RC tendinopathies lends further evidence to support the current best practice 
treatment. 
 
8.1.30 Implications for clinical practice 
This is a novel exploratory study investigating the efficacy of long-chain omega-3 PUFA 
supplements and exercise in the treatment of RC tendinopathy. It provides clinicians with 
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evidence from a double blind randomised controlled trial. Based on the findings of this study, 
clinicians can feel confident that when advising patients with RC tendinopathy (who have the 
same clinical presentation as those in the current study) that at a similar dose of long-chain 
omega-3 PUFA to that given within this study (2.6g DHA and EPA, 9g/d of fish oil) and duration 
(eight weeks) that the supplementation does not afford any benefit over a placebo. The 
findings of this study also lend support to the argument that an exercise group plus a home 
exercise plan is an effective treatment in reducing pain and increasing function in those with 
RC tendinopathy. 
 
8.1.31 Strengths and limitations 
8.1.31.1 Use of self-report adherence measures 
One limitation of this study is that it was powered on only the primary outcome measure, the 
Oxford Shoulder Score, but several outcome measures were collected during the assessment 
process. 
 
The intervention was given for a period of eight weeks and at a dosage of 3g long-chain 
omega-3 PUFA per day. These parameters were chosen based on the available research 
discussed in chapter 4. However it is possible that neither the dose given nor the duration of 
the treatment were sufficient to elicit a response and this would be an area warranting further 
research. 
 
Within the statistical approach used in this study (ANCOVA) the data was adjusted only for the 
confounders collected including BMI, gender and age. However there may have been other 
confounders which were not collected and not adjusted for. 
 
Olive oil was selected as the choice of placebo oil in this study as discussed in section 
8.1.28.1.2 (pg 197). Health claims have been attributed to virgin olive oil (Buckland and 
Gonzalez 2015) however the olive oil used in this study was refined olive oil-British 
Pharmacopeia specification and the majority of the polyphenols (which might have a 
beneficial effect, yet to be proven) are removed in the refining process. A possible alternative 
placebo oil would be a mixed oil which reflects the background dietary fat intake of the 
participants and thus could not be suggested to attribute any added health benefits. 
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It is acknowledged that there was no wash out period for participants entering the trial who 
had previously been taking long-chain omega-3 PUFA supplements. This may have influenced 
the results however anyone already taking over 1g of long-chain omega-3 PUFA was excluded 
from entry into the trial.  
 
Another limitation is the use of self-report measured of adherence to exercise and dietary 
surveys. It is recognised that patient self-report and completion of paper diaries can yield data 
of questionable validity (Stone, Shiffman et al. 2003). It is also acknowledged that the 
tendency to over-estimate adherence to a treatment is in the region of 10% (Moseley 2006). 
However this method was used in this investigation due to its practicality and limited 
resources available, such as no access to an electronic or online recording system. Adherence 
to the exercise class was also noted centrally and so whilst the amount of home exercise 
performed was also self-reported, the adherence to the shoulder exercise class was collected 
by the treating therapist. Similarly the diaries and the returned capsule count gave a self-
report method of collecting data regarding adherence to the supplements; the total lipid 
analysis provided another measure of adherence which was not subject to potential bias. 
Interestingly, the number of capsules annotated as being taken in the diaries was on average 
less than the number calculated from the returned pill count, indicating that in this cohort of 
participants over estimation of the adherence to the supplements was not a feature.  
 
Dietary surveys are reliant on self-reported food intake. Misreporting of food consumption, 
most often underreporting (either due to hide poor eating habits or make it simpler to 
record), in self-reported dietary methods is a well-documented issue (Black, Prentice et al. 
1993, Livingstone and Black 2003). In order to overcome this we used a cut off of 1.2 for the 
ratio of reported energy intake to calculated basal metabolic rate (basal metabolic rate 
calculated using the Schofield equation)(Goldberg, Black et al. 1991). Using the 1.2 BMR cut-
off suggests that 47% of the participants were under-reporting their dietary energy intake. 
However, in the case of micronutrient intake especially those which are found in a limited 
variety of foods such as calcium, vitamin D and long-chain omega-3 fatty acid under-reporting 
of energy intake is unlikely to be a problem particularly if the under-reporting of energy intake 
was from food with low nutrient density such as alcoholic drinks, confectionary and sugar 
sweetened beverages.  
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8.1.31.2 Unmasking of group allocation  
Reassessment by the CI may have inadvertently resulted in unmasking of group allocation in a 
few cases due to comments made by the participants regarding ‘fishy burps’. This may have 
introduced a risk of bias into the results. However, in an attempt to minimise any possible 
effect this might have had, no results were analysed until data from all participants had been 
collected.  
 
8.1.31.3 Multiple examiners 
First assessments and follow ups were not always conducted by the same examiner within the 
study. Having multiple examiners can introduce a measurement error. The reliability study 
indicated that the inter-tester reliability of the impairment measures methods was adequate. 
The primary outcome measure was the OSS which was a self-administrated questionnaire, and 
as such, it is unlikely that the results of the self-administered questionnaires would be 
influenced by a change in the examiner. There were different treating physiotherapists across 
the sites and over time but this is reflective of clinical practice. 
 
8.1.32 Further research 
Due to the design of this trial it is not possible to determine whether the use of either 
supplement resulted in an additional benefit in outcome above just attending the shoulder 
class. A similar trial comparing long-chain omega-3 PUFA with a placebo and no supplement 
would answer this question.  
 
The use of biomarkers to assess the impact of the intervention on any inflammation in the 
rotator cuff or circulatory inflammatory markers would add a valuable insight. 
 
Additional studies investigating if there are any effects of long-chain omega-3 PUFAs at 
differing higher doses, differing ratios of EPA versus DHA and longer durations would also 
allow the question of the efficacy of long-chain omega-3 PUFAs in the treatment of RC 
tendinopathy to be fully answered.  
 
Conclusions 
This study is the first double blinded, randomised controlled trial with sufficient long term 
follow up to assess the efficacy of long-chain omega-3 PUFA supplements in the treatment of 
RC tendinopathy. The results of this study provide clinicians with evidence to advise and guide 
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patients that at 9g/d (2.6g EPA and DHA) for eight weeks, long-chain omega-3 PUFA provide 
no extra benefit for those with rotator cuff tendinopathy. In addition, the results also allow 
clinicians to be confident that following a well-structured exercise programme results in 
clinically meaningful changes in disability, function and pain. 
 
Summary Points 
 Change in self-reported pain and disability scores were similar between groups over 
all outcome points.  
 It is also not clear from this study whether at a higher dose and/or for a longer 
duration long-chain omega-3 PUFAs might have an effect on disability and function in 
RC tendinopathy.  
 A significant decrease in disability and pain as measured by the SPADI may indicate 
further research is warranted to explore this finding.  
 The findings of this study indicate that for individuals with RC tendinopathy, long-
chain omega-3 PUFA or a placebo supplement in addition to exercise would result in 
similar outcomes at one year. 
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Chapter 9 : Exploring experiences, 
barriers, motivators and enablers to 
nutritional supplement use and 
exercise in rotator cuff 
tendinopathy: a qualitative study 
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Introduction  
Exercise is the mainstay of physiotherapy treatment for rotator cuff (RC) tendinopathy 
(Littlewood, Ashton et al. 2012), often delivered in class based settings with home exercise 
plans in support. Little is known about the barriers, enablers and motivators in RC exercise 
based treatment. More is known regarding adherence to exercise in general but not in this 
cohort of patients. This study was designed to further explore this area.  
 
The questionnaire based study presented in Chapter 8 indicates that nutritional supplements 
are being taken by a proportion of people seeking treatment for their shoulder pain within in 
the United Kingdom (UK). As part of the randomised controlled trial (RCT) study participants 
were asked to take nine capsules a day for two months. The various motivators, enablers and 
barriers have been further explored here. This study is complements the results presented in 
Chapter 7, the main RCT, and it is in part aimed at making the findings of the main RCT more 
clinically transferrable, aiding translation and relevance to clinical health communities.  
 
There are several quantitative studies on exercise in RC tendinopathy (Bang and Deyle 2000, 
Haahr and Andersen 2006, Kuhn 2009, Kukkonen, Joukainen et al. 2014, Littlewood, Bateman 
et al. 2016) but those investigating qualitative aspects are lacking. Similarly there is limited 
published information relating to the experiences of individuals who have participated in an 
exercise class based programme as well as carrying out concomitant home exercises.  
 
It is envisaged that through the identification of barriers to treatment adherence, clinicians 
may be able to develop and suggest methods to enhance adherence to exercise prescription 
for people with RC tendinopathy. This study also aimed to identify those barriers and highlight 
enablers or suggestions for strategies to overcome them.  
 
Adherence is defined as “the act or quality of sticking to something.”(Ireland 2003). The word 
adherence has largely replaced the terms compliance and concordance in describing a 
patient’s disposition to follow precise instruction or prescribed treatment regimen. 
Compliance implies a more passive role by the patient whereas the word adherence carries 
with it more positive connotations and is more in line with the preferential collaborative 
approach where patients are actively involved in their management (Huss, Travis et al. 1997). 
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Adherence has been described as the “most unpredictable, least controllable variable in a 
medical intervention” (Groth and Wulf 1995). By its very nature clinical outcome is intrinsically 
linked to adherence (Abbott, Dodd et al. 1994, Groth and Wulf 1995, Ireland 2003). Non-
adherence has been reported to attribute to the ongoing disability with subsequent or 
associated reduction in the ability to work and loss of wages (Kirwan, Tooth et al. 2002). 
Although studies have highlighted the importance of compliance or adherence in securing a 
successful outcome, in the clinical setting adherence is often erratic (Vermeire, Hearnshaw et 
al. 2001, Hayden, van Tulder et al. 2005). Adherence does not appear to be an all or nothing 
issue; rather it appears to be one of gradation, with some patients adhering to different 
degrees and with different components of treatment (Sluijs, Kok et al. 1993, Abbott, Dodd et 
al. 1994). 
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9.1.1 Aim of research  
The objective was; 
To explore factors affecting adherence to a prescribed exercise programme and with the 
taking of the provided supplements. 
 
The primary research question for this chapter was: 
What are the enablers, barriers to adherence to an exercise based intervention and 
supplement prescription for RC tendinopathy? 
 
9.1.2 Study design 
Qualitative methods were employed to explore factors affecting adherence to a prescribed 
exercise programme and with taking the provided supplements. These are further detailed in 
Chapter 5.3.6  
 
9.1.3 Positionality of researcher 
The researcher was the chief investigator (CI) of a double blind placebo controlled RCT 
entitled: (The efficacy of polyunsaturated fatty acids and exercise in the treatment of RC 
tendinopathy. Trial registration: ISRCTN 17856844). The CI was responsible for recruiting, 
consenting and delivering the intervention for all the participants who then took part in this 
qualitative study. Within this qualitative study she developed the research protocol, recruited 
and consented the participants. She then conducted the interviews, transcribed the 
interviews, coded the transcripts and led the development of the themes from the data. Cross 
verification or researcher triangulation was achieved with a supervisor (JL) independently 
coding and analysing the transcripts and a consensus being reached as to the themes and sub-
themes. 
 
9.1.4 Ethics 
The original randomised controlled trial (The efficacy of polyunsaturated fatty acids and 
exercise in the treatment of RC tendinopathy ISRCTN 17856844) received ethical approval 
from Bromley Research Ethics Committee, Bromley Primary Care Trust, Bassetts House, 
Broadwater Gardens, Farnborough, Kent BR6 7UA (REC ref: 08/H0805/21) on 28th May 2008 
(Appendix 11.13) and recruitment began in December 2008. The committee approved an 
amendment for this ancillary study on 12th September 2012 (Appendix 11.26), to collect 
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additional qualitative data via interviews with a sample of participants who had completed the 
original trial.  
 
9.1.5 Participants and recruitment 
A grounded theory approach was taken, with interviews conducted until theoretical saturation 
was reached (Glaser and Strauss 2009, Berterö 2012). A minimum of ten and a maximum of 
forty participants were sought to be interviewed, dependent on when theoretical saturation 
was achieved as well as resources available. Participants were purposively sampled from 
participants taking part in the RCT, to ensure the views of people from different age groups, 
gender and social backgrounds were captured. Participants who completed the main study 
between January 2012 and April 2013 (n=45) were approached by email, post or telephone 
and invited to attend for an interview at the Clinical Research Facility at St Thomas’ Hospital, 
London, UK. All participants were interviewed at least one year after their randomisation into 
the trial. 
 
All participants had been given the opportunity to attend eight RC exercises classes and been 
provided with eight weeks of supplements (either placebo or PUFA). As the group allocation 
code had not been broken at the time of the interviews it was not known whether or not the 
participant had been in the treatment or placebo group in the original trial.  
 
9.1.5.1 Inclusion criteria:  
 Consent to participate. 
 Participated in the central study trial (The efficacy of polyunsaturated fatty acids and 
exercise in the treatment of RC tendinopathy ISRCTN 17856844). 
 
9.1.6 Consent and confidentiality:  
Participation in the interviews was entirely voluntary. The invitation to participate in the 
interviews was sent either by email or via letter through the postal service and was 
accompanied by an additional information sheet (Appendix 11.27) that explained the purpose 
of the interviews and potential benefits of participating in this investigation. A follow up 
phone call was organised to individual participants to explain the study further, to clarify any 
uncertainties and then ascertain if the participants would like to take part. Signed consent 
(Appendix 11.28) was obtained by the CI from those attending in person, before the interview 
commenced. Interview data was confidential and all information anonymised. The interviews 
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were recorded on two digital Dictaphones which were then transcribed and assigned an 
anonymised code to ensure no one was identifiable from the transcript. After transcribing, the 
recordings were destroyed.  
 
9.1.7 Data collection  
Interviews were conducted and transcribed by the CI. Further details can be found in Chapter 
5.3.6. 
 
9.1.8 Interviews  
Face to face semi-structured interviews were conducted with the participants soon after they 
had completed the main study (The efficacy of polyunsaturated fatty acids and exercise in the 
treatment of RC tendinopathy) to explore their experiences during the year-long study. 
 
An iterative research strategy was adopted, with open questions framed around the interview 
schedule/ topic guide (Table 9.1), starting with general questions which were then honed to 
more specific questions based on the responses of the participant but within the wider 
context of the research aims. Interviews took between 12-35 minutes each.  
 
In developing the interview a deductive approach was taken, using topics generated from the 
CI’s personal experience, reflection, as well as the literature. A list of topics to be explored was 
generated, from which questions were developed. At the start of each interview the 
participant was welcomed and thanked and this was followed by information provided by the 
CI of the participant’s involvement in the study (start date and intervention). The purpose of 
this was to relax the participant and provide focus.  
 
Each participant was then asked a series of questions (Table 9.1), however they were not 
necessarily asked in the same order as detailed in the Table, as is common practice in semi-
structured interview methods (Whiting 2008). Further questions were asked if clarification 
was required or if probing was necessary to gain more details.  
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Table 9.1 Interview schedule/ topic guide. 
Topic Questions and prompts 
Overview of experience. Can you give me an overview of your experience of the study? 
Prompts: can you describe your experience, what was your lasting memory or overall 
impression of doing the exercises and taking the supplements, your shoulder pain? 
Aspects of exercise programme most/least enjoyed. Were there any aspects of the exercise programme which most/ least enjoyed? What were they? 
Aspects of taking supplements most/least enjoyed. Were there any aspects of taking the supplements which you most/ least enjoyed? What 
were they? 
Aspects of the exercise programme easiest/hardest to 
implement. 
Were there any aspects of the exercise programme which you found easiest/ hardest to 
implement? What were they? 
Aspects of taking the supplements easiest/hardest to 
implement. 
Were there any aspects of taking the supplements which you found easiest/ hardest to 
implement? 
Aspects the exercise programme, if any, continued 
beyond the study. 
Were there any aspects the exercise programme, if any, continued beyond the study? If so 
which ones and to what extent? Any reasons why you continued? Any perceived benefits? Do 
you plan to continue long term? 
Aspects of the supplement use, if any, continued 
beyond the study. 
Were there any aspects of the supplement use, if any, continued beyond the study? If so 
which ones and to what extent? Any reasons why you continued? Any perceived benefits or 
side effects? Do you plan to continue long term? 
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Factors or strategies which participants found helped 
them to take the supplements (Enablers). 
Did you have any or find any factors or strategies which you found helped you to take the 
supplements (enablers)? If so what and how did they help you? 
Prompts: Support from family or friends, individual skills such as organising and planning, 
written advice, email/phone support? Provision of supplements and the way in which they 
were provided? 
Factors or strategies which participants found helped 
them to complete the exercises (Enablers). 
Did you have any or find any factors or strategies which you found helped you to complete 
the exercises (enablers)? If so what and how did they help you? 
Prompts: Support from family or friends, individual skills such as organising and planning, 
motivation? Provision of exercise booklet, theraband, having attended the exercise class and 
email/phone support? 
Factors or problems which participants encountered 
which prevented or limited their ability to take the 
supplements (Barriers). 
Were there any factors or problems which you encountered which prevented or limited your 
ability to take the supplements (barriers)? If so what, is there anything which could be done 
to alleviate them? 
Factors or problems which participants encountered 
which prevented or limited their ability to carry out 
the exercise programme (barriers). 
Were there any factors or problems which you encountered which prevented or limited your 
ability to carry out the exercise programme (barriers)? If so what, is there anything which 
could be done to alleviate them? 
Physical experiences during the intervention (for 
example feelings of wellbeing, altered bowel habits). 
Can you discuss any physical experiences during the intervention (for example feelings of 
wellbeing, altered bowel habits)? If yes how did these affect you? Any side effects? 
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Emotional experiences during the intervention (for 
example feelings of control/ lack of control). 
Can you discuss any emotional experiences during the intervention (for example feelings of 
control/ lack of control)? Do you remember any feelings or emotions during the study? If yes 
what were they, when did they occur? Prompts: feeling more or less in control of their 
condition and its treatment- ask for reasons why. Feeling more of less certain of a positive 
outcome from treatment? 
Social consequences of the intervention and taking 
part in a study. 
Did you find any social consequences of taking part in the study or doing the exercises/ taking 
the supplements? If yes how did you manage these? 
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9.1.9 Data analysis 
A thematic style of analysis was used to explore across the data set to identify repeating 
patterns of meaning. This is the most common style of analysis of qualitative data and through 
its theoretical flexibility and freedom it can provide a rich and detailed interpretation of the 
data (Braun and Clarke 2006). An inductive approach was taken where there were no pre-
determined themes set to explore and the analysis was data driven. The thematic analysis was 
undertaken using the six point guide described by (Braun and Clarke 2006). The six stages 
included; familiarisation with the data through reading and re-reading; the generation of 
initial codes using Nvivo V10 software (QSR International (UK) Ltd, London UK); then analysing 
and grouping the codes to generate themes, review, discussion and consensus between the 
researchers regarding the themes, their name and definition. Extracts from the interviews 
were chosen to illustrate effectively the themes and sub themes. A conceptual diagram was 
constructed to demonstrate the relationships between the themes and sub themes. The final 
stage was writing of the discussion presented in this chapter where relevant literature was 
reviewed and cross comparisons made with the findings of this study to enable synthesis for 
the reader.  
 
Triangulation was achieved through checking of the transcripts against the original recordings 
and the discussions between the researchers regarding codes, themes and analysis. 
 
Findings and results  
 
9.1.10 Sample description  
Twelve participants were interviewed for this study. The characteristics of the participant 
group are detailed in Table 9.2. There were an equal number of males and females and an 
equal number allocated to the treatment and placebo groups. This was determined after the 
group allocation codes were opened. The majority were aged between 50-69 years (50%) and 
employed (58%). The mean change (improvement) in the OSS over the 12 month period was 
14.17 (range 0-22), with 6 points change representing a clinically meaningful change (van 
Kampen, Willems et al. 2013). The mean percentage change in pain intensity as measured by 
the numerical was 81% decrease which equates to a substantial improvement (Dworkin, Turk 
et al. 2008). The characteristics are representative of the participant group of the randomised 
controlled trial (The efficacy of polyunsaturated fatty acids and exercise in the treatment of RC 
tendinopathy ISRCTN 17856844) and reflect the purposeful sampling method used.  
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Table 9.2 Participant demographics 
Variable Interview participants 
(n=12) 
RCT participants 
(n=73) 
Gender: male  6 (50%) 37 (%) 
Age (years) 54.83 (18.24) 52.14 (14.06)    
Allocated to treatment group  6 (50%) 38 (52.1%) 
Oxford shoulder score at baseline  35.67 (6.15) 31.88 (8.06) 
Oxford shoulder score at 1 year 45.83 (3.27) 43.05 (6.22) 
Numerical rating score at baseline 5.33 (2.75) 6.12 (1.99) 
Numerical rating score at 1 year 0.92 (1.49) 2.14 (2.44) 
% change in numerical rating score 81% (31.55) 65% (35.82)       
Post intervention EPA & DHA plasma levels 
(% of fatty acids) 
6.06 (4.03) 1.51 (0.50) 
Supplements taken (from returned pill 
count) 
482.91 (142.41) 446.62 (125.22) 
n of exercise classes attended 6.8 (2.48) 6.04 (2.44) 
Legend; n=number. Summary measures represent means (SD/ %). 
 
Thematic analysis and discussion  
This study provides an invaluable insight into the individual participant’s experiences through 
the trial and helps guide and shape future studies and current practice. The context of RC 
tendinopathy must be considered when discussing participant’s experiences and their 
adherence to treatment in particular. The context of a condition is known to be an important 
influence on how a patient absorbs information and decides to use that information (Scott, 
Estabrooks et al. 2008). Patients with chronic conditions have been found to be less 
compliant, although not statistically significant, than those with acute post-operative 
conditions (Sluijs, Kok et al. 1993). RC tendinopathy is considered a medium term condition, 
with symptoms which usually resolve to some extent with treatment over a period of six to 
nine months and therefore the expectations of those with RC disease might be expected to be 
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different than those with a lifelong condition such as rheumatoid arthritis. It is well recognised 
that the motivation to adhere with treatment can differ depending on the condition and 
population (Shaw, Williams et al.).  
 
Four main themes were identified from the analysis of the transcripts: 
1. Experiences relating to participation in a scientific study 
2. Self-efficacy 
3. Enablers/facilitators and barriers to exercise 
4. Enablers/facilitators and barriers to taking supplements  
 
Within each theme there were sub themes reflecting the breadth of information and answers 
given in the interviews (Table 9.3). The sub-themes were often interlinked across themes.  
 
Table 9.3 Themes and sub themes developed from interview transcripts 
Theme A: Experience of participation in a scientific study 
I) Reasons for consenting into trial; perceived personal benefit, altruism, interest in 
nutritional supplements 
II) Experience of being a study participant, including patient-study team 
relationships. 
III) Perceived personal benefit from being in the trial 
IV) Adherence due to obligation 
V) Importance of feedback and on-going monitoring 
Theme B: Self efficacy 
I) Education  
II) Self-efficacy and coping 
Theme C: Enablers/facilitators and barriers to exercise 
I) Perceived benefit 
II) Perceived seriousness of the condition  
III) Motivation  
IV) Self-discipline 
V) Barriers: time, pain (both increase and decrease), equipment 
VI) Equipment  
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VII) Strategies 
VIII) Classes 
IX) Patient therapist relationship 
Theme D: Enablers/facilitators and barriers to taking supplements  
I) Enablers: ease of taking the supplements 
II) Perceived benefit 
III) Side effects 
IV) Barriers 
V) Strategies 
VI) Ongoing supplementation 
 
9.1.11 Theme A: Experience of participation in a scientific study 
It was unsurprising that the first theme related to the participation in a scientific study due to 
the opening question asking participants to give an overview of their experience in the trial. It 
was broken down into five sub-themes;  
 
I) Their reasons for consenting into trial including perceived personal benefit, 
altruism and interest in nutritional supplements  
II) Their experience of being a study participant, including patient-study team 
relationships. 
III) Their perceived personal benefit from being in the trial 
IV) Adherence due to obligation  
V) The importance of feedback and on-going monitoring. 
 
9.1.11.1 Reasons for consenting into the trial:  
Participants explained that they had been motivated to take part in the trial, in part because 
they had a desire to help others and for the general good.  
 
“I felt that the study would benefit myself plus other people.” Participant 57. 
 
However this willingness to help others or altruism was not their only motivator to take part 
and was often cited as a secondary motivator with considerations of personal benefit 
emerging as a key motivating factor for trial participation. This is often known as ‘conditional 
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altruism’ (McCann, Campbell et al. 2010), where participants are happy to help others but 
need to see that they too will benefit from the participation in the study personally. In this 
nature some participants described it almost as a win-win situation where they felt they could 
receive personal benefit whilst helping others. These findings of conditional altruism within 
this study are in concordance with other studies with the primary motivating factor being 
perceptions of perceived benefit to them personally (Lawton, Fox et al. 2003, Garcea, Lloyd et 
al. 2005, McCann, Campbell et al. 2010, Locock and Smith 2011, Irani and Richmond 2015). 
 
Participants were motivated to take part in the study by both the trial processes (specialist 
assessments and additional symptom monitoring and assistance as part of the trial follow up 
which they were aware was over and above routine treatment) and by the interventions (the 
PUFA or placebo supplements which was over and above routine treatment) which were 
perceived as sources of potential benefit.  
 
Some participants were clearly interested in the concept of nutritional supplements being 
used to ‘treat’ their shoulder pain and this curiosity was part of their motivation to participate; 
 
“I just wanted my shoulder to get better and I thought it would be interesting to find out if the 
fish oils helped. I hadn’t thought of taking a nutritional supplement.” Participant 60.  
 
There is much publicity in the media regarding nutritional supplements and fish oils or omega 
3s in particular (Greiner, Clegg Smith et al. 2010). There are frequent news articles highlighting 
their benefit for a wide range of conditions and it’s likely that that this widespread exposure 
to these positive messages might influence the wider population and their interest in the use 
of nutrition (Rahmawaty, Charlton et al. 2013). 
 
9.1.11.2 Experience of being a study participant: 
The majority of the participants reported they found the overall experience of taking part in 
the trial enjoyable and interesting with one presenting a more ambivalent view;  
 
“I enjoyed it and found it interesting.” Participant 64. 
“Very positive.” Participant 60. 
“Very good overall experience.” Participant 57. 
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Although one participant was not so emphatic with his response regarding his experience in 
the trial, 
 
“I didn’t suffer from it and I can’t say I actually benefitted from it.” Participant 74. 
 
As part of their experience in the study, participants discussed their relationship with the 
study team and the participants emphasised the importance of the clinical relationship that 
the participant has with the research team. 
 
“It was so nice to come, I never wanted to miss it….it was a treat. I think that’s an important 
thing to remember.” Participant 60. 
 
“It was certainly a pleasant way to spend some time.” Participant 76. 
 
The context of these comments must be considered in that the participant was telling the 
interviewer who had also delivered the study intervention. Therefore there is an inherent bias 
which must be acknowledged. 
 
Another aspect of the trial participation which participants commented on was the feeling of 
obligation to the trial or the scientific process of the trial which increased their motivation or 
ability to adhere with the prescribed treatments. 
 
“Because I knew I was in the programme I took them.” Participant 56. 
“The study gave me the incentive to carry on doing the exercises and so I was quite pleased 
with that and also to have a measure made of how well I was progressing.” Participant 62. 
 
This comment raises the theme of the importance of monitoring or follow up to support 
successful engagement with the treatment protocol but also was cited as one of the benefits 
of participating in the trial.  
 
9.1.11.3 Perceived personal benefit gained from participation in the trial: 
The majority of participants reported they felt they benefited from the treatment provided 
and their involvement within the trial. 
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“I was relieved of all that misery and torture by joining the study so it has been extremely 
helpful to me, extremely.” Participant 70. 
 
“It has been good because I felt that physio didn’t achieve as much as I had hoped it would. 
The study gave me the incentive to carry on doing the exercises and so I was quite pleased with 
that and also to have a measure made of how well I was progressing.” Participant 62. 
 
Feedback was highlighted as a key benefit which some participants reported gave them 
motivation to continue.  
 
“Because I received regular feedback, so I was motivated to carry on.” Participant 60. 
 
The additional monitoring and supervision that the participants received as part of the trial 
with was additional to routine treatment was also cited as a positive benefit of participation. 
 
“It was really good to have those follow ups and ask questions and to modify exercises. I found 
that really useful…..to actually be able to speak to a physio and get a second opinion about my 
progress and to alleviate any worries that I had as well, so I found that very useful and it was 
good that you had that consistently.” Participant 75. 
 
“Follow up at six months or a year is really helpful as you can use it as a marker to see where 
you are.” Participant 57. 
 
“I was pleased the study was going on longer than that [shoulder class] so it gave me a 
programme to work to…but more monitoring would do it you know. This is what I feel I had 
being part of the study but which I didn’t get as part of routine treatment.” Participant 62. 
 
“I would have stopped doing it [the exercises] then [on discharge from the class at eight weeks] 
so the further follow up was very useful to me.” Participant 60. 
 
One participant voiced his concerns about being discharged from the shoulder class. 
 
“They were quite happy to discharge me without seeing me first, it was a bit 
disheartening…..whether I would have gone as far as going to my GP to get a further referral I 
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just don’t know…I might have. Or I might have tried the osteopath again, although that hadn’t 
been successful.” Participant 62. 
 
Others felt that they were recovering well on discharge from the class and would have been 
happy to cease treatment at that point with no further desire to have been followed up or 
monitored; 
 
“The assessments, I wouldn’t honestly say I found them helpful because the condition was 
clearing up….I would have been happy to leave physio at 8 weeks.” Participant 76. 
 
The expressed preference of the majority of participants for the ongoing support and follow 
up is in concordance with studies investigating barriers and enablers to adherence with a 
home exercise programme for RC tendinopathy (Sluijs, Kok et al. 1993, Locock and Smith 
2011, Littlewood, Malliaras et al. 2014). The feedback and monitoring is essential in conveying 
the importance and value of the rehabilitative process, progressing exercises where 
appropriate in order to gain maximal outcome as well as recognising the patient’s efforts, 
their progress and achievements. Patients may be motivated by a desire to please or not let 
down healthcare professionals (Riolo 1993, Littlewood, Malliaras et al. 2014). 
 
9.1.12 Theme B: Self-Efficacy 
Self-efficacy in terms of healthcare was first defined by as, 
 
“The belief in one’s capabilities to organise and execute the course of action required to 
produce given attainments” (Bandura 1977) p3.  
 
The degree of an individual’s self-efficacy is important in the rehabilitation process as it can 
influence the engagement of the individual in the rehabilitation and the extent to which they 
will preserve when faced with difficulties or distractions (Barlow 2010) and can determine 
how they incorporate a treatment plan or exercise programme into their everyday lives 
(Littlewood, Malliaras et al. 2014). 
 
The importance placed on being able to manage their own condition through improved 
knowledge and a feeling of increased control was highlighted as a theme within the 
participants’ transcripts. 
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“I was very down in the dumps because I was constantly in discomfort and no-one was 
listening and once I’d started the exercises and whatever I was taking I found it was a lot 
easier because I felt it was something I could manage myself and I could control what I was 
doing.” Participant 57. 
 
“I’ve been through a series of classes and I’ve seen the benefits. I’ve just come to the 
realisation that it is something that I just have to manage and by doing the exercises I feel I 
can manage it...exercise is key for me.” Participant 75. 
 
Part of achieving self-management and self-efficacy is through providing the participants with 
greater knowledge and education about their condition.  
 
“It [the trial] changed the way I was thinking about the shoulder and I find exercises that help 
......They explain regarding your shoulder or chronic pain so you have more control what to do 
or what not to do, and things that can improve your situation. That was also good.” Participant 
56. 
 
Despite the education sessions within the classes, the contact with physiotherapists and 
participation in the study with contact with the study team two participants expressed that 
they still did not really know what had been wrong with their shoulder and if he had been 
asked to describe it one said he would say;  
 
“Well my shoulder hurt and after a while it stopped hurting.” Participant 76. 
 
“I still am [vague] about what was actually wrong. Other than the fact it is clearly something 
that has been around for a long while and flared up but I don’t really know why it should have 
suddenly gone or why it’s taken so long to get right.” Participant 62. 
 
Education regarding the condition, the treatment options available and the expected recovery 
period have all been found to be key components to facilitate adherence to treatment (Ireland 
2003). This is especially the case with RC tendinopathy where a meaningful recovery often 
takes several months (Bennell, Wee et al. 2010). Indeed one participant commented;  
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“At first I expected to see an improvement within a few weeks but it was so small. They tried to 
encourage me saying it was a long haul and by the end they said it would be six to nine 
months. I think it might have helped to know the six to nine month time frame at the 
beginning.” Participant 62. 
 
This illustrates and emphasises the need to find strategies to educate patients regarding 
expected rehabilitation and recovery times in order to ensure their expectations are realistic.  
 
9.1.12.1 Enablers/facilitators/motivators and barriers to exercise 
Enablers and barriers are to be discussed the same section as for some factors such as pain, it 
was found to interestingly be a barrier for some and a facilitator for others. 
 
9.1.12.1.1 Enablers – Exercise class 
The exercise group was cited as being good fun and helpful by several participants;  
 
“The group aspect was good, it was really fun......I enjoyed doing the exercises every Thursday 
morning, it was one hours really fun and that really helped me a lot.” Participant 56. 
 
Group exercise has been found to be beneficial in other physiotherapy studies where peer 
support has been cited as a benefit of class based exercise over individual exercise (Lewis, 
Hewitt et al. 2005, Kaapa, Frantsi et al. 2006). 
 
The enjoyment of the exercise class coupled with the supervision and assistance given to them 
within the class proved to be an enabler to them exercising.  
 
“I think I found it helpful to ahhh have the class to go to because it meant that I was doing the 
exercises better.” Participant 66. 
 
The schedule provided by coming to a weekly class also served as an enabler or motivator for 
a couple of participants; 
 
“Having a schedule coming up here provided a bit of an incentive.” Participant 62. 
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“I’m not very good at doing exercise...I get bored very easily so that type of thing [exercise 
class] is good for me.” Participant 66. 
 
The expectation that they were there to exercise was also expressed to be an enabler, 
“The classes were easy because it was an environment where it was expected that there were 
things to be done.” Participant 62. 
 
The valued placed on the knowledge and expertise of the physiotherapists running the class 
was highlighted as another key area.  
 
“It was great there was a dedicated physiotherapy team.” Participant 75. 
One participant made a comment regarding the number of physios or assistants supervising in 
the class; 
 
“Continuity of physios in the class would have helped as I had to keep reminding them of what 
I was doing........Fewer physios were better than lots as then they knew what was going on.” 
Participant 57. 
 
This raises an important point in that quantity of staff in a class setting does not always 
improve the level of care. Thus implying there is a critical mass or level of staffing where 
disadvantages outweigh the benefits. 
 
9.1.12.1.2 Enabler- self-discipline 
Self-discipline was mentioned as a key enabler for one participant, this was coupled with their 
strong internal locus of control; 
  
“I was very strict with myself about doing the home exercises.” Participant 57. 
 
Locus of control is known to be a factor when considering adherence and those with an 
internally orientated locus of control is believed to be more likely to be health conscious and 
to be adherent with treatment programmes (Groth and Wulf 1995). 
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9.1.12.1.3 Enabler- pain 
Pain was found to have been a motivator, enabler and facilitator to exercise. In some, exercise 
decreased their shoulder pain and therefore this increased their motivation and incentive to 
continue with the exercises and get continued and or increased relief. Initially it is often the 
pain at its peak which has led the person to seek treatment and thus it served as a prompt or 
reminder to do the exercises. 
 
“As I was getting better, my motivation increased.” Participant 60.  
 
This concept also links into perceived benefit from the treatment where if the treatment 
works then the patient is believed to be more likely to continue with it. Littlewood et al (2014) 
found that quick and meaningful relief in pain or response to therapy was a crucial feature of 
continued adherence to treatment.  
 
Pain was also used to assist in the self-management of the condition. Participants described 
re-starting the exercises when they experienced pain again.  
 
“My arm does start aching and I go straight back into exercise mode and it relieves the 
condition.” Participant 57.  
 
By finding something that they could do to alleviate the pain when it returned supported 
development of their control and self-management;  
“Pain is reminding me usually to do it [the exercise programme].” Participant 75.  
 
In this case pain served as the prompt to remind the participant to carry out her exercises. 
 
9.1.12.1.4 Enabler- perceived benefit of treatment 
As mentioned previously the perception that the treatment they were undergoing appeared 
to have helped some to continue adhering to the exercise prescribed; 
 
“I knew if I didn’t do it [the home exercise programme] it wouldn’t improve and strangely 
enough I do get occasions where my arm does start aching and I go straight back into exercise 
mode and it relieves the condition.” Participant 57. 
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“It’s easier to do the exercises when you can feel a definite benefit. It’s always hard to exercise 
to prevent something from getting worse.” Participant 66. 
 
Similar themes emerged from a study investigating non-adherence with exercise programmes 
in patients with cystic fibrosis (Abbott, Dodd et al. 1994). The authors commented that the 
patients in their study appeared to use their symptoms as an indicator to continue or stop the 
treatment, thereby focusing on the short-term benefits or disadvantages of treatment as 
compared with the long-term benefits. Adherence improved when immediate benefits could 
be seen by the patient, supporting the belief that patients who believe in their treatment are 
more likely to comply. This is interlinked with the relationship between the perceived balance 
between the costs and benefits of rehabilitation (Groth and Wulf 1995). 
 
Participants also acknowledged the possible role that natural resolution might have made in 
their improvement; 
“My improvement must be due to the exercises although I don’t know how much I would have 
improved with no treatment at all.” Participant 62. 
 
“It was getting better but whether it was getting better due to treatment or just natural 
progression of things improving themselves with exercise and all I can’t really say.” Participant 
74. 
 
9.1.12.1.5 Enabler equipment 
Several participants reported the Theraband ™ (Performance Health, Akron, Ohio, USA) which 
was provided to the participants to allow them to carry out the home exercise programme, as 
a key enabler. They found the resistance exercises were effective and found it a reminder or 
visual prompt to do them; 
 
“Working with the band is probably a good idea because you can do it everywhere and 
anywhere.” Participant 64. 
 
“The elastic band, I think, is worth the money and I liked being able to go up the levels….I felt 
like I was progressing.” Participant 60. 
 
The use of the gym equipment proved to be an enabler for the class;  
 
 
229 
 
“Lots of equipment in the room and most I couldn’t have at home or replicate the gym at home 
so it [the class] was really useful.” Participant 75. 
 
9.1.12.1.6 Enabler- participation within the study and the further follow up 
The follow up period to one year was cited by some participants as giving the motivation to 
continue to do the exercises; 
 
“The study gave me the incentive to carry on doing the exercises.” Participant 62. 
 
9.1.12.1.7 Barriers to exercise within the trial: 
There were several barriers cited by the participants preventing them from either fully or 
partially adhering to the exercise regimen including time, memory, the exercise class, 
equipment, self-discipline, pain, perceived seriousness of the condition and participants cited 
both time and memory as reasons for not being able to do the exercises as prescribed; 
   
“Never find time.” Participant 56 and “Failing memory made me forget occasionally.” 
Participant 69. 
 
Time and the need to fit in an extra thing during the day have been frequently cited in the 
literature as barriers to exercise (Sluijs, Kok et al. 1993, Littlewood, Malliaras et al. 2014). 
 
9.1.12.1.8 Barrier- timing, frequency and location of class 
Timing and distance to class were both cited as barriers to attending  
 
“I was working so it was difficult with the timing.” Participant 60. 
“Distance to the class was too much of a barrier.” Participant 69. 
 
In terms of frequency there were differing views. For some once a week was perfect; 
“Once a week was enough because it could then be fitted into your work schedule.” Participant 
57. 
 
Another said “I wish you could have a class every day.” Participant 56. 
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The actual number of classes offered was also a subject of discordance with one participant 
being “pretty unhappy” Participant 62 at discharge, and others reporting “the proof is in the 
pudding that there were enough classes and I don’t have a problem now.” Participant 64. 
 
9.1.12.1.9 Barrier equipment: 
Whilst the Theraband ™ and gym equipment were enablers for some the lack of equipment 
was found to be a barrier for home exercise as participants felt they did not have the 
necessary equipment; 
 
“At home it was difficult to do the exercises due to the lack of equipment.” Participant 60. 
 
This theme was repeated by several other participants; 
 
“They [the home exercises] were quite hard. I know this is silly but it was quite hard in a way to 
do them at home. They are quite awkward things and you don’t have the right kind of 
equipment as you have in the gym.....It was a bit awkward to find a suitable place.” Participant 
76. 
 
9.1.12.1.10 Barrier- self-discipline and lack of motivation  
Some participants expressed it was their lack of motivation and self-discipline which was the 
overwhelming barrier to exercise; 
 
“At home there was the problem with self-discipline, finding the time for it. But I have got 
loads of time but still its self-discipline that’s always the problem......the big problem was lack 
of motivation.” Participant 62. 
 
It is unsurprising that this was expressed in the data within this study as low self-efficacy, 
depression, anxiety, helplessness and poor self-discipline have all been found to be barriers to 
treatment adherence (Jack, McLean et al. 2010). 
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9.1.12.1.11 Barrier pain: 
Pain has been found in the literature to be a barrier to exercise, especially worsening pain 
with exercise (Minor and Brown 1993, Jack, McLean et al. 2010). Pain both increasing and 
reducing levels of pain were found to function as a barrier. In some participants as their pain 
decreased and shoulder function increased the motivation to do the exercises decreased as 
there seemed less of a need for them;  
 
“Those exercises were hurting me and I was not benefitting at all.” Participant 70. 
 
“There was one exercise that I was given earlier that I thought at the time might have made 
things worse, so I stopped doing it” participant 69. 
 
A common theme amongst a proportion of the participants was that pain acted as a prompt to 
remind the patients to do the exercises when they experienced their shoulder pain. It stands 
to reason that these were also the participants who reported reduced adherence to exercise 
as their pain diminished and with it the reminder to do their exercises; 
 
“As with everything, as progress is made its harder to get the incentive to keep up with the 
exercises.” Participant 62. 
  
Here motivation is also the barrier as their improvement continues their motivation drops; 
 
“I didn’t continue with them because the shoulder seemed to be improving and there didn’t 
seem to be a need for them.” Participant 74. 
 
The relationship between the reduction in the impact that the condition is having on the 
person’s life and the reduction in the adherence is intrinsically interlinked. As the illness 
becomes less important in the person’s life and the perceived seriousness of it reduces. Sluijis 
et al (1993) who investigated physiotherapist’s and patient’s beliefs regarding adherence with 
exercises in the private sector in the Netherlands found that the degree of disability provided 
the strongest link with the level of adherence with an exercise programme. Those whose 
condition caused greater difficulties with functioning demonstrated greater adherence to the 
home exercise programme than those who had less hindrance from their condition; 
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“I think the low level of my condition meant I was not highly motivated [to do the exercises].” 
Participant 76. 
 
9.1.12.1.12 Barrier -Efficacy of exercises:  
As mentioned in the enablers to exercise section the perceived effectiveness of the exercises 
the participants had been given was a key factor in whether they continued with them or not; 
  
“I was not benefiting from those exercises at all.” Participant 70. 
 
The individualisation of treatment in a class setting is a challenge and some class attendees 
run the risk of feeling that they are bring given a one size fits all approach as one participant 
voiced in the interview; 
 
“There were several people in the group, everybody doing the same exercise and I did those 
exercises. I had several sessions but it didn’t help at all.” Participant 70. 
 
9.1.12.1.13 Barriers- expectations  
Expectations of both the clinicians and the participants were raised as themes within the 
interviews. Expectation is a complex theme as it encompasses a patient’s expectations that 
the treatment will ultimately improve their condition. In addition, it includes, expectations of 
what the treatment involves and their role to play in treatment. As well as, the 
physiotherapists’ expectations of the improvement a patient should have made at discharge 
and the expectations of the participants in the exercise class of their fellow exercisers; 
 
“I think some of the people there were just going through the motions. But I wasn’t because I 
wanted to get it right. So I was a bit unhappy about that.” Participant 62. 
 
The physiotherapy team were felt to have “low expectations” according to some participants 
at discharge and one reported; 
 
“They were quite prepared to discharge me without seeing me first, it was a bit disheartening.” 
Participant 62.  
Others reported; 
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“I was 60% better and so there was still something there…..probably I would have been able to 
at least carry on [with the exercises] until I felt that it was good enough.” Participant 66. 
 
9.1.12.1.14 Strategies to help with adherence and motivation to exercise 
Interviewees described particular strategies which they adopted and found to be beneficial in 
helping them adhere to the exercise programme. These all centred on building the exercises 
into their everyday well established routine; 
“I always did the exercises when I had my shower in the morning and got dressed and went 
into exercise mode. I did it without fail so it was easier when I linked it to an activity.” 
Participant 57. 
 
“Band is tied to the handle of my office door so I can’t get out without doing them.” Participant 
78. 
 
Or whilst doing something else which served as a distraction; 
 
“I tried to do it when there was something on the radio that I could do at the same time” 
Participant 69. 
 
Other studies have found that those who integrated their exercise programme into their 
lifestyle managed a great level of adherence with minimal behavioural change (Williams and 
Adams 2000). 
 
9.1.12.2  Enablers/ facilitators/ motivators and barriers to taking supplements 
Adherence to medication is known to be inconsistent with 30-50% of medications not being 
taken as recommended, irrespective of the seriousness of the condition for which the 
medication is being taken (Haynes, McKibbon et al. 1996, DiMatteo 2004). One participant 
within this study ceased taking the supplements after two weeks due to difficulty taking them; 
the others reported to being fundamentally adherent to taking the supplements as recorded 
in the diaries and when the returned capsule count was assessed.  
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One participant voiced their difficulty in swallowing the supplements due to their physical size 
and quantity; 
“I found them [the capsules] quite difficult to take. I am not the best with tablets anyway but 
they were really big so swallowing was an issue and the taste.” Participant 75. 
 
Others had no problems and found them; 
“Quite easy to take.” Participant 64. 
 
“They are quite big tablets and there are three of them, so you are certainly very conscious 
that you are taking lots of tablets.” Participant 66. 
 
Whilst this on the surface might be considered a barrier it could also be considered as a 
motivator due to the fact that by being cognizant of taking tablets you are doing something 
for the condition as highlighted by the comment; 
 
“The tablets made me feel much better but I don’t know how far that is if you take lots of 
tablets you must feel much better.” Participant 66. 
Others also reported that whilst they were taking the nine capsules a day they had no 
problems in remembering to take them but once the dose was stopped and they returned to 
one a day or their usual intake they had difficulty in remembering;  
 
“Oddly enough it was really easy to take the nine a day. As soon as I was only taking one or 
two I kept forgetting them. So I was very good as long as I was taking nine.” Participant 60. 
 
“Just the fact you are taking nine a day you tend not to forget about it too easily.” Participant 74. 
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9.1.12.2.1 Perceived benefit:  
The participants’ perception of the beneficial effect of the supplements emerged as a theme 
but interestingly a lack of perceived benefit did not appear to affect adherence unlike with the 
home exercise programme; 
 
“I suppose the benefits weren’t really very obvious. I understood what they were for but there 
wasn’t an immediate pay off.” Participant 76. 
 
This is possibly due to the fact that the participants were aware they were enrolled in the 
study; 
 
“Because I knew I was in the programme and I have to take them.” Participant 56. 
 
Other participants had differing perceptions of the benefits afford by the supplements they 
were taking; 
 
“I felt a little more energetic after taking those pills.” Participant 70. 
 
“I felt a real difference taking the supplements…..very quickly notice a benefit in being able to 
move more freely. I am not sure if this was due to the exercises or supplements.” Participant 57.  
 
“I think they’ve made me stronger. I feel I do have lots of skin problems always and I felt it 
helped with those as well.” Participant 60. 
 
“The tablets made me feel much better....I occasionally get aching knees and aching back and I 
was kind of telling myself, ohhh I feel they are much better too so, I remember having the 
feeling that they felt better whilst taking the tablets but again I couldn’t really be sure whether 
it was.” Participant 66. 
 
9.1.12.2.2 Enablers 
Being used to taking daily medication served as a routine to help remind to take the capsules; 
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”I already had a good pill routine established morning and night it was a scheduled thing and 
that’s easy to remember.” Participant 62. 
 
Several participants cited taking the supplements with meals as part of a well-established 
routine helped prompt them or remind them to take them. This may have been due to the 
suggested capsule administration instructions given to each participant. 
 
“Linking to meals reminded me to take them. I put them out in the morning and carried them 
around with me.” Participant 57. 
 
The pots of pills served as a visual reminder or prompt to take the supplements with 
participants reporting they kept them in the by their bed, in the kitchen or by their coffee or 
kettle in order to prompt them to take them; 
 
“Wherever I go I just carry one pot with me so that would remind me.” Participant 56. 
“Two big containers of pills were a reminder in themselves.” Participant 74. 
 
9.1.12.2.3 Barriers: 
Some participants reported forgetting to take the supplements; 
 
“It is hard to take 9 a day. It’s not hard physically it’s just hard to remember to take them.” 
Participant 78. 
 
9.1.12.3 Side effects: 
The interviewees were asked if they had noticed any side effects whilst taking the pills. Two 
responded by saying they had had side effects; 
 
”Bowel movements seemed to be a bit more solid than usual.” Participant 74. 
 
“I think some of the supplements gave me a dodgy tummy but I can’t be sure whether it was 
that or something else. I wouldn’t be convinced that they did.” Participant 78. 
 
 
 
237 
One participant did raise the question of if there are any health side effects of taking the fish 
oils and the amount of mercury that can be in oily fish. However, this had not affected his 
decision to adhere with the treatment. 
 
9.1.12.4 Strategies to help with adherence and motivation to taking the supplements  
Participants suggested ways in which their adherence could have been enhanced within the 
trial but these are also potential strategies which might enhance adherence in clinical practice; 
  
“The fact you had to take them in the day as well when you are working it just wasn’t practical 
for me, so maybe stronger dose and smaller capsules.” Participant 75. 
 
“Mechanisms, calendar appointments that would be relatively easy to set up on phones.” 
Participant 76. 
 
“A daily notification o even an email from yourselves you know it would be really helpful.” 
Participant 76. 
 
Discussion 
The themes and sub-themes expressed within this study are pertinent to clinical practice and 
inform clinicians regarding the barriers and facilitators to adherence. Barriers and enablers to 
exercise indicate that there are few key areas which could be enhanced in order to maximise 
patient’s engagement with their treatment.  
 
With regards to exercise, the participants reported they valued the follow up and more 
intensive monitoring and feedback regarding their progress and condition which they received 
on the trial. This increased monitoring has also been shown to statistically improve outcomes 
in a study investigating the effects of monitoring on outcome for a group of patients 
undergoing exercise therapy for lower back pain. The experimental group (n=20) undertook a 
supervised and monitored pre designed exercise programme, where each session was 
monitored by a certified strength and conditioning specialist within a health club, compared to 
the control group (n-20) who were given the pre designed exercises and advised to exercise 
four times within a health club a week for six months. Statistically significant increases in 
strength and aerobic fitness along (p=0.01) with decreases in pain (p=0.01) and body fat 
(p=0.05) were observed in the experimental group. The mean number of exercise sessions 
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completed (90.8 out of 96 in the experimental group compared to 31.9 in the control) was 
also statistically significant (p=0.01) indicating that the supervision and monitoring had a 
profound effect of adherence within this cohort of patients. It is unrealistic to imagine that 
this level of supervision would be possible in current clinical practice within the NHS. However 
it might be possible to schedule an additional review appointment a few months after the 
time the patient is discharged. This might further encourage and motivate the individual to 
continue with the exercise programme and may (if future research demonstrates) translate to 
improved outcomes. 
  
This additional review appointment could potentially take the form of; face to face 
appointments, a telephone call, or email correspondence depending on resource availability 
and patient preference. This review appointment could also serve to progress their exercises if 
required, so that they were more relevant to that patient at that time. This links with another 
enabler that was highlighted within the current study; being the importance of the perceived 
benefit of treatment. This further emphasises the need for the right exercises or treatment 
plan for that individual so that they can see that progress is being made. Accurate information 
must be given to the patient at the beginning of treatment informing them of the expected 
timescales involved. The participants responses also suggest that the right equipment should 
be provided and possibly a suggestion or collaborative approach to working out how this 
might be incorporated into their day or routine.  
 
It might be beneficial in a class setting to allow patients to manage their own attendance and 
discharge. This study highlighted that some participants felt they had attended enough or too 
many classes and others would have preferred more. One suggestion might be that patients 
could elect when to leave the class and continue with exercises at home. Thus reducing non-
attendance and allowing those who need more classes to access these within reason.  
 
In terms of enablers and barriers to supplement use, the participants in this study highlighted 
that the size, taste and number of capsules they were asked to take were in some cases 
problematic. The MaxEPA capsules used in this study were chosen for specific reasons 
detailed in Chapter 8.2.7 including the availability of a matched placebo. However nutritional 
supplement manufacturers do produce and sell ‘ maximum strength’ and ’high strength’ 
capsules which would mean that, in order to achieve a similar dose as the 2.6g 
Docoshexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) given in the RCT, patients would 
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instead need to take four to five capsules rather than nine a day. This may lead to better 
adherence and could be taken with breakfast and evening meals. However, some participants 
raised the point that it was easier to remember to take them when there were so many.  
 
Participants cited forgetfulness as a barrier and suggestions were made regarding smart 
phone reminders or daily emails from the research team in order to aid memory. M-health or 
mobile-health is a term which is used to describe the support of health care and public health 
through the use of mobile devices (Free, Phillips et al. 2013). A systematic review investigating 
the effect of m-health on chronic disease concluded there was mixed evidence supporting its 
use (Hamine, Gerth-Guyette et al. 2015). The potential for benefit is clear with the widespread 
use of mobile and wireless devices throughout the world but currently evidence to support its 
influence on adherence is inconclusive.  
 
The importance of linking taking supplements with an already established routine was 
highlighted within the transcripts. The established routines were either pill taking routines and 
the supplements were simply viewed as another medication. Or functional routines such as 
washing, dressing or meal times, where the taking of the supplements were incorporated as 
part of that daily routine. These strategies could be suggested and discussed with patients to 
collaboratively problem solve in order to maximise adherence in a clinical setting.  
 
The media coverage of nutritional supplements is patchy at best and often of questionable 
quality (Bartlett, Sterne et al. 2002, Robinson, Coutinho et al. 2013). One participant was 
interested in the study and keen to learn more about PUFAs in part due to positive media 
coverage. Another raised concerns regarding the possibility of mercury accumulation from 
taking fish oils. This was in direct response to a news article that the participant had read. The 
influence the media has on health perceptions is substantial and the importance of 
appropriately balanced and accurate reporting in the press cannot be overemphasised.  
 
9.1.13 Strengths and limitations 
The sample size was small within this study and participants were selected pragmatically due 
to the resources available.  
 
The concept of this qualitative study was conceived and developed during recruitment for the 
main RCT and as such the resources were limited as the majority of resources were already 
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committed. Thus, whilst it was the aim of this study that theoretical saturation would be 
reached it is unlikely to have occurred.  
 
A grounded theory approach was used in this study to influence subsequent interviews after 
analysis of preceding data. Whilst this allows rich and detailed data collection to occur over 
time and at many different levels it also carries with it the risk of researcher bias with 
preconceived assumptions and the potential narrowing of the topic field. In order to try to 
mitigate this the researcher’s ideas and thoughts during and before the process were 
documented. This heightened her awareness to her preconceptions and how this might 
interact with the data. Each interview was conducted stating with broad opening questions to 
allow the participant to steer the conversation and provide the information they felt was 
relevant. 
 
The interviewer was the physiotherapist whom had assessed the participants, delivered the 
intervention and designed the study. This carries an inherent bias. Whilst the interviewees 
were put at ease and invited to explore the negative as well as the positive aspects of the trial 
and the experiences some might have been reluctant about being honest or held back with 
some of their responses. However the positionality of the interviewer also brought some 
advantages, an in-depth understanding of the intervention and a working therapist-patient 
relationship having met the participants on a minimum of five occasions previously. It must 
also be acknowledged that although there was triangulation of the data from a supervisor 
who is also a physiotherapist to agree themes the interpretation of the data is largely the 
perspective of one physiotherapist. Another researcher examining the raw data might well 
have elicited different themes.  
 
The interviews were conducted ten months after the intervention had ceased. This 
undoubtedly challenges the recall of the events, experiences and feelings at the time the 
participant was involved in the RCT. 
 
The key strength of this study is in the additional information it provides to support the RCT, 
by, providing a voice for the participant’s views and opinions through its qualitative 
methodology. It raises pertinent questions regarding the duration and nature of routine follow 
up for patients with RC tendinopathy within the NHS.  
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Additionally, the level of education attained by the participants was also not recorded in this 
study. This has previously been shown to be significantly related to adherence (Sluijs, Kok et 
al. 1993, Groth and Wulf 1995).  
 
Conclusion 
This study explored the experiences of participants’ taking part in the main RCT and the 
enablers or barriers to adherence with the exercise based intervention and the prescribed 
supplements. 
 
Participants valued their experience within the study as largely being a positive one. The main 
enablers to exercise were highlighted as equipment, the perceived benefit from the actual 
exercises, and the longer follow up and more intensive monitoring and feedback received in 
the trial. Barriers included motivation, lack of suitable equipment and pain whether it 
improving or worsening. Enablers to supplement taking included, perceived benefit of the 
supplements and a systematic pill taking routine. Barriers were largely the size, taste and 
quantity of supplements to be taken, remembering to take them, and, a lack of perceived 
benefit.  
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Introduction 
Research investigations have repeatedly demonstrated that exercise is an effective treatment 
for people diagnosed with rotator cuff (RC) tendinopathy (Ainsworth, Lewis et al. 2009, 
Littlewood, Bateman et al. 2016). Exercise is as effective as surgery in the treatment of 
subacromial impingement syndrome (Haahr and Andersen 2006, Ketola, Lehtinen et al. 2009, 
Ketola, Lehtinen et al. 2013), partial thickness RC tears (Denkers, Pletsch et al. 2012) and 
atraumatic full thickness tears (Ainsworth 2006). However, comparable to the outcomes from 
surgical trials, not all patients achieve full resolution of their symptoms with a graduated 
exercise programme.  
 
Inflammation is considered to be present as part of the continuum of pathology in RC 
tendinopathy (Dean, Franklin et al. 2012, Rees, Stride et al. 2013, Dean, Gettings et al. 2015). 
Non steroidal anti inflammatory drugs and cortico-steroids are commonly prescribed to treat 
RC tendinopathy (Buchbinder, Green et al. 2003, Arroll and Goodyear-Smith 2005, Boudreault, 
Desmeules et al. 2014) but these medications are associated with side effects including; 
nausea, dyspepsia, vomiting, abdominal pain and heartburn (Brun and Jones 2001), 
gastrointestinal ulceration (Rainsford 1999), and impaired tendon healing (Dean, Franklin et al. 
2014) and also do not always alleviate the symptoms (Coombes, Bisset et al. 2010). Due to 
incomplete resolution of symptoms with current treatments, new therapies that may target 
the underlying patho-aetiology and may be less harmful than conventional therapies 
(Rainsford 1999, Brun and Jones 2001, Dean, Franklin et al. 2014) need be considered and 
trialled. Long-chain omega-3 polyunsaturated fatty acids (PUFA) were claimed to be effective 
in the treatment of a range of tendinopathies including supraspinatus, infraspinatus, long head 
of biceps, medial and lateral epicondylitis and patellar tendinopathy (Mavrogenis, 
Johannessen et al. 2004). However this study was associated with a high risk of bias because 
analysis was not on an intention-to-treat basis and non-compliers were excluded from the 
data analysis. 
 
One reason long-chain omega-3 PUFAs may benefit people diagnosed with RC tendinopathy is 
because they have the potential to target inflammatory cells and processes (Calder 2006, Das 
2006). Research investigating the effectiveness of long-chain omega-3 PUFAs in this condition 
would be of clinical relevance due to their potential role in symptom reduction with a lower 
risk profile that other interventions (Rainsford 1999, Brun and Jones 2001, Dean, Franklin et al. 
2014). 
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As such, one aim of this thesis was to investigate the use of long-chain omega-3 PUFAs and 
exercise in the treatment of RC tendinopathy. 
 
This hypothesis formed the main clinical investigation of this thesis. Other research was 
conducted to support the main clinical trial. A reliability study was conducted (Chapter 6) to 
determine the intra and inter-tester reliability of the impairment outcome measures used in 
this investigation. This work has subsequently been published (Dollings, Sandford et al. 2011). 
 
Additional research investigated the reasons for self-prescription of dietary supplements in a 
cohort of people attending physiotherapy for shoulder pain. To achieve this, a cross sectional 
survey was conducted. An additional qualitative study explored the enablers and barriers to 
both exercise and supplement consumption for people diagnosed with RC tendinopathy.  
 
This group of studies, which explores novel treatments for RC tendinopathy, is particularly 
pertinent in the current health care environment of ‘health based practice’ where 
maximisation of an individual’s health and well-being for the long term as well as treating the 
presenting complaint is paramount (Dean, Al-Obaidi et al. 2011). 
 
Summary of findings 
 
10.1.1 Questionnaire study: 
The survey study revealed that 38% of respondents were taking dietary supplements. Eighty-
two percent of those taking supplements (n=82) reported taking supplements to address their 
shoulder pain. The most commonly listed supplement was cod liver oil, but this was, on 
average, consumed at a dose which would not be expected to have an anti-inflammatory 
effect. In this investigation, women were found to be taking more supplements than men, and 
increased supplement use was found to be associated with increasing age. Friends and family 
were ranked the highest in sources of influence with regards to supplement use followed by 
the media and internet. One key point derived from the survey study was that the uncertainty 
of the evidence and the perceived lack of efficacy of supplements which proved to be a barrier 
to use and this was also echoed in the qualitative study (Chapter 9). The concerns expressed 
by the respondents of the questionnaire pertaining to lack of efficacy of supplements were 
supported by the findings of main clinical study.  
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10.1.2 Evidence from randomized controlled trial: 
The placebo-controlled RCT described in this thesis failed to demonstrate any benefit of long-
chain omega-3 PUFA supplementation on clinical outcomes in RC tendinopathy. However, 
there was tentative evidence to suggest a more rapid improvement in disability and pain as 
measured by Shoulder Pain and Disability Index (SPADI) (p=0.003) in the long-chain omega-3 
PUFA treated group at the three month time point. However, as this was not the specified 
primary outcome, this could be a chance finding and needs confirmation. Participants received 
9g of oil daily which would be estimated to provide 2.6 g of EPA and DHA or approximately 3 g 
long-chain omega-3 fatty acids/d. While higher doses may theoretically have effects, the level 
of supplementation used is at the upper limit likely to be consumed for non-medicinal 
purposes. 
 
10.1.3 Qualitative study; 
The qualitative study demonstrated that participants valued their participation within the RCT 
expressing it was largely a positive experience. The principal enablers to exercise were 
highlighted as; equipment, the perceived benefit of the exercises and long term follow up and 
supervision. Barriers to exercise included poor motivation, lack of suitable equipment and 
pain either worsening or improving. Enablers to supplement use were found to be; perceived 
benefit of the supplements and a well-established pill taking routine. Barriers to supplement 
use were; the large size, taste and quantity of capsules to be taken along with the lack of 
perceived benefit from them.  
 
No adverse effects were reported by the participants within the study other than mild gastro-
intestinal upsets by two participants, both of which were in the long-chain omega-3 PUFA 
treatment group. 
 
Strengths and Limitations 
A strength of the randomised controlled trial is in its double-blind design and the use of 
multiple clinical outcomes. However, the more outcomes specified, the greater the likelihood 
that some may be found to be significant. The primary hypothesis looked for a difference in 
OSS of 6 points whereas the observed difference between treatments was 0.2 points. The 6-7 
point improvement in disability and pain observed in both treatment groups over the first two 
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months of treatment is in keeping with the results of other studies investigating the efficacy of 
exercise and physiotherapy in RC tendinopathy (Littlewood, Bateman et al. 2016).  
 
At the time the RCT was being designed the primary outcome measure, the OSS, was and 
remains for some, the most clinically preferred shoulder outcome measure (Varghese, Lamb et 
al. 2014) and is still in common use in research (Carr, Rees et al. 2014). The SPADI (a secondary 
outcome measure used in this study) may be more responsive than the OSS (Ekeberg, Bautz-
Holter et al. 2008). The test re-test reliability was found to be greater for the SPADI than the 
OSS in subacromial impingement with the weighted Kappa coefficients being moderate to very 
good for the SPADI (0.51 to 0.80) and fair to good for the OSS (0.13 to 0.78) (Cloke, Lynn et al. 
2005). This could offer a further possible explanation for the significant difference in disability 
and pain (as measured by the SPADI) observed in favour of the long-chain omega-3 PUFA 
group at three months.  
 
Another potential limitation was that there was more than one physiotherapist examining 
participants and this is a potential source of error. However, the reliability study 
demonstrated adequate inter-rater reliability of the impairment measures between the two 
examiners. The primary outcome and other secondary measures were self-report 
questionnaires and so it is thought the risk of error through this means is likely to be small. 
 
10.1.4 Natural recovery 
The course of natural improvement of RC tendinopathy is currently uncertain. Those with 
musculoskeletal symptoms such as RC tendinopathy often seek treatment at the peak of their 
symptoms and subsequent improvement is usually inevitable (Krogsboll, Hrobjartsson et al. 
2009). It is also possible that the improvement in disability and pain observed in both groups 
was due to natural resolution. Without a control group it is impossible to quantify the effect 
that natural resolution had on the symptoms of the participants within the RCT in this thesis. 
However in other studies that have included a no treatment control group minimal 
improvements have been observed in pain and function (Lombardi, Magri et al. 2008). 
 
Within this study only 35% of participants reported that they were completely pain free at one 
year. With this high number of cases reporting discomfort, even if mild, at one year following 
treatment, raises the question of whether treatment is being directed in the correct manner 
or at the correct tissues. Recent research has highlighted the potential involvement of 
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reorganisation of the somatosensory and motor cortices in the ongoing symptoms of RC 
tendinopathy (Ngomo, Mercier et al. 2015).  
 
10.1.5 Heterogeneous sample  
The diagnostic criteria were based on clinical signs and symptoms that have also been 
commonly used in other clinical research studies on RC tendinopathy (Haahr, Ostergaard et al. 
2005, Ketola, Lehtinen et al. 2013, Littlewood, Bateman et al. 2016). However, there were a 
proportion of participants who reported night pain and being unable to sleep on their affected 
shoulder. Some reported pain on a particular movement and others did not. The mechanisms 
of injury varied amongst the group. These differing presentations suggest the potential for a 
wide range of structural pathologies within the sample. With randomisation it is anticipated 
that these will be equally distributed between the two groups. However, it is possible that for 
one sub group of participants within the experimental group, the long-chain omega-3 PUFA 
supplements might have conferred an additional benefit but that these results became diluted 
due to the heterogeneous nature of the group. However, sub group analyses showed no 
significant differences between the treatment groups for presence of night pain, presence of 
constant pain, mechanism of injury or pain on movement as having an influence on outcome 
as measured by the OSS.  
 
Similarly, the individual response to a fixed dose of omega -3 PUFA has been shown to vary 
considerably. Following supplementation for 28 days with 4g EPA and DHA, plasma EPA levels 
had increased by 1.1-6.36% and DHA by 3.4-6.3% (Wei and Jacobson 2011). A poor responder 
to supplementation might have had the effect of diluting any benefit of the long-chain omega-
3 PUFA on pain and disability within the sample.  
 
The present study showed clear increases in plasma EPA and DHA from baseline mean values 
of 1.2 and 2.1 % respectively to 3.7% and 3.5% on active treatment with no change in the 
placebo group. No evidence could be found relating the proportion of EPA and DHA in plasma 
lipids with decline OSS. 
 
10.1.6 Effect from common interventions 
This trial was designed to test for differences between long-chain omega-3 PUFA 
supplementation versus placebo. Temporal changes in symptom scores may occur with time 
and would be expected to improve with the exercise. It is not possible to attribute such effects 
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to other components of the supplements but the potential effects of the vitamin E content 
will be discussed.  
 
Both supplements contained 18mg of vitamin E per day if all nine capsules were consumed. 
This was added to prevent the deleterious effects on vitamin E status resulting from an 
increased intake of long-chain omega-3 PUFAs. The UK has no dietary recommendation for 
vitamin E but the European Food Safety Authority (EFSA) has suggested intakes of 11 and 13 
mg tocopherols equivalents/d are adequate intakes (EFSA NDA Panel (EFSA Panel on Dietetic 
Products 2015). It has been suggested that greater intake of vitamin E than used in the 
present study might have a beneficial antioxidant effect in people with osteoarthritis (Scherak, 
Kolarz et al. 1990, Rhouma, de Oliveira El Warrak et al. 2013). However, there are no placebo 
controlled trials to support this claim in tendon related conditions. The amount of Vitamin E 
provided by the MaxEPA and placebo capsules was similar to that provided by the Pharma 
Biosport antioxidant tablet (15mg Vitamin E) alongside the fish oil capsules in the Mavrogenis 
(2004) and Roe (2005) studies. Roe et al (2005) found similar findings to the current RCT with 
no additional benefit provided by the omega 3 PUFA and antioxidant supplements, whereas 
Mavrogeneis (2004) reported significant improvements in the treatment group.  
 
Both treatment groups also received physiotherapy follow up over a longer period (one year) 
than routine treatment (usually eight weeks). In the qualitative study, follow up was reported 
as an enabler to continued adherence to exercise by the participants which may have had an 
influence on the reduction in disability and pain observed within this study. The participants 
were reviewed and assessed a minimum of an extra three visits above and beyond ‘normal’ 
treatment and for a further ten months than normal. During the follow up visits and 
assessments participants received feedback regarding their progress, informal advice and 
answers to any questions regarding their condition or exercises. These interactions may have 
resulted in improvements in pain and disability. Interaction with a physiotherapist and the 
therapist-patient relationship has been reported to result in a positive influence on treatment 
outcome (Hall, Ferreira et al. 2010). The importance and benefit of the therapist-patient 
relationship was also cited in the qualitative interviews where participants stated the value 
they placed on this relationship. 
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10.1.7 Dose, duration and method of providing long-chain omega-3 PUFA 
Long-chain omega-3 PUFAs are normally supplied as triglyceride oils or ethyl esters and 
occasionally as phospholipids (Schuchardt and Hahn 2013). The material used in the present 
study (MaxEPA) holds a medicines’ licence (PL 19488/0353) for the treatment of 
hypertriglyceridemia and has been used in hundreds of clinical trials including those in which 
inflammation was modulated. It is usually compared with olive oil placebo. MaxEPA has a 
well-defined formulation that is consistent with that described in the European Pharmacopiea 
for fish oil rich in long-chain omega-3 fatty acids. Fish is the main dietary source of long-chain 
omega-3 PUFAs and it is present mainly as triglycerides. While claims have been made that 
phospholipid forms of long-chain omega-3 PUFA may be better absorbed and incorporated 
into body lipids (Ghasemifard, Turchini et al. 2014) there is a lack of evidence to support that 
any such differences are significant. EPA may have a greater anti-inflammatory effect than 
DHA (Mickleborough, Tecklenburg et al. 2009) and future studies might consider the effects of 
higher doses of purified EPA on the resolution of RC injury. 
 
Several respondents stated in the survey study that the reason they have not considered 
taking supplements was due to the quality and balanced nature of their diet. These opinions 
are supported by the findings of the main clinical study. 
 
Summary  
The findings in the main clinical investigation are in keeping with the trend towards no effect 
in trials of long-chain omega-3 PUFA in the prevention of coronary heart disease (Nestel, 
Clifton et al. 2015). It is possible that the theoretical action of long-chain omega-3 PUFA on 
inflammation is not borne out in humans or the dose and the vehicle delivering the long-chain 
omega-3 PUFA is not appropriate to effect a change in symptoms in RC tendinopathy.  
 
Clinical relevance of these findings: 
The data presented in the questionnaire study (Chapter 7) suggest that one-third of people 
with shoulder pain take supplements, mainly fish oil containing long-chain omega-3 fatty 
acids. However, the findings of the randomized controlled trial presented in thesis do not 
support the use of long-chain omega-3 PUFA supplements in the management of RC 
tendinopathy. The results support the current best practice management of RC tendinopathy 
with exercise.  
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The qualitative study highlighted that longer term follow-up may improve the patient 
experience and enhance adherence within this group of patients. Follow-up could take the 
form of face to face contact, telephone calls or email interaction. The possibility of self-
managing discharge from exercise class was raised providing more individualised treatment 
rather than a fixed number of classes for all. Pain and the perceived effectiveness of an 
intervention proved to be strong drivers for adherence. It is recommended that these factors 
are considered when prescribing a home exercise programme or treatment plan in order to 
maximise adherence and outcome. 
 
A further contribution of this thesis is to add to the body of knowledge required to understand 
better the extent of supplement use in people diagnosed with shoulder pain. The survey study 
revealed that a significant percentage of patients with shoulder pain most likely will be taking 
dietary supplements. This should be remembered when undertaking a subjective examination 
and dietary supplement use should be noted alongside medications. Health professionals 
were the third most frequently cited source of information regarding supplements 
highlighting the importance of ensuring appropriate information is being provided by 
adequately informed practitioners.  
 
Suggestions for future research 
Potential future research questions that have arisen from the work associated with this these 
include: 
 A similar trial as the main clinical trial but using an oil rich in EPA to provide up to 5g/d 
without significant amounts of DHA.  
 A similar trial as the main clinical trial using suitably powered to use SPADI as the 
primary outcome measure, taking into account the variability of the SPADI outcome 
measure. 
 Further research is required to understand the potential impact of long-chain omega-
3 PUFA on inflammation. 
 Further research is needed to examine other aspects of life-style that might contribute 
to more rapid resolution of symptoms of rotator cuff tendinopathy including weight 
loss. 
 A study which targets a sub-classification of participants with rotator cuff 
tendinopathy which may be more suggestive of active inflammatory processes eg 
early onset. 
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 A study which uses biomarkers to assess the impact of the long-chain omega-3 PUFA 
intervention on inflammatory markers for rotator cuff tendinopathy. 
 A study which investigates whether a review appointment a few months after 
discharge does afford improved outcomes compared to current routine treatment. 
 A study which evaluates the outcomes of increased patient choice for discharge within 
an exercise class for RC tendinopathy. 
 
Conclusions 
One of the main findings from this thesis is that supplementation with omega 3 PUFA at 9g 
per day does not confer additional benefit over the recommend treatment of exercise in the 
treatment of individuals with RC tendinopathy. With 65% of participants within the RCT still 
reporting pain at one year, the search for ways to enhance treatment outcomes continues. 
Treatment adjuncts, lifestyle alterations and effective ways of addressing the Central Nervous 
System contribution to the pain all need to be considered in order to better manage the 
common and disabling condition of RC tendinopathy.  
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Oxford shoulder Score (OSS)  
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Shoulder pain and disability index (SPADI) 
 
SPADI  Shoulder Pain And Disability Index (Roach et al 1991) 
 
Part I: 
Place a mark on the line to show how much PAIN you have had in the past week for each 
question. 
 
Example 
No pain  Worst pain imaginable 
 
1. At its worst? 
No pain  Worst pain imaginable 
 
2. When lying on the involved side? 
No pain  Worst pain imaginable 
 
3. When reaching for something on a high shelf? 
No pain  Worst pain imaginable 
 
4. When touching the back of your neck? 
No pain  Worst pain imaginable 
 
5. When pushing with the involved arm? 
No pain  Worst pain imaginable 
 
Part II: 
Place a mark on the line to show how much DIFFICULTY you have had in the past week to 
do the activity listed below. 
 
1. Washing your hair? 
No difficulty  So difficult required help 
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2. Washing your back? 
No difficulty  So difficult required help 
 
3. Putting on an undershirt or pullover shirt? 
No difficulty  So difficult required help 
 
 
4. Putting on a shirt that buttons down the front? 
No difficulty  So difficult required help 
 
5. Putting on your pants? 
No difficulty  So difficult required help 
 
6. Placing an object on a high shelf? 
No difficulty  So difficult required help 
 
7. Carrying a heavy object of 10 pounds or more? 
No difficulty  So difficult required help 
 
8. Removing something from your back pocket? 
No difficulty  So difficult required help 
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Short Form 36 (SF 36) 
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Euro Qol 5D 3L (EQ 5D 3L) 
 
 
 
 
Health Questionnaire 
(English version for the UK) 
(Validated for use in Eire) 
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By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today. 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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We would like you to indicate on this scale 
how good or bad your own health is today, 
in your opinion. Please do this by drawing a 
line from the box below to whichever point 
on the scale indicates how good or bad your 
health state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own 
health state 
today 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Worst 
imaginable 
health state 
0 
Best  
imaginable 
health state 
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Patient Specific Functional Score (PSFS) 
 
 
 
 
St Thomas' Hospital 
Physiotherapy Department 
PATIENT-SPECIFIC FUNCTIONAL SCALE 
 
Name:___________________________  Date:___________ 
DOB:___________ 
 
□ Baseline Assessment  □Follow-up Assessment 
 
Identify up to 3 important activities that you are unable to do or have difficulty with as a result of your problem. 
 
Activity 1:_________________________________________________________________ 
 
Scoring scheme: 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
      Unable to                                                                                                       Able to perform 
 Perform activity                                                                                                  activity at pre-injury level 
 
Activity 2:_________________________________________________________________ 
 
Scoring scheme: 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
      Unable to                                                                                                       Able to perform 
 Perform activity                                                                                                  activity at pre-injury level 
 
 
Activity 3:_________________________________________________________________ 
 
Scoring scheme: 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
      Unable to                                                                                                       Able to perform 
 Perform activity                                                                                                  activity at pre injury level 
 
 
 
       Total Score = ____ (total) x 100 =      
 
 
 
                 % 
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Ethical approval for reliability study  
 
 
 
Hannah Dollings 
c/o Dr Matt Morrissey 
School of Biomedical & Health Sciences 
Shepherd’s House, Guy’s Campus 
King’s College London 
SE1 1UL 
 
18 June 2009 
 
Dear Hannah  
 
BDM/08/09-86 The intra- and inter-rater reliability of the JTech Commander PowerTrack II 
in the measurement of shoulder strength in asymptomatic subjects 
 
Thank you for sending in the amendments requested to the above project. I am pleased to 
inform you that these meet the requirements of the BDM and therefore that full approval is 
now granted.  on the understanding that: 
1. The sentence “There is minimal likelihood of inducing any discomfort on performing 
these tests on asymptomatic individuals however should it occur the assessment will 
be discontinued” is alsoadded in the recruitment email and the amended recruitment 
email is submitted for our records 
Please ensure that you follow all relevant guidance as laid out in the King's College London 
Guidelines on Good Practice in Academic Research 
(http://www.kcl.ac.uk/college/policyzone/attachments/good_practice_May_08_FINAL.pdf). 
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For your information ethical approval is granted until 18/06/2010. If you need approval 
beyond this point you will need to apply for an extension to approval at least two weeks prior 
to this explaining why the extension is needed, (please note however that a full re-application 
will not be necessary unless the protocol has changed). You should also note that if your 
approval is for one year, you will not be sent a reminder when it is due to lapse. 
 
If you do not start the project within three months of this letter please contact the Research 
Ethics Office. Should you need to modify the project or request an extension to approval you 
will need approval for this and should follow the guidance relating to modifying approved 
applications: http://www.kcl.ac.uk/research/ethics/applicants/modifications.html 
 
Any unforeseen ethical problems arising during the course of the project should be reported 
to the approving committee/panel. In the event of an untoward event or an adverse reaction 
a full report must be made to the Chairman of the approving committee/review panel within 
one week of the incident. 
 
Please would you also note that we may, for the purposes of audit, contact you from time to 
time to ascertain the status of your research.  
 
If you have any query about any aspect of this ethical approval, please contact your 
panel/committee administrator in the first instance 
(http://www.kcl.ac.uk/research/ethics/contacts.html). We wish you every success with this 
work. 
 
With best wishes 
 
Yours sincerely 
 
 
c.c.  
 
Dr Matt Morrissey 
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Participant information sheet for reliability study  
 
INFORMATION SHEET FOR PARTICIPANTS 
REC Reference Number:  BDM/09/09-86 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
Title: The intra- and inter-rater reliability of the JTech Commander PowerTrack II in the 
measurement of shoulder strength in asymptomatic subjects  
We would like to invite you to participate in this original postgraduate research project.  You 
should only participate if you want to; choosing not to take part will not disadvantage you in 
any way. Before you decide whether you want to take part, it is important for you to 
understand why the research is being done and what your participation will involve.  Please 
take time to read the following information carefully and discuss it with others if you wish.  
Ask us if there is anything that is not clear or if you would like more information. 
 
Aims of the research and possible benefits 
The aim of this study is to investigate the reliability of the JTech Commander PowerTrack II in 
the measurement of shoulder muscle strength in asymptomatic subjects. The JTech 
Commander PowerTrack II is a hand held dynamometer used to measure muscle strength 
(also called a muscle strength testing device).  If this method of testing strength of the 
shoulder area is proved to be reliable it will be used in physiotherapy practice to improve the 
assessment of patients with shoulder pain. 
 
Who are we recruiting? 
We are recruiting participants who have no history of shoulder pain and are over the age of 18 
years. The exclusion criteria to taking part in the project include; pregnancy, individuals under 
the age of 18, those unable to give informed consent and individuals with a history of shoulder 
pain. 
 
What will happen if I agree to take part? 
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If you agree to take part you will be asked to attend a testing session which will last for two 
and a half hours. During this time you will be given an opportunity to ask any questions and 
then be asked to sign a consent form. Your shoulder range of movement will be measured and 
your shoulder strength will be tested using the muscle strength testing device which is in use 
currently within physiotherapy practice. You will be asked move your arm into four different 
movements (flexion, abduction, rotation and taking your hand behind your back). You will 
then be asked to push against the rubberised pad of a small, hand-held machine as hard as 
you can three times for each of nine specific  muscle groups; shoulder flexors, extensors, 
abductors, internal and external rotators, elbow flexors, empty can and full can tests. Each 
test will be measured three times before moving onto the next test.  All tests will be carried 
out in the order stated above and will be followed by a 15 minute break.  You will then be 
tested by the second examiner. This sequence will then be repeated by the first and then 
second examiner. Once you have completed all 4 strength testing sequences your involvement 
in the project will be complete.  
Any risks? 
The tests which are being investigated are routinely carried out in clinical practice and so the 
only identified risk from participating in this study would be the minimal likelihood of 
experiencing discomfort upon testing.  Should this occur the assessment will be discontinued.  
 
Possible benefits  
There are no perceived benefits for the individuals taking part in the study. However it will 
enable clinicians to improve their assessment of shoulder conditions and therefore will have 
an impact on patient care. We will provide all participants with a one page summary of the 
results of the study if interested. 
 
Arrangements for ensuring anonymity and confidentiality.   
All data collected will be fully anonoymised and at no point will it be traceable back to the 
individual. The two examiners (Hannah Dollings and Fiona Sandford) and the supervisor, Dr 
Matt Morrissey, will be the only persons with access to the data. 
Name and contact details of the researcher: 
Hannah Dollings can be contacted via Dr Matt Morrissey at the address and telephone 
number below. 
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It is up to you to decide whether to take part or not.  If you decide to take part you are still 
free to withdraw at any time and without giving a reason. 
If you decide to take part you will be given this information sheet to keep and be asked to sign 
a consent form. 
 
If this study has harmed you in any way you can contact King's College London using the 
details below for further advice and information:  
Dr Matt Morrissey, 
Senior Lecturer of Physiotherapy, 
School of Biomedical & Health Sciences,  
Shepherds House,  
Guys Campus,  
Kings College London 
SE1 1UL 
0207 848 6678 
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Consent form for reliability study  
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES 
 
Please complete this form after you have read the Information Sheet and/or listened to an 
explanation about the research. 
 
Title of Study: The intra- and inter-rater reliability of the JTech Commander PowerTrack II in 
the measurement of shoulder strength in asymptomatic subjects  
 
King’s College Research Ethics Committee Ref:  BDM/08/09-86 
 
 Thank you for considering taking part in this research. The person organizing the 
research must explain the project to you before you agree to take part. 
 
 If you have any questions arising from the Information Sheet or explanation already 
given to you, please ask the researcher before you decide whether to join in. You will 
be given a copy of this Consent Form to keep and refer to at any time. 
 
 I understand that if I decide at any other time during the research that I no longer wish 
to participate in this project, I can notify the researchers involved and be withdrawn 
from it immediately. 
 
 I consent to the processing of my personal information for the purposes explained to 
me.  I understand that such information will be handled in accordance with the terms 
of the Data Protection Act 1998. 
 
 
Participant’s Statement: 
 
I _____________________________________________________________________ 
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agree that the research project named above has been explained to me to my satisfaction and 
I agree to take part in the study. I have read both the notes written above and the Information 
Sheet about the project, and understand what the research study involves. 
 
Signed      Date 
 
 
 
Investigator’s Statement: 
 
 _____________________________________________________________________ 
 
I confirm that I have carefully explained the nature, demands and any foreseeable risks (where 
applicable) of the proposed research to the volunteer. 
 
 
Signed      Date 
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Ethical approval for questionnaire study 
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           Participant information sheet for questionnaire study 
PARTICIPANT INFORMATION SHEET 
V1 dated 21.4.2010 
 
Study title “Shoulder pain and the use of nutritional supplements”: 
A questionnaire based investigation. 
 
2.  Invitation paragraph 
You are being invited to take part in a research study that is aiming to investigate if 
people with shoulder pain use nutritional or food supplements; such as vitamins and 
fish oils, to help with symptom control and management of the condition. This 
investigation involves a questionnaire which will take approximately 30 minutes to 
complete. After that your involvement in this study will be complete. No identifiable 
personal data will be collected and no-one will know what you wrote. Before you decide 
to participate it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and 
discuss it with friends, relatives and your GP or Consultant if you wish.  Please ask us if 
there is anything that is not clear or if you would like more information.  Please take 
time to decide whether or not you wish to take part. This study forms part of a PhD 
(Doctoral) degree programme. 
3.  What is the purpose of the study? 
Many people take nutritional and food supplements for musculoskeletal problems 
including those involving the shoulder region. However, very little research has been 
conducted to determine what affect they actually have. We are interested in learning 
from people who currently have shoulder pain about their experiences with nutritional/ 
food supplements. This includes views from people who regularly take food 
supplements, people who have tried them only once or twice, and from people who 
have never taken them. 
4.  Why have I been chosen? 
We have approached you because you have shoulder pain and we are interested in 
learning about your views and experiences with nutritional/ food supplements. 
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5.  What will happen to me if I take part? 
If, after reading this information document you would like to participate, the principal 
investigator will ask you to complete a consent document. This is a formal requirement 
for all research studies. After completing the consent form you will be given an 
envelope containing the questionnaire. The questionnaire booklet should take 
approximately 30 minutes to complete. Once completed the questionnaire booklet is 
placed back in the envelope which you may seal and hand back to the principal 
investigator. You may fill these forms in before or after your treatment or if you prefer 
you may take them home and complete them there and bring them when you return 
next time. The questionnaires contain no information that can identify you personally 
and you are under no obligation to participate in this study. Not participating will not 
affect the treatment you receive in any way. 
6.  What do I have to do? 
If you agree to participate you will need to follow the procedure outlined in section 5. 
7.  What is the procedure that is being tested? 
We are not testing any new products or procedures in this study, we only wish to learn 
about your experiences with nutritional/ food supplements. This may range from 
considerable experience to no experience at all. 
8. What are the side effects of taking part? 
As this is a questionnaire based study we do not perceive that there will be any side 
effects if you take part. Completion of the questionnaire should take approximately 30 
minutes. 
9. What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks for those taking part in this study.  
10. What are the possible benefits of taking part? 
We hope that this research will provide a greater understanding about the use and 
perceived benefits of taking nutritional/ food supplements for people who are 
experiencing shoulder pain. 
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11. What if something goes wrong? 
We do not anticipate that anything will go wrong in this study as we are not trying any 
new procedure. This is a questionnaire based study. 
12. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be 
kept strictly confidential and no personal or identifiable information about you is 
collected in the questionnaires. 
13. What will happen to the results of the research study? 
We hope to use the information we obtain from this study to inform other health 
professionals about our results. We therefore ask your permission to publish the data 
we obtain. The results will probably be published about one year after the end of the 
study.  If you are interested in finding out about our results, you may contact the 
Physiotherapy Department where you are receiving treatment to enquire about the 
findings and a summary will be made available to you though the postal service or via 
email from the chief investigator. If you so wish you may also discuss the findings with 
the chief investigator once the results have been published. 
14. Who is organising and funding the research? 
The main sponsor for this study is the Chelsea and Westminster Hospital NHS 
Foundation Trust. 
15. Who has reviewed this study? 
This study has been reviewed by NHS ethics but also by the local practice ethics committee.  
16. Contact for further information 
Fiona Sandford, Lead research physiotherapist on 07836 622076 or 
Fiona.sandford@kcl.ac.uk 
17. For ethical or medical reasons recommendations are sometimes made for certain 
people not to participate in a specific research investigation. We will ask everyone 
participating in this study the following questions.  
In this investigation we will only include people who; 
(i)   have had shoulder pain for more than one month and  
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(ii)  are older than 18 years of age. 
18.  After you have read this information sheet 
Please take your time in order to decide if you would like to participate or not. If you 
wish please discuss your possible involvement with family, friends and other health 
professionals. 
If you agree to participate in this study, we will ask you to fill in and sign a Research 
Consent Form, in front of someone who will witness the signature. This will be done 
before you are given the questionnaire. You may complete the questionnaire in the 
clinic or at home. If you wish, please keep this information sheet. 
If you choose not to participate your treatment will not be affected in any way. You may 
decline from participating at any stage (even after you have signed the consent form) 
and you do not have to give a reason. 
Thank you for taking the time to read this information sheet. 
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Consent form for questionnaire study 
Research Participant Consent Form 
 
Title of Project: Shoulder pain and the use of nutritional supplements:  
 A questionnaire based investigation. 
 
Participant Declaration 
 
  Please initial box 
 if correct 
 
I have been given the chance to read and understand the information 
sheet (V1 dated 21.4.2010) relating to the above study. 
  
   
I have been given the opportunity to ask questions and discuss the 
study. 
  
   
I have been made aware of the risks/ benefits.    
   
   
I understand that I am free to withdraw from this study at any time 
without prejudice to my future care/ treatment. 
  
   
I understand that as this is an anonymous questionnaire study there are 
no compensation procedures / policies in place, other than routine NHS 
compensation procedures. 
  
   
I am over 18 years of age and I have had shoulder pain for more than 1 
month. 
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Title of Project:  Shoulder pain and the use of nutritional supplements:  
 A questionnaire based investigation. 
 
I agree to take part in the above study 
 
 
Signature ……………………………………………………………… 
 
Name  ……………………………………………………………… 
 
Date  ……………………………………………………………… 
 
 
Person responsible for obtaining Informed Consent: 
'To the best of my knowledge I have provided the above individual with sufficient information to 
enable them to give informed consent'. 
 
Signature ……………………………………………………………… 
 
Name  ……………………………………………………………… 
 
Date  ……………………………………………………………… 
 
Position ……………………………………………………………… 
 
 
Witnessed by: 
 
Signature ……………………………………………………………… 
 
Name  ……………………………………………………………… 
 
Date  ……………………………………………………………… 
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Questionnaire booklet 
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The Oxford Shoulder Score, Shoulder Pain and Disability Index, Euro Qol 5D 3L and SF 36 
followed on in the booklet but can be seen in Appendices 11.1-11.4 
 Ethical approval for RCT 
 
Bromley Local Research Ethics Committee 
Bromley PCT, Bassetts House, 
Broadwater Gardens 
Farnborough 
Kent 
BR6 7UA 
 
Telephone: 01689 880592  
Facsimile: 01689 855662 
22 May 2008 
 
Mrs Fiona  Sandford 
Clinical Specialist Physiotherapist  
Guys and St Thomas' NHS Foundation Trust 
Physiotherapy Department, 3rd Floor 
Lambeth Wing, St Thomas' Hospital,  
Lambeth Palace Road,  
London  SE1 7EH 
 
 
Dear Mrs Sandford 
Full title of study: Randomised single-blinded placebo-controlled study investigating the 
role of poly-unsaturated fatty acids in addition to exercise in the 
management of rotator cuff (rc) tendinopathy. 
REC reference number: 08/H0805/21 
 
The Research Ethics Committee reviewed the above application at the meeting held on 15 May 2008. Thank 
you for attending to discuss the study. 
 
Ethical opinion 
1. Members agreed that the reference to CERES in the Participant Information Sheet should be deleted as this 
body no longer exists.  You agreed to remove this.  
2. Members noted that the Participant Information Sheet stated that participants with communication 
difficulties would be excluded, although this was contrary to A33-1 of the application form. You stated that 
these participants could be included in the study and agreed to amend the Participant Information Sheet 
accordingly. 
 
Members of the Committee present gave a favourable ethical opinion of the above research on the basis 
described in the application form, protocol and supporting documentation, subject to the conditions specified 
below. 
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Ethical review of research sites 
The Committee agreed that all sites in this study should be exempt from site-specific assessment (SSA).  There 
is no need to submit the Site-Specific Information Form to any Research Ethics Committee.  The favourable 
opinion for the study applies to all sites involved in the research.  
 
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior to the start of the study. 
Management permission or approval must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
 
Management permission at NHS sites (“R&D approval”) should be obtained from the relevant care 
organisation(s) in accordance with NHS research governance arrangements.  Guidance on applying for NHS 
permission is available in the Integrated Research Application System or at http://www.rdforum.nhs.uk. 
 
Approved documents 
The documents reviewed and approved at the meeting were: 
Document    Version    Date    
Application    07 April 2008  
Investigator CV    24 April 2008  
Protocol  2  24 April 2008  
Covering Letter    22 April 2008  
Peer Review    25 February 2008  
Statistician Comments    18 October 2007  
Questionnaire: SF36 Health Survey    07 April 2008  
Questionnaire: SPADI    07 April 2008  
Questionnaire: EQ-5D    07 April 2008  
Questionnaire: Oxford Shoulder Score    07 April 2008  
Advertisement  1  04 April 2008  
GP/Consultant Information Sheets  1  02 April 2008  
Participant Information Sheet: I version for each site  1  02 April 2008  
Participant Consent Form: 1 version for each site  1  02 April 2008  
CV for Catherine Collins    24 April 2008  
CV for Professor Tom Sanders    24 April 2008  
CV for Matt Morrisey    24 April 2008  
  286 
CV for Professor Axford    24 April 2008  
CV for Jeremy Lewis     24 April 2008  
Data collection sheet  1  02 April 2008  
Food, drink & supplement record  1  02 April 2008  
Letter from St Georges MRC    01 April 2008  
Email from W Vasdias (Seven Seas)    31 October 2007  
Shoulder Class Information  1  23 April 2008  
Flow Chart  1  02 April 2008  
Email from MHRA    11 April 2008  
Shoulder Class Patient Information Booklet  1  02 April 2008  
Research particpants' exercise and tablet diary  1  04 April 2008  
Peer review    22 November 2007  
Peer review    12 November 2007  
 
Membership of the Committee 
The members of the Ethics Committee who were present at the meeting are listed on the attached sheet. 
 
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees (July 2001) and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 
After ethical review 
Now that you have completed the application process please visit the National Research Ethics Website > 
After Review  
 
You are invited to give your view of the service that you have received from the National Research Ethics 
Service and the application procedure.  If you wish to make your views known please use the feedback form 
available on the website. 
 
The attached document “After ethical review – guidance for researchers” gives detailed guidance on 
reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Progress and safety reports 
 Notifying the end of the study 
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The NRES website also provides guidance on these topics, which is updated in the light of changes in reporting 
requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to 
improve our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk. 
 
08/H0805/21                                    Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
Yours sincerely 
 
 
 
 
Ms Carol Jones 
REC Chair 
Email: janine.peters@bromleypct.nhs.uk 
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Participant information leaflet for RCT 
 
 
 
 
St Thomas' Hospital 
Physiotherapy Department 
Third Floor Lambeth Wing 
St Thomas’ Hospital 
Lambeth Palace Road 
London SE1 7EH 
Tel: 020 7188 4174 
Mobile : 07836 622086 
Fiona.sandford@kcl.ac.uk 
 
 
PARTICIPANT INFORMATION SHEET  
Version 3. 05.11.08 
 
1.  Study title 
A Randomised single-blinded placebo-controlled study investigating the role of poly-unsaturated fatty acids in 
addition to exercise in the management of rotator cuff (rc) tendinopathy. 
R&D Ref No: 08/H0805/21  
2.  Invitation paragraph 
You are being invited to take part in a research study that is aiming to investigate if poly-unsaturated 
acids (also known as fish oils or omega 3s) is helpful in the treatment in the shoulder tissues of people 
who have been diagnosed with problems of the rotator cuff (muscles and tendons of the shoulder). 
 
Before you decide to participate it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and discuss it with 
friends, relatives and your GP or Consultant if you wish.  Please ask us if there is anything that is not clear 
or if you would like more information.  Please take time to decide whether or not you wish to take part. 
 
3.  What is the purpose of the study? 
Shoulder pain is extremely common. One of the main causes of shoulder pain involves problems of the 4 
deep tendons or the shoulder (known as the rotator cuff tendons) and a fluid filled sack that normally sits 
above these tendons to make shoulder movement occur more easily. There are a number of causes of 
shoulder pain relating to these tissues ranging from inflammation to degeneration. Currently there are 
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many different treatments for this condition. One widely accepted treatment is exercise and manual 
therapy (joint mobilisations performed by a physiotherapist). Some patients have reported that they have 
found benefit from taking supplements containing poly- unsaturated fatty acids (also known as fish oils or 
omega 3s). If a significant difference can be seen in those who take the supplements it may lead to new 
treatments for these conditions. 
 
The purpose of this study is to determine if taking supplements containing poly unsaturated fatty acids 
(also known as fish oils or omega 3s) has a beneficial effect on function and pain for people who have 
been diagnosed with problems of the rotator cuff.  
 
4.  Why have I been chosen? 
Most probably you will be reading this document because you have shoulder pain that has been 
diagnosed as involving the shoulder tendons. 
 
Poly-unsaturated fatty acids (also known as fish oils or omega 3s) have been shown to have positive 
effects on heart disease, rheumatoid arthritis and on tendon conditions in athletes.  Therefore it was 
believed that they might also help those with tendon problems of the shoulder. The supplements will be 
supplied by a company called seven seas which is a well known company on the high street and also 
supplies the NHS with prescribed supplements. The exercise class and home exercise programme which 
you will undertake is part of the normal treatment you would receive from your Physiotherapist.  
 
We are approaching you because we would like to determine how if taking a supplement supplied by 
seven seas containing poly unsaturated fatty acids (also known as fish oils or omega 3s) has a beneficial 
effect on pain and outcome in people with shoulder tendon problems. You will be one of a number of 
people who will be included in this investigation. We guarantee that no-one will be able to identify you in 
the published results and your participation will remain anonymous. 
 
5.  What will happen to me if I take part? 
If you are interesting in participating in this study we will give you this patient information document to 
take and read. We would recommend that you take your time to consider involvement with this study 
and you may choose to discuss your possible involvement with family and friends. You may choose to 
discuss this with other healthcare professionals and if you wish, you are also welcome to discuss your 
involvement with the Lead Investigator of this study, Fiona Sandford. Fiona Sandford’s contact 
information is on the top of this form and if you allow she will contact you to discuss any questions and to 
confirm or cancel (if you chose not to take part) your assessment with her. If you do not wish to be 
contacted you are free to still attend the assessment with the Lead Investigator and still be a part of the 
study. 
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If you agree to participate you will be asked to sign a consent form at the time of your shoulder 
assessment. If you sign the form we will perform a series of tests and fill in some questionnaires that will 
take about 30 minutes. These tests will examine the range of movement of your shoulder joint and the 
strength of your shoulder muscles. They will be the same tests you initially had before your diagnosis was 
made. The reason why we are repeating them just before you start the treatment is so that we have an 
accurate baseline level of you shoulder problem to then compare any improvements to. Some of these 
tests may cause pain or some discomfort but they are routine tests used in clinics to make a diagnosis of 
shoulder tendon problems. Following the tests you will be asked to have a blood test. This tells us the 
level of essential fats in your blood. It will be taken by a specialist nurse or phlebotomist (a health care 
professional who takes blood). They will take a 5ml sample (the amount of a tea spoon). This blood will be 
tested in a laboratory and then destroyed. It will not be kept nor any other tests run on it. Again it will not 
be identifiable to your name.  
 
You will then attend the shoulder class the following week. Here you will be given your supplements to 
take home. These supplements will either contain poly-unsaturated fatty acids (also known as fish or 
omega 3s) 170mg eicosapentaenoic acid (EPA), 115mg docasahexaenoic acid (DHA) and anti-oxidants 
(100 units/g Vitamin E and 10units/g Vitamin D) or a mixed oil and the anti-oxidants (100 units/g Vitamin 
E and 10units/g Vitamin D). You will be asked to take whichever supplement you are allocated for a total 
of 8 weeks. During this time you will be asked to record your supplement taking in your study diary. You 
will have a home exercise programme which we will ask you to carry out once a day. We will also ask you 
to record what exercises you completed and how you felt. You will also attending the shoulder class once 
weekly.  
 
At the end of the 8 week class you will be reassessed. Again we will perform the same tests and 
questionnaires you had at the start of the programme. Again this will take approximately 30 minutes. You 
will also be asked to go for another blood test so that we can compare the levels of fats in your blood. 
This blood test will be the same as the test you had at the start. 
We will then ask you to return to be re-assessed at 3, 6 and 12 months from your start date in the class. 
This is to reassess you again using the same tests and questionnaires as we did at the beginning but not 
the blood tests. As we are asking you to return for these extra assessments we will reimburse you for 
your travel expenses if required (up to the value of a travel card). 
 
 Following this your involvement with this study will be over. 
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If you decide not to participate you will not be required to sign the research consent form and you will 
have treatment on your painful shoulder. Not participating in this research will not effect your treatment 
in any way and it is up to you whether you participate or not. 
 
6.  What do I have to do? 
The first thing you need to do is decide if you would like to participate or not. This is entirely your decision 
and deciding not to participate will not affect the quality of your care. If you do decide to participate you 
will need to follow the procedure outlined in section 5.  
 
7.  What is the procedure that is being tested? 
We are trying to determine if poly unsaturated fatty acids (also known as fish oils or Omega 3s) have a 
beneficial effect on function in patients with rotator cuff disease. 
 
8.   What are the side effects of taking part? 
Polyunsaturated fatty acids (also known as fish oils or Omega 3s) are known to be safe in the doses being 
used in this trial. Reported side effects have included an upset stomach or stomach pain, black tarry 
stools, bruising and heartburn. If you were to feel any of these symptoms we ask you to stop taking the 
tablets and either see your Gp or call the lead investigator Fiona Sandford for further advice. 
Some of the shoulder tests may be painful. In most cases this will be similar to the pain you are 
experiencing in your shoulder. The tests are used to determine which structure or structures are involved 
with your pain. Sometimes this changes over time and that is why we would like to re-examine your 
shoulder prior to you starting the shoulder class. 
The blood test may be uncomfortable but the health care professionals are trained to take blood and a 
very small sample is going to be taken. 
 
9.  What are the possible disadvantages and risks of taking part? 
There are no perceived disadvantages or risks for those taking part in this study. The examination 
procedures are ones used routinely in the clinical examination of the shoulder. They may be associated 
with some discomfort or pain during the tests. If any side effects of the supplements are experienced, we 
recommend that the supplements are stopped immediately. 
 
10.  What are the possible benefits of taking part? 
We hope that this research will help us eventually help relieve pain in shoulder pain syndromes. It might 
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help other patients with shoulder pain by eventually learning new ways of treating this common problem. 
However, as with all research, this cannot be guaranteed.  
11.    What if something goes wrong? 
We do not anticipate for anything to go wrong in this study as we are not trying any new procedure or 
supplement, we are simply investigating if an existing supplement has a benefit in patients who have 
been diagnosed with rotator cuff tendon problems. 
However, if you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds for legal 
action but you may have to pay for it. Regardless of this, if you wish to complain about any aspect of the 
way you have been approached or treated during the course of this study, the normal NHS complaints 
mechanisms may be available to you. 
12.  Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you that leaves the hospital relating to this study will have your 
name and address removed so that it will not be possible to recognise you from it. 
If you do participate your GP (and Consultant if appropriate) will be sent a letter notifying them of your 
participation in this study (if you give your permission for this letter to be sent). 
13.  What will happen to the results of the research study? 
We hope to use the information we obtain from this study to inform other health professionals about our 
results. We therefore ask your permission to publish the data we obtain. However, we guarantee to keep 
your name and identity confidential and this will not be made available to anyone at any stage. The 
results will probably be published about one year after the end of the study and if you are interested in 
finding out about our results, we would be happy to send you a one page summary of our findings.  
14.  Who is organising and funding the research? 
This research is a collaborative study between the Physiotherapy and Dietetics and Nutrition departments 
at both Guys and St Thomas' Foundation NHS Trust and St George’s Foundation NHS Trust. 
15.  Who has reviewed this study? 
This study has been reviewed by international experts. In addition it has been reviewed by the Hospital’s 
Research and Development committees and Bromley Ethics Committee. 
16.  Contact for further information 
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If you would like any further information about this study, please feel free to contact Fiona Sandford, 
Clinical Specialist Physiotherapist, on telephone number 0207 188 4174 or 07836 622076, or e-mail 
Fiona.sandford@kcl.ac.uk. 
17.  Most research projects recommend that certain patients don't participate in a specific study. This is   
usually for ethical or medical reasons. We will ask everyone participating in this study the following 
questions.  
Are you younger than 18 years of age?      Yes No 
Are you pregnant, suspect you are pregnant, 
or attempting to become pregnant?      Yes No 
If you answer yes to any of these questions we will thank you for taking time to consider this study but 
we will be unable to include you in this research.  
We will also be conducting clinical tests to ensure that you have not got any other shoulder condition that 
requires different treatment. If you have you will be offered the appropriate management for that 
condition. This will mean that you will not be able to participate in this study.  
If you are a patient and decide to participate in this research (and are eligible to participate) then we 
will also ask you if you would like us to send a letter to your GP or consultant, informing them that you 
are participating in this study. 
18.  After you have read this information sheet 
Please take your time in order to decide if you would like to participate or not. If you choose please 
discuss your possible involvement with family, friends and other health professionals. 
If you agree to participate in this study, we will ask you to fill in and sign a Research Consent Form, in 
front of someone who will witness the signature. This will be done at the time of your assessment. At the 
same time we will re-test your shoulder with muscle strength tests and measure how much movement 
there is available in your shoulder. You will then be asked to have the blood test. This will take place just 
after the assessment. 
If you wish, please keep this information sheet. 
If you choose to participate we will give you a copy of your signed consent form. 
If you choose not to participate you will go ahead with your physiotherapy treatment and your decision 
not to participate will not affect your treatment. 
Thank you for taking the time to read this information sheet.  
  294 
Consent form for RCT 
 
 
 
 
St Thomas' Hospital 
Physiotherapy Department 
Third Floor Lambeth Wing 
St Thomas’ Hospital 
Lambeth Palace Road 
London SE1 7EH 
Tel: 020 7188 4174 
                                                                                                  Fax: 020 7188 4166  
 
Title of Project: A Randomised single-blinded placebo-controlled study investigating the role of poly-
unsaturated fatty acids in addition to exercise in the management of rotator cuff (rc) tendinopathy. 
Protocol Version: Version 1 date 02.04.08 
Local Research Ethics Number:  08/H0805/21 
Patient Hospital Number:    Patient Study Identification Number: 
Patient Initials: 
Participant Declaration 
  If Correct 
Please initial box 
I have been given the chance to read and understand the information 
sheet (dated 02.104.08- Version1)  relating to the above study 
  
I have been given the opportunity to ask questions and discuss the 
study. 
 
  
   
I have been made aware of the risks/ benefits 
  
  
   
I understand that authorised individuals may look at my medical notes 
and give permission for these individuals to have access 
 
  
   
I understand that I am free to withdraw from this study at any time 
without prejudice to my future care/ treatment 
  
  
   
Research Subject Consent Form 
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I have had the compensation procedures explained to me  
  
   
I would like my GP or consultant to know that I am participating in this 
research project.  
  
   
I would like to receive a one page summary of the findings of this study.
  
  
  
Title of Project:  A Randomised single-blinded placebo-controlled study investigating the role of poly-
unsaturated fatty acids in addition to exercise in the management of rotator cuff (rc) tendinopathy. 
Local Research Ethics Number:    
Patient Hospital Number:    
I agree to take part in the above study 
 
Signature ……………………………………………………………… 
Name  ……………………………………………………………… 
Date  ……………………………………………………………… 
 
Person responsible for obtaining Informed Consent: 
'To the best of my knowledge I have provided the above individual with sufficient information to enable 
them to give informed consent'. 
 
Signature ……………………………………………………………… 
Name  ……………………………………………………………… 
Date  ……………………………………………………………… 
Position ……………………………………………………………… 
Witnessed by: 
Signature ……………………………………………………………… 
Name  ……………………………………………………………… 
Date  ………………………………………………………………
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Four day food diary  
 
 
 
 
St Thomas' Hospital 
Physiotherapy Department 
Third Floor Lambeth Wing 
St Thomas’ Hospital 
Lambeth Palace Road 
London SE1 7EH 
Tel: 020 7188 4174 
Food, drink & 
supplement 
record 
Version 1    date: 02.04.2008 
Name: ____________________________________________ 
Date of 1st Shoulder Class ____________________________ 
Date of 2nd Assessment ______________________________ 
Date of 3rd Assessment ______________________________ 
Date of 4th Assessment ______________________________ 
Date of 5th Assessment ______________________________ 
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Food, Drink & Supplement record  
Why do I need to keep a dietary record? 
It is important prior to starting the trial that we know your normal intake. This will be 
used to support and help explain any results are found in the trial. A Registered 
Dietitians (RDs) will assess the food diary at the end of the trial.  
This food diary will help you record what you eat, drink and any supplements that you 
might take. 
Please be as honest as possible. Please also complete it for 2 work or ‘usual’ days and 2 
weekend days or days off. 
How do I keep a dietary record? 
Imagine that you are trying to describe an item of clothing to a friend. For them to 
‘picture’ it they would have to be given some details. For example, if you describe a shirt 
as made of fine cotton with fine pale blue stripes and a small collar, then it would give 
your friend much more of an idea as to what you are describing.  
 
The same applies to keeping a dietary record. If you just write a ‘shopping list’ of foods, 
it’s difficult to determine how much, or what type of food that you normally eat.   
 
So a good diary describes what you normally eat or drink, so that when the dietician 
looks at it, it’s easy to work out what you ate. The main points of a good diary are: 
 
1. How much food or drink? 
What would you describe as a portion of chicken? A leg, a quarter, a large breast, or 4 
wings? Make it easier for the dietician by describing what your normal portion is.  
If you eat prepared foods, then just write down the weight on the packet, and whether 
you ate all of the contents or just some. e.g 1 chicken kiev, (Tesco, box of two 250g)  
 
2. What type of food or drink? 
 Bread is a popular food available in many varieties: white, brown, wholemeal, 
bread rolls or sliced bread –  
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 thick, medium or thin cut. 
 Milk could be full fat, semi or fully skimmed, evaporated milk or dried powder.  
 Cereal could be cornflakes, branflakes, Weetabix, porridge oats or muesli. 
 
Please help the dietitian by explaining what type of food you eat. If you only eat one 
sort of bread, list it once and then any ‘bread’ entry will be assumed to be the same 
type.  
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Food, Drink & Supplement record  
Typical food and drink intake: 
Usual day (your diet most of the 
time eg during a working week)  
Day 1 
meal Weekend/ alternate day  
(other food and drink choices) 
Day 2 
 Breakfast:  
 
 
 
 Mid-morning  
  
 
 
Lunchtime 
 
 
 
 
 
 Mid-
afternoon 
 
  
 
 
Evening meal 
 
 
 
 
 
 
 
 
 
 
 
Evening 
/bedtime 
drinks/ snacks 
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Food, Drink & Supplement record  
Typical food and drink intake: 
Usual day (your diet most of the time 
eg during a working week)  
Day 3 
meal Weekend/ alternate day  
(other food and drink choices)   
Day4 
 Breakfast:  
 
 
 
 Mid-morning  
  
 
 
Lunchtime 
 
 
 
 
 Mid-
afternoon 
 
  
 
Evening meal 
 
 
 
 
 
 
 
 
 
 
Evening/ 
bedtime 
drinks/snacks 
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Food, Drink & Supplement record 
What else do you take? 
It’s common for people with arthritis to take nutritional supplements along with medication 
for their arthritis or other health conditions.  
 
It would help your dietician if you could list any supplements or medicines you take: 
 
Supplements include: 
Any vitamin, mineral, herbal or homeopathic supplement, in liquid or tablet form. Please list 
the name of the supplements, the manufacturer (who name of the company who make or sell 
them) and the amount you take each day: 
 
 
 
 
 
 
 
What medicines do you take? 
These are the medicines you obtain on prescription from your GP or hospital doctor. 
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Email regarding oxidation status of supplements at end of study 
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Assessment form- baseline 
Physiotherapy Department 
3rd Floor, Lambeth Wing 
St Thomas’ Hospital 
Lambeth Palace  Road 
London SE1 7EH 
Tel:  020 7188 4174 
A Randomised single-blinded placebo-controlled study investigating the role of poly-unsaturated fatty 
acids in addition to exercise in the management of rotator cuff (rc) tendinopathy. 
 
Data Collection Sheet  (version 2 date 29.09.2008) 
 
 
Participant Number:      
Today’s date:                  /       /   
Symptomatic shoulder: Right  /  Left 
Duration of symptoms: Years          
Months     Weeks    Days    
Onset:    trauma  /   non-traumatic  How?:         
Nature of symptoms (tick appropriate):     Constant pain  
Pain increases with movement: yes   /   no If yes, main movement     
Is night pain present:    yes   /   no If yes, is it possible to sleep on painful side?    yes   /   no 
On a scale of 0-10 (where 0 = ‘no pain’ and 10= the worst imaginable pain’) where would you place your pain 
on that scale?    /10 
 
Sticker if available 
 
Name:       
 
Hospital Number:     
 
D.O.B:             /       /               Age:   
 
Gender:  male  /   female 
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Inclusion criteria [tick if present]  
[circle those present] 
 
 
 
or Hawkins and Kennedy Test 
 
      and / or ‘empty cans 
 
  
Exclusion criteria [tick if present] 
 
s 
 
 
 
 
illing to take fish oils 
Pregnant or attempting to become pregnant or breast feeding 
 
 
 
Medications/Allergies: 
Other comments: 
 
 
 
 
 
 
 
Weight:                                Height…………………………. BMI…………………. 
 
Smoker:    No…………………Yes       how many per day………….. 
 
Waist Circumference………………………………………. 
  305 
Clinical Findings 
Painful shoulder (circle) Left                      Right 
 
Oxford Shoulder Disability Score  
/ 48 
 
 
SPADI Score   
 
EQ-D5 Score  
  
SF-36 Score  
  
 
 
 
 
Left Right 
Neer Impingement sign +ve   /   -ve +ve   /   -ve 
Hawkins and Kennedy test +ve   /   -ve +ve   /   -ve 
Pain on palpation of gtr tuberosity Yes   /   No Yes    /    No 
 
    
R.O.M active / passive 
    
Flexion              (X° measured with 
inclinometer) 
    
Abduction          (X° measured with 
inclinometer) 
    
ER by side     (cm measured with tape 
measure) 
    
HBB  
(lateral buttock, posterior buttocks, 
sacrum, lower lumbar, lumbo 
thoracic region, lower thoracic, 
inferior angle scapula, middle 
scapula, superior angle scapula) - 
write level 
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Resisted mvts. & Strength Left  Right  
Abduction 10° (pain, pain and 
weakness, weakness) 
    
Flexion  10° (pain, pain and 
weakness, weakness) 
    
Full cans         (pain, pain and 
weakness, weakness) 
 
    
Empty cans     (pain, pain and 
weakness, weakness) 
 
    
ER by side      (pain, pain and 
weakness, weakness) 
    
IR by side        (pain, pain and 
weakness, weakness) 
    
Biceps             (pain, pain and 
weakness, weakness) 
    
 
 
Comments: 
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Exercise booklet 
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  310 
 
  311 
 
  312 
 
  
  313 
 
  
  314 
 
  
  315 
 
  
  316 
 
  
  317 
 
  
  318 
 
  
  319 
 
  
  320 
 
  
  321 
 
  
  322 
 
  
  323 
 
  
  324 
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  326 
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Study diary  
These were in A4 format for the participants. 
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Baseline outcome measures in each treatment group 
The outcome measures were compared and analysed at baseline including the primary 
outcome measure the oxford shoulder score and all secondary outcome measures. Significant 
differences were observed in baseline measures of the SF 36 mental component scores 
(p=0.02) and SF36 role limitations due to emotional problems (p=0.04). 
Table 11.1 Baseline outcome measures 
Domain Outcome measure Placebo Treatment P value 
Function  Oxford shoulder score (OSS)  
0-48 48=highest 
31.71 (8.41) 32.03 (7.85) 0.87 
SPADI, 0-100; 100=highest 43.92  
(29.39-58.46) 
38.85  
(20.13-55.02) 
0.20₸ 
Patient specific functional 
scale,0-100; 100=highest 
33.33  
(26.67-50) 
35.00  
(20.00-50.83) 
0.90₸ 
Pain Pain score (NRS) 
0-10; 0=highest 
6.26 (1.83) 5.99 (0.26) 
 
0.57 
Quality of life- 
generic 
EQ-5D utility score 
-0.5-1.0; 1=highest 
0.68 (0.23) 0.70 (0.26) 0.75 
EQ-5D health quality VAS 
0-100; 100=highest 
74.92 (13.59) 70.24 (19.39) 0.47 
Quality  
of life- specific 
SF36 MCS  
 0-100; 100=highest  
54.67 (8.03) 49.64 (10.13) 0.02* 
SF36 PCS 
 0-100; 100=highest 
37.95 (8.18) 41.54 (8.26) 0.07 
Sf36 physical role 25 (0-75) 50 (0-100)) 0.51₸ 
SF36 physical functioning 65.86 (20.77) 68.16 (23.20) 0.66 
SF36 bodily pain 47.89 (19.07)  51.61 (21.70) 0.44 
SF36 general health 67.80 (15.44) 70.03 (19.89) 0.60 
SF36 vitality 60.57 (6.54) 60.57 (18.14) 1.00 
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SF36 social functioning  78.86 (22.09) 73.36 (22.36) 0.39 
SF36 role limitations due to 
emotional problems 
80.95 (35.51) 61.40 (44.88) 0.04* 
SF36 mental health 79.94 (15.13) 78.38 (14.75) 0.30 
Impairment 
measures- ROM 
Gh jt flexion (degrees) 141.11 
920.89) 
140.37 (18.25) 0.87 
Gh jt abduction (degrees) 134.60 (28.38) 131.47 (27.93) 0.64 
Gh jt external rotation 
(degrees) 
41.08 (5.73) 39.29 (6.12) 0.20 
Hand behind back (cm) 31.03 (10.13) 30.79 (12.20) 0.93 
Impairment 
measures- 
Strength  
(measured in 
pounds) 
Gh jt flexion  21.59 (6.09) 21.13 (9.65) 0.82 
Gh jt abduction 21.62 (8.99) 19.33 (8.46) 0.27 
‘Full can’ 9.50  
(5.20-120) 
6.35 
(4.65-12.1) 
0.26₸ 
‘Empty can’ 9.20  
(5.20-12.20) 
6.35  
(3.78-10.18) 
0.10₸ 
External rotation  16.20  
(9.70-21.30) 
12.45  
(9.10-16.08) 
0.09₸ 
Internal rotation 18.30 
(13.00-25.50) 
15.85  
(11.45-23.35) 
0.25₸ 
Elbow flexion  23.50  
(17-33.50) 
22.60  
(12.50-33.10) 
0.61₸ 
Summary measures represent means (SD), independent t-test or ₸ represents Mann Whitney and 
median (interquartile ranges). *represents a statistically significant difference. Gh jt= gleno humeral 
joint, MCS= mental component score (SF36), PCS= physical component score (SF36)  
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Baseline characteristics of those completing the trial and those who did not 
Baseline characteristics of those participants completing and not completing are 
presented in Table11.2.  
For those not completing the longevity outcome at one year:  
The baseline disability as measured by Oxford Shoulder Score (OSS), was 
significantly more severe in non-completers (26, SD =8.07) compared to those 
who completed the trial (32.6 SD=7.8, t(71)=2.25, p=0.03, 95%CI= 0.74 to 12.46). 
Similarly the baseline SPADI score for the non completers (61.27±18.98) showed 
significantly higher levels of disability than the completers (38.32±20.97, p=0.004, 
95%CI=-38.47 to -7.42). All baseline health related quality of life scores were 
statistically significantly lower in the non-completer group EQD5-3L (p=0.0001, 
95% CI=0.17 to 0.50), EQD5- VAS score (p=0.0004, 95% CI=9.91 to 32.27) and the 
SF-36 PCS and MCS (p=0.0008, 95%CI =4.36 to 15.98 and p=0.025, 95%CI=1.01 to 
14.75) respectively. With regards to the impairment measures, there was only a 
statistically significant difference in the range of motion of flexion (p=0.004. 
95%CI of the difference=6.98 to 34.52), abduction (p=0.03, 95%CI of the 
difference=2.95 to 43.60) and hand behind back (p=0.05, 95%CI of the 
difference=-16.49 to -0.14) all displaying a significantly lower range in those who 
did not complete the trial. Finally the baseline EPA + DHA levels in the non-
completers plasma was statistically significantly higher in the non-completers 
group (p=0.02, 95% CI of the difference =-3.08 to -0.73).  
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Table 11.2 Baseline characteristics of participants that did and did not complete the trial at one year 
Domain Variable/ outcome measure Participants completing the trial   
(N=65) 
Participants not completing the 
trial (N=8) 
P value 
Demographics Allocated to treatment group  33/65 (50.8%) 5/8 (62.5%) 0.76‡ 
Gender: male  33/65 (50.7%) 4/8 (50%) 1.0‡ 
Age (years) 52.91 (14.43) 45.88 (8.98) 0.18 
Body mass index (kgm⁻²) 27.58 (6.96) 32.38 (4.84) 0.06 
Waist circumference (cm) 96.03(14.86) 102.43 (12.64) 0.25 
Baseline EPA & DHA plasma levels (%) 3.17 (1.30) 5.07 (2.78) 0.002* 
Symptom duration (months) 21.30 (38.56) 28.69 (38.33) 0.43₸ 
Analgesia: yes 11/65 (16.9%) 2/8 (25%) 0.64‡ 
Function Oxford Shoulder Score (OSS) (0-48; 48= highest) 32.60 (7.82) 26.00 (8.07) 0.03* 
SPADI (0-100; 100=highest) 38.32 (20.97) 61.27 (18.98) 0.004* 
Patient specific functional score (0-100; 
100=highest) 
37.85 (20.00) 35 (20.93) 0.97₸ 
Pain Pain score (NRS) (0-10; 0=highest) 6.01 (2.05) 7.00 (1.07) 0.19 
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Quality of life - 
generic 
Quality of life (EQ-5D)   (-0.5-1.0; 1=highest) 0.73 (0.18) 0.39 (0.43) 0.03*‡ 
Health quality EQ -5D   (0-100; 100=highest) 74.84 (15.51) 53.25 (16.57) 0.0004* 
Quality of life – 
specific  
SF36  
(0-100; 
100=highest) 
 
Physical role 51.92 (38.86) 3.13 (8.84) 0.008*‡ 
(95%CI=21.16-
76.44) 
Physical functioning 69.38 (21.17) 48.13 (19.99) 0.009* 
(5.53-36.98) 
Bodily pain 52.45 (19.23) 28.50 (18.02) 0.03*₸   
(95%CI=9.67-
38.23)                 
General health perceptions 70.80 (16.80) 54.00 (19.84) 0.011*  
(95%CI=4.00-
29.60) 
Vitality 60.80 (13.32) 58.75 (19.96) 0.70 
Social functioning 78.65 (20.46) 50.00 (20.04 0.00*  
(95%CI=13.40-
43.91) 
Role limitations due to emotional problems  77.44 (37.32) 16.66 (35.63) 0.00*₸ 
(95%CI=(33.01-
88.53) 
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Mental health 76.31 (19.96) 72.00 (21.59) 0.49 
Physical component summary  40.93 (8.05) 30.76 (4.62) 0.0008* 
Mental component summary 52.92 (9.12) 45.04 (9.85) 0.025* 
Impairment 
measures-ROM 
(degrees) 
Flexion 143.0 (16.0) 122.25 (33.42) 0.004* 
Abduction 135.52 (25.71) 112.25 (38.22) 0.025* 
External rotation 40.45 (6.03) 37.75 (5.04)` 0.23 
Hand behind back 30.0 (10.61) 38.31 (13.64) 0.046* 
Impairment 
measures- 
Strength 
(pounds) 
Flexion 21.96 (7.72) 16.04 (9.67) 0.53 
Abduction 21.07 (8.65) 15.23 (8.14) 0.195₸ 
Full can 8.86 (5.52) 8.70 (6.79) 0.84₸ 
Empty can 8.59 (4.90) 5.56 (4.51) 0.15₸ 
External rotation 14.30 (6.24) 11.64 (6.63) 0.15₸ 
Internal rotation 18.45 (7.95) 14.31 (9.01) 0.18 
 Elbow flexion 26.60 (14.48) 20.48 (18.08) 0.28  
Legend; N= number, CI= 95% confidence interval of the difference. Summary measures are means and (SD) bwteen group comparison analysed using independent samples 
t test or †denotes Chi squared test, ‡= Fischer’s Exact test and ₸Mann Whitney. 
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SF 36 domains across all time points for both groups 
Domain Time point  Placebo Treatment Treatment effect 
(95% CI) 
P value  ANCOVA 
Physical role  Baseline N=35   42.86 (38.14) N=38 50.00(41.51)  0.45  
2 months N=32 70.31(31.39) N=36 62.28 (40.65) 5.03(-12.72-22.79) 0.57 0.57 
3 months N=31  66.94 (37.30)  N=31  75.81(35.05) -8.87(-27.26-9.52) 0.34 0.78 
6 months N=30  75.00 (27.85)  N=32   70.31 (40.88)  4.69(-13.20-22.58) 0.60 0.65 
12 months N= 32   78.13 (32.84) N= 32  75.00(39.14) 3.13(21.18-21.19) 0.73 0.31 
Physical 
functioning  
Baseline N=35  65.86 (20.77) N=38   68.16 (23.20)  0.66  
2 months N=32  76.72 (19.90) N=36  78.47 (19.00) -1.75 (-11.18-7.67) 0.71 0.65 
3 months N=31  74.19 (20.86) N=31  83.23(15.84) -9.03(-18.44-0.38) 0.06 0.14 
6 months N=30  77.50 (18.65)  N=32   84.84 (12.15) -7.34(-15.29-0.60) 0.07 0.029*(0.012           
to 0.38) 
12 months N= 32   79.38 (19.71) N= 32  79.69(23.35) -0.31 (-11.11-10.48) 0.95 0.77 
Bodily pain 
 
Baseline N=35 47.89 (19.07) N=38 51.61 (21.70)  0.44  
2 months N=32  64.66 (19.72) N=36  67.31 (18.09) -2.65 (-11.81 to 
6.51) 
0.57 0.67 
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3 months N=31  62.23 (20.29) N=31  71.06 (19.09) -8.84 (-18.85 to 
1.17) 
0.08 0.12 
6 months N=30  73.37 (18.25) N=32   74.47 (21.46) --2.10 (-11.26 to 
9.05) 
0.83 0.53 
12 months N= 32   69.63 (22.20) N= 32  80.22 (19.39) -10.59 (-21.02 to -
0.18) 
0.05* 0.04*(-0.105 to 
0.479) 
General health 
perceptions 
Baseline N=35  67.80 (15.44) N=38   70.03 (19.89)  0.60  
2 months N=32  70.09 (16.66) N=36  74.64 (19.20) -4.55 (-13.30-4.21) 0.30 0.21 
3 months N=31  69.61 (16.68)  N=31  74.19(19.90) -4.58(13.91-4.75) 0.33 0.72 
6 months N=30  72.20 (11.46)  N=32   75.69 (17.35)  -3.49(-11.01-4.03) 0.36 0.56 
12 months N= 32   70.72 (16.66) N= 32  71.88(20.47) -1.16(-10.48-8.17) 0.81 0.70 
Vitality Baseline N=35  60.57 (6.54) N=38   60.57 (18.14)  1.00  
 2 months N=32  63.75 (14.26) N=36  64.31 (16.87) -0.56 (-8.17-7.06) 0.89 0.62 
3 months N=31  65.97(13.57) N=31  64.35(17.31) 1.61(-6.29-9.51) 0.68 0.96 
6 months N=30  67.50 (14.78)  N=32   64.84  (16.78)  2.66(-5.40-10.71) 0.51 0.94 
12 months N= 32   65.78 (16.71) N= 32  62.81(18.45) 2.97 (-5.83-11.76) 0.50 0.98 
Social functioning Baseline N=35  78.86 (22.09) N=38   73.36 (22.36)  0.39  
2 months N=32  84.38 (20.58) N=36  81.25 (20.16) 3.13(-6.75-13.00) 0.53 0.90 
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3 months N=31  82.66(24.08)  N=31  85.08(18.94) (-13.43-8.59) 0.66 0.60 
6 months N=30  89.58 (13.16)  N=32   84.77 (19.76) 4.82(-3.77-13.41) 0.27 0.56 
12 months N= 32   85.55 (18.81) N= 32  84.37(23.55) 1.17 (-9.48-11.82) 0.83 0.74 
Role limitations 
due to emotional 
problems 
Baseline N=35 80.95 (35.51) N=38 61.40 (44.88)  0.04*  
2 months N=32  77.08 (35.36) N=36  74.07 (39.93) 3.01 (-15.35 to 
21.37) 
0.75 0.64 
3 months N=31  88.18 (23.64) N=31  86.02 (29.53) 2.15 (-11.44 to 
15.75) 
0.75 0.65 
6 months N=30  87.78 (23.95) N=32  76.04 (35.15) 11.74 (-3.65 to 
27.12) 
0.13 0.64 
12 months N= 32   86.46 (29.16) N= 32  77.08 (35.36) 9.38 (-6.82 to 25.57) 0.25 0.47 
Mental health Baseline N=35  74.94 (15.13) N=38   78.38 (14.75)  0.30  
2 months N=32  78.38 (14.75) N=36  75.89 (16.27) 2.49 (-5.07 to 10.04) 0.51 0.96 
3 months N=31  82.55 (10.93) N=31  79.68 (14.93) 2.87 (-3.78 to 9.52) 0.39 0.85 
6 months N=30  78.13 (11.00) N=32   78.03 (15.62)  0.10 (-6.80 to 7.01) 0.98 0.72 
12 months N= 32   76.38 (14.20) N= 32  76.88 (16.47) -0.50 (-8.18 to 7.18) 0.90 0.24 
Summary measures are means and (SD) analysed using independent samples t test and between group comparison by univariate ANCOVA adjusted for baseline value, age, 
gender and BMI. Scores are an aggregate percentage where 0= worst possible functioning and 100=best. *signifies a statistically significant change. 
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Shoulder range of motion across all time points for both groups 
Outcome 
measure 
time point  Placebo  Treatment  P value ANCOVA 
Symptomatic 
GHJ flexion 
(measured in 
degrees) 
 
Baseline 141.11 
(20.89) 
140.37 (18.25) 0.87  
2 months 144.52 
(19.35) 
145.24 (18.99) 0.87 0.45 
3 months 146.61 
(13.40) 
152.77 (11.80) 0.06 0.005* 
6 months 150.57 
(16.00) 
151.09 (16.62) 0.9 0.45 
12 months 149.69 
(13.77) 
151.65 (17.20) 0.62 0.36 
Symptomatic 
GHJ abduction 
(measured in 
degrees) 
 
Baseline 134.60 
(28.38) 
131.47 (27.93) 0.64  
2 months 144.27 
(20.32) 
138.11 (24.33) 0.26 0.49 
3 months 140.39 
(20.32) 
148.36 (12.42) 0.05* 0.006* 
6 months 149.20 
(17.59) 
148.13 (17.39) 0.81 0.86 
12 months 146.13 
(18.50) 
150.84 916.24) 0.29 0.11 
Symptomatic 
GHJ external 
rotation 
(measured           
in cm) 
 
Baseline 41.08 
(5.73) 
39.29 (6.12) 0.20  
2 months 41.36 
(5.90) 
40.54 (4.93) 0.53 0.69 
3 months 42.02 
(6.89) 
41.92 (5.60) 0.95 0.08 
6 months 42.41 
(6.35) 
40.56 (7.18) 0.28 0.10 
12 months 43.98 
(5.73) 
42.36 (5.51) 0.26 0.90 
Symptomatic Baseline 31.03 30.79 (12.20) 0.93  
 338 
 
GHJ hand 
behind back 
(measured in 
cm) 
(10.13) 
2 months 28.26 
(10.17) 
28.63 (10.40) 0.88 0.79 
3 months 27.53 
(10.22) 
25.78 (9.15) 0.49 0.41 
6 months 26.15 
(7.75) 
24.59 (6.46) 0.39 0.43 
12 months 24.83 
(10.28) 
23.38 (7.49) 0.54 0.60 
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Shoulder strength across all time points for both groups. 
Outcome 
measure 
Assessment 
time point  
Placebo  Treatment  P value ANCOVA 
Symptomatic 
GHJ flexion 
(measured in 
pounds) 
 
Baseline 21.59 (6.09) 21.13 (9.65) 0.82  
2 months 24.52 (7.07) 22.76 (10.45) 0.42 0.89 
3 months 25.20 (7.55) 22.09 (10.34) 0.18 0.64 
6 months 27.06 (7.41) 26.39 (11.27) 0.76 0.44 
12 months 26.62 (8.68) 25.57 (9.86) 0.66 0.26 
Symptomatic 
GHJ 
abduction 
(measured in 
pounds) 
 
Baseline 21.62 (8.99) 19.33 (8.46) 0.27  
2 months 25.70 (8.71) 22.42 (9.88) 0.15 0.71 
3 months 25.55 (9.55) 22.28 (9.68) 0.19 0.90 
6 months 26.70 (7.16) 24.85 (9.44) 0.39 0.63 
12 months 27.58 (7.54) 27.15 (10.14) 0.85 0.13 
Symptomatic 
full can 
strength 
(measured in 
pounds) 
 
Baseline 9.40 (5.42) 8.33 (5.83) 0.42  
2 months 11.43 (5.97) 10.23 (7.46) 0.45 0.92 
3 months 12.23 (6.54) 10.82 (7.59) 0.44 0.27 
6 months 12.37 (5.89) 11.69 (7.12) 0.69 0.35 
12 months 13.04 (5.14) 12.56 (7.04) 0.76 0.15 
Symptomatic 
empty can 
strength 
(measured in 
pounds) 
Baseline 9.13 (4.44) 7.46 (5.26) 0.15  
2 months 11.78 (5.51) 10.31 (6.91) 0.33 0.60 
3 months 12.64 (5.43) 9.88 (6.58) 0.007 0.61 
6 months 13.10 (5.10) 11.53 (6.50) 0.30 0.16 
12 months 14.25 (7.99) 12.78 (6.53) 0.43 0.48 
Symptomatic 
external 
rotation 
strength 
(measured in 
pounds) 
Baseline 15.44 (6.28) 12.70 (6.08) 0.06  
2 months 16.78 (5.75) 15.55 (7.58) 0.45 0.59 
3 months 17.75 (6.62) 16.23 (7.55) 0.40 0.22 
6 months 18.74 (5.75) 16.74 (6.91) 0.2 0.68 
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12 months  17.75 (5.53) 18.69 (7.15) 0.56 0.005* 
Symptomatic 
internal 
rotation 
strength 
(measured in 
pounds) 
Baseline 19.17 (8.11) 16.91 (8.07) 0.24  
2 months 22.13 (8.88) 19.10 (9.79) 0.18 0.90 
3 months 23.83 (9.88) 21.38 (10.95) 0.36 0.55 
6 months 24.32 (9.75) 20.67 (10.48) 0.16 0.63 
12 months  24.55 (9.06) 23.07 (10.93) 0.56 0.60 
Symptomatic 
elbow flexion  
strength 
(measured in 
pounds) 
Baseline 26.72 (14.86) 25.19 (15.09) 0.67  
2 months 31.28 (13.46) 29.44 (16.26) 0.61 0.61 
3 months 32.90 (15.44) 30.27 (17.57) 0.53 0.78 
6 months 32.63 (13.05) 33.00 (16.10) 0.92 0.21 
12 months  33.26 (17.05)  31.68 (15.69) 0.71 0.59 
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Ethical approval for qualitative study 
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Participant information sheet for qualitative study 
INFORMATION SHEET FOR PARTICIPANTS 
REC Reference Number: 08/H0805/21 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
Factors affecting compliance to exercise program and supplement use in the 
management of rotator cuff tendinopathy. 
 
Thank you for your recent participation in the randomized single-blinded placebo 
controlled study investigating the role of poly-unsaturated fatty acids in addition to 
exercise in the management of Rotator cuff tendinopathy.  
 
We would now like to invite you to participate further in this study, if you would like to.  
You should only participate if you want to; choosing not to take part will not disadvantage 
you in any way.   
 
Before you decide whether you want to take part, it is important for you to understand 
why the research is being done and what your participation will involve.  Please take time 
to read the following information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear or if you would like more information.  
 
What is the purpose of the research study?   
 
We would like to hear about your experiences while doing the exercises and taking the 
supplements during the study, including things that helped you to carry out the exercises 
and take the nine pills and things that made it difficult to follow. The purpose of the 
research study is to explore the factors affecting compliance or adherence to carrying out 
prescribed exercises and to taking supplements. The findings will benefit health 
professionals and public health practitioners in their roles supporting individuals to carry 
out physiotherapy exercises and take supplements to treat musculo-skeletal pain such as 
rotator cuff tendinopathy. 
 
Why am I being invited to take part?    
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You have been invited to take part in this study because you recently took part in study.  
You are well-placed to discuss your experiences of taking the pills and doing the exercises, 
and provide insights into how it felt.  
 
Do I have to take part?   
 
No. It is up to you to decide whether or not to take further part in this study. If you choose 
to participate you are free to withdraw at any time without giving a reason and without 
your decision impacting in any way on your future interaction with the researchers from 
study or Guys and St Thomas’ NHS Foundation Trust.   
 
What would be involved?   
 
You may be asked to attend an individual interview either on a separate occasion or as 
part of your final assessment in the study with the chief investigator and clinical specialist 
physiotherapist, Fiona Sandford.  The agenda will be flexible so that you can raise anything 
of particular relevance or importance to you.   
 
Interviews will last up to one hour and will be recorded on a tape recorder and by pen and 
paper, transcribed into print and then analysed.  The discussion will focus on your 
experiences of taking part in the study. 
 
You will be reimbursed for your travel expenses up to the value of an off peak one day 
zone 1-4 travel card on provision of a receipt. 
 
Will I be identifiable in the transcription of the interview or in any subsequent verbal or 
written report?  
 
No. Participation in the interview is completely confidential and all information you 
provide will be anonymised. You will not be personally identifiable in the typed 
transcription (you will be given a pseudonym) or in any subsequent verbal or written 
account. The tapes will not be heard by anyone other than the researcher and neither 
your name nor your place of work will appear in the printed copy.  
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Once transcribed, the tape recording will be permanently deleted.  You will be offered a 
copy of the transcript of the interview, if you wish to receive it.  Nothing discussed during 
the interview or focus group will be divulged to a third party outside of the research team 
and only the research team will have access to the transcripts from the study. Where 
direct quoting is used in any report or publication, these will be anonymised and will be 
chosen in order to prevent them from being linked with any individual.  The results of the 
study will eventually be published.  You will be offered a summary of the final research 
report once it has been published. 
 
How quickly must I decide if I want to participate? 
 
A researcher will be in contact with you in the next two weeks to answer any questions 
you might have and to ask if you are willing to participate and, if you are willing, to 
arrange a time convenient for you to attend the interview.  
 
It is up to you to decide whether to take part or not. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. You are free 
to refuse to discuss specific questions during the interview should you wish, without giving 
a reason. You are also free to withdraw from the study at any time prior to data analysis, 
without giving a reason, and any data collected by that point will not be used in the 
analysis. Once data analysis is underway it will not be possible to withdraw your data, as 
by this stage it will be anonymised.  
 
What are the possible benefits of taking part? 
 
Although you are unlikely to obtain any individual benefit from participating further in the 
study, the results will be of benefit to health care practitioners, future research projects 
and public health policy makers in the area of rotator cuff tendinopathy, physiotherapy 
and supplementation.  
 
What are the potential risks or disadvantages of taking part?  
 
There are unlikely to be any risks or disadvantages to you by taking part.   
If you have any questions or would like to discuss this in more detail then please contact 
the investigator: 
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Fiona Sandford, Chief investigator and clinical Specialist Physiotherapist email: 
Fiona.sandford@kcl.ac.uk or 07836622076 
 
What will happen if anything goes wrong?  
 
We do not anticipate for anything to go wrong in this study. If you wish to complain about 
any aspect of the way you have been approached or treated during the course of this 
study, the normal NHS complaints mechanisms are available to you. 
 
Thank you for taking the time to read this and your interest in the study. 
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Consent form for qualitative study 
 
 
 
 
St Thomas' Hospital 
Physiotherapy Department 
Third Floor Lambeth Wing 
St Thomas’ Hospital 
Lambeth Palace Road 
London SE1 7EH 
Tel: 020 7188 4174 
                                                                                                  Fax: 020 7188 4166  
 
Title of Project: Factors affecting compliance to exercise program and supplement use in the 
management of rotator cuff tendinopathy 
Protocol Version: Version 1 date: 25.07.2012 
Local Research Ethics Number:  08/H0805/21 
 
Participant Declaration 
 
  If Correct 
Please initial box 
I have been given the chance to read and understand the information 
sheet (dated 05.09.2012 version2)  relating to the above study 
 
  
I have been given the opportunity to ask questions and discuss the 
study. 
 
  
I have been made aware of the risks/ benefits 
  
  
I understand that authorised individuals may look at my medical notes 
and give permission for these individuals to have access 
 
  
   
I understand that I am free to withdraw from this study at any time 
without prejudice to my future care/ treatment 
  
  
   
Research Subject Consent Form 
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I consent to audio taping of the interview/discussion  
  
  
I would like to receive a one page summary of the findings of this study.
  
  
  
     
Title of Project: Factors affecting compliance to exercise program and supplement use in the 
management of rotator cuff tendinopathy 
 
Protocol Version: Version 1 date: 25.07.2012 
 
Local Research Ethics Number:  08/H0805/21 
 
Patient Hospital Number:     
 
 
I agree to take part in the above study 
 
Signature ……………………………………………………………… 
 
Name  ……………………………………………………………… 
 
Date  ……………………………………………………………… 
 
Person responsible for obtaining Informed Consent: 
'To the best of my knowledge I have provided the above individual with sufficient information to enable 
them to give informed consent'. 
 
 
Signature ……………………………………………………………… 
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Name  ……………………………………………………………… 
 
Date  ……………………………………………………………… 
 
Position ……………………………………………………………… 
 
 
Witnessed by: 
 
 
Signature ……………………………………………………………… 
 
Name  ……………………………………………………………… 
 
Date  ……………………………………………………………… 
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Publication in Journal of Hand Therapy from Chapter 2 
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Publication in Shoulder and Elbow from Chapter 4 
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